

October 2025

Volume 32

Editors:

Kaye Wilson, Doris Chong, Sophie Molloy
email: enquiry@pharmac.govt.nz
Telephone +64 4 460 4990
Level 9, 40 Mercer Street
PO Box 10 254 Wellington

Freephone Information Line

0800 66 00 50 (9am – 5pm weekdays)

Circulation

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month by subscribing at pharmac.govt.nz/subscribe.

Production

Typeset automatically from XML and T_EX.
XML version of the Schedule available from schedule.pharmac.govt.nz/pub/schedule

Programmers

Anrik Drenth
email: texschedule@pharmac.govt.nz
©Pharmaceutical Management Agency
ISSN 1179-3686



This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to Pharmac and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/.

Attribution to Pharmac should be in written form and not by reproduction of the Pharmac logo. While care has been taken in compiling this Schedule, Pharmac takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Introducing Pharmac 2

Section A General Rules 5

Section B Alimentary Tract & Metabolism 6

Blood & Blood Forming Organs 36

Cardiovascular System 46

Dermatologicals 67

Genito Urinary System 76

Hormone Preparations – Systemic 83

Infections – Agents For Systemic Use 95

Musculoskeletal System 119

Nervous System 124

Oncology Agents & Immunosuppressants 153

Respiratory System & Allergies 266

Sensory Organs 277

Various 282

Section C Extemporaneous Compounds (ECPs) 284

Section D Special Foods 286

Section I National Immunisation Schedule 309

Index 325

Introducing Pharmac

The Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmac negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list.

Pharmac's role:

“to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.”

Pae Ora (Healthy Futures) Act 2022

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at <https://pharmac.govt.nz/about>.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in Health NZ Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in Health NZ Hospitals for which national prices have been negotiated by Pharmac.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to Health NZ Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements Pharmac has with the supplier and, for Pharmaceuticals used in Health NZ Hospitals, on any logistics arrangements put in place.

This book contains sections A to D and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in Health NZ Hospitals. Section H lists the Pharmaceuticals that can be used in Health NZ Hospitals and is a separate publication.

The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example

ANATOMICAL HEADING			
THERAPEUTIC HEADING			
CHEMICAL			
Presentation, form and strength		Subsidy (Manufacturer's Price) \$ Per	Fully Brand or Subsidised Generic ✓ Manufacturer
Presentation - Available on a PSO		10.00 100	Brand A ✓ Brand B
Presentation - Retail pharmacy-specialist		15.00 50	✓ Brand C
Presentation - Retail pharmacy-specialist		18.00 250 ml OP	✓ Brand D
a) Prescriptions must be written by a paediatrician or paediatric cardiologist; or b) on the recommendation of a paediatrician or a paediatric cardiologist			
CHEMICAL			
* Presentation, form and strength		26.53 100	Brand E
		(35.27)	
Sole Supply/Principal Supply ▲ Three months supply may be dispensed at one time if endorsed 'certified exemption' by the prescriber or pharmacist.			
✓ Fully Subsidised			

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Practitioner's Supply Order

Conditions of and restrictions on prescribing (including Special Authority where it applies)

Three months or six months, as applicable, dispensed all-at-once

Brand or manufacturer's name

Sole Subsidised Supply product or Principal Supply Status

Fully subsidised product

Original Pack - Subsidy is rounded up to a multiple of whole packs

Quantity the Subsidy applies to

Subsidy paid on a product before mark-ups and GST

Manufacturer's Price if different from Subsidy

Glossary

Units of Measure

gram	g	microgram.....	mcg	millimole.....	mmol
kilogram.....	kg	milligram	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

Abbreviations

Ampoule	Amp	Gelatinous	Gel	Solution.....	Soln
Capsule	Cap	Granules	Gran	Suppository.....	Supp
Cream.....	Crm	Infusion	Inf	Tablet.....	Tab
Device.....	Dev	Injection	Inj	Tincture.....	Tinc
Dispersible.....	Disp	Liquid.....	Liq	Trans Dermal Delivery	
Effervescent.....	Eff	Long Acting.....	LA	System.....	TDDS
Emulsion.....	Emul	Ointment.....	Oint		
Enteric Coated.....	EC	Sachet	Sach		

Read the [General Rules](https://pharmac.govt.nz/section-a) : <https://pharmac.govt.nz/section-a>.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Antacids and Antiflatulents

Antacids and Reflux Barrier Agents

ALGINIC ACID

Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet.....	8.06	30	✓	Gaviscon Infant
---	------	----	---	-----------------

SODIUM ALGINATE

* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour.....	1.80 (17.99)	60		Gaviscon Extra Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml.....	1.50 (7.50)	500 ml		Acidex

Phosphate Binding Agents

ALUMINIUM HYDROXIDE

* Tab 600 mg	12.56	100	✓	Alu-Tab
--------------------	-------	-----	---	---------

CALCIUM CARBONATE

Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) –				
Subsidy by endorsement	39.00 47.30	500 ml 473 ml	✓	Roxane Calcium carbonate PAI ^{S29}

Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate and the prescription is endorsed accordingly.

Antidiarrhoeals

Agents Which Reduce Motility

LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a PSO

* Tab 2 mg	10.75	400	✓	Nodia
* Cap 2 mg	12.00	400	✓	Diamide Relief

Rectal and Colonic Anti-inflammatories

BUDESONIDE

Cap modified-release 3 mg – Special Authority see SA1886 below – Retail pharmacy	33.38	90	✓	Budesonide Te Arai
Budesonide Te Arai to be Principal Supply on 1 December 2025				

► [SA1886](#) Special Authority for Subsidy

Initial application — (Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2.1 Diabetes; or
- 2.2 Cushingoid habitus; or
- 2.3 Osteoporosis where there is significant risk of fracture; or
- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogeneic bone marrow transplantation*.

Note: Indication marked with * is an unapproved indication.

Initial application — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
 - 3.1 Diabetes; or
 - 3.2 Cushingoid habitus; or
 - 3.3 Osteoporosis where there is significant risk of fracture; or
 - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
 - 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth) .

Note: Indication marked with * is an unapproved indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications).....	57.09	15 g OP	✓ Colifoam
--	-------	---------	------------

HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE

Topical aerosol foam, 1% with pramoxine hydrochloride 1%.....	26.55	10 g OP	✓ Proctofoam ^{S29}
---	-------	---------	-----------------------------

MESALAZINE

Tab 400 mg	49.50	100	✓ Asacol
	71.00	90	✓ Octasa ^{S29}
Tab long-acting 500 mg.....	56.10	100	✓ Pentasa
Tab 800 mg	85.50	90	✓ Asacol
			✓ Asacol ^{S29} ^{S29}
Tab 1,600 mg	85.50	60	✓ Asacol ^{S29}
Modified release granules, 1 g	118.10	100 OP	✓ Pentasa
Enema 1 g per 100 ml	41.30	7	✓ Pentasa
Suppos 500 mg	22.80	20	✓ Asacol
Suppos 1 g	50.96	28	✓ Pentasa

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OLSALAZINE				
Tab 500 mg	56.02	60	✓	Atnahs Olsalazine \$29
	93.37	100	✓	Dipentum
Cap 250 mg	53.00	100	✓	Dipentum
SODIUM CROMOGLICATE				
Cap 100 mg	113.35	100	✓	Ralicrom
SULFASALAZINE				
* Tab 500 mg	19.49	100	✓	Salazopyrin
* Tab EC 500 mg	20.54	100	✓	Salazopyrin EN

Local preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE				
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g	13.05	30 g OP	✓	Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg	8.61	12	✓	Ultraproct
HYDROCORTISONE WITH CINCHOCAINE				
Oint 5 mg with cinchocaine hydrochloride 5 mg per g	15.00	30 g OP	✓	Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g	9.90	12	✓	Proctosedyl

Management of Anal Fissures

GLYCERYL TRINITRATE – Special Authority see SA1329 below – Retail pharmacy				
* Oint 0.2%	22.00	30 g OP	✓	Rectogesic

► [SA1329](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has a chronic anal fissure that has persisted for longer than three weeks.

Antispasmodics and Other Agents Altering Gut Motility

GLYCOPYRRONIUM BROMIDE				
Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on a PSO	19.00	5	✓	Robinul
HYOSCINE BUTYLBROMIDE				
* Tab 10 mg	2.25	20	✓	Hyoscine Butylbromide (Adiramedita)
* Inj 20 mg, 1 ml – Up to 5 inj available on a PSO	1.91	5	✓	Spazmol
MEBEVERINE HYDROCHLORIDE				
* Tab 135 mg	8.50	90	✓	Colofac

Antulcerants

Antisecretory and Cytoprotective

MISOPROSTOL – Wastage claimable				
* Tab 200 mcg – Up to 120 tab available on a PSO	47.73	120	✓	Cytotec

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Helicobacter Pylori Eradication

CLARITHROMYCIN

Tab 500 mg – Subsidy by endorsement.....	14.58	14	✓ Klacid
a) Maximum of 28 tab per prescription			
b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly.			
Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole.			

H2 Antagonists

FAMOTIDINE – Only on a prescription

* Tab 20 mg	4.86	100	✓ Famotidine Hovid \$29
* Tab 40 mg	10.27	100	✓ Famotidine Hovid MY \$29
* Inj 10 mg per ml, 4 ml – Subsidy by endorsement	CBS	10	✓ Mylan \$29
Subsidy by endorsement – Subsidised for patients receiving treatment as part of palliative care.			

Proton Pump Inhibitors

LANSOPRAZOLE

* Cap 15 mg	4.04	100	✓ Lanzol Relief
* Cap 30 mg	5.43	100	✓ Lanzol Relief

OMEPRAZOLE

For omeprazole suspension refer Standard Formulae, [page 284](#)

* Cap 10 mg	2.06	90	✓ Omeprazole Teva ✓ Omeprazole actavis 10
* Cap 20 mg	2.02	90	✓ Omeprazole Teva ✓ Omeprazole actavis 20
* Cap 40 mg	3.18	90	✓ Omeprazole Teva ✓ Omeprazole actavis 40
* Powder – Only in combination.....	42.50	5 g	✓ Midwest
Only in extemporaneously compounded omeprazole suspension.			
* Inj 40 mg ampoule with diluent.....	37.38	5	✓ Dr Reddy's Omeprazole ✓ Ocicure \$29

PANTOPRAZOLE

* Tab EC 20 mg	1.99	90	✓ Panzop Relief
* Tab EC 40 mg	2.74	90	✓ Panzop Relief

Site Protective Agents

COLLOIDAL BISMUTH SUBCITRATE

Tab 120 mg	14.51	50	✓ Gastrodenol \$29
------------------	-------	----	--

SUCRALFATE

Tab 1 g	35.50 (48.28)	120	Carafate
---------------	------------------	-----	----------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Bile and Liver Therapy

RIFAXIMIN – Special Authority see [SA1461 below](#) – Retail pharmacy

Tab 550 mg	625.00	56	✓ Xifaxan
------------------	--------	----	------------------

➤ [SA1461](#) Special Authority for Subsidy

Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Diabetes

Hyperglycaemic Agents

DIAZOXIDE – Special Authority see [SA1320 below](#) – Retail pharmacy

Cap 25 mg	110.00	100	✓ Proglificem ^{\$29}
Cap 100 mg	280.00	100	✓ Proglificem ^{\$29}
Oral liq 50 mg per ml	620.00	30 ml OP	✓ e5 Pharma ^{\$29}

➤ [SA1320](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

GLUCAGON HYDROCHLORIDE

Inj 1 mg syringe kit – Up to 5 kit available on a PSO.....	32.00	1	✓ Glucagen Hypokit
--	-------	---	---------------------------

Insulin - Short-acting Preparations

INSULIN NEUTRAL

▲ Inj human 100 u per ml, 3 ml	42.66	5	✓ Actrapid Penfill ✓ Humulin R
▲ Inj human 100 u per ml, 10 ml vial.....	25.26	1 OP	✓ Actrapid ✓ Humulin R

Insulin - Intermediate-acting Preparations

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

▲ Inj 100 iu per ml, 3 ml prefilled pen.....	52.15	5	✓ NovoMix 30 FlexPen
--	-------	---	-----------------------------

INSULIN DEGLUDEC WITH INSULIN ASPART

▲ Inj degludec 70 u with insulin aspart 30 u, 100 u per ml, 3 ml.....	80.00	5	✓ Ryzodeg 70/30 Penfill
---	-------	---	--

INSULIN ISOPHANE

▲ Inj human 100 u per ml, 3 ml	29.86	5	✓ Humulin NPH ✓ Protaphane Penfill
▲ Inj human 100 u per ml, 10 ml vial.....	17.68	1 OP	✓ Humulin NPH ✓ Protaphane

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN ISOPHANE WITH INSULIN NEUTRAL				
▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓	Humulin 30/70
▲ Inj human with neutral insulin 100 u per ml, 10 ml vial.....	25.26	1 OP	✓	PenMix 30
			✓	Humulin 30/70
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE				
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml.....	42.66	5	✓	Humalog Mix 25
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml.....	42.66	5	✓	Humalog Mix 50
Insulin - Long-acting Preparations				
INSULIN GLARGINE				
▲ Inj 100 u per ml, 10 ml.....	63.00	1	✓	Lantus
▲ Inj 100 u per ml, 3 ml.....	94.50	5	✓	Lantus
▲ Inj 100 u per ml, 3 ml disposable pen.....	94.50	5	✓	Lantus SoloStar
Insulin - Rapid Acting Preparations				
INSULIN ASPART				
▲ Inj 100 u per ml, 10 ml.....	30.03	1	✓	NovoRapid
▲ Inj 100 u per ml, 3 ml.....	51.19	5	✓	NovoRapid Penfill
▲ Inj 100 u per ml, 3 ml syringe	51.19	5	✓	NovoRapid FlexPen
INSULIN GLULISINE				
▲ Inj 100 u per ml, 10 ml.....	27.03	1	✓	Apidra
▲ Inj 100 u per ml, 3 ml.....	46.07	5	✓	Apidra
▲ Inj 100 u per ml, 3 ml disposable pen.....	46.07	5	✓	Apidra SoloStar
INSULIN LISPRO				
▲ Inj 100 u per ml, 3 ml.....	59.52	5	✓	Humalog
▲ Inj 100 u per ml, 10 ml vial.....	34.92	1 OP	✓	Humalog
Alpha Glucosidase Inhibitors				
ACARBOSE				
* Tab 50 mg	11.20	90	✓	Accarb
* Tab 100 mg	17.38	90	✓	Accarb
Oral Hypoglycaemic Agents				
GLIBENCLAMIDE				
* Tab 5 mg	7.50	100	✓	Daonil
GLICLAZIDE				
* Tab 80 mg	20.10	500	✓	Glizide
GLIPIZIDE				
* Tab 5 mg	6.86	100	✓	Minidiab
METFORMIN HYDROCHLORIDE				
* Tab immediate-release 500 mg.....	14.74	1,000	✓	Metformin Viatris
* Tab immediate-release 850 mg.....	11.28	500	✓	Metformin Viatris
PIOGLITAZONE				
* Tab 15 mg	6.15	90	✓	Vexazone
* Tab 30 mg	7.25	90	✓	Vexazone
* Tab 45 mg	12.00	90	✓	Vexazone

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
VILDAGLIPTIN				
* Tab 50 mg	35.00	60	✓	Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE				
* Tab 50 mg with 1,000 mg metformin hydrochloride	35.00	60	✓	Galvumet
* Tab 50 mg with 850 mg metformin hydrochloride	35.00	60	✓	Galvumet

GLP-1 Agonists

DULAGLUTIDE – Special Authority see [SA2509 below](#) – Retail pharmacy

Note: Not to be given in combination with another funded GLP-1 agonist or empagliflozin / empagliflozin with metformin hydrochloride unless receiving empagliflozin / empagliflozin with metformin hydrochloride for the treatment of heart failure.

Inj 1.5mg per 0.5 ml prefilled pen 115.23 4 ✓ **Trulicity**

➔ [SA2509](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has type 2 diabetes; and
- 2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of all of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin; and
- 3 Any of the following:
 - 3.1 Patient is Māori or any Pacific ethnicity*; or
 - 3.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 3.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 3.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 3.5 Patient has diabetic kidney disease (see note b)*.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause identified.
- c) Funded GLP-1a treatment is not to be given in combination with funded (empagliflozin / empagliflozin with metformin hydrochloride) unless receiving funded (empagliflozin or empagliflozin in combination with metformin hydrochloride) for the treatment of heart failure.

LIRAGLUTIDE – Special Authority see [SA2510 on the next page](#) – Retail pharmacy

a) Maximum of 9 inj per prescription

b)

a) Note: Not to be given in combination with another funded GLP-1 agonist or empagliflozin / empagliflozin with metformin hydrochloride unless receiving empagliflozin / empagliflozin with metformin hydrochloride for the treatment of heart failure.

b) Maximum of 1 pack of 3 (6 mg per ml, 3 ml) prefilled pens will be funded per month.

Inj 6 mg per ml, 3 ml prefilled pen 383.72 3 ✓ **Victoza**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2510 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has type 2 diabetes; and
- 2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of all of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin; and
- 3 Any of the following:
 - 3.1 Patient is Māori or any Pacific ethnicity*; or
 - 3.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 3.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 3.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 3.5 Patient has diabetic kidney disease (see note b)*.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause identified.
- c) Funded GLP-1a treatment is not to be given in combination with funded (empagliflozin /empagliflozin with metformin hydrochloride) unless receiving funded (empagliflozin or empagliflozin in combination with metformin hydrochloride) for the treatment of heart failure.

SGLT2 Inhibitors

►SA2408 Special Authority for Subsidy

Initial application — (heart failure reduced ejection fraction) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has heart failure; and
- 2 Patient is in NYHA functional class II or III or IV; and
- 3 Either:
 - 3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 40%; or
 - 3.2 An ECHO is not reasonably practicable, and in the opinion of the treating practitioner the patient would benefit from treatment; and
- 4 Patient is receiving concomitant optimal standard funded chronic heart failure treatment.

Initial application — (Type 2 Diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has previously received an initial approval for a GLP-1 agonist; or
- 2 All of the following:
 - 2.1 Patient has type 2 diabetes; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

2.2 Any of the following:

- 2.2.1 Patient is Māori or any Pacific ethnicity*; or
- 2.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
- 2.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
- 2.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
- 2.2.5 Patient has diabetic kidney disease (see note b)*; and

2.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause.
- c) Funded [empagliflozin / empagliflozin with metformin hydrochloride] treatment is not to be given in combination with a funded GLP-1 unless receiving (empagliflozin / empagliflozin with metformin hydrochloride) for the treatment of heart failure.

EMPAGLIFLOZIN – Special Authority see [SA2408 on the previous page](#) – Retail pharmacy

* Tab 10 mg	58.56	30	✓ Jardiance
* Tab 25 mg	58.56	30	✓ Jardiance

EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE – Special Authority see [SA2408 on the previous page](#) – Retail pharmacy

* Tab 5 mg with 1,000 mg metformin hydrochloride	58.56	60	✓ Jardiamet
* Tab 5 mg with 500 mg metformin hydrochloride	58.56	60	✓ Jardiamet
* Tab 12.5 mg with 1,000 mg metformin hydrochloride	58.56	60	✓ Jardiamet
* Tab 12.5 mg with 500 mg metformin hydrochloride	58.56	60	✓ Jardiamet

Diabetes Management

Ketone Testing

BLOOD KETONE DIAGNOSTIC TEST STRIP – Subsidy by endorsement

- a) Not on a BSO
- b) Maximum of 20 strip per prescription
- c) Up to 10 strip available on a PSO
- d) Patient has any of the following:
 - 1) type 1 diabetes; or
 - 2) permanent neonatal diabetes; or
 - 3) undergone a pancreatectomy; or
 - 4) cystic fibrosis-related diabetes; or
 - 5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly.

Test strips	15.50	10 strip OP	✓ KetoSens
-------------------	-------	-------------	-------------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Dual Blood Glucose and Blood Ketone Testing

DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER – Subsidy by endorsement

- Maximum of 1 pack per prescription
- Up to 1 pack available on a PSO
- A dual blood glucose and blood ketone diagnostic test meter is subsidised for a patient who has:
 - type 1 diabetes; or
 - permanent neonatal diabetes; or
 - undergone a pancreatectomy; or
 - cystic fibrosis-related diabetes; or
 - metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly. Only 1 meter per patient will be subsidised (no repeat prescriptions). For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips	20.00	1 OP	✓ CareSens Dual
---	-------	------	-----------------

Blood Glucose Testing

BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement

- Maximum of 1 pack per prescription
- Up to 1 pack available on a PSO
- A diagnostic blood glucose test meter is subsidised for a patient who:
 - is receiving insulin or sulphonylurea therapy; or
 - is pregnant with diabetes; or
 - is on home TPN at risk of hypoglycaemia or hyperglycaemia; or
 - has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or type 2 diabetes and metabolic syndrome.

The prescription must be endorsed accordingly. Only one CareSens meter per patient will be subsidised (no repeat prescriptions). Patients already using the CareSens N POP meter and CareSens N meter are not eligible for a new meter, unless they have:

- type 1 diabetes; or
- permanent neonatal diabetes; or
- undergone a pancreatectomy; or
- cystic fibrosis-related diabetes.

For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 diagnostic test strips	10.00	1 OP	✓ CareSens N
			✓ CareSens N POP
	20.00		✓ CareSens N Premier

Note: Only 1 meter available per PSO

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test available on a PSO

The number of test strips available on a prescription is restricted to 50 unless:

- 1) Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- 4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- 5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Test strips	10.56	50 test OP	✓ CareSens N
			✓ CareSens PRO

BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)

The number of test strips available on a prescription is restricted to 50 unless:

- 1) Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- 4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- 5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips.....	33.69	50 test OP	✓ SensoCard
--------------------------------	-------	------------	-------------

Insulin Syringes and Needles

Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or liraglutide or when prescribed for a patient and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or liraglutide.

INSULIN PEN NEEDLES – Maximum of 200 dev per prescription

* 29 g x 12.7 mm	10.95	100	✓ B-D Micro-Fine
* 31 g x 5 mm	12.26	100	✓ B-D Micro-Fine
* 31 g x 6 mm	9.50	100	✓ Berpu
* 31 g x 8 mm	10.95	100	✓ B-D Micro-Fine
* 32 g x 4 mm	10.95	100	✓ B-D Micro-Fine

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 200 dev per prescription				
* Syringe 0.3 ml with 29 g × 12.7 mm needle	13.56	100	✓	B-D Ultra Fine
	1.36	10		
	(1.99)			B-D Ultra Fine
* Syringe 0.3 ml with 31 g × 8 mm needle	13.56	100	✓	B-D Ultra Fine II
	1.30	10		
	(1.99)			B-D Ultra Fine II
* Syringe 0.5 ml with 29 g × 12.7 mm needle	13.56	100	✓	B-D Ultra Fine
	1.36	10		
	(1.99)			B-D Ultra Fine
* Syringe 0.5 ml with 31 g × 8 mm needle	13.56	100	✓	B-D Ultra Fine II
	1.36	10		
	(1.99)			B-D Ultra Fine II
* Syringe 1 ml with 29 g × 12.7 mm needle	13.56	100	✓	B-D Ultra Fine
	1.36	10		
	(1.99)			B-D Ultra Fine
* Syringe 1 ml with 31 g × 8 mm needle	13.56	100	✓	B-D Ultra Fine II
	1.36	10		
	(1.99)			B-D Ultra Fine II

Insulin Pumps

INSULIN PUMP WITH ALGORITHM – Special Authority see [SA2367 below](#) – Retail pharmacy

- Maximum of 1 dev per prescription
- Only on a prescription
- Maximum of 1 insulin pump per patient each four year period.

Min basal rate 0.02 U/h	8,970.00	1	✓	mylife YpsoPump with CamAPS FX
Min basal rate 0.1 U/h	7,653.00	1	✓	Tandem t:slim X2 with Basal-IQ
			✓	Tandem t:slim X2 with Control-IQ

►SA2367 Special Authority for Subsidy

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Any of the following:
 - The patient has type 1 diabetes; or
 - The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or
 - The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
 - The patient has atypical inherited forms of diabetes; and
- Patient has been evaluated by a diabetes multidisciplinary team for their suitability for insulin pump therapy; and
- In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system.

Renewal — (type 1 diabetes) from any relevant practitioner. Approvals valid for 6 months where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Insulin Pump Consumables

►SA2380 Special Authority for Subsidy

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has type 1 diabetes; or
 - 1.2 The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or
 - 1.3 The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
 - 1.4 The patient has atypical inherited forms of diabetes; and
- 2 Patient has been evaluated by a diabetes multidisciplinary team for their suitability for insulin pump therapy; and
- 3 In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system.

Renewal — (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

INSULIN PUMP CARTRIDGE – Special Authority see [SA2380 above](#) – Retail pharmacy

- a) Maximum of 50 cart per prescription
- b) Only on a prescription
- c) Maximum of 190 cartridges will be funded per year.

* Cartridge 300 u, t:lock x 10 86.00 10 OP ✓ **Tandem Cartridge**

INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special Authority see [SA2380 above](#) – Retail pharmacy

- a) Maximum of 5 set per prescription
- b) Only on a prescription
- c) Maximum of 19 infusion sets will be funded per year.

* 6 mm steel needle; 60 cm tubing x 10	130.00	1 OP	✓ MiniMed Sure-T MMT-864A
* 6 mm steel needle; 80 cm tubing x 10	130.00	1 OP	✓ MiniMed Sure-T MMT-866A
* 8 mm steel needle; 60 cm tubing x 10	130.00	1 OP	✓ MiniMed Sure-T MMT-874A
* 8 mm steel needle; 80 cm tubing x 10	130.00	1 OP	✓ MiniMed Sure-T MMT-876A

(MiniMed Sure-T MMT-864A 6 mm steel needle; 60 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Sure-T MMT-866A 6 mm steel needle; 80 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Sure-T MMT-874A 8 mm steel needle; 60 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Sure-T MMT-876A 8 mm steel needle; 80 cm tubing x 10 to be delisted 1 October 2026)

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGHT INSERTION) – Special Authority see SA2380 on the previous page – Retail pharmacy			
a) Maximum of 5 sets per prescription			
b) Only on a prescription			
c) Maximum of 19 infusion sets will be funded per year.			
* 5.5 mm steel cannula; straight insertion; 45 cm line x 10 with 10 needles.....	136.00	1 OP	✓ mylife Orbit micro
* 5.5 mm steel needle; straight insertion; 60 cm line x 10 with 10 needles.....	136.00	1 OP	✓ mylife Orbit micro
* 5.5 mm steel needle; straight insertion; 80 cm line x 10 with 10 needles.....	136.00	1 OP	✓ mylife Orbit micro
* 8.5 mm steel needle; straight insertion; 60 cm line x 10 with 10 needles.....	136.00	1 OP	✓ mylife Orbit micro
* 8.5 mm steel needle; straight insertion; 80 cm line x 10 with 10 needles.....	136.00	1 OP	✓ mylife Orbit micro
* 6 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles.....	182.00	1 OP	✓ TruSteel
* 8 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles.....	182.00	1 OP	✓ TruSteel
* 6 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles.....	182.00	1 OP	✓ TruSteel
* 8 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles.....	182.00	1 OP	✓ TruSteel

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA) – Special Authority see SA2380 on page 18 – Retail pharmacy				
a) Maximum of 5 set per prescription				
b) Only on a prescription				
c) Maximum of 19 infusion sets will be funded per year.				
* 13 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-381A
* 17 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-377A
* 17 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-378A
* 6 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-398A
* 6 mm teflon needle, 45 cm blue tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-941A
* 6 mm teflon needle, 45 cm pink tubing × 10.....	130.00	1 OP	✓	MiniMed Mio MMT-921A
* 6 mm teflon needle, 60 cm blue tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-943A
* 6 mm teflon needle, 60 cm pink tubing × 10.....	130.00	1 OP	✓	MiniMed Mio MMT-923A
* 6 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-399A
* 6 mm teflon needle, 80 cm blue tubing.....	130.00	1 OP	✓	MiniMed Mio MMT-945A
* 6 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-965A
* 6 mm teflon needle, 80 cm pink tubing × 10.....	130.00	1 OP	✓	MiniMed Mio MMT-925A
* 9 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-396A
* 9 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-397A
* 9 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-975A

(MiniMed Silhouette MMT-381A 13 mm teflon needle, 60 cm tubing × 10 to be delisted 1 October 2026)

(MiniMed Silhouette MMT-377A 17 mm teflon needle, 110 cm tubing × 10 to be delisted 1 October 2026)

(MiniMed Silhouette MMT-378A 17 mm teflon needle, 60 cm tubing × 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-398A 6 mm teflon needle, 110 cm tubing × 10 to be delisted 1 October 2026)

(MiniMed Mio MMT-941A 6 mm teflon needle, 45 cm blue tubing × 10 to be delisted 1 October 2026)

(MiniMed Mio MMT-921A 6 mm teflon needle, 45 cm pink tubing × 10 to be delisted 1 October 2026)

(MiniMed Mio MMT-943A 6 mm teflon needle, 60 cm blue tubing × 10 to be delisted 1 October 2026)

(MiniMed Mio MMT-923A 6 mm teflon needle, 60 cm pink tubing × 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-399A 6 mm teflon needle, 60 cm tubing × 10 to be delisted 1 October 2026)

(MiniMed Mio MMT-945A 6 mm teflon needle, 80 cm blue tubing to be delisted 1 October 2026)

(MiniMed Mio MMT-965A 6 mm teflon needle, 80 cm clear tubing × 10 to be delisted 1 October 2026)

(MiniMed Mio MMT-925A 6 mm teflon needle, 80 cm pink tubing × 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-396A 9 mm teflon needle, 110 cm tubing × 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-397A 9 mm teflon needle, 60 cm tubing × 10 to be delisted 1 October 2026)

(MiniMed Mio MMT-975A 9 mm teflon needle, 80 cm clear tubing × 10 to be delisted 1 October 2026)

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION WITH INSERTION DEVICE) – Special Authority see SA2380 on page 18 – Retail pharmacy			
a) Maximum of 5 sets per prescription			
b) Only on a prescription			
c) Maximum of 19 infusion sets will be funded per year.			
* 13 mm teflon cannula; angle insertion; insertion device; 110 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 30
* 13 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 30
INSULIN PUMP INFUSION SET (TEFLON CANNULA, FLEXIBLE INSERTION WITH INSERTION DEVICE) – Special Authority see SA2380 on page 18 – Retail pharmacy			
a) Maximum of 5 set per prescription			
b) Only on a prescription			
c) Maximum of 19 infusion sets will be funded per year.			
* 6 mm teflon cannula; flexible insertion; insertion device; 46 cm line x 10 with 10 needles	157.00	1 OP	✓ mylife Inset soft
* 6 mm teflon cannula; flexible insertion; insertion device; 60 cm line with integrated inserter x 10 with 10 needles	157.00	1 OP	✓ mylife Inset soft
* 6 mm teflon cannula; flexible insertion; insertion device; 80 cm line x 10 with 10 needles	157.00	1 OP	✓ mylife Inset soft
* 9 mm teflon cannula; flexible insertion; insertion device; 60 cm line x 10 with 10 needles	157.00	1 OP	✓ mylife Inset soft
* 9 mm teflon cannula; flexible insertion; insertion device; 80 cm line x 10 with 10 needles	157.00	1 OP	✓ mylife Inset soft
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION WITH INSERTION DEVICE) – Special Authority see SA2380 on page 18 – Retail pharmacy			
a) Maximum of 5 sets per prescription			
b) Only on a prescription			
c) Maximum of 19 infusion sets will be funded per year.			
* 6 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
* 6 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
* 9 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
* 9 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
INSULIN PUMP INFUSION SET (TEFLON CANNULA, VARIABLE INSERTION) – Special Authority see SA2380 on page 18 – Retail pharmacy			
a) Maximum of 5 set per prescription			
b) Only on a prescription			
c) Maximum of 19 infusion sets will be funded per year.			
* 13 mm teflon cannula; variable insertion; 60 cm line x 10 with 10 needles	182.00	1 OP	✓ VariSoft

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN PUMP RESERVOIR – Special Authority see SA2380 on page 18 – Retail pharmacy				
a) Maximum of 90 cart per prescription				
b) Only on a prescription				
c) Maximum of 360 reservoirs will be funded per year.				
* 10 x 1.6 ml glass reservoir for YpsoPump	50.00	10 OP	✓	mylife YpsoPump Reservoir
* 10 x luer lock conversion cartridges 1.8 ml for paradigm pumps	50.00	10 OP	✓	ADR Cartridge 1.8
* Cartridge for 7 series pump; 3.0 ml x 10	50.00	10 OP	✓	MiniMed 3.0 Reservoir MMT-332A
(ADR Cartridge 1.8 10 x luer lock conversion cartridges 1.8 ml for paradigm pumps to be delisted 1 October 2026)				
(MiniMed 3.0 Reservoir MMT-332A Cartridge for 7 series pump; 3.0 ml x 10 to be delisted 1 October 2026)				

Continuous Glucose Monitor

CONTINUOUS GLUCOSE MONITOR (INTEROPERABLE) – Special Authority see [SA2371 below](#) – Retail pharmacy
Only on a prescription

* Sensor (9) and transmitter (Dexcom G6) – Maximum of 1 dev per prescription	990.00	1 OP	✓	Dexcom G6
Maximum of 5 dev will be funded per year.				
* Sensor (Dexcom G7) – Maximum of 9 dev per prescription	110.00	1	✓	Dexcom G7
Maximum of 40 dev will be funded per year.				
* Sensor (Freestyle Libre 3 Plus) – Maximum of 6 dev per prescription	99.46	1	✓	Freestyle Libre 3 Plus
Maximum of 28 dev will be funded per year.				

►SA2371 Special Authority for Subsidy

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 Any of the following:

- 1.1 The patient has type 1 diabetes; or
- 1.2 The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit; or
- 1.3 The patient has Type 3c diabetes considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatotomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
- 1.4 The patient has atypical inherited forms of diabetes; and

2 In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system.

Renewal — (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
CONTINUOUS GLUCOSE MONITOR (STANDALONE) – Special Authority see SA2370 below – Retail pharmacy			
Only on a prescription			
* Sensor (Dexcom ONE+) – Maximum of 9 dev per prescription 81.00	1	✓	Dexcom ONE+
Maximum of 40 dev will be funded per year.			
* Sensor (Freestyle Libre 2 Plus) – Maximum of 6 dev per prescription..... 99.46	1	✓	Freestyle Libre 2 Plus
Maximum of 28 dev will be funded per year.			
* Sensor (Freestyle Libre 2) – Maximum of 7 dev per prescription..... 92.83	1	✓	Freestyle Libre 2
Maximum of 29 dev will be funded per year.			
<i>(Freestyle Libre 2 Sensor (Freestyle Libre 2) to be delisted 1 May 2026)</i>			

► **SA2370** **Special Authority for Subsidy**

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 The patient has type 1 diabetes; or
- 2 The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit; or
- 3 The patient has Type 3c diabetes considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
- 4 The patient has atypical inherited forms of diabetes.

Renewal — (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

Digestives Including Enzymes

PANCREATIC ENZYME

Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)	100	✓	Creon 10000
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U)	100	✓	Creon 25000
Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph Eur U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U)	20 g OP	✓	Creon Micro

URSODEOXYCHOLIC ACID – Special Authority see [SA2448 below](#) – Retail pharmacy

Cap 250 mg	100	✓	Ursosan
------------------	-----	---	----------------

► **SA2448** **Special Authority for Subsidy**

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner.

Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogeneic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Initial application — (prevention of sinusoidal obstruction syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified where the individual has leukaemia/lymphoma and requires prophylaxis for medications/therapies with a high risk of sinusoidal obstruction syndrome.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription

* Powder for oral soln.....	22.10	500 g OP	✓ Konsyl-D
-----------------------------	-------	----------	-------------------

Faecal Softeners

DOCUSATE SODIUM – Only on a prescription

* Tab 50 mg	3.20	100	✓ Coloxyl
* Tab 120 mg	4.98	100	✓ Coloxyl

DOCUSATE SODIUM WITH SENNOSIDES

Tab 50 mg with sennosides 8 mg.....	3.50	200	✓ Laxsol
-------------------------------------	------	-----	-----------------

POLOXAMER – Only on a prescription

Not funded for use in the ear.

* Oral drops 10%.....	4.17	30 ml OP	✓ Coloxyl
-----------------------	------	----------	------------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Opioid Receptor Antagonists - Peripheral

METHYLNALTREXONE BROMIDE – Special Authority see [SA1691 below](#) – Retail pharmacy

Inj 12 mg per 0.6 ml vial	36.00	1	✓ Relistor
	246.00	7	✓ Relistor

►SA1691 Special Authority for Subsidy

Initial application — (Opioid induced constipation) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient is receiving palliative care; and
- 2 Either:
 - 2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
 - 2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

Osmotic Laxatives

GLYCEROL

* Suppos 2.8/4.0 g – Only on a prescription	12.39	20	✓ Lax-suppositories Glycerol
---	-------	----	---------------------------------

LACTULOSE – Only on a prescription

* Oral liq 10 g per 15 ml	6.16	500 ml	✓ Laevolac
---------------------------------	------	--------	------------

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE

Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	8.50	30	✓ APO Health Macrogol ^{\$29}
	10.15		✓ Molaxole
	12.19		✓ Movicol

(APO Health Macrogol ^{\$29} Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg to be delisted 1 January 2026)

SODIUM ACID PHOSPHATE – Only on a prescription

Enema 16% with sodium phosphate 8%	3.70	1	✓ Fleet Phosphate Enema
--	------	---	----------------------------

SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription

Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	36.89	50	✓ Micolette
---	-------	----	-------------

Stimulant Laxatives

BISACODYL – Only on a prescription

* Tab 5 mg	5.80	200	✓ Bisacodyl Viatrix
* Suppos 10 mg	4.14	10	✓ Lax-Suppositories

SENNA – Only on a prescription

* Tab, standardised	2.17	100	
	(9.38)		Senokot
	0.43	20	
	(2.06)		Senokot

SODIUM PICOSULFATE – Special Authority see [SA2053 on the next page](#) – Retail pharmacy

Oral soln 7.5 mg per ml	7.40	30 ml OP	✓ Dulcolax SP Drop
-------------------------------	------	----------	--------------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA2053 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:
Both:

- 1 The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable; and
- 2 The patient would otherwise require a high-volume bowel cleansing preparation or hospital admission.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Metabolic Disorder Agents

ALGLUCOSIDASE ALFA – Special Authority see [SA1986 below](#) – Retail pharmacy

Inj 50 mg vial	1,142.60	1	✓ Myozyme
----------------------	----------	---	-----------

►SA1986 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:

- 1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
- 2 Any of the following:
 - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
 - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
 - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
 - 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

ARGININE – Special Authority see [SA2042 on the next page](#) – Retail pharmacy

Tab 1,000 mg	CBS	90	✓ Clinicians
Cap 500 mg	CBS	50	✓ Solgar
Powder	CBS	400 g	✓ Biomed

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA2042 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to arginine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

- Both:
- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to arginine supplementation; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

BETAINE – Special Authority see [SA1987 below](#) – Retail pharmacy

Powder for oral soln.....	575.00	180 g OP	✓ Cystadane
---------------------------	--------	----------	-------------

►SA1987 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has a confirmed diagnosis of homocystinuria; and
- 2 Any of the following:
 - 2.1 A cystathionine beta-synthase (CBS) deficiency; or
 - 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
 - 2.3 A disorder of intracellular cobalamin metabolism; and
- 3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Renewal only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

COENZYME Q10 – Special Authority see [SA2039 below](#) – Retail pharmacy

Cap 120 mg.....	CBS	30	✓ Solgar
Cap 160 mg.....	CBS	60	✓ Go Healthy

►SA2039 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to coenzyme Q10 supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

- Both:
- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to coenzyme Q10 supplementation; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

GALSULFASE – Special Authority see [SA1988 below](#) – Retail pharmacy

Inj 1 mg per ml, 5 ml vial.....	2,234.00	1	✓ Naglazyme
---------------------------------	----------	---	-------------

►SA1988 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
- 1 The patient has been diagnosed with mucopolysaccharidosis VI; and
 - 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency by either enzyme activity assay in leukocytes or skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and

continued...

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 3 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

IDURSULFASE – Special Authority see [SA1623 below](#) – Retail pharmacy

Inj 2 mg per ml, 3 ml vial.....	4,608.30	1	✓ Elaprase
---------------------------------	----------	---	------------

►SA1623 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 24 weeks for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
 - 2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

LARONIDASE – Special Authority see [SA1695 below](#) – Retail pharmacy

Inj 100 U per ml, 5 ml vial.....	1,335.16	1	✓ Aldurazyme
----------------------------------	----------	---	--------------

►SA1695 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 24 weeks for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

LEVOCARNITINE – Special Authority see [SA2040 on the next page](#) – Retail pharmacy

Tab 500 mg	CBS	30	✓ Solgar
Cap 250 mg	CBS	30	✓ Solgar
Cap 500 mg	CBS	60	✓ Balance
		300	✓ Metabolics
Oral liq 1 g per 10 ml	CBS	118 ml	✓ Lacuna ^{\$29}
			✓ Novitium Sugar
			Free ^{\$29}
Oral liq 500 mg per 10 ml	CBS	300 ml	✓ Balance

(Novitium Sugar Free ^{\$29} Oral liq 1 g per 10 ml to be delisted 1 February 2026)

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA2040 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to carnitine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to carnitine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

RIBOFLAVIN – Special Authority see SA2041 below – Retail pharmacy

Tab 100 mg	CBS	100	✓ Country Life ✓ Puritan's Pride Vitamin B-2 100 mg S29
Cap 100 mg	CBS	100	✓ Solgar

►SA2041 Special Authority for Subsidy

Initial application only from a metabolic physician or neurologist. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation.

Renewal only from a metabolic physician or neurologist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

SAPROPTERIN DIHYDROCHLORIDE – Special Authority see SA1989 below – Retail pharmacy

Tab soluble 100 mg	1,452.70	30 OP	✓ Kuvan
--------------------------	----------	-------	---------

►SA1989 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
- 2 Treatment with sapropterin is required to support management of PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Renewal only from a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
 - 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
- 2 Any of the following:
 - 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
 - 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
 - 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE – Special Authority see [SA1599 below](#) – Retail pharmacy

Soln 100 mg per ml CBS 100 ml ✓ **Amzoate** S29

➤ **SA1599** Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder.

Renewal only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

SODIUM PHENYLBUTYRATE – Special Authority see [SA1990 below](#) – Retail pharmacy

Grans 483 mg per g 2,016.00 174 g OP ✓ **Pheburane**

➤ **SA1990** Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

Renewal only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

TAURINE – Special Authority see [SA2043 below](#) – Retail pharmacy

Cap 500 mg CBS 50 ✓ **Solgar**
 Cap 1,000 mg CBS 90 ✓ **Life Extension**
 Powder CBS 300 g ✓ **Life Extension**

➤ **SA2043** Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected specific mitochondrial disorder that may respond taurine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

TRIENTINE – Special Authority see [SA2324 below](#) – Retail pharmacy

Cap 250 mg 2,022.00 100 ✓ **Trientine Waymade**

➤ **SA2324** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Wilson disease; and
- 2 Treatment with D-penicillamine has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit; and
- 3 Treatment with zinc has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit, or zinc is considered clinically inappropriate as the person has symptomatic liver disease and requires copper chelation.

Gaucher's Disease

TALIGLUCERASE ALFA – Special Authority see [SA2137 on the next page](#) – Retail pharmacy

Inj 200 unit vial 1,072.00 1 ✓ **Elelyso**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2137 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:

- 1 The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by enzyme replacement therapy (ERT) or the disease might be reasonably expected to compromise a response to ERT; and
- 3 Any of the following:
 - 3.1 Patient has haematological complications of Gaucher disease; or
 - 3.2 Patient has skeletal complications of Gaucher disease; or
 - 3.3 Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
 - 3.4 Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
 - 3.5 Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period; and
- 4 Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

Note: Indication marked with * is an unapproved indication

Renewal only from a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician.

Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started; and
- 2 Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3 Radiological (MRI) signs of bone activity performed at two years since initiation of treatment, and five yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 5 Patient is adherent with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE

Soln 0.15% – Higher subsidy of \$22.60 per 500 ml with

Endorsement	9.00	500 ml	
	(22.60)		Difflam

Additional subsidy by endorsement for a patient who has oral mucositis as a result of treatment for cancer, and the prescription is endorsed accordingly.

CARMELLOSE SODIUM WITH GELATIN AND PECTIN

Paste	17.20	56.7 g OP	✓ Stomahesive
	4.55	15 g OP	
	(7.90)		Orabase
	1.52	5 g OP	
	(3.60)		Orabase
Powder	8.48	28 g OP	
	(10.95)		Stomahesive

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TRIAMCINOLONE ACETONIDE Paste 0.1%	5.49	5 g OP	✓	Kenalog in Orabase
Oropharyngeal Anti-infectives				
AMPHOTERICIN B Lozenges 10 mg	5.86	20	✓	Fungilin
MICONAZOLE Oral gel 20 mg per g	5.19	40 g OP	✓	Decozol
NYSTATIN Oral liq 100,000 u per ml	2.22	24 ml OP	✓	Niostat
Vitamins				
Vitamin B				
HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO	3.95	3	✓	Hydroxocobalamin Panpharma
PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription * Tab 25 mg – No patient co-payment payable..... * Tab 50 mg	3.43 23.45	90 500	✓ ✓	Vitamin B6 25 Pyridoxine multichem
THIAMINE HYDROCHLORIDE – Only on a prescription * Tab 50 mg	4.65	100	✓	Thiamine multichem
VITAMIN B COMPLEX * Tab, strong, BPC	11.25	500	✓	Bplex
Vitamin C				
ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription * Tab 100 mg	16.00	500	✓	Cvite
Vitamin D				
ALFACALCIDOL * Cap 0.25 mcg	26.32	100	✓	One-Alpha
* Cap 1 mcg	87.98	100	✓	One-Alpha
* Oral drops 2 mcg per ml	60.68	20 ml OP	✓	One-Alpha
CALCITRIOL * Cap 0.25 mcg	7.89	100	✓	Calcitriol XL ^{\$29}
			✓	Calcitriol-AFT
* Cap 0.5 mcg	13.68	100	✓	Calcitriol XL ^{\$29}
			✓	Calcitriol-AFT
COLECALCIFEROL * Cap 1.25 mg (50,000 iu) – Maximum of 12 cap per prescription..... * Oral liq 188 mcg per ml (7,500 iu per ml)	3.65 9.00	12 5 ml OP	✓ ✓	Vit.D3 Clinicians

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Multivitamin Preparations

MULTIVITAMIN RENAL – Special Authority see [SA1546 below](#) – Retail pharmacy

* Cap 7.28 30 ✓ Clinicians Renal Vit

►SA1546 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
- 2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73 m² body surface area (BSA).

MULTIVITAMINS – Special Authority see [SA1036 below](#) – Retail pharmacy

* Powder 74.88 200 g OP ✓ Paediatric Seravit

►SA1036 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a previous approval for multivitamins.

VITAMINS

* Tab (BPC cap strength) 18.50 1,000 ✓ Mvite

* Cap (fat soluble vitamins A, D, E, K) – Special Authority see

[SA1720 below](#) – Retail pharmacy 23.40 60 ✓ Vitabdeck

►SA1720 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome; or
- 3 Patient has severe malabsorption syndrome.

Minerals

Calcium

CALCIUM CARBONATE

* Tab 1.25 g (500 mg elemental) 7.28 250 ✓ Calci-Tab 500

* Tab eff 1.25 g (500 mg elemental) – Subsidy by endorsement 260.00 100 ✓ Calcium 500 mg

Hexal ^{\$29}

Subsidy by endorsement – Only when prescribed for paediatric patients (< 5 years) where calcium carbonate oral liquid is considered unsuitable.

CALCIUM GLUCONATE

* Inj 10%, 10 ml ampoule 32.00 10 ✓ Max Health -
Hameln ^{\$29}

Iodine

POTASSIUM IODATE

* Tab 253 mcg (150 mcg elemental iodine) 5.99 90 ✓ NeuroTabs

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Iron				
FERROUS FUMARATE				
* Tab 200 mg (65 mg elemental)	3.49	100	✓	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID				
* Tab 310 mg (100 mg elemental) with folic acid 350 mcg	5.98	100	✓	Ferro-F-Tabs
FERROUS SULFATE				
Tab long-acting 325 mg (105 mg elemental)	2.55	30	✓	Ferrograd
Note: No new patients to be initiated on ferrous sulfate tablet.				
* Oral liq 30 mg (6 mg elemental) per 1 ml	10.25	250 ml	✓	Ferro-Liquid
	13.10	500 ml	✓	Ferodan
<i>(Ferrograd Tab long-acting 325 mg (105 mg elemental) to be delisted 1 March 2026)</i>				
<i>(Ferodan Oral liq 30 mg (6 mg elemental) per 1 ml to be delisted 1 February 2026)</i>				
IRON (AS FERRIC CARBOXYMALTOSE) – Special Authority see SA2394 below – Retail pharmacy				
Inj 50 mg per ml, 10 ml vial	150.00	1	✓	Ferinject

►SA2394 Special Authority for Subsidy

Initial application — (Anaemia) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with anaemia; and
- 2 Any of the following:
 - 2.1 Serum ferritin level is 20 mcg/L or less; or
 - 2.2 Both:
 - 2.2.1 Serum ferritin is between 20 and 50 mcg/L; and
 - 2.2.2 C-Reactive Protein (CRP) is at least 5 mg/L; or
 - 2.3 Patient has chronic inflammatory disease with symptoms of anaemia despite normal iron levels; and
- 3 Any of the following:
 - 3.1 Oral iron treatment has proven ineffective; or
 - 3.2 Oral iron treatment has resulted in dose-limiting intolerance; or
 - 3.3 Rapid correction of anaemia is required.

Renewal — (Anaemia) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient continues to have anaemia with a serum ferritin level of 20 mcg/L, or less or between 20 and 50 mcg/L with CRP of at least 5 mg/L, or has chronic inflammatory disease with symptoms of anaemia despite normal iron levels; and
- 2 A trial (or re-trial) with oral iron is clinically inappropriate.

Initial application — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of an internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with iron-deficiency anaemia; and
- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or
 - 2.4 Rapid correction of anaemia is required.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient continues to have iron-deficiency anaemia; and
- 2 A re-trial with oral iron is clinically inappropriate.

IRON POLYMALTOSE

* Inj 50 mg per ml, 2 ml ampoule	37.95	5	✓ Ferrosig
--	-------	---	------------

Magnesium

MAGNESIUM HYDROXIDE

Suspension 8%.....	33.60	355 ml	✓ Phillips Milk of Magnesia ^{\$29}
--------------------	-------	--------	---

MAGNESIUM SULPHATE

* Inj 2 mmol per ml, 5 ml ampoule	37.53	10	✓ Martindale
* Inj 2 mmol per ml, 10 ml ampoule	75.06	10	✓ Inresa ^{\$29}

Zinc

ZINC SULPHATE

* Cap 137.4 mg (50 mg elemental)	11.00	100	✓ Zincaps
			✓ Zincaps S29 ^{\$29}

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Antianaemics

Hypoplastic and Haemolytic

►SA2266 Special Authority for Subsidy

Initial application — (chronic renal failure) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; or
 - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

Renewal — (chronic renal failure) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

EPOETIN ALFA – Special Authority see SA2266 above – Retail pharmacy

Wastage claimable

Inj 1,000 iu in 0.5 ml, syringe.....	250.00	6	✓ Binocrit
Inj 2,000 iu in 1 ml, syringe.....	100.00	6	✓ Binocrit
Inj 3,000 iu in 0.3 ml, syringe.....	150.00	6	✓ Binocrit
Inj 4,000 iu in 0.4 ml, syringe.....	96.50	6	✓ Binocrit
Inj 5,000 iu in 0.5 ml, syringe.....	125.00	6	✓ Binocrit
Inj 6,000 iu in 0.6 ml, syringe.....	145.00	6	✓ Binocrit
Inj 8,000 iu in 0.8 ml, syringe.....	175.00	6	✓ Binocrit
Inj 10,000 iu in 1 ml, syringe.....	197.50	6	✓ Binocrit
Inj 40,000 iu in 1 ml, syringe.....	250.00	1	✓ Binocrit

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Megaloblastic				
FOLIC ACID				
* Tab 0.8 mg	26.60	1,000	✓	Folic Acid multichem
* Tab 5 mg	5.82	100	✓	Folic Acid Viatrix
Oral liq 50 mcg per ml	31.77	25 ml OP	✓	Biomed

Antifibrinolytics, Haemostatics and Local Sclerosants

EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm]

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treators Group in conjunction with the National Haemophilia Management group.

Inj 250 iu vial.....	612.50	1	✓	Alprolix
Inj 500 iu vial.....	1,225.00	1	✓	Alprolix
Inj 1,000 iu vial.....	2,450.00	1	✓	Alprolix
Inj 2,000 iu vial.....	4,900.00	1	✓	Alprolix
Inj 3,000 iu vial.....	7,350.00	1	✓	Alprolix
Inj 4,000 iu vial.....	9,800.00	1	✓	Alprolix

ELTROMBOPAG – Special Authority see SA1743 below – Retail pharmacy

Wastage claimable

Tab 25 mg	1,550.00	28	✓	Revolade
Tab 50 mg	3,100.00	28	✓	Revolade

➔SA1743 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist.

Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Initial application — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist.

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

and significant mucocutaneous bleeding.

Initial application — (severe aplastic anaemia) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

Renewal — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Renewal — (severe aplastic anaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EMICIZUMAB – [Xpharm] – Special Authority see [SA2272 below](#)

Inj 30 mg in 1 ml vial.....	3,570.00	1	✓ Hemlibra
Inj 60 mg in 0.4 ml vial.....	7,138.00	1	✓ Hemlibra
Inj 105 mg in 0.7 ml vial.....	12,492.00	1	✓ Hemlibra
Inj 150 mg in 1 ml vial.....	17,846.00	1	✓ Hemlibra

➔ [SA2272](#) Special Authority for Subsidy

Initial application — (Severe Haemophilia A with or without FVIII inhibitors) only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has severe congenital haemophilia A with a severe bleeding phenotype (endogenous factor VIII activity less than or equal to 2%); and
- 2 Emicizumab is to be administered at a dose of no greater than 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – [Xpharm]

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

Inj 1 mg syringe	1,178.30	1	✓ NovoSeven RT
Inj 2 mg syringe	2,356.60	1	✓ NovoSeven RT
Inj 5 mg syringe	5,891.50	1	✓ NovoSeven RT
Inj 8 mg syringe	9,426.40	1	✓ NovoSeven RT

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xpharm]			
For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
Inj 500 U	1,315.00	1	✓ FEIBA NF
Inj 1,000 U	2,630.00	1	✓ FEIBA NF
Inj 2,500 U	6,575.00	1	✓ FEIBA NF
MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xpharm]			
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.			
Inj 250 iu prefilled syringe	287.50	1	✓ Xyntha
Inj 500 iu prefilled syringe	575.00	1	✓ Xyntha
Inj 1,000 iu prefilled syringe	1,150.00	1	✓ Xyntha
Inj 2,000 iu prefilled syringe	2,300.00	1	✓ Xyntha
Inj 3,000 iu prefilled syringe	3,450.00	1	✓ Xyntha
NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpharm]			
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
Inj 1,000 iu vial	870.00	1	✓ RIXUBIS
Inj 2,000 iu vial	1,740.00	1	✓ RIXUBIS
Inj 3,000 iu vial	2,610.00	1	✓ RIXUBIS
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – [Xpharm]			
For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
Inj 500 iu vial	420.00	1	✓ Advate
Inj 1,000 iu vial	840.00	1	✓ Advate
Inj 2,000 iu vial	1,680.00	1	✓ Advate
Inj 3,000 iu vial	2,520.00	1	✓ Advate
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – [Xpharm]			
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.			
Inj 250 iu vial	237.50	1	✓ Kogenate FS
Inj 500 iu vial	475.00	1	✓ Kogenate FS
Inj 1,000 iu vial	950.00	1	✓ Kogenate FS
Inj 2,000 iu vial	1,900.00	1	✓ Kogenate FS
Inj 3,000 iu vial	2,850.00	1	✓ Kogenate FS
RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – [Xpharm]			
For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.			
Inj 1,000 iu vial	1,200.00	1	✓ Adynovate
Inj 2,000 iu vial	2,400.00	1	✓ Adynovate
SODIUM TETRADECYL SULPHATE			
* Inj 3% 2 ml	28.50 (73.00)	5	Fibro-vein
TRANEXAMIC ACID			
Tab 500 mg	10.45	60	✓ Mercury Pharma
	45.68	100	✓ Cyklokapron

(Cyklokapron Tab 500 mg to be delisted 1 November 2025)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Vitamin K				
PHYTOMENADIONE				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO.....	8.00	5	✓	Konaktion MM Paediatric
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	9.21	5	✓	Konaktion MM

Antithrombotic Agents

Antiplatelet Agents

ASPIRIN				
* Tab 100 mg	12.65	990	✓	Ethics Aspirin EC
CLOPIDOGREL				
* Tab 75 mg	5.07	84	✓	Arrow - Clopid
Arrow - Clopid to be Principal Supply on 1 December 2025				
DIPYRIDAMOLE				
Note: No new patients to be initiated on dipyridamole.				
Tab long-acting 150 mg.....	13.93	60	✓	Pytazen SR
Cap modified-release 200 mg	55.13	60	✓	Dipyridamole - Strides ^{\$29}
(Pytazen SR Tab long-acting 150 mg to be delisted 1 January 2026)				
TICAGRELOR – Special Authority see SA1955 below – Retail pharmacy				
* Tab 90 mg	20.35	56	✓	Ticagrelor Sandoz

➡ [SA1955](#) Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Initial application — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient has had a neurological stenting procedure* in the last 60 days; or
 - 1.2 Patient is about to have a neurological stenting procedure performed*; and
- 2 Either:
 - 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
 - 2.2 Either:
 - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
 - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

Initial application — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Initial application — (Stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Renewal — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Notes: indications marked with * are unapproved indications.

Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

Heparin and Antagonist Preparations

ENOXAPARIN SODIUM – Special Authority see [SA2152 below](#) – Retail pharmacy

Inj 20 mg in 0.2 ml syringe.....	21.90	10	✓ Clexane
Inj 40 mg in 0.4 ml syringe.....	29.74	10	✓ Clexane
Inj 60 mg in 0.6 ml syringe.....	42.47	10	✓ Clexane
Inj 80 mg in 0.8 ml syringe.....	56.62	10	✓ Clexane
Inj 100 mg in 1 ml syringe.....	70.91	10	✓ Clexane
Inj 120 mg in 0.8 ml syringe.....	88.11	10	✓ Clexane Forte
Inj 150 mg in 1 ml syringe.....	100.70	10	✓ Clexane Forte

➔ [SA2152](#) Special Authority for Subsidy

Initial application — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner.

Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant

continued...

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Initial application — (Short-term use during treatment of COVID-19 with nirmatrelvir with ritonavir) from any relevant practitioner. Approvals valid for 2 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is receiving an anticoagulation treatment that has drug/drug interactions with ritonavir that increases risk of bleeding; and
- 2 Patient meets the Access Criteria for COVID-19 antivirals published on the Pharmac website*; and
- 3 Other antiviral treatments for COVID-19 have been considered and are not clinically suitable options.

Renewal — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 10 ml vial.....	127.44	25	✓ Pfizer ^{§29}
Inj 1,000 iu per ml, 5 ml ampoule	25.49	10	✓ Wockhardt ^{§29}
	103.70		✓ Wockhardt PSF ^{§29}
	127.44	50	✓ Pfizer
Inj 5,000 iu per ml, 5 ml vial.....	83.00	10	✓ Heparin Sodium Panpharma
Inj 5,000 iu per ml, 1 ml	70.33	5	✓ Hospira
Inj 25,000 iu per ml, 0.2 ml.....	25.78	5	✓ Hospira

(Pfizer ^{§29} Inj 1,000 iu per ml, 10 ml vial to be delisted 1 January 2026)

(Wockhardt ^{§29} Inj 1,000 iu per ml, 5 ml ampoule to be delisted 1 January 2026)

(Wockhardt PSF ^{§29} Inj 1,000 iu per ml, 5 ml ampoule to be delisted 1 January 2026)

HEPARINISED SALINE

Inj 10 iu per ml, 5 ml	96.91	50	✓ Pfizer
------------------------------	-------	----	----------

Oral Anticoagulants

DABIGATRAN

Cap 75 mg – No more than 2 cap per day	27.99	60	✓ Pradaxa
Cap 110 mg.....	27.99	60	✓ Pradaxa
Cap 150 mg.....	27.99	60	✓ Pradaxa

RIVAROXABAN

Tab 10 mg – No more than 1 tab per day.....	15.60	30	✓ Xarelto
Tab 15 mg – Up to 14 tab available on a PSO	14.56	28	✓ Xarelto
Tab 20 mg	14.56	28	✓ Xarelto

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
WARFARIN SODIUM				
Note: Marevan and Coumadin are not interchangeable.				
* Tab 1 mg	3.46	50	✓	Coumadin
	7.50	100	✓	Marevan
* Tab 2 mg	4.31	50	✓	Coumadin
* Tab 3 mg	12.00	100	✓	Marevan
* Tab 5 mg	5.93	50	✓	Coumadin
	13.50	100	✓	Marevan

Blood Colony-stimulating Factors

FILGRASTIM – Special Authority see [SA1259 below](#) – Retail pharmacy

Inj 300 mcg per 0.5 ml prefilled syringe.....	86.60	10	✓	Nivestim
Inj 480 mcg per 0.5 ml prefilled syringe.....	133.72	10	✓	Nivestim

►SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia ($ANC < 0.5 \times 10^9/L$); or
- 5 Treatment of drug-induced prolonged neutropenia ($ANC < 0.5 \times 10^9/L$).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM – Special Authority see [SA1912 below](#) – Retail pharmacy

Inj 6 mg per 0.6 ml syringe	69.50	1	✓	Ziextenzo
-----------------------------------	-------	---	---	-----------

►SA1912 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%).

Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

GLUCOSE [DEXTROSE]

* Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO	34.75	5	✓	Biomed
* Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO	17.50	1	✓	Biomed

POTASSIUM CHLORIDE

* Inj 75 mg per ml, 10 ml	65.00	50	✓	Juno
			✓	LumaCina
			✓	Pfizer ^{S29}

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM BICARBONATE				
Inj 8.4%, 50 ml.....	24.70	1	✓	Biomed
a) Up to 5 inj available on a PSO				
b) Not in combination				
Inj 8.4%, 100 ml.....	25.31	1	✓	Biomed
a) Up to 5 inj available on a PSO				
b) Not in combination				
SODIUM CHLORIDE				
Not funded for use as a nasal drop. Not funded for nebuliser use except when used in conjunction with an antibiotic intended for nebuliser use.				
Inj 23.4% (4 mmol/ml), 20 ml ampoule	40.15	5	✓	Biomed
For Sodium chloride oral liquid formulation refer Standard Formulae, page 284				
Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO	4.12	20	✓	Fresenius Kabi
Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO	7.50	50	✓	Fresenius Kabi
Inj 0.9%, 20 ml ampoule	5.20	20	✓	Fresenius Kabi
Inj 0.9%, 1,000 ml bag – Up to 2 bag available on a PSO	1.58	1	✓	Baxter
Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)				
Inj 0.9%, 500 ml bag – Up to 4 bag available on a PSO	1.53	1	✓	Baxter
Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)				
TOTAL PARENTERAL NUTRITION (TPN)				
Infusion	CBS	1 OP	✓	TPN
WATER				
1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or				
2) On a bulk supply order; or				
3) When used in the extemporaneous compounding of eye drops; or				
4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only.				
Inj 10 ml ampoule – Up to 5 inj available on a PSO	7.60	50	✓	Fresenius Kabi
			✓	Multichem
Inj 20 ml ampoule – Up to 5 inj available on a PSO	5.00	20	✓	Fresenius Kabi

Oral Administration

CALCIUM POLYSTYRENE SULPHONATE				
Powder	169.85	300 g OP	✓	Calcium Resonium
COMPOUND ELECTROLYTES				
Powder for oral soln – Up to 5 sach available on a PSO	9.50	50	✓	Electral
Electral to be Principal Supply on 1 December 2025				
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]				
Soln with electrolytes	6.53	1 OP	✓	Hydralyte - Lemonade
PHOSPHORUS				
Tab eff 500 mg (16 mmol)	82.50	100	✓	Phosphate Phebra
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26 (17.10)	60		Chlorvescent
* Tab long-acting 600 mg (8 mmol)	16.15	200	✓	Span-K

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM BICARBONATE				
Cap 840 mg	8.52	100	✓	Sodibic
			✓	Sodibic
SODIUM POLYSTYRENE SULPHONATE				
Powder	84.65	454 g OP	✓	Resonium-A

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Alpha-Adrenoceptor Blockers				
Alpha Adrenoceptor Blockers				
DOXAZOSIN				
* Tab 2 mg	17.35	500	✓	Doxazosin Clinect
* Tab 4 mg	20.94	500	✓	Doxazosin Clinect
PHENOXYBENZAMINE HYDROCHLORIDE				
* Cap 10 mg	65.00	30	✓	BNM ^{\$29}
PRAZOSIN				
* Tab 1 mg	5.53	100	✓	Arrotex-Prazosin S29 ^{\$29}
	9.98		✓	Minipress ^{\$29}
* Tab 2 mg	7.00	100	✓	Arrotex-Prazosin S29 ^{\$29}
	13.29		✓	Minipress ^{\$29}
* Tab 5 mg	11.70	100	✓	Arrotex-Prazosin S29 ^{\$29}
	22.00		✓	Minipress ^{\$29}
* Cap 1 mg	15.40	100	✓	Prazosin Mylan ^{\$29}
* Cap 2 mg	15.58	100	✓	Prazosin Mylan ^{\$29}
* Cap 5 mg	23.32	100	✓	Prazosin Mylan ^{\$29}
Agents Affecting the Renin-Angiotensin System				
ACE Inhibitors				
CAPTOPRIL				
* Oral liq 5 mg per ml	86.00	100 ml OP	✓	DP-Captopril
Oral liquid restricted to children under 12 years of age.				
ENALAPRIL MALEATE				
* Tab 5 mg	1.75	90	✓	Acetec
* Tab 10 mg	1.97	90	✓	Acetec
* Tab 20 mg	2.35	90	✓	Acetec
LISINOPRIL				
* Tab 5 mg	12.00	90	✓	Teva Lisinopril
* Tab 10 mg	12.00	90	✓	Teva Lisinopril
* Tab 20 mg	16.00	90	✓	Teva Lisinopril
PERINDOPRIL				
* Tab 2 mg	1.79	30	✓	Coversyl
* Tab 4 mg	2.44	30	✓	Coversyl
* Tab 8 mg	3.94	30	✓	Coversyl
QUINAPRIL				
* Tab 5 mg	10.24	90	✓	Arrow-Quinapril 5
* Tab 10 mg	12.51	90	✓	Arrow-Quinapril 10
* Tab 20 mg	14.83	90	✓	Arrow-Quinapril 20

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RAMIPRIL				
* Cap 1.25 mg.....	17.25	90	✓	<u>Tryzan</u>
* Cap 2.5 mg.....	16.50	90	✓	<u>Tryzan</u>
* Cap 5 mg.....	16.88	90	✓	<u>Tryzan</u>
* Cap 10 mg.....	17.63	90	✓	<u>Tryzan</u>

Angiotensin II Antagonists

CANDESARTAN CILEXETIL

* Tab 4 mg.....	2.68	90	✓	<u>Candestar</u>
* Tab 8 mg.....	2.67	90	✓	<u>Candestar</u>
* Tab 16 mg.....	4.22	90	✓	<u>Candestar</u>
* Tab 32 mg.....	5.24	90	✓	<u>Candestar</u>

LOSARTAN POTASSIUM

* Tab 12.5 mg.....	2.00	84	✓	<u>Losartan Actavis</u>
* Tab 25 mg.....	2.29	84	✓	<u>Losartan Actavis</u>
* Tab 50 mg.....	2.86	84	✓	<u>Losartan Actavis</u>
* Tab 100 mg.....	4.57	84	✓	<u>Losartan Actavis</u>

Angiotensin II Antagonists with Diuretics

CANDESARTAN CILEXETIL WITH HYDROCHLOROTHIAZIDE

* Tab 16 mg with hydrochlorothiazide 12.5 mg.....	4.10	30	✓	<u>APO-Candesartan HCTZ 16/12.5</u>
* Tab 32 mg with hydrochlorothiazide 12.5 mg.....	5.25	30	✓	<u>APO-Candesartan HCTZ 32/12.5</u>

LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE

* Tab 50 mg with hydrochlorothiazide 12.5 mg.....	4.00	30	✓	<u>Arrow-Losartan & Hydrochlorothiazide</u>
---	------	----	---	---

Angiotensin II Antagonists with Nephilysin Inhibitors

SACUBITRIL WITH VALSARTAN – Special Authority see [SA2302 below](#) – Retail pharmacy

Tab 24.3 mg with valsartan 25.7 mg.....	190.00	56	✓	<u>Entresto 24/26</u>
Tab 48.6 mg with valsartan 51.4 mg.....	190.00	56	✓	<u>Entresto 49/51</u>
Tab 97.2 mg with valsartan 102.8 mg.....	190.00	56	✓	<u>Entresto 97/103</u>

►SA2302 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has heart failure; and
- 2 Any of the following:
 - 2.1 Patient is in NYHA/WHO functional class II; or
 - 2.2 Patient is in NYHA/WHO functional class III; or
 - 2.3 Patient is in NYHA/WHO functional class IV; and
- 3 Either:
 - 3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; or
 - 3.2 An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment; and
- 4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, [page 124](#)

AMIODARONE HYDROCHLORIDE

▲ Tab 100 mg	4.95	30	✓ Aratac
▲ Tab 200 mg	5.86	30	✓ Aratac
Inj 50 mg per ml, 3 ml ampoule – Up to 10 inj available on a PSO	17.96	10	✓ Max Health

ATROPINE SULPHATE

* Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	16.10	10	✓ Hikma ^{\$29} ✓ Martindale
--	-------	----	---

DIGOXIN

* Tab 62.5 mcg – Up to 30 tab available on a PSO	8.58	240	✓ Lanoxin PG
* Tab 250 mcg – Up to 30 tab available on a PSO	18.75	240	✓ Lanoxin
* Oral liq 50 mcg per ml	16.60	60 ml	✓ Lanoxin ✓ Lanoxin S29 ^{\$29}

DISOPYRAMIDE PHOSPHATE

▲ Cap 100 mg	23.87	100	✓ Rythmodan
	55.90	84	✓ Rythmodan - Cheplafarm ^{\$29} ✓ Rythmodan Neon ^{\$29}

(Rythmodan Cap 100 mg to be delisted 1 November 2025)

FLECAINIDE ACETATE

▲ Tab 50 mg	19.95	60	✓ Flecaïnide BNM
▲ Cap long-acting 100 mg	35.78	90	✓ Flecaïnide Controlled Release Teva
▲ Cap long-acting 200 mg	54.28	90	✓ Flecaïnide Controlled Release Teva
Inj 10 mg per ml, 15 ml ampoule	102.79 108.16	5	✓ Almarytm ^{\$29} ✓ Tambocor ✓ Tambocor German ^{\$29}

MEXILETINE HYDROCHLORIDE

▲ Cap 150 mg	162.00	100	✓ Teva ^{\$29}
▲ Cap 250 mg	202.00	100	✓ Teva ^{\$29}

PROPAFENONE HYDROCHLORIDE

▲ Tab 150 mg	40.90	50	✓ Rytmonorm
--------------------	-------	----	-------------

Antihypotensives

MIDODRINE – Special Authority see [SA1474 on the next page](#) – Retail pharmacy

Tab 2.5 mg	36.68	100	✓ Midodrine Medsurge
Tab 5 mg	58.88	100	✓ Midodrine Medsurge

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1474 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta-Adrenoceptor Blockers

Beta Adrenoceptor Blockers

ATENOLOL

* Tab 50 mg	11.00	500	✓ Viatis
* Tab 100 mg	18.50	500	✓ Atenolol Viatis
* Oral liq 25 mg per 5 ml	49.85	300 ml OP	✓ Atenolol AFT

Restricted to children under 12 years of age.

BISOPROLOL FUMARATE

* Tab 2.5 mg	1.36	90	✓ Ipca-Bisoprolol
* Tab 5 mg	1.91	90	✓ Ipca-Bisoprolol
* Tab 10 mg	2.71	90	✓ Ipca-Bisoprolol

CARVEDILOL

* Tab 6.25 mg	2.24	60	✓ Carvedilol Sandoz
* Tab 12.5 mg	2.30	60	✓ Carvedilol Sandoz
* Tab 25 mg	2.95	60	✓ Carvedilol Sandoz

LABETALOL

* Tab 100 mg	14.50	100	✓ Trandate
	49.54		✓ Biocon §29
* Tab 200 mg	27.00	100	✓ Trandate
	42.07		✓ Presolol §29
* Inj 5 mg per ml, 20 ml ampoule	59.06	5	
	(88.60)		Trandate

METOPROLOL SUCCINATE

* Tab long-acting 23.75 mg.....	4.20	90	✓ Myloc CR
* Tab long-acting 47.5 mg.....	3.65	90	✓ Myloc CR
* Tab long-acting 95 mg.....	5.24	90	✓ Myloc CR
* Tab long-acting 190 mg.....	9.76	90	✓ Myloc CR

METOPROLOL TARTRATE

* Tab 50 mg	5.66	100	✓ IPCA-Metoprolol
* Tab 100 mg	7.55	60	✓ IPCA-Metoprolol
* Tab long-acting 200 mg.....	23.40	28	✓ Slow-Lopresor
* Inj 1 mg per ml, 5 ml vial.....	26.50	5	✓ Metoprolol IV Mylan
			✓ Metoprolol IV Viatis

NADOLOL

* Tab 40 mg	19.19	100	✓ Nadolol BNM
* Tab 80 mg	30.39	100	✓ Nadolol BNM

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PROPRANOLOL				
* Tab 10 mg	7.04	100	✓	Drofate
* Tab 40 mg	8.75	100	✓	IPCA-Propranolol
* Cap long-acting 160 mg	18.17	100	✓	Cardinol LA
* Oral liq 4 mg per ml – Special Authority see SA1327 below – Retail pharmacy.....	CBS	500 ml	✓	Hikma- Propranolol S29
			✓	Roxane- Propranolol S29

► **SA1327** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.

SOTALOL

* Tab 80 mg	22.50	300	✓	Sotalol Viatrix S29
	40.00	500	✓	Mylan
* Tab 160 mg	20.00	100	✓	Mylan

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE

* Tab 2.5 mg	1.45	90	✓	Vasorex
* Tab 5 mg	1.21	90	✓	Vasorex
* Tab 10 mg	1.31	90	✓	Vasorex

FELODIPINE

* Tab long-acting 2.5 mg.....	2.18	30	✓	Plendil ER
* Tab long-acting 5 mg.....	6.57	90	✓	Felo 5 ER
* Tab long-acting 10 mg.....	6.95	90	✓	Felo 10 ER

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
NIFEDIPINE				
* Tab long-acting 10 mg – Subsidy by endorsement	19.42	56	✓	Tensipine MR10 ^{\$29}
Subsidised for patients who were taking nifedipine tab long-acting 10 mg prior to 1 July 2023 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of nifedipine tab long-acting 10 mg.				
* Tab long-acting 20 mg.....	17.72	100	✓	Nyefax Retard
* Tab long-acting 30 mg.....	4.78	14	✓	Mylan Italy (24 hr release) ^{\$29}
	34.10	100	✓	Mylan (24 hr release) ^{\$29}
* Tab long-acting 60 mg.....	52.81	100	✓	Mylan (24 hr release) ^{\$29}

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE				
* Cap long-acting 120 mg.....	65.35	500	✓	Diltiazem CD Clinect
Diltiazem CD Clinect to be Principal Supply on 1 December 2025				
* Cap long-acting 180 mg.....	7.00	30	✓	Cardizem CD
* Cap long-acting 240 mg.....	9.30	30	✓	Cardizem CD
PERHEXILINE MALEATE				
* Tab 100 mg.....	62.90	100	✓	Pexsig
VERAPAMIL HYDROCHLORIDE				
* Tab 40 mg.....	7.01	100	✓	Isoptin
* Tab 80 mg.....	11.74	100	✓	Isoptin
* Tab long-acting 120 mg.....	36.02	100	✓	Isoptin Retard ^{\$29}
			✓	Isoptin SR
* Tab long-acting 240 mg.....	15.12	30	✓	Isoptin SR
* Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO.....	25.00	5	✓	Isoptin

Centrally-Acting Agents

CLONIDINE				
* Patch 2.5 mg, 100 mcg per day – Only on a prescription.....	11.70	4	✓	Mylan
* Patch 5 mg, 200 mcg per day – Only on a prescription.....	12.80	4	✓	Mylan
* Patch 7.5 mg, 300 mcg per day – Only on a prescription.....	17.90	4	✓	Mylan
CLONIDINE HYDROCHLORIDE				
* Tab 25 mcg.....	29.74	112	✓	Clonidine Teva
* Tab 150 mcg.....	40.41	100	✓	Catapres
* Inj 150 mcg per ml, 1 ml ampoule	14.10	5	✓	Catapres
METHYLDOPA				
* Tab 250 mg.....	15.10	100	✓	Methyldopa Viatrix

Diuretics

Loop Diuretics

BUMETANIDE				
* Tab 1 mg.....	16.36	100	✓	Burinex
* Inj 500 mcg per ml, 4 ml vial.....	7.95	5	✓	Burinex

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FUROSEMIDE [FRUSEMIDE]				
Tab 40 mg – Up to 30 tab available on a PSO	12.80	1,000	✓	IPCA-Frusemide
* Tab 500 mg	25.00	50	✓	Urex Forte
* Oral liq 10 mg per ml	11.20	30 ml OP	✓	Lasix
* Inj 10 mg per ml, 25 ml ampoule	60.65	6	✓	Lasix
* Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	2.40	5	✓	Furosemide-Baxter

Potassium Sparing Diuretics

AMILORIDE HYDROCHLORIDE

Tab 5 mg	81.07	100	✓	Padagis ^{\$29}
Oral liq 1 mg per ml	171.41	28	✓	Wockhardt ^{\$29}
Oral liq 1 mg per ml	35.40	25 ml OP	✓	Biomed
EPLERENONE – Special Authority see SA1728 below – Retail pharmacy				
Tab 25 mg	15.84	30	✓	Inspra
Tab 50 mg	25.00	30	✓	Inspra

►SA1728 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Both:
- 1 Patient has heart failure with ejection fraction less than 40%; and
 - 2 Either:
 - 2.1 Patient is intolerant to optimal dosing of spironolactone; or
 - 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

SPIRONOLACTONE

* Tab 25 mg	4.20	100	✓	Spiractin
* Tab 100 mg	11.40	100	✓	Spiractin
Oral liq 5 mg per ml	35.70	25 ml OP	✓	Biomed

Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE

* Tab 5 mg with furosemide 40 mg	8.63	28	✓	Frumil
--	------	----	---	---------------

AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE

* Tab 5 mg with hydrochlorothiazide 50 mg	5.00	50	✓	Moduretic
---	------	----	---	------------------

Thiazide and Related Diuretics

BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]

* Tab 2.5 mg – Up to 150 tab available on a PSO	51.50	500	✓	Arrow- Bendrofluazide
---	-------	-----	---	--

May be supplied on a PSO for reasons other than emergency.

* Tab 5 mg	61.00	500	✓	Arrow- Bendrofluazide
------------------	-------	-----	---	--

CHLOROTHIAZIDE

Oral liq 50 mg per ml	30.67	25 ml OP	✓	Biomed
-----------------------------	-------	----------	---	---------------

CHLORTALIDONE [CHLORTHALIDONE]

* Tab 25 mg	6.95	50	✓	Hygroton
-------------------	------	----	---	-----------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INDAPAMIDE				
* Tab 2.5 mg	16.00	90	✓	Dapa-Tabs
METOLAZONE				
Tab 5 mg	CBS	50	✓	Zaroxolyn S29

Vasopressin receptor antagonists

TOLVAPTAN – Special Authority see [SA2166 below](#) – Retail pharmacy

Tab 15 mg	873.50	28 OP	✓	Jinarc
Tab 30 mg	873.50	28 OP	✓	Jinarc
Tab 45 mg + 15 mg	1,747.00	56 OP	✓	Jinarc
Tab 60 mg + 30 mg	1,747.00	56 OP	✓	Jinarc
Tab 90 mg + 30 mg	1,747.00	56 OP	✓	Jinarc

►SA2166 Special Authority for Subsidy

Initial application — (autosomal dominant polycystic kidney disease) only from a renal physician or any relevant practitioner on the recommendation of a renal physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease; and
- 2 Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 mL/min/1.73 m² at treatment initiation; and
- 3 Either:
 - 3.1 Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 5 mL/min/1.73 m² within one-year; or
 - 3.2 Patient's disease is rapidly progressing, with an average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m² per year over a five-year period.

Renewal — (autosomal dominant polycystic kidney disease) only from a renal physician or any relevant practitioner on the recommendation of a renal physician. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m²; and
- 2 Patient has not undergone a kidney transplant.

Lipid-Modifying Agents

Fibrates

BEZAFIBRATE				
* Tab 200 mg	22.65	90	✓	Bezalip
* Tab long-acting 400 mg	21.54	30	✓	Bezalip Retard

Other Lipid-Modifying Agents

ACIPIMOX				
* Cap 250 mg	38.19	30	✓	Olbetam

Resins

COLESTYRAMINE				
Powder for oral suspension 4 g sachet	61.50	50	✓	Colestyramine - Mylan S29
			✓	Quantalan sugar free S29

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HMG CoA Reductase Inhibitors (Statins)				
ATORVASTATIN				
* Tab 10 mg	0.31	30	✓	<u>Lorstat</u>
	5.16	500	✓	<u>Lorstat</u>
* Tab 20 mg	8.12	500	✓	<u>Lorstat</u>
* Tab 40 mg	13.79	500	✓	<u>Lorstat</u>
* Tab 80 mg	25.39	500	✓	<u>Lorstat</u>
PRAVASTATIN				
* Tab 20 mg	7.16	100	✓	<u>Clinect</u>
* Tab 40 mg	12.25	100	✓	<u>Clinect</u>
ROSUVASTATIN – Special Authority see SA2093 below – Retail pharmacy				
* Tab 5 mg	1.29	30	✓	<u>Rosuvastatin Viatris</u>
* Tab 10 mg	1.69	30	✓	<u>Rosuvastatin Viatris</u>
* Tab 20 mg	2.71	30	✓	<u>Rosuvastatin Viatris</u>
* Tab 40 mg	4.55	30	✓	<u>Rosuvastatin Viatris</u>

►SA2093 Special Authority for Subsidy

Initial application — (cardiovascular disease risk) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient is considered to be at risk of cardiovascular disease; and
 - 1.2 Patient is Māori or any Pacific ethnicity; or

2 Both:

- 2.1 Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and
- 2.2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (familial hypercholesterolemia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and
- 2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (established cardiovascular disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Patient has proven coronary artery disease (CAD); or
 - 1.2 Patient has proven peripheral artery disease (PAD); or
 - 1.3 Patient has experienced an ischaemic stroke; and
- 2 LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (recurrent major cardiovascular events) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
- 2 LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SIMVASTATIN				
* Tab 10 mg	1.68	90	✓	<u>Simvastatin Mylan</u>
			✓	<u>Simvastatin Viatris</u>
* Tab 20 mg	2.54	90	✓	<u>Simvastatin Viatris</u>
* Tab 40 mg	4.11	90	✓	<u>Simvastatin Viatris</u>
* Tab 80 mg	8.81	90	✓	<u>Simvastatin Viatris</u>

Selective Cholesterol Absorption Inhibitors

EZETIMIBE				
* Tab 10 mg	1.76	30	✓	<u>Ezetimibe Sandoz</u>
EZETIMIBE WITH SIMVASTATIN				
Tab 10 mg with simvastatin 10 mg	5.15	30	✓	<u>Zimybe</u>
Tab 10 mg with simvastatin 20 mg	6.15	30	✓	<u>Zimybe</u>
Tab 10 mg with simvastatin 40 mg	7.15	30	✓	<u>Zimybe</u>
Tab 10 mg with simvastatin 80 mg	8.15	30	✓	<u>Zimybe</u>

Nitrates

GLYCERYL TRINITRATE				
* Oral pump spray, 400 mcg per dose – Up to 250 dose available on a PSO	7.48	250 dose OP	✓	<u>Nitrolingual Pump Spray</u>
* Patch 25 mg, 5 mg per day	15.73	30	✓	<u>Nitroderm TTS</u>
* Patch 50 mg, 10 mg per day	18.62	30	✓	<u>Nitroderm TTS</u>
ISOSORBIDE MONONITRATE				
* Tab 20 mg	22.49	100	✓	<u>Ismo 20</u>
* Tab long-acting 40 mg	9.80	30	✓	<u>Ismo 40 Retard</u>
* Tab long-acting 60 mg	13.50	90	✓	<u>Duride</u>

Sympathomimetics

ADRENALINE				
Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO	4.98	5	✓	<u>Aspen Adrenaline</u>
	13.27		✓	<u>DBL Adrenaline</u>
Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO	27.00	5	✓	<u>Hospira</u>
	49.00	10	✓	<u>Aspen Adrenaline</u>

Vasodilators

HYDRALAZINE HYDROCHLORIDE				
* Tab 25 mg – Special Authority see SA1321 on the next page – Retail pharmacy	CBS	1	✓	<u>Hydralazine</u>
		56	✓	<u>Onelink</u> ^{S29}
		84	✓	<u>AMDIPHARM</u> ^{S29}
		100	✓	<u>Camber</u> ^{S29}
* Inj 20 mg ampoule	25.90	5	✓	<u>Apresoline</u>

►►SA1321 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 For the treatment of refractory hypertension; or
- 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

MINOXIDIL

▲ Tab 10 mg	47.04	60	✓ Minoxidil Roma ^{\$29}
	78.40	100	✓ Loniten

NICORANDIL

▲ Tab 10 mg	27.81	60	✓ Max Health
▲ Tab 20 mg	35.12	60	✓ Max Health

PAPAVERINE HYDROCHLORIDE

* Inj 12 mg per ml, 10 ml ampoule	257.12	5	✓ Hospira
---	--------	---	-----------

PENTOXIFYLLINE [OXPENTIFYLLINE]

Tab 400 mg	44.37	50	✓ Trental 400
------------------	-------	----	---------------

Endothelin Receptor Antagonists

AMBRISENTAN – Special Authority see [SA2486 below](#) – Retail pharmacy

Tab 5 mg	200.00	30	✓ Ambrisentan Viatris
Tab 10 mg	200.00	30	✓ Ambrisentan Viatris

►►SA2486 Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

- 5.1 Ambrisentan is to be used as PAH monotherapy; and
- 5.2 Any of the following:
 - 5.2.1 Patient has experienced intolerable side effects with both sildenafil and bosentan; or
 - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Ambrisentan is to be used as PAH dual therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; or
 - 5.2.2 Patient has experienced intolerable side effects on bosentan; or
 - 5.2.3 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.4 Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive).

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Ambrisentan is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Both:
 - 5.2.2.1 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.2.2.2 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where the patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BOSENTAN – Special Authority see SA2254 below – Retail pharmacy				
Tab 62.5 mg	100.00	60	✓	Bosentan Dr Reddy's
Tab 125 mg	100.00	60	✓	Bosentan Dr Reddy's

► **SA2254** Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Bosentan is to be used as PAH monotherapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute contraindication to sildenafil; or
 - 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

continued...

- 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
- 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
- 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Bosentan is to be used as part of PAH dual therapy; and
- 6 Either:
 - 6.1 Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated risk stratification tool**; or
 - 6.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy.

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Bosentan is to be used as part of PAH triple therapy; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

5.2 Any of the following:

5.2.1 Patient is on the lung transplant list; or

5.2.2 Patient is presenting in NYHA/WHO functional class IV; or

5.2.3 Both:

5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and

5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from bosentan treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Special Authority see [SA2255 below](#) – Retail pharmacy

Tab 25 mg	0.72	4	✓ Vedafil
Tab 50 mg	1.45	4	✓ Vedafil
Tab 100 mg	11.22	12	✓ Vedafil

➔SA2255 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Initial application — (Pulmonary arterial hypertension*) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:

4.1 All of the following:

4.1.1 PAH is confirmed by right heart catheterisation; and

4.1.2 A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg; and

4.1.3 A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg; and

4.1.4 Pulmonary vascular resistance (PVR) of at least 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

continued...

- 4.1.5 Any of the following:
 - 4.1.5.1 PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures.

Initial application — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has a documented history of traumatic or non-traumatic spinal cord injury; and
- 2 Patient has erectile dysfunction secondary to spinal cord injury requiring pharmacological treatment.

Renewal — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Note: Indications marked with * are Unapproved Indications.

† The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Prostacyclin Analogues

EPOPROSTENOL – Special Authority see [SA2256](#) below – Retail pharmacy

Inj 500 mcg vial.....	36.61	1	✓ Veletri
Inj 1.5 mg vial	73.21	1	✓ Veletri

► [SA2256](#) Special Authority for Subsidy

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- guidelines) † ; or
- 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
- 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 All of the following:
 - 5.1 Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.3 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool.

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 Both:
 - 5.1 Epoprostenol is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

continued...

5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from epoprostenol treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

ILOPROST – Special Authority see [SA2257](#) below – Retail pharmacy

Nebuliser soln 10 mcg per ml, 2 ml	166.53	30	✓ Vebulis
--	--------	----	------------------

Vebulis to be Principal Supply on 1 December 2025

►SA2257 Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Iloprost is to be used as PAH monotherapy; and
 - 5.2 Either:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan); or
 - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

- continued...
- practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:
- All of the following:
- 1 Patient has pulmonary arterial hypertension (PAH); and
 - 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
 - 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
 - 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
 - 5 All of the following:
 - 5.1 Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Either:
 - 5.2.1 Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist; and
 - 5.3 Either:
 - 5.3.1 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; or
 - 5.3.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy.

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
- 1 Patient has pulmonary arterial hypertension (PAH); and
 - 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
 - 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
 - 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
- 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and

5 Both:

- 5.1 Iloprost is to be used as PAH triple therapy; and
- 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Antiacne Preparations

For systemic antibacterials, refer to INFECTIONS, Antibacterials, [page 95](#)

ADAPALENE

a) Maximum of 30 g per prescription		
b) Only on a prescription		
Gel 0.1%.....	22.89	30 g OP ✓ Differin

ISOTRETINOIN – Special Authority see [SA2449 below](#) – Retail pharmacy

Cap 5 mg.....	11.26	60 ✓ Oratane
Cap 10 mg.....	18.75	120 ✓ Oratane
Cap 20 mg.....	26.73	120 ✓ Oratane

►SA2449 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, paediatrician, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Any of the following:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential; or
 - 3.3 Patient is a child and it is considered not appropriate to exclude pregnancy or start contraceptives or undertake pregnancy-related isotretinoin counselling.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
- 2 Patient is not of child bearing potential; or
- 3 Patient is a child and it is considered not appropriate to exclude pregnancy or start contraceptives or undertake pregnancy-related isotretinoin counselling.

TRETINOIN

Crm 0.5 mg per g – Maximum of 50 g per prescription	16.82	50 g OP ✓ ReTrieve
---	-------	--------------------

Antibacterials Topical

For systemic antibacterials, refer to INFECTIONS, Antibacterials, [page 95](#)

HYDROGEN PEROXIDE

* Crm 1%.....	4.89	15 g OP ✓ Crystaderm
Crystaderm to be Principal Supply on 1 January 2026		

MUPIROCIN

Oint 2%.....	6.60 (13.00)	15 g OP Bactroban
a) Only on a prescription		
b) Not in combination		

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM FUSIDATE [FUSIDIC ACID]				
Crm 2%.....	1.69	5 g OP	✓	Foban
a) Maximum of 5 g per prescription				
b) Only on a prescription				
c) Not in combination				
Oint 2%.....	1.69	5 g OP	✓	Foban
a) Maximum of 5 g per prescription				
b) Only on a prescription				
c) Not in combination				
SULFADIAZINE SILVER				
Crm 1%.....	10.80	50 g OP	✓	Flamazine
a) Up to 250 g available on a PSO				
b) Not in combination				

Antifungals Topical

For systemic antifungals, refer to INFECTIONS, Antifungals, [page 102](#)

AMOROLFINE				
a) Only on a prescription				
b) Not in combination				
Nail soln 5%.....	21.87	5 ml OP	✓	MycoNail
CLOTRIMAZOLE				
* Crm 1%.....	1.10	20 g OP	✓	Clomazol
a) Only on a prescription				
b) Not in combination				
* Soln 1%.....	4.36 (7.55)	20 ml OP		Canesten
a) Only on a prescription				
b) Not in combination				
ECONAZOLE NITRATE				
Crm 1%.....	8.04	20 g OP	✓	Pevaryl
a) Only on a prescription				
b) Not in combination				
Foaming soln 1%, 10 ml sachets.....	9.89 (18.64)	3		Pevaryl
a) Only on a prescription				
b) Not in combination				
MICONAZOLE NITRATE				
* Crm 2%.....	0.90	15 g OP	✓	Multichem
a) Only on a prescription				
b) Not in combination				
* Lotn 2%.....	4.36 (10.03)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				
* Tinct 2%.....	4.36 (12.10)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Antipruritic Preparations

CALAMINE

- a) Only on a prescription
- b) Not in combination

Crm, aqueous, BP	3.45	100 g	✓ <u>healthE Calamine Aqueous</u>
------------------------	------	-------	-----------------------------------

CROTAMITON

- a) Only on a prescription
- b) Not in combination

Crm 10%.....	3.49	20 g OP	✓ <u>Itch-Soothe</u>
--------------	------	---------	----------------------

MENTHOL – Only in combination

- 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain
- 2) With or without other dermatological galenicals.

Crystals.....	6.92	25 g	✓ <u>MidWest</u>
	29.60	100 g	✓ <u>MidWest</u>

Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, [page 84](#)

Corticosteroids - Plain

BETAMETHASONE DIPROPIONATE

Crm 0.05%.....	2.96	15 g OP	✓ <u>Diprosone</u>
	36.00	50 g OP	✓ <u>Diprosone</u>
Oint 0.05%.....	2.96	15 g OP	✓ <u>Diprosone</u>
	36.00	50 g OP	✓ <u>Diprosone</u>
Oint 0.05% in propylene glycol base	4.33	30 g OP	✓ <u>Diprosone OV</u>

BETAMETHASONE VALERATE

* Crm 0.1%.....	5.85	50 g OP	✓ <u>Beta Cream</u>
* Oint 0.1%.....	7.90	50 g OP	✓ <u>Beta Ointment</u>
* Lotn 0.1%	30.00	50 ml OP	✓ <u>Betnovate</u>

CLOBETASOL PROPIONATE

* Crm 0.05%.....	3.75	30 g OP	✓ <u>Dermol</u>
* Oint 0.05%.....	3.68	30 g OP	✓ <u>Dermol</u>

CLOBETASONE BUTYRATE

Crm 0.05%.....	5.38	30 g OP	
	(10.00)		Eumovate

HYDROCORTISONE

* Crm 1% – Only on a prescription.....	1.78	30 g OP	✓ <u>Ethics</u>
	20.40	500 g	✓ <u>Noumed</u>
* Powder – Only in combination.....	49.95	25 g	✓ <u>ABM</u>
Up to 5% in a dermatological base (not proprietary Topical Corticosteroid – Plain) with or without other dermatological galenicals			

HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN

Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – Only on a prescription.....	12.83	250 ml	✓ <u>DP Lotn HC</u>
---	-------	--------	---------------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HYDROCORTISONE BUTYRATE				
Lipocream 0.1%.....	4.85	100 g OP	✓	Locoid Lipocream
Oint 0.1%.....	10.28	100 g OP	✓	Locoid
Milky emul 0.1%	12.33	100 ml OP	✓	Locoid Crelo
METHYLPREDNISOLONE ACEPONATE				
Crm 0.1%.....	4.95	15 g OP	✓	Advantan
Oint 0.1%.....	4.95	15 g OP	✓	Advantan
MOMETASONE FUROATE				
Crm 0.1%.....	2.25	15 g OP	✓	Elocon Alcohol Free
	3.50	50 g OP	✓	Elocon Alcohol Free
Oint 0.1%.....	2.25	15 g OP	✓	Elocon
	3.50	50 g OP	✓	Elocon
Lotn 0.1%	4.99	30 ml OP	✓	Elocon
TRIAMCINOLONE ACETONIDE				
Crm 0.02%.....	6.49	100 g OP	✓	Aristocort
Oint 0.02%.....	6.54	100 g OP	✓	Aristocort

Corticosteroids - Combination

BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]				
Crm 0.1% with sodium fusidate (fusidic acid) 2%.....	3.49	15 g OP		Fucicort
	(10.45)			
a) Maximum of 15 g per prescription				
b) Only on a prescription				
HYDROCORTISONE WITH MICONAZOLE – Only on a prescription				
* Crm 1% with miconazole nitrate 2%.....	2.85	15 g OP	✓	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription				
Oint 1% with natamycin 1% and neomycin sulphate 0.5%.....	4.34	15 g OP	✓	Pimafucort
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN				
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g – Only on a prescription	3.49	15 g OP		Viaderm KC
	(9.28)			

Barrier Creams and Emollients

Barrier Creams

DIMETHICONE				
* Crm 5% pump bottle.....	4.30	460 g OP	✓	healthE Dimethicone 5%
* Crm 10% pump bottle.....	4.52	460 g OP	✓	healthE Dimethicone 10%
ZINC AND CASTOR OIL				
* Oint.....	4.25	500 g	✓	Evara

Emollients

AQUEOUS CREAM				
* Crm.....	1.65	500 g	✓	Evara
CETOMACROGOL				
* Crm BP.....	2.29	500 g	✓	Cetomacrogol-AFT

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
CETOMACROGOL WITH GLYCEROL			
Crm 90% with glycerol 10%.....	1.92	460 g OP	✓ Evava
	3.25	920 g OP	✓ Evava
Evava to be Principal Supply on 1 December 2025			
EMULSIFYING OINTMENT			
* Oint BP.....	3.13	500 g	✓ Evava Emulsifying Ointment
OIL IN WATER EMULSION			
* Crm.....	2.10	500 g	✓ Fatty Emulsion Cream (Evava)
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50%.....	4.94	500 g OP	✓ White Soft Liquid Paraffin AFT
UREA			
* Crm 10%.....	1.37	100 g OP	✓ healthE Urea Cream
WOOL FAT WITH MINERAL OIL – Only on a prescription			
* Lotn hydrous 3% with mineral oil.....	5.60	1,000 ml	
	(14.96)		DP Lotion
	(20.53)		Alpha-Keri Lotion
	1.40	250 ml OP	
	(5.87)		DP Lotion
	5.60	1,000 ml	
	(23.91)		BK Lotion
	1.40	250 ml OP	
	(7.73)		BK Lotion

Other Dermatological Bases

PARAFFIN			
White soft – Only in combination.....	4.74	450 g	✓ EVARA White Soft Paraffin
	19.00	2,500 g	✓ EVARA White Soft Paraffin

Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.

Minor Skin Infections

POVIDONE IODINE			
Oint 10%.....	7.40	65 g OP	✓ Betadine
a) Maximum of 130 g per prescription			
b) Only on a prescription			
Antiseptic Solution 10%.....	4.99	100 ml	✓ Riodine
Antiseptic soln 10%.....	3.83	15 ml	✓ Riodine
	6.99	500 ml	✓ Riodine
Skin preparation, povidone iodine 10% with 30% alcohol.....	1.63	100 ml	
	(3.48)		Betadine Skin Prep

Parasitocidal Preparations

DIMETHICONE

* Lotn 4%	4.25	200 ml OP	✓ healthE Dimethicone 4% Lotion
-----------------	------	-----------	---------------------------------------

IVERMECTIN – Special Authority see [SA2511 below](#) – Retail pharmacy

Tab 3 mg – Up to 100 tab available on a PSO	17.20	4	✓ Stromectol
---	-------	---	--------------

- 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.
- 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.
- 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or prisons.

►SA2511 Special Authority for Subsidy

Initial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 The person has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
- 2 Both:
 - 2.1 The person has a confirmed diagnosis of scabies or is a close contact of a scabies case; and
 - 2.2 Either:
 - 2.2.1 The person is unable to complete topical therapy; or
 - 2.2.2 Previous treatment with topical therapy has been tried and not cleared the infestation.

Initial application — (Other parasitic infections) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 filariasis; or
- 2 cutaneous larva migrans (creeping eruption); or
- 3 strongyloidiasis; or
- 4 The individual has a travel or residence history that requires presumptive parasite treatment.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 The person has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
- 2 Both:
 - 2.1 The person has a confirmed diagnosis of scabies or is a close contact of a scabies case; and
 - 2.2 Either:
 - 2.2.1 The person is unable to complete topical therapy; or
 - 2.2.2 Previous treatment with topical therapy has been tried and not cleared the infestation.

Renewal — (Other parasitic infections) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 filariasis; or
- 2 cutaneous larva migrans (creeping eruption); or
- 3 strongyloidiasis.

PERMETHRIN

Lotn 5%	4.28	30 ml OP	✓ A-Scabies
---------------	------	----------	-------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Psoriasis and Eczema Preparations

ACITRETIN – Special Authority see [SA2024 below](#) – Retail pharmacy

Cap 10 mg.....	26.20	60	✓ Novatretin
Cap 25 mg.....	57.37	60	✓ Novatretin

►SA2024 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
- 2 Patient is not of child bearing potential.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Foam spray 500 mcg with calcipotriol 50 mcg per g	59.95	60 g OP	✓ Enstilar
Gel 500 mcg with calcipotriol 50 mcg per g.....	40.92	60 g OP	✓ Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g.....	14.31	30 g OP	✓ Daivobet

CALCIPOTRIOL

Oint 50 mcg per g.....	40.00	120 g OP	✓ Daivonex
------------------------	-------	----------	-------------------

COAL TAR

Soln BP – Only in combination	36.25	200 ml	✓ Midwest
1) Up to 10% only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain 2) With or without other dermatological galenicals.			

COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR

Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5%	6.59 (8.00)	75 g OP	Egopsoryl TA
	3.43 (4.35)	30 g OP	

COAL TAR WITH SALICYLIC ACID AND SULPHUR

Soln 12% with salicylic acid 2% and sulphur 4% oint.....	7.95	40 g OP	✓ Coco-Scalp
--	------	---------	---------------------

PIMECROLIMUS – Special Authority see [SA1970 on the next page](#) – Retail pharmacy

a) Maximum of 15 g per prescription b) Note: a maximum of 15 g per prescription and no more than one prescription per 12 weeks.			
Cream 1%.....	33.00	15 g OP	✓ Elidel

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

►SA1970 Special Authority for Subsidy

Initial application only from a dermatologist, paediatrician, ophthalmologist or any relevant practitioner on the recommendation of a dermatologist, paediatrician or ophthalmologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has atopic dermatitis on the eyelid; and
- 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure.

PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCEIN – Only on a prescription

* Soln 2.3% with trolamine laurilsulfate and fluorescein sodium.....5.41 500 ml ✓ **Pinetarsol**

SALICYLIC ACID

Powder – Only in combination.....18.88 250 g ✓ **Midwest**

- 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible
- 2) With or without other dermatological galenicals.

SULPHUR

Precipitated – Only in combination.....6.35 100 g ✓ **Midwest**

- 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain
- 2) With or without other dermatological galenicals.

TACROLIMUS

Oint 0.1% – Special Authority see [SA2074 below](#) – Retail

pharmacy.....33.00 30 g OP ✓ **Zematop**

a) Maximum of 30 g per prescription

b) Note: a maximum of 30 g per prescription and no more than one prescription per 12 weeks.

►SA2074 Special Authority for Subsidy

Initial application only from a dermatologist, paediatrician or any relevant practitioner on the recommendation of a dermatologist, paediatrician, . Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has atopic dermatitis on the face; and
- 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids.

Scalp Preparations

BETAMETHASONE VALERATE

* Scalp app 0.1%12.95 100 ml OP ✓ **Beta Scalp**

CLOBETASOL PROPIONATE

* Scalp app 0.05%6.90 30 ml OP ✓ **Dermol**

HYDROCORTISONE BUTYRATE

Scalp lotn 0.1%.....6.57 100 ml OP ✓ **Locoid**

KETOCONAZOLE

Shampoo 2%.....4.09 100 ml OP ✓ **Sebizole**

a) Maximum of 100 ml per prescription

b) Only on a prescription

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Sunscreens

SUNSCREENS, PROPRIETARY – Subsidy by endorsement

Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.

Lotn,.....	6.50	200 g OP	✓ Marine Blue Lotion SPF 50+
------------	------	----------	---------------------------------

Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, [page 73](#)

PODOPHYLLOTOXIN

Soln 0.5%	33.60	3.5 ml OP	✓ Condylone ✓ Condylone S29 \$29
-----------------	-------	-----------	--

- a) Maximum of 3.5 ml per prescription
- b) Only on a prescription

Other Skin Preparations

Antineoplastics

FLUOROURACIL SODIUM

Crm 5%.....	5.56	20 g OP	✓ <u>Efudix</u>
-------------	------	---------	-----------------

IMIQUIMOD

Crm 5%, 250 mg sachet.....	21.72	24	✓ Perrigo
----------------------------	-------	----	-----------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Contraceptives - Non-hormonal

Condoms

CONDOMS

* 49 mm – Up to 144 dev available on a PSO	14.25	144	✓ Moments
* 53 mm.....	1.15	10	✓ Moments
	14.25	144	✓ Moments
a) Maximum of 60 dev per prescription			
b) Up to 60 dev available on a PSO			
* 53 mm, 0.05 mm thickness.....	1.15	10	✓ Moments
	14.25	144	✓ Moments
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 53 mm, chocolate, brown	1.15	10	✓ Moments
	14.25	144	✓ Moments
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 53 mm, strawberry, red.....	1.15	10	✓ Moments
	14.25	144	✓ Moments
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm.....	1.15	10	✓ Moments
	14.50	144	✓ Moments
a) Maximum of 60 dev per prescription			
b) Up to 60 dev available on a PSO			
* 56 mm, 0.05 mm thickness.....	2.00	12	✓ Gold Knight
	24.10	144	✓ Gold Knight
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, 0.05mm thickness (bulk pack)	20.17	144	✓ Gold Knight
a) Maximum of 60 dev per prescription			
b) Up to 60 dev available on a PSO			
* 56 mm, 0.08 mm thickness.....	1.15	10	✓ Moments
	14.25	144	✓ Moments
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, 0.08 mm thickness, red	1.15	10	✓ Moments
	14.25	144	✓ Moments
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, chocolate	1.79	12	✓ Gold Knight
	21.45	144	✓ Gold Knight
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, strawberry.....	1.79	12	✓ Gold Knight
	21.45	144	✓ Gold Knight
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 60 mm.....	1.82	12	✓ Gold Knight XL
	21.89	144	✓ Gold Knight XL
a) Maximum of 60 dev per prescription			

▲ Three months to 60 days available on a PSO if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months to six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
a) Maximum of 60 dev per prescription				
b) Up to 60 dev available on a PSO				

Contraceptive Devices

INTRA-UTERINE DEVICE

a) Up to 40 dev available on a PSO				
b) Only on a PSO				
* IUD 29.1 mm length x 23.2 mm width.....	29.80	1	✓	Choice 380 7med Nsha Silver/ copper Short
* IUD 33.6 mm length x 29.9 mm width.....	26.80	1	✓	TCu 380 Plus Normal
* IUD 35.5 mm length x 19.6 mm width.....	33.00	1	✓	Cu 375 Standard

Contraceptives - Hormonal

Combined Oral Contraceptives

►SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

* Tab 20 mcg with desogestrel 150 mcg and 7 inert tab – Up to				
84 tab available on a PSO.....	10.00	84	✓	Mercilon 28

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – Up to 84 tab available on a PSO	1.50	84	✓	Lo-Oralcon 20 ED
* Tab 30 mcg with levonorgestrel 150 mcg.....	6.62	63		
	(16.50)			Microgynon 30
a) Higher subsidy of \$15.00 per 63 tab with Special Authority see SA0500 on the previous page				
b) Up to 63 tab available on a PSO				
* Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – Up to 84 tab available on a PSO	1.50	84	✓	Oralcon 30 ED
ETHINYLOESTRADIOL WITH NORETHISTERONE				
Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO.....	12.25	84	✓	Alyacen
			✓	Brevinor 1/28
Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO.....	21.99	84	✓	Norimin
<i>(Alyacen Tab 35 mcg with norethisterone 1 mg and 7 inert tab to be delisted 1 January 2026)</i>				

Progestogen-only Contraceptives

►SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

DESOGESTREL				
* Tab 75 mcg – Up to 84 tab available on a PSO	24.50	84	✓	Cerazette
LEVONORGESTREL				
* Tab 30 mcg – Up to 112 tab available on a PSO	22.00	112	✓	Microlut
* Intra-uterine device 52 mg – Up to 25 dev available on a PSO.....	269.50	1	✓	Mirena
* Intra-uterine device 13.5 mg – Up to 10 dev available on a PSO	215.60	1	✓	Jaydess
* Subdermal implant (2 x 75 mg rods) – Up to 40 impl available on a PSO	106.92	2 OP	✓	Jadelle

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MEDROXYPROGESTERONE ACETATE				
Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO	10.56	1	✓	Depo-Provera
NORETHISTERONE				
Tab 350 mcg – Up to 84 tab available on a PSO	12.25	84	✓	Norethindrone - CDC
			✓	Noriday
			✓	Noriday 28

(Norethindrone - CDC Tab 350 mcg to be delisted 1 January 2026)

Emergency Contraceptives

LEVONORGESTREL				
* Tab 1.5 mg	1.75	1	✓	Levonorgestrel BNM
a) Maximum of 2 tab per prescription				
b) Up to 5 tab available on a PSO				
c) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.				

Antiandrogen Oral Contraceptives

Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:

- A maximum \$5.00 prescription charge (patient co-payment) may apply.
- prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to any non contraceptive prescription charges that apply, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

CYPROTERONE ACETATE WITH ETHINYLLOESTRADIOL

* Tab 2 mg with ethinylloestradiol 35 mcg and 7 inert tabs – Up to 168 tab available on a PSO	5.08	168	✓	Ginet
---	------	-----	---	--------------

Gynaecological Anti-infectives

ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID

Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator	8.43 (24.87)	100 g OP		Aci-Jel
--	-----------------	----------	--	----------------

CLOTRIMAZOLE

* Vaginal crm 1% with applicators.....	3.50	35 g OP	✓	Clomazol
* Vaginal crm 2% with applicators.....	3.85	20 g OP	✓	Clomazol

MICONAZOLE NITRATE

* Vaginal crm 2% with applicator	6.89	40 g OP	✓	Micreme
--	------	---------	---	----------------

NYSTATIN

Vaginal crm 100,000 u per 5 g with applicator(s)	5.70	75 g OP	✓	Nilstat
--	------	---------	---	----------------

Myometrial and Vaginal Hormone Preparations

ERGOMETRINE MALEATE

Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	160.00	5	✓	DBL Ergometrine
---	--------	---	---	------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OESTRIOL				
* Crm 1 mg per g with applicator.....	6.95	15 g OP	✓	Ovestin
* Pessaries 500 mcg.....	7.55	15	✓	Ovestin
OXYTOCIN – Up to 5 inj available on a PSO				
Inj 5 iu per ml, 1 ml ampoule	5.98	5	✓	Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule	7.18	5	✓	Oxytocin BNM
OXYTOCIN WITH ERGOMETRINE MALEATE – Up to 5 inj available on a PSO				
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule	41.47	5	✓	Syntometrine

Pregnancy Tests - hCG Urine

BETA-HCG LOW SENSITIVITY URINE TEST KIT – Up to 15 test available on a PSO

Note: For use in abortion services only.

Midstream..... 16.28 1 test OP ✓ **CheckTop**

PREGNANCY TESTS - HCG URINE

a) Up to 200 test available on a PSO

b) Only on a PSO

Cassette 16.00 40 test OP ✓ **David One Step
Cassette
Pregnancy Test**

Urinary Agents

For urinary tract Infections refer to INFECTIONS, Antibacterials, [page 115](#)

5-Alpha Reductase Inhibitors

FINASTERIDE – Special Authority see [SA0928 below](#) – Retail pharmacy

* Tab 5 mg 4.79 100 ✓ **Ricit**

➔ [SA0928](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Alpha-1A Adrenoreceptor Blockers

TAMSULOSIN HYDROCHLORIDE – Special Authority see [SA1032 below](#) – Retail pharmacy

* Cap 400 mcg 28.56 100 ✓ **Tamsulosin-Rex**

➔ [SA1032](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Other Urinary Agents

OXYBUTYNIN

* Tab 5 mg	5.42	100	✓	Alchemy Oxybutynin
------------------	------	-----	---	-----------------------

POTASSIUM CITRATE

Oral liq 3 mmol per ml – Special Authority see [SA1083 below](#) –

Retail pharmacy.....	37.49	200 ml OP	✓	Biomed
----------------------	-------	-----------	---	--------

► [SA1083](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

SODIUM CITRO-TARTRATE

* Grans eff 4 g sachets	3.50	28	✓	<u>Ural</u>
-------------------------------	------	----	---	-------------

SOLIFENACIN SUCCINATE

Tab 5 mg	1.95	30	✓	<u>Solifenacin succinate Max Health</u>
----------------	------	----	---	---

	3.15		✓	<u>Solifenacin Viatris</u>
Tab 10 mg	3.53	30	✓	<u>Solifenacin succinate Max Health</u>

(Solifenacin Viatris Tab 5 mg to be delisted 1 November 2025)

Detection of Substances in Urine

ORTHO-TOLIDINE

* Compound diagnostic sticks.....	7.50 (8.25)	50 test OP		Hemastix
-----------------------------------	----------------	------------	--	----------

TETRABROMOPHENOL

* Blue diagnostic strips.....	13.92	100 test OP	✓	Albustix
-------------------------------	-------	-------------	---	----------

Obstetric Preparations

Antiprogesterones

MIFEPRISTONE

Tab 200 mg – Up to 15 tab available on a PSO	83.90	1	✓	Mifegyne
	180.00	3	✓	Mifegyne

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

Calcium Homeostasis

CALCITONIN

* Inj 100 iu per ml, 1 ml ampoule	121.00	5	✓ Miacalcic ✓ Miacalcic S29 S29
---	--------	---	---

CINACALCET – Special Authority see [SA2170 below](#) – Retail pharmacy

Tab 30 mg – Wastage claimable	25.24	28	✓ Cinacalcet Devatis
Tab 60 mg – Wastage claimable	50.47	28	✓ Cinacalcet Devatis

► [SA2170](#) Special Authority for Subsidy

Initial application — (parathyroid carcinoma or calciphylaxis) only from a nephrologist or endocrinologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
 - 1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
 - 1.3 The patient is symptomatic; or
- 2 All of the following:
 - 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy); and
 - 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
 - 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

Renewal — (parathyroid carcinoma or calciphylaxis) only from a nephrologist or endocrinologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

Initial application — (primary hyperparathyroidism) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has primary hyperparathyroidism; and
- 2 Either:
 - 2.1 Patient has hypercalcaemia of more than 3 mmol/L with or without symptoms; or
 - 2.2 Patient has hypercalcaemia of more than 2.85 mmol/L with symptoms; and
- 3 Surgery is not feasible or has failed; and
- 4 Patient has other comorbidities, severe bone pain, or calciphylaxis.

Initial application — (secondary or tertiary hyperparathyroidism) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has tertiary hyperparathyroidism and markedly elevated parathyroid hormone (PTH) with hypercalcaemia; or
 - 1.2 Patient has symptomatic secondary hyperparathyroidism and elevated PTH; and
- 2 Patient is on renal replacement therapy; and
- 3 Any of the following:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3.1 Residual parathyroid tissue has not been localised despite repeat unsuccessful parathyroid explorations; or
- 3.2 Parathyroid tissue is surgically inaccessible; or
- 3.3 Parathyroid surgery is not feasible.

Renewal — (secondary or tertiary hyperparathyroidism) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

- Either:
- 1 The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically acceptable parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or
 - 2 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate.

ZOLEDRONIC ACID

Inj 4 mg per 5 ml, vial	15.65	1	✓	Zoledronic acid Injection Mylan ^{S29}
			✓	Zoledronic acid Viartis

Corticosteroids and Related Agents for Systemic Use

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml	19.20 (36.96)	5		Celestone Chronodose
---	------------------	---	--	-------------------------

DEXAMETHASONE

* Tab 0.5 mg – Up to 60 tab available on a PSO	1.80	30	✓	Dexamethasone
* Tab 4 mg – Up to 30 tab available on a PSO	3.18	30	✓	Dexamethasone
Oral liq 1 mg per ml	53.86	25 ml OP	✓	Biomed

DEXAMETHASONE PHOSPHATE

Dexamethasone phosphate injection will not be funded for oral use.

* Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.88	10	✓	Dexamethasone Medsurge
	7.86		✓	Hameln
* Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	10.98	10	✓	Dexamethasone Medsurge
	13.10		✓	Hameln

(Hameln Inj 4 mg per ml, 1 ml ampoule to be delisted 1 March 2026)

(Hameln Inj 4 mg per ml, 2 ml ampoule to be delisted 1 March 2026)

FLUDROCORTISONE ACETATE

* Tab 100 mcg	8.05	100	✓	Florinef
Florinef to be Principal Supply on 1 December 2025				

HYDROCORTISONE

* Tab 5 mg	8.10	100	✓	Douglas
* Tab 20 mg	20.32	100	✓	Douglas
* Inj 100 mg vial	3.96	1	✓	Solu-Cortef
a) Not on a BSO				
b) Up to 5 inj available on a PSO				

METHYLPREDNISOLONE

* Tab 4 mg	112.00	100	✓	Medrol
* Tab 100 mg	223.10	20	✓	Medrol

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)				
Inj 40 mg vial	22.30	1	✓	Solu-Medrol-Act-O-Vial
Inj 125 mg vial	34.10	1	✓	Solu-Medrol-Act-O-Vial
Inj 500 mg vial	43.01	1	✓	Solu-Medrol-Act-O-Vial
Inj 1 g vial	52.54	1	✓	Solu-Medrol
METHYLPREDNISOLONE ACETATE				
Inj 40 mg per ml, 1 ml vial.....	47.06	5	✓	Depo-Medrol
PREDNISOLONE				
* Oral liq 5 mg per ml – Up to 30 ml available on a PSO Restricted to children under 12 years of age.	6.00	30 ml OP	✓	Redipred
PREDNISONE				
* Tab 1 mg	18.58	500	✓	Prednisone Clinect
* Tab 2.5 mg	21.04	500	✓	Prednisone Clinect
* Tab 5 mg – Up to 30 tab available on a PSO	19.30	500	✓	Prednisone Clinect
* Tab 20 mg – Up to 30 tab available on a PSO	50.51	500	✓	Prednisone Clinect
TETRACOSACTRIN				
* Inj 250 mcg per ml, 1 ml ampoule	86.25	1	✓	Synacthen
			✓	UK Synacthen
* Inj 1 mg per ml, 1 ml ampoule	690.00	1	✓	Synacthen Depot
			✓	Synacthene Retard ^{S29}
TRIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml ampoule	21.42	5	✓	Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule	52.63	5	✓	Kenacort-A 40

Sex Hormones Non Contraceptive

Androgen Agonists and Antagonists

CYPROTERONE ACETATE				
Tab 50 mg	17.05	50	✓	Siterone
Tab 100 mg	31.00	50	✓	Siterone
TESTOSTERONE				
Gel (transdermal) 16.2 mg per g, 88 g	52.00	60 OP	✓	Testogel
TESTOSTERONE CIPIONATE				
Inj 100 mg per ml, 10 ml vial.....	85.00	1	✓	Depo-Testosterone
TESTOSTERONE ESTERS				
Inj 250 mg per ml, 1 ml	12.98	1	✓	Sustanon Ampoules
TESTOSTERONE UNDECANOATE				
Cap 40 mg – Subsidy by endorsement	36.00	100	✓	Steril-Gene ^{S29}
Subsidy by endorsement – subsidised for patients who were taking testosterone undecanoate cap 40mg prior to 1 November 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of testosterone undecanoate cap 40 mg in the preceding 12 months.				
Inj 250 mg per ml, 4 ml vial.....	86.00	1	✓	Reandron 1000

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
Hormone Replacement Therapy - Systemic			
Oestrogens			
OESTRADIOL			
* Tab 1 mg	4.12	28 OP	
	(11.10)		Estrofem
* Tab 2 mg	4.12	28 OP	
	(11.10)		Estrofem
* Gel (transdermal) 0.06% (750 mcg/actuation).....	14.25	80 g OP	✓ Estroge!
Patch 25 mcg per day.....	8.89	8	✓ Estradiol TDP Mylan
	13.50		✓ Estraderm MX S29
	16.23		✓ Estradot
	21.35		✓ Lyllana
a) No more than 2 patch per week			
b) Only on a prescription			
c) Estradiol TDP Mylan to be Principal Supply on 1 December 2025			
Patch 50 mcg per day.....	9.26	8	✓ Estradiol TDP Mylan
	10.75		✓ Estradiol Viatris
	14.50		✓ Estraderm MX S29
			✓ Estradiol Sandoz
	15.79		✓ Estradot
	21.55		✓ Lyllana
a) No more than 2 patch per week			
b) Only on a prescription			
c) Estradiol TDP Mylan to be Principal Supply on 1 December 2025			
Patch 75 mcg per day.....	10.33	8	✓ Estradiol TDP Mylan
	11.88		✓ Estradiol Viatris
	14.50		✓ Estradiol Sandoz
	16.53		✓ Estradot
	22.37		✓ Lyllana
a) No more than 2 patch per week			
b) Only on a prescription			
c) Estradiol TDP Mylan to be Principal Supply on 1 December 2025			
Patch 100 mcg per day.....	10.59	8	✓ Estradiol TDP Mylan
	12.95		✓ Estradiol Viatris
	14.50		✓ Estradiol Sandoz
	15.50		✓ Estraderm MX S29
	16.18		✓ Estradot
	22.77		✓ Lyllana

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
a) No more than 2 patch per week b) Only on a prescription c) Estradiol TDP Mylan to be Principal Supply on 1 December 2025 (Estraderm MX ^{\$29} Patch 25 mcg per day to be delisted 1 December 2025) (Lyllana Patch 25 mcg per day to be delisted 1 December 2025) (Estradiol Viatrix Patch 50 mcg per day to be delisted 1 December 2025) (Estraderm MX ^{\$29} Patch 50 mcg per day to be delisted 1 December 2025) (Estradiol Sandoz Patch 50 mcg per day to be delisted 1 December 2025) (Lyllana Patch 50 mcg per day to be delisted 1 December 2025) (Estradiol Viatrix Patch 75 mcg per day to be delisted 1 December 2025) (Estradiol Sandoz Patch 75 mcg per day to be delisted 1 December 2025) (Lyllana Patch 75 mcg per day to be delisted 1 December 2025) (Estradiol Viatrix Patch 100 mcg per day to be delisted 1 December 2025) (Estradiol Sandoz Patch 100 mcg per day to be delisted 1 December 2025) (Estraderm MX ^{\$29} Patch 100 mcg per day to be delisted 1 December 2025) (Lyllana Patch 100 mcg per day to be delisted 1 December 2025)				
OESTRADIOL VALERATE				
* Tab 1 mg	12.36	84	✓	Progynova
Progynova to be Principal Supply on 1 December 2025				
* Tab 2 mg	12.36	84	✓	Progynova
Progynova to be Principal Supply on 1 December 2025				
OESTROGENS				
* Conjugated, equine tab 300 mcg.....	3.01 (19.25)	28		Premarin
* Conjugated, equine tab 625 mcg.....	4.12 (19.25)	28		Premarin
Progestogens				
MEDROXYPROGESTERONE ACETATE				
* Tab 2.5 mg	6.56	30	✓	Provera
	8.75	56	✓	Provera
* Tab 5 mg	9.80	56	✓	Provera
	20.13	100	✓	Provera
* Tab 10 mg	10.28	30	✓	Provera
Progestogen and Oestrogen Combined Preparations				
OESTRADIOL WITH NORETHISTERONE				
* Tab 1 mg with 0.5 mg norethisterone acetate	5.40 (18.10)	28 OP		Kliovance
* Tab 2 mg with 1 mg norethisterone acetate	5.40 (18.10)	28 OP		Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6).....	5.40 (18.10)	28 OP		Trisequens
Other Oestrogen Preparations				
OESTRIOL				
* Tab 2 mg	7.70	30	✓	Ovestin

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Other Progestogen Preparations				
MEDROXYPROGESTERONE ACETATE				
Tab 100 mg	133.57	100	✓	Provera HD
NORETHISTERONE				
* Tab 5 mg – Up to 30 tab available on a PSO	5.49	30	✓	Primolut N
PROGESTERONE				
* Cap 100 mg	14.85	30	✓	Utrogestan
Thyroid and Antithyroid Agents				
CARBIMAZOLE				
* Tab 5 mg	7.56	100	✓	Neo-Mercazole
Neo-Mercazole to be Principal Supply on 1 December 2025				
LEVOTHYROXINE				
* Tab 25 mcg.....	5.55	90	✓	Synthroid
* Tab 50 mcg.....	1.71	28	✓	Mercury Pharma
	5.79	90	✓	Synthroid
	64.28	1,000	✓	Eltroxin
* Tablet 50 mcg.....	12.86	200	✓	Eltroxin
* Tab 100 mcg.....	1.78	28	✓	Mercury Pharma
	6.01	90	✓	Synthroid
	66.78	1,000	✓	Eltroxin
* Tablet 100 mcg.....	13.36	200	✓	Eltroxin
PROPYLTHIOURACIL – Special Authority see SA1199 below – Retail pharmacy				
Tab 50 mg	35.00	100	✓	PTU ^{S29}

►SA1199 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones

Growth Hormones

SOMATROPIN (OMNITROPE) – Special Authority see [SA2032 below](#) – Retail pharmacy

* Inj 5 mg cartridge.....	80.21	1	✓	<u>Omnitrope</u>
* Inj 10 mg cartridge.....	80.21	1	✓	<u>Omnitrope</u>
* Inj 15 mg cartridge.....	139.50	1	✓	<u>Omnitrope</u>

►SA2032 Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist.

Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2 All of the following:

- 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
- 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
- 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
- 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under ; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years or under (female patients) or < 16 years (male patients); and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- The patient's height is more than 2 standard deviations below the mean; and
- Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- The patient is under the supervision of a specialist with expertise in renal medicine; and
- Either:
 - The patient has a GFR less than or equal to 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l)) × 40 = corrected GFR (ml/min/1.73m²) in a child who may or may not be receiving dialysis; or
 - The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- No malignancy has developed after growth hormone therapy was commenced; and
- The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- The patient has not received renal transplantation since starting growth hormone treatment; and
- If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Any of the following:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within $\pm 1SD$ of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within $\pm 1SD$ of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients; or
- 3 All of the following:
 - 3.1 The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication; and
 - 3.2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
 - 3.3 The patient has severe growth hormone deficiency (see notes); and
 - 3.4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
 - 3.5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

GnRH Analogues

GOSERELIN

Implant 3.6 mg, syringe	66.48	1	✓ Zoladex
Implant 10.8 mg, syringe	138.23	1	✓ Zoladex

LEUPRORELIN

Additional subsidy by endorsement where the patient is a child or adolescent and is unable to tolerate administration of goserelin and the prescription is endorsed accordingly.

Inj 3.75 mg prefilled dual chamber syringe – Higher subsidy of			
\$221.60 per 1 inj with Endorsement	66.48	1	
	(221.60)		Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe – Higher subsidy			
of \$591.68 per 1 inj with Endorsement	177.50	1	
	(591.68)		Lucrin Depot 3-month

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Vasopressin Agonists				
DESMOPRESSIN				
Wafer 120 mcg	47.00	30	✓	Minirin Melt
DESMOPRESSIN ACETATE				
Tab 100 mcg.....	25.00	30	✓	Minirin
Tab 200 mcg.....	54.45	30	✓	Minirin
Inj 4 mcg per ml, 1 ml	67.18	10	✓	Minirin
▲ Nasal spray 10 mcg per dose, 6 ml.....	34.95	60 OP	✓	Desmopressin- PH&T

Other Endocrine Agents

CABERGOLINE

Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA2070 below	4.43	2	✓	Dostinex
	17.94	8	✓	Dostinex

► [SA2070](#) Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Hyperprolactinemia; or
- 2 Acromegaly*; or
- 3 Inhibition of lactation.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment.

Note: Indication marked with * is an unapproved indication.

CLOMIFENE CITRATE

Tab 50 mg	29.84	10	✓	Mylan Clomiphen ^{\$29}
-----------------	-------	----	---	------------------------------------

METYRAPONE

Cap 250 mg.....	558.00	50	✓	Metopirone
-----------------	--------	----	---	------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Anthelmintics

ALBENDAZOLE – Special Authority see [SA2512 below](#) – Retail pharmacy

Tab 400 mg	469.20	60	✓ Eskazole ^{\$29}
------------------	--------	----	----------------------------

►SA2512 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:
Either:

- 1 The individual has hydatids; or
- 2 The individual has a travel or residence history that requires presumptive parasite treatment.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

MEBENDAZOLE – Only on a prescription

Tab 100 mg	5.18	6	✓ <u>Vermox</u>
Oral liq 100 mg per 5 ml	2.18	15 ml	
	(7.83)		Vermox

PRAZIQUANTEL

Tab 600 mg	68.00	8	✓ <u>Biltricide</u>
	87.68		✓ <u>Distoside</u> ^{\$29}

(Biltricide Tab 600 mg to be delisted 1 April 2026)

Antibacterials

- a) For topical antibacterials, refer to DERMATOLOGICALS, [page 67](#)
- b) For anti-infective eye preparations, refer to SENSORY ORGANS, [page 277](#)

Cephalosporins and Cephamycins

CEFACLOR MONOHYDRATE

Cap 250 mg	29.73	100	✓ <u>Ranbaxy-Cefaclor</u>
Grans for oral liq 125 mg per 5 ml – Wastage claimable.....	5.83	100 ml	✓ <u>Ranbaxy-Cefaclor</u>

CEFALEXIN

Cap 250 mg	3.85	20	✓ <u>Cephalexin ABM</u>
Cap 500 mg	5.85	20	✓ <u>Cephalexin ABM</u>
Grans for oral liq 25 mg per ml – Wastage claimable.....	7.88	100 ml	✓ <u>Flynn</u>
Grans for oral liq 50 mg per ml – Wastage claimable.....	10.38	100 ml	✓ <u>Flynn</u>
	11.75		✓ <u>Cefalexin Sandoz</u>

CEFAZOLIN – Subsidy by endorsement

Only if prescribed for dialysis or cellulitis in accordance with a Health NZ Hospital approved protocol and the prescription is endorsed accordingly.

Inj 500 mg vial	3.39	5	✓ <u>Cefazolin-AFT</u>
Inj 1 g vial	3.59	5	✓ <u>Cefazolin-AFT</u>
Inj 2 g vial	7.09	5	✓ <u>Cefazolin-AFT</u>

CEFTRIAXONE – Subsidy by endorsement

- a) Up to 10 inj available on a PSO
- b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningococcal disease, and the prescription or PSO is endorsed accordingly.

Inj 500 mg vial	0.94	1	✓ <u>Ceftriaxone-AFT</u>
Inj 1 g vial	3.49	5	✓ <u>Ceftriaxone-AFT</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CEFUROXIME AXETIL – Subsidy by endorsement				
Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Tab 250 mg	CBS	20	✓	Ascend- Cefuroxime ^{S29}

Macrolides

AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by Special Authority see [SA1683 below](#)
A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised on Special Authority.

Tab 250 mg	8.19	30	✓	Apo-Azithromycin
Tab 500 mg – Up to 8 tab available on a PSO	2.80	2	✓	Zithromax
Zithromax to be Principal Supply on 1 January 2026				
Grans for oral liq 200 mg per 5 ml (40 mg per ml) – Wastage claimable	16.97	15 ml	✓	Zithromax

►SA1683 Special Authority for Waiver of Rule

Initial application — (bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
- 2 Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
- 3 Patient has cystic fibrosis and has chronic infection with *Pseudomonas aeruginosa* or *Pseudomonas*-related gram negative organisms*; or
- 4 Patient has an atypical *Mycobacterium* infection.

Note: Indications marked with * are unapproved indications.

Initial application — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
- 2 Patient is aged 18 and under; and
- 3 Either:
 - 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
 - 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications.

Renewal — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- 2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- 3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

The patient must not have had more than 1 prior approval.

Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see [SA1857 on the next page](#)

Tab 250 mg	7.31	12	✓	Klaricid ^{S29}
	8.53	14	✓	Klacid
Grans for oral liq 250 mg per 5 ml – Wastage claimable.....	192.00	50 ml	✓	Klacid

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1857 Special Authority for Waiver of Rule

Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Atypical mycobacterial infection; or
- 2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents.

Initial application — (Helicobacter pylori eradication) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 For the eradication of helicobacter pylori in a patient unable to swallow tablets; and
- 2 For use only in combination with omeprazole and amoxicillin as part of a triple therapy regimen.

Initial application — (Prophylaxis of infective endocarditis) from any relevant practitioner. Approvals valid for 3 months where prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ERYTHROMYCIN (AS LACTOBIONATE)

Inj 1 g vial	10.00	1	✓ Erythrocin IV
Erythrocin IV to be Principal Supply on 1 December 2025			

ERYTHROMYCIN ETHYL SUCCINATE

Tab 400 mg	35.82	100	✓ E-Mycin
a) Up to 20 tab available on a PSO			
b) Up to 2 x the maximum PSO quantity for RFPP			
Grans for oral liq 200 mg per 5 ml	6.53	100 ml	✓ E-Mycin
a) Up to 300 ml available on a PSO			
b) Up to 2 x the maximum PSO quantity for RFPP			
c) Wastage claimable			
Grans for oral liq 400 mg per 5 ml	9.41	100 ml	✓ E-Mycin
a) Up to 200 ml available on a PSO			
b) Wastage claimable			

ROXITHROMYCIN

Tab 150 mg	13.19	50	✓ Arrow- Roxithromycin
Tab 300 mg	25.00	50	✓ Arrow- Roxithromycin

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Penicillins				
AMOXICILLIN				
Cap 250 mg.....	54.00	500	✓	Miro-Amoxicillin
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
Cap 500 mg.....	41.00	500	✓	Miro-Amoxicillin
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml.....	2.22	100 ml	✓	Alphamox 125
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 250 mg per 5 ml.....	2.81	100 ml	✓	Alphamox 250
a) Up to 300 ml available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
c) Wastage claimable				
Inj 250 mg vial	15.97	10	✓	Ibiamox
Inj 500 mg vial	17.43	10	✓	Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO	21.64	10	✓	Ibiamox
AMOXICILLIN WITH CLAVULANIC ACID				
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab available on a PSO	1.59	10	✓	Curam Duo 500/125
Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25 mg per ml.....	8.50	100 ml	✓	Augmentin
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 mg per ml – Up to 200 ml available on a PSO	5.61	100 ml OP	✓	Amoxiclav Devatis Forte
BENZATHINE BENZYL PENICILLIN				
Inj 900 mg (1.2 million units) vial	43.24	1	✓	Benzetacil \$29
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj available on a PSO	432.37	10	✓	Bicillin LA
BENZYL PENICILLIN SODIUM [PENICILLIN G]				
Inj 600 mg (1 million units) vial – Up to 5 inj available on a PSO	16.50	10	✓	Sandoz
FLUCLOXACILLIN				
Cap 250 mg – Up to 30 cap available on a PSO	22.58	250	✓	Staphlex
Cap 500 mg – Up to 30 cap available on a PSO	72.71	500	✓	Staphlex
Grans for oral liq 25 mg per ml.....	4.89	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 50 mg per ml.....	5.89	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Inj 250 mg vial	42.60	10	✓	Flucloxin
Inj 500 mg vial	45.63	10	✓	Flucloxin
Inj 1 g vial – Up to 5 inj available on a PSO	6.00	5	✓	Flucil

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PHENOXYMETHYLPENICILLIN (PENICILLIN V)				
Cap 250 mg – Up to 30 cap available on a PSO	7.68	50	✓	Cilicaine VK
Cap 500 mg	13.72	50	✓	Cilicaine VK
a) Up to 20 cap available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml	5.75	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 250 mg per 5 ml	5.89	100 ml	✓	AFT
a) Up to 300 ml available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP				
c) Wastage claimable				

Tetracyclines

DOXYCYCLINE				
* Tab 100 mg – Up to 30 tab available on a PSO	64.43	500	✓	Doxine
MINOCYCLINE HYDROCHLORIDE				
* Tab 50 mg – Additional subsidy by Special Authority see SA1355 below – Retail pharmacy	5.79 (12.05)	60		Mino-tabs
* Cap 100 mg	19.32 (52.04)	100		Minomycin

►SA1355 Special Authority for Manufacturers Price

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has rosacea.

TETRACYCLINE – Special Authority see SA2513 below – Retail pharmacy

Tab 250 mg	68.44	28	✓	Accord S29
------------------	-------	----	---	-------------------

►SA2513 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and
- 2 For use only in combination with bismuth as part of a quadruple therapy regimen.

Renewal from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 For the eradication of helicobacter pylori following unsuccessful treatment with, or noncompletion of second line therapy; and
- 2 For use only in combination with bismuth as part of a quadruple therapy regimen.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, [page 67](#)

CIPROFLOXACIN

Recommended for patients with any of the following:

- microbiologically confirmed and clinically significant pseudomonas infection; or
- prostatitis; or
- pyelonephritis; or
- gonorrhoea.

Tab 250 mg – Up to 5 tab available on a PSO	1.95	28	✓	Ipca-Ciprofloxacin
Tab 500 mg – Up to 5 tab available on a PSO	3.10	28	✓	Ipca-Ciprofloxacin
Tab 750 mg	4.80	28	✓	Ipca-Ciprofloxacin

CLINDAMYCIN

Cap hydrochloride 150 mg	4.94	24	✓	Dalacin C
Inj 150 mg per ml, 4 ml ampoule	35.10	10	✓	Hameln
	48.78		✓	Dalacin C

(Hameln Inj 150 mg per ml, 4 ml ampoule to be delisted 1 March 2026)

COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Subsidy by endorsement

Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

Inj 2 million iu, 10 ml vial.....	216.67	10	✓	Colomycin ^{S29}
-----------------------------------	--------	----	---	---------------------------------

GENTAMICIN SULPHATE

Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement.....	36.70	5	✓	Cidomycin P/Free ^{S29}
---	-------	---	---	--

Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.

Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement.....	95.00	5	✓	DBL Gentamicin
--	-------	---	---	-----------------------

Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.

Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	18.38	10	✓	Gentamicin Amdipharm ^{S29}
			✓	Pfizer
	91.90	50	✓	Gentamicin Noridem ^{S29}

Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.

(Gentamicin Amdipharm ^{S29} Inj 40 mg per ml, 2 ml ampoule to be delisted 1 December 2025)

(Gentamicin Noridem ^{S29} Inj 40 mg per ml, 2 ml ampoule to be delisted 1 December 2025)

MOXIFLOXACIN – Special Authority see [SA1740 below](#) – Retail pharmacy

No patient co-payment payable

Tab 400 mg	42.00	5	✓	Avelox
------------------	-------	---	---	---------------

► [SA1740](#) Special Authority for Subsidy

Initial application — (Tuberculosis) only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- Both:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 1.1 Active tuberculosis*; and
- 1.2 Any of the following:
 - 1.2.1 Documented resistance to one or more first-line medications; or
 - 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*; or
- 3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

Note: Indications marked with * are unapproved indications.

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) only from a sexual health specialist or Practitioner on the recommendation of a sexual health specialist. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic; and
- 2 Either:
 - 2.1 Has tried and failed to clear infection using azithromycin; or
 - 2.2 Has laboratory confirmed azithromycin resistance; and
- 3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are unapproved indications.

PAROMOMYCIN – Special Authority see [SA1689 below](#) – Retail pharmacy

Cap 250 mg	126.00	16	✓ Humatin \$29
------------------	--------	----	-------------------------------

► **SA1689** Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolytica carriage.

Renewal only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolytica carriage.

SODIUM FUSIDATE [FUSIDIC ACID]

Tab 250 mg	135.70	36	✓ Fucidin
------------------	--------	----	-----------

SULFADIAZINE SODIUM – Special Authority see [SA1331 below](#) – Retail pharmacy

Tab 500 mg	150.70	100	✓ Sulfadiazin-Heyl \$29
------------------	--------	-----	--

► **SA1331** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

the following criteria:

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

TOBRAMYCIN

Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement.....	15.50	5	✓	Tobramycin (Viatris)
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Solution for inhalation 60 mg per ml, 5 ml – Subsidy by endorsement.....	395.00	56 dose	✓	Tobramycin BNM
a) Wastage claimable				
b) Only if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly.				

TRIMETHOPRIM

* Tab 300 mg – Up to 30 tab available on a PSO.....	27.83	50	✓	TMP
---	-------	----	---	------------

TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]

* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO.....	115.74	500	✓	Trisul
* Oral liq 8 mg sulphamethoxazole 40 mg per ml – Up to 200 ml available on a PSO.....	4.95	100 ml	✓	Deprim

VANCOMYCIN – Subsidy by endorsement

Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly.				
Inj 500 mg vial	3.38	1	✓	Mylan

Antifungals

- a) For topical antifungals refer to DERMATOLOGICALS, [page 68](#)
- b) For topical antifungals refer to GENITO URINARY, [page 80](#)

FLUCONAZOLE

Cap 50 mg.....	4.10	28	✓	Mylan
Cap 150 mg.....	0.45	1	✓	Mylan
Cap 200 mg.....	8.90	28	✓	Mylan
Powder for oral suspension 10 mg per ml – Special Authority see SA1359 below – Retail pharmacy.....	129.02	35 ml	✓	Diflucan
Wastage claimable				

►SA1359 Special Authority for Subsidy

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 Patient is at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

Renewal — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Renewal — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient remains immunocompromised; and
- 2 Patient remains at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

ITRACONAZOLE

Cap 100 mg	6.83	15	✓ Itraconazole Crescent ^{\$29}
	27.32	60	✓ Itraconazole Itrazole ^{\$29}
Oral liq 10 mg per ml – Special Authority see SA1322 below – Retail pharmacy.....	141.80	150 ml OP	✓ Itraconazole Kent ^{\$29}

(Itrazole ^{\$29} Cap 100 mg to be delisted 1 December 2025)

➔SA1322 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist, clinical immunologist or any relevant practitioner on the recommendation of a infectious disease physician, clinical microbiologist or clinical immunologist. Approvals valid for 6 months where the patient has a congenital immune deficiency.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

KETOCONAZOLE

Tab 200 mg – PCT	CBS	30	✓ Burel ^{\$29}
		100	✓ Strides Shasun ^{\$29}
			✓ Taro ^{\$29}
			✓ Teva- Ketoconazole ^{\$29}

NYSTATIN

Tab 500,000 u	14.16 (17.09)	50	Nilstat
Cap 500,000 u	12.81 (15.47)	50	Nilstat

POSACONAZOLE – Special Authority see [SA2383 on the next page](#) – Retail pharmacy

Tab modified-release 100 mg	123.60	24	✓ Posaconazole Juno
Posaconazole Juno to be Principal Supply on 1 December 2025			
Oral liq 40 mg per ml	308.26	105 ml OP	✓ Devatis
Devatis to be Principal Supply on 1 December 2025			

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

►SA2383 Special Authority for Subsidy

Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

Initial application — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Posaconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing posaconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

Renewal — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Posaconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing posaconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

TERBINAFINE

* Tab 250 mg 8.97 84 ✓ **Deolate**

VORICONAZOLE – Special Authority see SA2384 on the next page – Retail pharmacy

Tab 50 mg 71.00 56 ✓ **Vttack**

Tab 200 mg 263.00 56 ✓ **Vttack**

Powder for oral suspension 40 mg per ml – Wastage claimable 1,523.22 70 ml ✓ **Vfend**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2384 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

Initial application — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Voriconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing voriconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

Renewal — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Voriconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing voriconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

Antimalarials

PRIMAQUINE – Special Authority see [SA1684 on the next page](#) – Retail pharmacy

Tab 15 mg	395.00	100
	400.00	

✓ Bayshore S29

✓ Sanofi

Primaquine S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

►SA1684 Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has relapsed vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Antitrichomonal Agents

METRONIDAZOLE

Tab 200 mg – Up to 30 tab available on a PSO	25.86	250	✓ Metronidamed
Tab 400 mg – Up to 15 tab available on a PSO	4.29	21	✓ Metronidamed
Oral liq benzoate 200 mg per 5 ml	25.00	100 ml	✓ Flagyl-S
Suppos 500 mg	24.48	10	✓ Flagyl

ORNIDAZOLE

Tab 500 mg	36.52	10	✓ Arrow-Ornidazole
------------------	-------	----	---------------------------

Antituberculotics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status.

BEDAQUILINE – Special Authority see [SA2244](#) below – Retail pharmacy

No patient co-payment payable

Tab 100mg	3,084.51	24 OP	✓ Sirturo
-----------------	----------	-------	------------------

►SA2244 Special Authority for Subsidy

Initial application — (multi-drug resistant tuberculosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The person has multi-drug resistant tuberculosis (MDR-TB); and
- 2 Ministry of Health's Tuberculosis Clinical Network has reviewed the individual case and recommends bedaquiline as part of the treatment regimen.

CLOFAZIMINE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist.

* Cap 50 mg	442.00	100	✓ Lamprene ^{\$29}
-------------------	--------	-----	-----------------------------------

CYCLOSERINE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.

Cap 250 mg	344.00	60	✓ Cyclorin ^{\$29}
------------------	--------	----	-----------------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DAPSONE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist				
Tab 25 mg	268.50	100	✓	Dapsone
Tab 100 mg	329.50	100	✓	Dapsone
ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician				
Tab 100 mg	85.73	100	✓	EMB Fatol \$29
Tab 400 mg	49.34	56	✓	Myambutol \$29
ISONIAZID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician				
* Tab 100 mg	94.50	100	✓	Isoniazid Teva \$29
	327.41		✓	Noumed Isoniazid
ISONIAZID WITH RIFAMPICIN – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician				
* Tab 100 mg with rifampicin 150 mg	89.82	100	✓	Rifinah
* Tab 150 mg with rifampicin 300 mg	179.13	100	✓	Rifinah
LINEZOLID – Special Authority see SA2234 below – Retail pharmacy				
No patient co-payment payable				
Tab 600 mg	194.60	10	✓	Zyvox
Oral liq 20 mg per ml	1,879.00	150 ml	✓	Zyvox
►SA2234 Special Authority for Subsidy				
Initial application — (multi-drug resistant tuberculosis) from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:				
Both:				
1 The person has multi-drug resistant tuberculosis (MDR-TB); and				
2 Ministry of Health's Tuberculosis Clinical Network has reviewed the individual case and recommends linezolid as part of the treatment regimen.				
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician				
Grans for oral liq 4 g sachet	280.00	30	✓	Paser \$29
PROTIONAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician				
Tab 250 mg	305.00	100	✓	Peteha \$29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PYRAZINAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician				
* Tab 500 mg	64.95	100	✓	AFT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, respiratory physician or gastroenterologist				
* Cap 150 mg	353.71	30	✓	Mycobutin
RIFAMPICIN – Subsidy by endorsement				
a) No patient co-payment payable				
b) For confirmed recurrent <i>Staphylococcus aureus</i> infection in combination with other effective anti-staphylococcal antimicrobial based on susceptibilities and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an internal medicine physician, clinical microbiologist, dermatologist, paediatrician, or public health physician.				
* Cap 150 mg	58.54	100	✓	Rifadin
* Cap 300 mg	122.06	100	✓	Rifadin
			✓	Rifadin Sanofi
* Oral liq 100 mg per 5 ml	12.60	60 ml	✓	Rifadin

Antivirals

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, [page 277](#)

Hepatitis B Treatment

ENTECAVIR				
* Tab 0.5 mg	12.04	30	✓	Entecavir (Rex)
LAMIVUDINE – Special Authority see SA1685 below – Retail pharmacy				
Tab 100 mg	12.06	28	✓	Zetlam
Oral liq 5 mg per ml	270.00	240 ml OP	✓	Zeffix
►SA1685 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year where used for the treatment or prevention of hepatitis B.				
Renewal from any relevant practitioner. Approvals valid for 2 years where used for the treatment or prevention of hepatitis B.				
TENOFOVIR DISOPROXIL				
Tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA2139., page 112				
* Tab 245 mg (300 mg as a maleate)	13.80	30	✓	Tenofovir Disoproxil Viatris
Tenofovir Disoproxil Viatris to be Principal Supply on 1 December 2025				
* Tab 245 mg (300 mg as a fumarate)	13.80	30	✓	Ricovir ^{S29}

Herpesvirus Treatments

ACICLOVIR				
* Tab dispersible 200 mg	2.05	25	✓	Lovir
* Tab dispersible 400 mg	7.55	56	✓	Lovir
* Tab dispersible 800 mg	7.43	35	✓	Lovir

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
VALACICLOVIR				
Tab 500 mg	9.64	30	✓	Vaclovir
Tab 1,000 mg	17.78	30	✓	Vaclovir
VALGANCICLOVIR – Special Authority see SA2514 below – Retail pharmacy				
Tab 450 mg	140.89	60	✓	Valganciclovir Viatris

► **SA2514** Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
 - 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or
- 2 Both:
 - 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and
 - 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive; and
- 3 Patient has a high risk of CMV disease.

Renewal — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone a lung re-transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive; and
- 3 Patient has a high risk of CMV disease.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis C Treatment

GLECAPREVIR WITH PIBRENTASVIR – [Xpharm]

Note the supply of treatment is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website <https://pharmac.govt.nz/maviret>

Tab 100 mg with pibrentasvir 40 mg	24,750.00	84 OP	✓ Maviret
--	-----------	-------	-----------

LEDIPASVIR WITH SOFOSBUVIR – [Xpharm] – Special Authority see [SA1605 below](#)

No patient co-payment payable

Tab 90 mg with sofosbuvir 400 mg.....	24,363.46	28	✓ Harvoni
---------------------------------------	-----------	----	-----------

► [SA1605](#) Special Authority for Subsidy

Special Authority approved by the Hepatitis C Treatment Panel (HepCTP)

Notes: By application to the Hepatitis C Treatment Panel (HepCTP).

Applications will be considered by HepCTP and approved subject to confirmation of eligibility.

Application details may be obtained from Pharmac's website <http://www.pharmac.govt.nz/maviret> or:

The Coordinator, Hepatitis C Treatment Panel

Pharmac, PO Box 10-254, WELLINGTON Tel: (04) 460 4990,

Email: heccpanel@pharmac.govt.nz

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Subsidy by endorsement; can be waived by Special Authority see [SA2520](#) below

- Funding for emtricitabine with tenofovir disoproxil for use as PrEP or PEP, should be applied using Special Authority SA2520.
- Endorsement for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV (when co-prescribed with other antiretrovirals) and percutaneous exposure): Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA2139 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement, for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV and percutaneous exposure), is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA2139, [page 112](#)

There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the Pharmac website.

* Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate).....	13.45	30	✓ Tenofovir Disoproxil Emtricitabine Viatr
--	-------	----	---

Tenofovir Disoproxil Emtricitabine Viatr to be Principal Supply on 1 December 2025

► [SA2520](#) Special Authority for Subsidy

Initial application — (Pre-exposure prophylaxis) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

- Both:
- Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
 - The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Notes: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines:

<https://ashm.org.au/HIV/PrEP/>

Renewal — (Pre-exposure prophylaxis) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

- Both:
- Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
 - The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Notes: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines:

<https://ashm.org.au/HIV/PrEP/>

Initial application — (post-exposure prophylaxis following exposure to HIV) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

- Both:
- Treatment course to be initiated within 72 hours post exposure; and
 - Any of the following:
 - Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

prophylaxis is appropriate; or

- 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

Renewal — (second or subsequent post-exposure prophylaxis) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is appropriate; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

COVID-19 Treatments

NIRMATRELVIR WITH RITONAVIR – PCT – Subsidy by endorsement

Subsidised for patients meeting access criteria for oral COVID-19 antiviral treatments (as on [Pharmac's website](#)) and where the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed when supplying by Direct Provision under the provisions in Part I of Section A of the Pharmaceutical Schedule.

Tab 150 mg with ritonavir 100 mg	1,274.00	30 OP	✓ Paxlovid
Tab 150 mg with ritonavir 100 mg, – [Xpharm].....	0.00	30	✓ Paxlovid (Pharmac)

(Paxlovid (Pharmac) Tab 150 mg with ritonavir 100 mg, to be delisted 1 December 2025)

REMDESIVIR – PCT only

Note: Subsidised for patients meeting access criteria for oral antiviral treatments (as on [Pharmac's website](#)).

Inj 100 mg vial	615.23	1	✓ Veklury
-----------------------	--------	---	-----------

Antiretrovirals

»SA2139 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the patient has confirmed HIV infection.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following exposure to HIV) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

Renewal — (second or subsequent post-exposure prophylaxis) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Note: No new patients to be initiated on efavirenz.

Tab 600 mg	65.38	30	✓	Efavirenz Milpharm ^{S29}
------------------	-------	----	---	--

(Efavirenz Milpharm ^{S29} Tab 600 mg to be delisted 1 November 2026)

ETRAVIRINE – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Tab 200 mg	770.00	60	✓	Intencele
------------------	--------	----	---	------------------

NEVIRAPINE – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Tab 200 mg	198.25	60	✓	Nevirapine Viatris
Oral suspension 10 mg per ml.....	203.55	240 ml OP	✓	Viramune Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAIR SULPHATE – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Tab 300 mg	180.00	60	✓	Ziagen
------------------	--------	----	---	---------------

ABACAIR SULPHATE WITH LAMIVUDINE – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Note: abacavir with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

Tab 600 mg with lamivudine 300 mg.....	35.00	30	✓	Abacavir/ Lamivudine Viatris
--	-------	----	---	---

EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Note: Efavirenz with emtricitabine and tenofovir disoproxil counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority

Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)	106.88	30	✓	TEEVIR ^{S29} Triovir ^{S29}
--	--------	----	---	---

Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate).....	106.88	30	✓	Viatris
--	--------	----	---	----------------

(Triovir ^{S29} Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) to be delisted 1 January 2026)

EMTRICITABINE – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Cap 200 mg	307.20	30	✓	Emtriva
------------------	--------	----	---	----------------

LAMIVUDINE – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Tab 150 mg	98.00	60	✓	Lamivudine Viatris
Oral liq 10 mg per ml	102.50	240 ml OP	✓	3TC

ZIDOVUDINE [AZT] – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Cap 100 mg	152.25	100	✓	Retrovir
Oral liq 10 mg per ml	30.45	200 ml OP	✓	Retrovir

ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see [SA2139 on page 112](#) – Retail pharmacy

Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

Tab 300 mg with lamivudine 150 mg.....	92.40	60	✓	Lamivudine/ Zidovudine Viatris
--	-------	----	---	---

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Protease Inhibitors				
ATAZANAVIR SULPHATE – Special Authority see SA2139 on page 112 – Retail pharmacy				
Cap 150 mg	85.00	60	✓	Atazanavir Mylan
	102.50		✓	Atazanavir Viatris
Cap 200 mg	152.30	60	✓	Atazanavir Viatris
<i>(Atazanavir Mylan Cap 150 mg to be delisted 1 November 2025)</i>				
DARUNAVIR – Special Authority see SA2139 on page 112 – Retail pharmacy				
Tab 400 mg	150.00	60	✓	Darunavir Viatris
Tab 600 mg	225.00	60	✓	Darunavir Viatris
LOPINAVIR WITH RITONAVIR – Special Authority see SA2139 on page 112 – Retail pharmacy				
Tab 100 mg with ritonavir 25 mg	150.00	60	✓	Lopinavir/Ritonavir Mylan
Tab 200 mg with ritonavir 50 mg	875.00	120	✓	Lopinavir/Ritonavir Mylan
RITONAVIR – Special Authority see SA2139 on page 112 – Retail pharmacy				
Tab 100 mg	43.31	30	✓	Norvir

Strand Transfer Inhibitors

DOLUTEGRAVIR – Special Authority see SA2139 on page 112 – Retail pharmacy				
Tab 50 mg	1,090.00	30	✓	Tivicay
DOLUTEGRAVIR WITH LAMIVUDINE – Special Authority see SA2139 on page 112 – Retail pharmacy				
Tab 50 mg with lamivudine 300 mg	1,090.00	30	✓	Dovato
RALTEGRAVIR POTASSIUM – Special Authority see SA2139 on page 112 – Retail pharmacy				
Tab 400 mg	1,090.00	60	✓	Isentress
Tab 600 mg	1,090.00	60	✓	Isentress HD

Immune Modulators

PEGYLATED INTERFERON ALFA-2A – Special Authority see SA2034 below – Retail pharmacy				
Note: Pharmac will consider funding ribavirin for the small group of patients who have a clinical need for ribavirin and meet Special Authority criteria. Please contact the Hepatitis C Coordinator at Pharmac on 0800-023-588 option 4.				
Inj 135 mcg prefilled syringe	887.35	1	✓	Pegasys (S29) ^{S29}
Inj 180 mcg prefilled syringe	748.50	4	✓	Pegasys
	1,355.71		✓	Pegasys S29 ^{S29}

➤ [SA2034](#) Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

Both:

- Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- Maximum of 48 weeks therapy.

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist.

Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naïve; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Initial application — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma*; or
- 2 All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 2.1 Patient has a myeloproliferative disorder*; and
- 2.2 Patient is intolerant of hydroxyurea; and
- 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or

3 Both:

- 3.1 Patient has a myeloproliferative disorder; and
- 3.2 Patient is pregnant, planning pregnancy or lactating.

Renewal — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:

3.1 Patient has a cutaneous T cell lymphoma*; or

3.2 Both:

3.2.1 Patient has a myeloproliferative disorder*; and

3.2.2 Either:

3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or

3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Note: Indications marked with * are unapproved indications.

Initial application — (post-allogeneic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse.

Renewal — (post-allogeneic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient is responding and ongoing treatment remains appropriate.

Note: Indications marked with * are unapproved indications.

Urinary Tract Infections

FOSFOMYCIN – Special Authority see SA2406 below – Retail pharmacy

Powder for oral solution, 3 g sachet 18.70

1

✓ **UroFos**

➔ **SA2406** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

Both:

- 1 Patient has an acute, symptomatic, bacteriologically-proven uncomplicated urinary tract infection (UTI)/cystitis with *Escherichia Coli*; and
- 2 Either:
 - 2.1 Microbiological testing confirms the pathogen is resistant to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin; or
 - 2.2 The patient has a contraindication or intolerance to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin that the pathogen is susceptible to.

Renewal from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

Both:

- 1 Patient has an acute, symptomatic, bacteriologically-proven uncomplicated urinary tract infection (UTI)/cystitis with *Escherichia Coli*; and
- 2 Either:
 - 2.1 Microbiological testing confirms the pathogen is resistant to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin; or
 - 2.2 The patient has a contraindication or intolerance to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin that the pathogen is susceptible to.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHENAMINE (HEXAMINE) HIPPURATE				
* Tab 1 g	19.95	100	✓	Hiprex
NITROFURANTOIN				
* Tab 50 mg – Up to 30 tab available on a PSO	22.20	100	✓	<u>Nifuran</u>
* Tab 100 mg	37.50	100	✓	<u>Nifuran</u>
* Cap modified-release 100 mg – Up to 15 cap available on a PSO	81.20	100	✓	<u>Macrobid</u>
NORFLOXACIN				
Tab 400 mg – Subsidy by endorsement	245.00	100	✓	Arrow-Norfloxacin
Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
Anticholinesterases			
NEOSTIGMINE METILSULFATE			
Inj 2.5 mg per ml, 1 ml ampoule	48.25	10	✓ Max Health
PYRIDOSTIGMINE BROMIDE			
▲ Tab 60 mg	50.28	100	✓ Mestinon
Non-Steroidal Anti-Inflammatory Drugs			
DICLOFENAC SODIUM			
* Tab EC 25 mg	2.19	50	✓ Diclofenac Sandoz
* Tab 50 mg dispersible	1.50	20	✓ Voltaren D
* Tab EC 50 mg	2.19	50	✓ Diclofenac Sandoz
* Tab long-acting 75 mg	10.00	100	✓ Voltaren SR
* Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO	13.20	5	✓ Voltaren
* Suppos 12.5 mg	2.04	10	✓ Voltaren
* Suppos 25 mg	2.44	10	✓ Voltaren
* Suppos 50 mg – Up to 10 supp available on a PSO	4.22	10	✓ Voltaren
* Suppos 100 mg	7.00	10	✓ Voltaren
IBUPROFEN			
* Tab 200 mg	21.40	1,000	✓ Relieve
* Tab long-acting 800 mg	3.65	30	✓ Ibuprofen SR BNM
* Oral liq 20 mg per ml	2.85	200 ml	✓ Ethics
KETOPROFEN			
* Cap long-acting 200 mg	12.07	28	✓ Oruvail SR
MEFENAMIC ACID			
* Cap 250 mg	1.25	50	
	(10.82)		Ponstan
	0.50	20	
	(7.50)		Ponstan
NAPROXEN			
* Tab 250 mg	39.23	500	✓ Noflam 250
* Tab 500 mg	34.45	250	✓ Noflam 500
* Tab long-acting 750 mg	10.40	28	✓ Naprosyn SR 750
* Tab long-acting 1 g	11.50	28	✓ Naprosyn SR 1000
TENOXICAM			
* Tab 20 mg	23.50	100	✓ Tilcotil
* Inj 20 mg vial	9.95	1	✓ AFT
NSAIDs Other			
CELECOXIB			
Cap 100 mg	3.45	60	✓ Celecoxib Pfizer
	3.60		✓ Celebrex
Cap 200 mg	3.20	30	✓ Celebrex
			✓ Celecoxib Pfizer

(Celecoxib Pfizer Cap 100 mg to be delisted 1 February 2026)

Topical Products for Joint and Muscular Pain

CAPSAICIN

Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy.....	9.75	45 g OP	✓ Zo-Rub Osteo ✓ Zostrix
--	------	---------	---

» [SA1289](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Antirheumatoid Agents

HYDROXYCHLOROQUINE SULPHATE

* Tab 200 mg	7.80	100	✓ Ipca-Hydroxychloroquine
--------------------	------	-----	----------------------------------

LEFLUNOMIDE

* Tab 10 mg	6.00	30	✓ Arava
* Tab 20 mg	6.00	30	✓ Arava

PENICILLAMINE

Tab 125 mg	67.23	100	✓ D-Penamine
Tab 250 mg	110.12	100	✓ D-Penamine

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

ALENDRONATE SODIUM

* Tab 70 mg	3.10	4	✓ Fosamax
-------------------	------	---	------------------

ALENDRONATE SODIUM WITH COLECALCIFEROL

* Tab 70 mg with colecalciferol 5,600 iu	1.99	4	✓ Fosamax Plus
--	------	---	-----------------------

Other Treatments

DENOSUMAB – Special Authority see [SA2441 below](#) – Retail pharmacy

Note: Denosumab inj 60 mg per 1 ml pre-filled syringe is Medsafe approved for use in osteoporosis. Denosumab inj 120 mg per 1.7 ml vial is Medsafe approved for use in hypercalcaemia of malignancy.

Inj 120 mg per 1.7 ml vial	500.00	1	✓ Xgeva
Inj 60 mg per 1 ml prefilled syringe.....	250.00	1	✓ Prolia

» [SA2441](#) Special Authority for Subsidy

Initial application — (Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has established osteoporosis; and
- 2 Any of the following:
 - 2.1 History of one significant osteoporotic fracture demonstrated radiologically, with a documented T-Score less than or equal to -2.5, that incorporates BMD measured using dual-energy x-ray absorptiometry (DEXA); or
 - 2.2 History of one significant osteoporotic fracture, demonstrated radiologically, and either the patient is elderly, or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- densitometry scanning cannot be performed because of logistical, technical or pathophysiological reasons; or
- 2.3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 2.4 Documented T-Score less than or equal to -3.0; or
- 2.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm that incorporates BMD measured using DEXA; and

3 Any of the following:

- 3.1 Bisphosphonates are contraindicated because the patient's creatinine clearance or eGFR is less than 35 mL/min; or
- 3.2 The patient has experienced at least two symptomatic new fractures or a BMD loss greater than 2% per year, after at least 12 months' continuous therapy with a funded antiresorptive agent; or
- 3.3 Bisphosphonates result in intolerable side effects; or
- 3.4 Intravenous bisphosphonates cannot be administered due to logistical or technical reasons.

Initial application — (Hypercalcaemia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has hypercalcaemia of malignancy; and
- 2 Patient has severe renal impairment.

PAMIDRONATE DISODIUM

Inj 3 mg per ml, 10 ml vial.....	32.49	1	✓ Pamisol
Inj 6 mg per ml, 10 ml vial.....	88.11	1	✓ Pamisol
Inj 9 mg per ml, 10 ml vial.....	94.34	1	✓ Pamisol

RALOXIFENE HYDROCHLORIDE – Special Authority see [SA1779 below](#) – Retail pharmacy

* Tab 60 mg	53.76	28	✓ Evista
-------------------	-------	----	----------

(Evista Tab 60 mg to be delisted 1 April 2026)

► **SA1779** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score less than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause – Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg 3.00 4 ✓ **Risedronate Sandoz**

TERIPARATIDE – Special Authority see [SA1139 below](#) – Retail pharmacy

Inj 250 mcg per ml, 2.4 ml 195.00 1 ✓ **Teriparatide - Teva**

► [SA1139](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID

Inj 0.05 mg per ml, 100 ml, bag 19.45 1 ✓ **Zoledronic Acid Viatris**

Hyperuricaemia and Antigout

ALLOPURINOL

* Tab 100 mg 17.99 1,000 ✓ **Ipca-Allopurinol**

* Tab 300 mg 22.50 500 ✓ **Ipca-Allopurinol**

BENZBROMARONE – Special Authority see [SA1963 below](#) – Retail pharmacy

Tab 50 mg 32.00 100 ✓ **Narcarcin mite** ^{§29}

► [SA1963](#) Special Authority for Subsidy

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
COLCHICINE				
* Tab 500 mcg.....	6.00	100	✓	Colgout
FEBUXOSTAT – Special Authority see SA2054 below – Retail pharmacy				
Tab 80 mg	4.73	28	✓	Febuxostat (Teva)
Tab 120 mg	11.78	28	✓	Febuxostat (Teva)

► **SA2054** Special Authority for Subsidy

Initial application — (Gout) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout..

Initial application — (Tumour lysis syndrome) only from a haematologist or oncologist. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome; and
- 2 Patient has a documented history of allopurinol intolerance.

Renewal — (Gout) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Renewal — (Tumour lysis syndrome) only from a haematologist or oncologist. Approvals valid for 6 weeks where the treatment remains appropriate and the patient is benefitting from treatment.

PROBENECID

* Tab 500 mg	66.95	100	✓	Probenecid-AFT
--------------------	-------	-----	---	-----------------------

Muscle Relaxants

BACLOFEN

* Tab 10 mg	3.70	100	✓	Pacifen
Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by endorsement.....	11.55	1	✓	Lioresal Intrathecal
Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.				
Inj 2 mg per ml, 5 ml ampoule – Subsidy by endorsement.....	490.91	10	✓	Sintetica Baclofen Intrathecal

Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.

DANTROLENE

Cap 25 mg	145.77	100	✓	Dantrium S29 S29
Cap 50 mg	77.00	100	✓	Dantrium

ORPHENADRINE CITRATE

Tab 100 mg	23.25	100	✓	Norflex
------------------	-------	-----	---	----------------

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Agents for Parkinsonism and Related Disorders

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

▲ Cap 100 mg	38.24	60	✓ Symmetrel
	63.73	100	✓ Symmetrel

APOMORPHINE HYDROCHLORIDE

▲ Inj 10 mg per ml, 2 ml ampoule	59.50	5	✓ Movapo
▲ Inj 10 mg per ml, 5 ml ampoule	121.84	5	✓ Movapo

ENTACAPONE

▲ Tab 200 mg	13.73	100	✓ <u>Entacapone Viatris</u>
--------------------	-------	-----	-----------------------------

LEVODOPA WITH BENSERAZIDE

* Tab dispersible 50 mg with benserazide 12.5 mg	13.25	100	✓ Madopar Rapid
* Cap 50 mg with benserazide 12.5 mg	13.75	100	✓ Madopar 62.5
* Cap 100 mg with benserazide 25 mg	15.80	100	✓ Madopar 125
* Cap long-acting 100 mg with benserazide 25 mg	22.85	100	✓ Madopar HBS
* Cap 200 mg with benserazide 50 mg	26.25	100	✓ Madopar 250

LEVODOPA WITH CARBIDOPA

* Tab 100 mg with carbidopa 25 mg	26.49	100	✓ <u>Sinemet</u>
* Tab long-acting 200 mg with carbidopa 50 mg	44.99	100	✓ <u>Sinemet CR</u>
* Tab 250 mg with carbidopa 25 mg	39.49	100	✓ <u>Sinemet</u>

LEVODOPA WITH CARBIDOPA AND ENTACAPONE

* Tab 50 mg with carbidopa 12.5 mg and entacapone 200 mg	27.01	100	✓ <u>Stalevo</u>
* Tab 100 mg with carbidopa 25 mg and entacapone 200 mg	34.18	100	✓ <u>Stalevo</u>
* Tab 150 mg with carbidopa 37.5 mg and entacapone 200 mg	44.96	100	✓ <u>Stalevo</u>
* Tab 200 mg with carbidopa 50 mg and entacapone 200 mg	51.23	100	✓ <u>Stalevo</u>

PRAMIPEXOLE HYDROCHLORIDE

▲ Tab 0.25 mg	5.23	100	✓ Ramipex
Ramipex to be Principal Supply on 1 December 2025			
▲ Tab 1 mg	17.73	100	✓ Ramipex
Ramipex to be Principal Supply on 1 December 2025			

RASAGILINE

* Tab 1 mg	53.50	30	✓ Azilect ^{\$29}
------------------	-------	----	---------------------------

ROPINIROLE HYDROCHLORIDE

▲ Tab 0.25 mg	4.05	84	✓ Ropin
▲ Tab 1 mg	4.95	84	✓ Ropin
▲ Tab 2 mg	6.48	84	✓ Ropin
▲ Tab 5 mg	14.50	84	✓ Ropin

TOLCAPONE

▲ Tab 100 mg	152.38	100	✓ Tasmar
--------------------	--------	-----	----------

Anticholinergics

BENZATROPINE MESYLATE

Tab 2 mg	10.99	60	✓ Bantzrop
Inj 1 mg per ml, 2 ml	95.00	5	✓ Phebra
a) Up to 10 inj available on a PSO			
b) Only on a PSO			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PROCYCLIDINE HYDROCHLORIDE				
Tab 5 mg	7.40	100	✓	Kemadrin

Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – Special Authority see [SA1403 below](#) – Retail pharmacy

Wastage claimable

Tab 50 mg	117.00	56	✓	Rilutek
-----------------	--------	----	---	---------

►SA1403 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limbs; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE				
Tab 25 mg	126.02	112	✓	Motetis

Anaesthetics

Local

LIDOCAINE [LIGNOCAINE]

Gel 2%, tube – Subsidy by endorsement	14.50	30 ml	✓	Xylocaine 2% Jelly
a) Up to 150 ml available on a PSO				
b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.				
Gel 2%, 11 ml urethral syringe – Subsidy by endorsement.....	65.45	10	✓	Instillagel Lido
a) Up to 5 each available on a PSO				
b) Subsidised only if prescribed for urethral, cervical or rectal administration and the prescription is endorsed accordingly.				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE				
Oral (gel) soln 2%.....	44.00	200 ml	✓	Mucosoothe
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO.....	15.00	25	✓	Lidocaine-Baxter
	17.50	50		
	(35.00)			Xylocaine
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO.....	27.50	25	✓	Lidocaine-Baxter
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO.....	12.00	5		
	(20.00)			Xylocaine
Inj 1%, 20 ml vial – Up to 5 inj available on a PSO.....	19.50	5	✓	Lidocaine-Baxter
Inj 2%, 20 ml vial – Up to 5 inj available on a PSO.....	14.00	5	✓	Lidocaine-Baxter
Inj 10%, 5 ml ampoule – Subsidy by endorsement.....	CBS	10	✓	Xylocard 500 ^{\$29}
Subsidised only for people receiving palliative care services where other analgesic agents haven't been effective.				

Topical Local Anaesthetics

➔SA0906 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

LIDOCAINE [LIGNOCAINE] – Special Authority see [SA0906 above](#) – Retail pharmacy

Crm 4%.....	7.60	5 g OP	✓	LMX4
	30.00	30 g OP	✓	LMX4

LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE – Special Authority see [SA0906 above](#) – Retail pharmacy

Crm 2.5% with prilocaine 2.5%.....	45.00	30 g OP	✓	EMLA
Crm 2.5% with prilocaine 2.5% (5 g tubes).....	45.00	5	✓	EMLA

Analgesics

For Anti-inflammatory NSAIDs refer to MUSCULOSKELETAL, [page 119](#)

Non-opioid Analgesics

ASPIRIN

* Tab dispersible 300 mg – Up to 30 tab available on a PSO.....5.65 100 ✓ **Ethics Aspirin**

CAPSAICIN – Subsidy by endorsement

Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.

Crm 0.075%.....	11.95	45 g OP	✓	Zo-Rub HP
			✓	Zostrix HP

NEFOPAM HYDROCHLORIDE

Tab 30 mg.....	23.40	90	✓	Acupan
----------------	-------	----	---	---------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PARACETAMOL				
Tab 500 mg - blister pack	19.75	1,000	✓	<u>Pacimol</u>
a) Maximum of 300 tab per prescription; can be waived by endorsement b) Up to 30 tab available on a PSO c) 1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. 2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.				
Tab 500 mg - bottle pack – Maximum of 300 tab per prescription; can be waived by endorsement	17.92	1,000	✓	<u>Noumed Paracetamol</u>
1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. 2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.				
Oral liq 120 mg per 5 ml	3.98	200 ml	✓	<u>Paracetamol (Ethics)</u>
a) Maximum of 600 ml per prescription; can be waived by endorsement b) Up to 200 ml available on a PSO c) Not in combination d) 1) Maximum of 200 ml per dispensing for non-endorsed patients. If quantities prescribed exceed 200 ml (for non-endorsed patients), then dispense in repeat dispensing not exceeding 200 ml per dispensing. 2) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater and the prescription is endorsed or annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. 3) Note: 200 ml presentations of paracetamol oral liquid may be supplied on BSO to a Vaccinator (other than a Pharmacist) under the provisions in Part I of Section A 4) Note: Direct Provision by a pharmacist of up to 200 ml permitted under the provisions in Part I of Section A in conjunction with immunisation of a child under 2 years of age with meningococcal B multicomponent vaccine.				
Oral liq 250 mg per 5 ml	3.35	200 ml	✓	<u>Pamol</u>
a) Maximum of 600 ml per prescription; can be waived by endorsement b) Up to 200 ml available on a PSO c) Not in combination d) 1) Maximum of 200 ml per dispensing for non-endorsed patients. If quantities prescribed exceed 200 ml (for non-endorsed patients), then dispense in repeat dispensing not exceeding 200 ml per dispensing. 2) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater and the prescription is endorsed or annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. 3) Note: 200 ml presentations of paracetamol oral liquid may be supplied on BSO to a Vaccinator (other than a Pharmacist) under the provisions in Part I of Section A 4) Note: Direct Provision by a pharmacist of up to 200 ml permitted under the provisions in Part I of Section A in conjunction with immunisation of a child under 2 years of age with meningococcal B multicomponent vaccine.				
* Suppos 125 mg	4.29	10	✓	<u>Gacet</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
* Suppos 250 mg	5.39	10	✓	<u>Gacet</u>
* Suppos 500 mg	16.55	50	✓	<u>Gacet</u>

Opioid Analgesics

CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency

Tab 15 mg	5.82	100	✓	<u>Noumed</u>
Noumed to be Principal Supply on 1 December 2025				
Tab 30 mg	6.88	100	✓	<u>Noumed</u>
Noumed to be Principal Supply on 1 December 2025				
Tab 60 mg	13.89	100	✓	<u>Noumed</u>
Noumed to be Principal Supply on 1 December 2025				

DIHYDROCODEINE TARTRATE

Tab long-acting 60 mg	9.20	60	✓	<u>DHC Continus</u>
-----------------------------	------	----	---	---------------------

FENTANYL

a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Inj 50 mcg per ml, 2 ml ampoule	4.25	10	✓	<u>Boucher and Muir</u>
Inj 50 mcg per ml, 10 ml ampoule	9.41	10	✓	<u>Boucher and Muir</u>
Patch 12 mcg per hour	6.02	5	✓	<u>Fentanyl Sandoz</u>
Patch 12.5 mcg per hour	6.02	5	✓	<u>Fentanyl Sandoz</u>
Patch 25 mcg per hour	6.91	5	✓	<u>Fentanyl Sandoz</u>
Patch 50 mcg per hour	9.28	5	✓	<u>Fentanyl Sandoz</u>
Patch 75 mcg per hour	15.50	5	✓	<u>Fentanyl Sandoz</u>
Patch 100 mcg per hour	16.37	5	✓	<u>Fentanyl Sandoz</u>

(Fentanyl Sandoz Patch 12.5 mcg per hour to be delisted 1 November 2025)

METHADONE HYDROCHLORIDE

a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab 5 mg	1.45	10	✓	<u>Methadone BNM</u>
Oral liq 2 mg per ml	7.80	200 ml	✓	<u>Biodone</u>
Oral liq 5 mg per ml	7.80	200 ml	✓	<u>Biodone Forte</u>
Oral liq 10 mg per ml	9.65	200 ml	✓	<u>Biodone Extra Forte</u>
Inj 10 mg per ml, 1 ml	72.99	10	✓	<u>AFT</u>

MORPHINE HYDROCHLORIDE

a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Oral liq 1 mg per ml	19.00	200 ml	✓	<u>RA-Morph</u>
Oral liq 2 mg per ml	23.55	200 ml	✓	<u>RA-Morph</u>
Oral liq 5 mg per ml	28.20	200 ml	✓	<u>RA-Morph</u>
Oral liq 10 mg per ml	40.25	200 ml	✓	<u>RA-Morph</u>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
MORPHINE SULPHATE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing frequency			
Tab immediate-release 10 mg.....	2.80	10	✓ Sevredol
Tab immediate-release 20 mg.....	5.52	10	✓ Sevredol
Cap long-acting 10 mg	3.00	10	✓ m-Eslon
Cap long-acting 30 mg	4.30	10	✓ m-Eslon
Cap long-acting 60 mg	9.00	10	✓ m-Eslon
Cap long-acting 100 mg	10.50	10	✓ m-Eslon
Oral liq 2 mg per ml	16.31	100 ml	✓ Wockhardt S29
	29.80		✓ Oramorph
			✓ Oramorph CDC
			S29 S29
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	5.96	5	✓ Medsurge
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	4.99	5	✓ Medsurge
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.93	5	✓ Medsurge
Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	7.28	5	✓ Medsurge
OXYCODONE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing frequency			
Tab controlled-release 5 mg.....	2.49	20	✓ Oxycodone Sandoz
Tab immediate-release 5 mg.....	13.77	100	✓ Oxycodone Amneal
Tab controlled-release 10 mg.....	2.49	20	✓ Oxycodone Sandoz
Tab immediate-release 10 mg.....	18.77	100	✓ Oxycodone Amneal
Tab controlled-release 20 mg.....	3.41	20	✓ Oxycodone Sandoz
Tab immediate-release 20 mg.....	26.77	100	✓ Oxycodone Amneal
Tab controlled-release 40 mg.....	6.67	20	✓ Oxycodone Sandoz
Tab controlled-release 80 mg.....	12.99	20	✓ Oxycodone Sandoz
Oral liq 1 mg per ml	37.08	250 ml	✓ Oxycodone Lucis
Inj 10 mg per ml, 1 ml ampoule	4.37	5	✓ Hameln
Inj 10 mg per ml, 2 ml ampoule	8.62	5	✓ Hameln
Inj 50 mg per ml, 1 ml ampoule	14.90	5	✓ Hameln
PARACETAMOL WITH CODEINE – Safety medicine; prescriber may determine dispensing frequency			
* Tab paracetamol 500 mg with codeine phosphate 8 mg.....	31.95	1,000	✓ Paracetamol + Codeine (Relieve)
PETHIDINE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing frequency			
Tab 50 mg	8.68	10	✓ Noumed Pethidine
Inj 50 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	29.88	5	✓ DBL Pethidine Hydrochloride
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	30.72	5	✓ DBL Pethidine Hydrochloride
TRAMADOL HYDROCHLORIDE			
Tab sustained-release 100 mg.....	1.95	20	✓ Tramal SR 100
Tab sustained-release 150 mg.....	2.95	20	✓ Tramal SR 150
Tab sustained-release 200 mg.....	3.80	20	✓ Tramal SR 200
Cap 50 mg.....	3.33	100	✓ Arrow-Tramadol

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Antidepressants

Cyclic and Related Agents

AMITRIPTYLINE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg	2.99	100	✓ Arrow-Amitriptyline
Tab 25 mg	1.99	100	✓ Arrow-Amitriptyline
Tab 50 mg	3.14	100	✓ Arrow-Amitriptyline

CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 25 mg	16.99	50	✓ APO Clomipramine
Cap 10 mg	35.50	28	✓ Clomipramine Teva

(Clomipramine Teva Cap 10 mg to be delisted 1 April 2026)

DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by endorsement

- a) Safety medicine; prescriber may determine dispensing frequency
b) Subsidy by endorsement – Subsidised for patients who were taking dosulepin [dothiepin] hydrochloride prior to 1 June 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dosulepin [dothiepin] hydrochloride.

Tab 75 mg	3.85	30	✓ Dosulepin Viatrix
Cap 25 mg	7.83	50	✓ Dosulepin Viatrix ^{\$29}

IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg	5.48	50	✓ Tofranil
	10.96	100	✓ Tofranil
Tab 25 mg	4.93	28	✓ Imipramine Crescent ^{\$29}
	8.80	50	✓ Tofranil

NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg	2.24	50	✓ Allegron
	2.46	100	✓ Norpress
Tab 25 mg	2.95	50	✓ Allegron
	6.29	180	✓ Norpress

Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

TRANLYCYPROMINE SULPHATE

* Tab 10 mg	22.94	50	✓ Parnate
-------------------	-------	----	------------------

Monoamine-Oxidase Type A Inhibitors

MOCLOBEMIDE

* Tab 150 mg	23.60	60	✓ Aurorix
* Tab 300 mg	38.50	60	✓ Aurorix

Selective Serotonin Reuptake Inhibitors

CITALOPRAM HYDROBROMIDE

* Tab 20 mg	2.86	84	✓ Celapram
-------------------	------	----	-------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ESCITALOPRAM				
* Tab 10 mg	0.79	28	✓	Ipca-Escitalopram
	1.07		✓	Escitalopram (Ethics)
* Tab 20 mg	1.49	28	✓	Ipca-Escitalopram
FLUOXETINE HYDROCHLORIDE				
* Tab dispersible 20 mg, scored – Subsidy by endorsement	2.37	28	✓	Fluox
Subsidised by endorsement				
1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or				
2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.				
* Cap 20 mg	3.50	90	✓	Arrow-Fluoxetine
PAROXETINE				
* Tab 20 mg	1.66	30	✓	Paxtine
	4.98	90	✓	Loxamine
<i>(Paxtine Tab 20 mg to be delisted 1 March 2026)</i>				
SERTRALINE				
* Tab 50 mg	0.99	30	✓	Setrona
* Tab 100 mg	1.74	30	✓	Setrona

Other Antidepressants

MIRTAZAPINE				
Tab 30 mg	2.34	30	✓	Noumed
Noumed to be Principal Supply on 1 January 2026				
Tab 45 mg	3.10	30	✓	Noumed
Noumed to be Principal Supply on 1 January 2026				
VENLAFAXINE				
* Cap 37.5 mg	8.29	84	✓	Enlafax XR
* Cap 75 mg	10.32	84	✓	Enlafax XR
* Cap 150 mg	13.95	84	✓	Enlafax XR

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement	27.92	5	✓	Hospira
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
c) PSO must be endorsed “not for anaesthetic procedures”.				
Rectal tubes 5 mg – Up to 5 tube available on a PSO	54.58	5	✓	Stesolid
PHENYTOIN SODIUM				
* Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	104.58	5	✓	Hospira
* Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available on a PSO	154.01	5	✓	Hospira
<i>(Hospira Inj 50 mg per ml, 2 ml ampoule to be delisted 1 February 2026)</i>				

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Control of Epilepsy				
CARBAMAZEPINE				
* Tab 200 mg	14.53	100	✓	Tegretol
* Tab long-acting 200 mg	16.98	100	✓	Tegretol CR
	33.96	200	✓	Tegretol CR
* Tab 400 mg	34.58	100	✓	Tegretol
* Tab long-acting 400 mg	39.17	100	✓	Tegretol CR
* Oral liq 20 mg per ml	26.37	250 ml	✓	Tegretol
CLOBAZAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	9.12	50	✓	Frisium
CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Oral drops 2.5 mg per ml	7.38	10 ml OP	✓	Rivotril
ETHOSUXIMIDE				
Cap 250 mg	78.89	56	✓	Essential Ethosuximide ^{\$29}
	140.88	100	✓	Zarontin
Oral liq 250 mg per 5 ml	56.35	200 ml	✓	Zarontin
<i>(Essential Ethosuximide ^{\$29} Cap 250 mg to be delisted 1 December 2025)</i>				
GABAPENTIN				
Note: Not subsidised in combination with subsidised pregabalin				
* Cap 100 mg	6.45	100	✓	Nupentin
* Cap 300 mg	8.45	100	✓	Nupentin
* Cap 400 mg	10.26	100	✓	Nupentin
LACOSAMIDE – Special Authority see SA2267 below – Retail pharmacy				
▲ Tab 50 mg	25.04	14	✓	Vimpat
▲ Tab 100 mg	50.06	14	✓	Vimpat
	200.24	56	✓	Vimpat
▲ Tab 150 mg	75.10	14	✓	Vimpat
	300.40	56	✓	Vimpat
▲ Tab 200 mg	400.55	56	✓	Vimpat
►SA2267 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:				
Both:				
1 Patient has focal epilepsy; and				
2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).				
Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.				
Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment.				
LAMOTRIGINE				
▲ Tab dispersible 2 mg	55.00	30	✓	Lamictal
▲ Tab dispersible 5 mg	50.00	30	✓	Lamictal
* Tab dispersible 25 mg	4.20	56	✓	Logem
* Tab dispersible 50 mg	5.11	56	✓	Logem
* Tab dispersible 100 mg	6.75	56	✓	Logem

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEVETIRACETAM				
Tab 250 mg	5.84	60	✓	Everet
Tab 500 mg	10.51	60	✓	Everet
Tab 750 mg	16.71	60	✓	Everet
Tab 1,000 mg	21.82	60	✓	Everet
Oral liq 100 mg per ml	44.78	300 ml OP	✓	Levetiracetam-AFT
Inj 100 mg per ml, 5 ml vial	38.95	10	✓	Levetiracetam-AFT
PHENOBARBITONE				
For phenobarbitone oral liquid refer Standard Formulae, page 284				
Tab 15 mg	248.50	500	✓	Noumed Phenobarbitone
Tab 30 mg	398.50	500	✓	Noumed Phenobarbitone
PHENYTOIN SODIUM				
* Tab 50 mg	75.00	200	✓	Dilantin Infatab
Cap 30 mg	74.00	200	✓	Dilantin
Cap 100 mg	37.00	200	✓	Dilantin
* Oral liq 30 mg per 5 ml	22.03	500 ml	✓	Dilantin Paediatric
PREGABALIN				
Note: Not subsidised in combination with subsidised gabapentin				
* Cap 25 mg	2.25	56	✓	Lyrica
* Cap 75 mg	2.65	56	✓	Pregabalin Pfizer
* Cap 150 mg	4.01	56	✓	Lyrica
* Cap 300 mg	7.38	56	✓	Pregabalin Pfizer
PRIMIDONE				
* Tab 250 mg	37.35	100	✓	Primidone Clinect
SODIUM VALPROATE				
Tab 100 mg	13.65	100	✓	Epilim Crushable
Tab 200 mg EC	27.44	100	✓	Epilim
Tab 500 mg EC	52.24	100	✓	Epilim
* Oral liq 200 mg per 5 ml	20.48	300 ml	✓	Epilim S/F Liquid
* Inj 100 mg per ml, 4 ml	41.50	1	✓	Epilim Syrup
STIRIPENTOL – Special Authority see SA2268 below – Retail pharmacy				
Cap 250 mg	509.29	60	✓	Diacomit
Powder for oral liq 250 mg sachet	509.29	60	✓	Diacomit

➔ **SA2268** Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Note: Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

▲ Tab 25 mg	11.07	60	✓	Arrow-Topiramate
	26.04		✓	Topiramate Actavis
	18.81	60	✓	Topamax
▲ Tab 50 mg	44.26		✓	Arrow-Topiramate
	31.99	60	✓	Topiramate Actavis
	75.25		✓	Topamax
▲ Tab 100 mg	55.19	60	✓	Arrow-Topiramate
	129.85		✓	Topiramate Actavis
	20.84	60	✓	Topamax
▲ Tab 200 mg	26.04	60	✓	Topamax

VIGABATRIN – Special Authority see [SA2088 below](#) – Retail pharmacy

▲ Tab 500 mg	119.30	100	✓	Sabril
▲ Powder for oral soln 500 mg per sachet.....	71.58	60	✓	Sabril

►SA2088 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; or
 - 1.3 Patient has tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields..

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields..

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Antimigraine Preparations

For Anti-inflammatory NSAIDs refer to MUSCULOSKELETAL, [page 119](#)

Acute Migraine Treatment

RIZATRIPTAN		
Tab orodispersible 10 mg	4.84	30 ✓ Rizamelt
SUMATRIPTAN		
Tab 50 mg	14.41	90 ✓ Sumagran
Tab 100 mg	22.68	90 ✓ Sumagran
Inj 12 mg per ml, 0.5 ml prefilled pen – Maximum of 10 inj per prescription	29.80	2 OP ✓ Clustran
Clustran to be Principal Supply on 1 December 2025		

Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, [page 49](#)

PIZOTIFEN		
* Tab 500 mcg	23.21	100 ✓ Sandomigran

Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, [page 8](#)

APREPITANT – Special Authority see SA0987 below – Retail pharmacy		
Cap 2 x 80 mg and 1 x 125 mg	21.90	3 OP ✓ Emend Tri-Pack

►SA0987 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE		
* Tab 16 mg	3.70	100 ✓ Serc
CYCLIZINE HYDROCHLORIDE		
Tab 50 mg	0.66	10 ✓ Nausicalm

CYCLIZINE LACTATE		
Inj 50 mg per ml, 1 ml ampoule – Up to 10 inj available on a PSO	16.36	10 ✓ Hameln

DOMPERIDONE		
* Tab 10 mg	3.80	100 ✓ Domperidone Viatris

Domperidone Viatris to be Principal Supply on 1 December 2025

HYOSCINE HYDROBROMIDE		
* Inj 400 mcg per ml, 1 ml ampoule	93.00	10 ✓ Martindale S29
Patch 1 mg per 72 hours – Special Authority see SA1998 on the next page – Retail pharmacy	88.50	10 ✓ Scopolamine Transdermal System Viatris

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA1998 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:
Either:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
- 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.

Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

METOCLOPRAMIDE HYDROCHLORIDE

* Tab 10 mg – Up to 30 tab available on a PSO	1.57	100	✓ Metoclopramide Actavis 10
* Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	7.00	10	✓ Baxter

ONDANSETRON

* Tab 4 mg	1.95	50	✓ Periset
Periset to be Principal Supply on 1 December 2025			
Tab disp 4 mg – Up to 10 tab available on a PSO	0.56	10	✓ Periset ODT
* Tab 8 mg	3.50	50	✓ Periset
Periset to be Principal Supply on 1 December 2025			
Tab disp 8 mg – Up to 10 tab available on a PSO	0.90	10	✓ Periset ODT

PROCHLORPERAZINE

* Tab 3 mg buccal	5.97 (30.00)	50	Prochlorperazine maleate (Brown & Burk)
* Tab 5 mg – Up to 30 tab available on a PSO	25.00	250	✓ Nausafix
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO	25.81	10	✓ Stemetil

Antipsychotics

General

AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 100 mg	5.84	30	✓ Sulprix
Tab 200 mg	14.47	60	✓ Sulprix
Tab 400 mg	35.06	60	✓ Sulprix

ARIPRAZOLE – Safety medicine; prescriber may determine dispensing frequency

Tab 5 mg	10.50	30	✓ Aripiprazole Sandoz
Tab 10 mg	10.50	30	✓ Aripiprazole Sandoz
Tab 15 mg	10.50	30	✓ Aripiprazole Sandoz
Tab 20 mg	10.50	30	✓ Aripiprazole Sandoz
Tab 30 mg	10.50	30	✓ Aripiprazole Sandoz

CHLORPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 25 mg – Up to 30 tab available on a PSO	15.62	100	✓ Largactil
Tab 100 mg – Up to 30 tab available on a PSO	36.73	100	✓ Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO	30.79	10	✓ Largactil

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CLOZAPINE – Hospital pharmacy [HP4]				
Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg	6.69	50	✓ Clopine	
	13.37	100	✓ Clozaril	
			✓ Clopine	
			✓ Clozaril	
Tab 50 mg	8.67	50	✓ Clopine	
	17.33	100	✓ Clopine	
Tab 100 mg	17.33	50	✓ Clopine	
			✓ Clozaril	
	34.65	100	✓ Clopine	
			✓ Clozaril	
Tab 200 mg	34.65	50	✓ Clopine	
	69.30	100	✓ Clopine	
Suspension 50 mg per ml.....	173.30	100 ml	✓ Versacloz	
HALOPERIDOL – Safety medicine; prescriber may determine dispensing frequency				
Tab 500 mcg – Up to 30 tab available on a PSO	6.23	100	✓ Serenace	
Tab 1.5 mg – Up to 30 tab available on a PSO	9.43	100	✓ Serenace	
Tab 5 mg – Up to 30 tab available on a PSO	14.86	50	✓ Serenace	
	29.72	100	✓ Serenace	
Oral liq 2 mg per ml – Up to 200 ml available on a PSO	23.84	100 ml	✓ Serenace	
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	21.55	10	✓ Serenace	
LEVOMEPRMAZINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg (33.8 mg as a maleate)	16.10	100	✓ Nozinan (Swiss)	
Tab 25 mg as a maleate.....	16.10	100	✓ Nozinan	
Tab 100 mg (135 mg as a maleate)	41.75	100	✓ Nozinan (Swiss)	
Tab 100 mg as a maleate.....	41.75	100	✓ Nozinan	
LEVOMEPRMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Inj 25 mg per ml, 1 ml ampoule	23.26	10	✓ Wockhardt	
Wockhardt to be Principal Supply on 1 December 2025				
LITHIUM CARBONATE – Safety medicine; prescriber may determine dispensing frequency				
Tab long-acting 400 mg.....	82.80	100	✓ Priadel	
Cap 250 mg	35.78	100	✓ Douglas	
OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 2.5 mg	1.40	30	✓ Zypine	
Tab 5 mg	1.93	30	✓ Zypine	
Tab orodispersible 5 mg.....	2.42	28	✓ Zypine ODT	
Tab 10 mg	1.93	30	✓ Zypine	
Tab orodispersible 10 mg.....	2.89	28	✓ Zypine ODT	
PERICYAZINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 2.5 mg	13.61	100	✓ Neulactil	
Tab 10 mg	48.45	100	✓ Neulactil	

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg	0.79	30	✓	Quetiapine Viatris \$29
	2.36	90	✓	Quetapel
	13.11	500	✓	Quetiapine Viatris \$29
Tab 100 mg	6.40	90	✓	Quetapel
Tab 200 mg	10.97	90	✓	Quetapel
Tab 300 mg	15.83	90	✓	Quetapel
RISPERIDONE – Safety medicine; prescriber may determine dispensing frequency				
Tab 0.5 mg	2.17	60	✓	Risperidone (Teva)
Tab 1 mg	2.44	60	✓	Risperidone (Teva)
Tab 2 mg	2.72	60	✓	Risperidone (Teva)
Tab 3 mg	4.50	60	✓	Risperidone (Teva)
Tab 4 mg	6.25	60	✓	Risperdal
			✓	Risperidone (Teva)
Oral liq 1 mg per ml	10.29	30 ml	✓	Risperon
ZIPRASIDONE – Safety medicine; prescriber may determine dispensing frequency				
Cap 20 mg	17.90	60	✓	Zusdone
Cap 40 mg	27.41	60	✓	Zusdone
Cap 60 mg	38.39	60	✓	Zusdone
Cap 80 mg	46.55	60	✓	Zusdone
ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	31.45	100	✓	Clopixol

Depot Injections

ARIPIPIRAZOLE – Special Authority see [SA2395 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 300 mg vial	273.56	1	✓	Abilify Maintena
Inj 400 mg vial	341.96	1	✓	Abilify Maintena

► [SA2395](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 Either:

- 1.1 The patient has had an initial Special Authority approval for risperidone depot injection, paliperidone depot injection or olanzapine depot injection; or
- 1.2 All of the following:
 - 1.2.1 The patient has schizophrenia or other psychotic disorder; and
 - 1.2.2 The patient has received treatment with oral atypical antipsychotic agents but has been unable to adhere; and
 - 1.2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months; or

- 2 Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been started on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection.

Notes: The Olanzapine depot injection Special Authority criteria that apply to criterion 2 in this Aripiprazole Special Authority

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

application are as follows:

- The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- All of the following:
 - The patient has schizophrenia; and
 - The patient has not been able to adhere with treatment using oral atypical antipsychotic agents; and
 - The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

FLUPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO	13.14	5	✓ Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO	20.90	5	✓ Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	40.87	5	✓ Fluanxol

HALOPERIDOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	28.39	5	✓ Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	55.90	5	✓ Haldol Concentrate
			✓ Haldol
			Decanoas S29

OLANZAPINE – Special Authority see SA2313 below – Retail pharmacy

- Safety medicine; prescriber may determine dispensing frequency
- Note – no new patients to be initiated on olanzapine.

Inj 210 mg vial	252.00	1	✓ Zyprexa Relprevv
Inj 300 mg vial	414.00	1	✓ Zyprexa Relprevv
Inj 405 mg vial	504.00	1	✓ Zyprexa Relprevv

►SA2313 Special Authority for Subsidy

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE – Special Authority see SA2396 below – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg syringe	194.25	1	✓ Invega Sustenna
Inj 50 mg syringe	271.95	1	✓ Invega Sustenna
Inj 75 mg syringe	357.42	1	✓ Invega Sustenna
Inj 100 mg syringe	435.12	1	✓ Invega Sustenna
Inj 150 mg syringe	435.12	1	✓ Invega Sustenna

►SA2396 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection or aripiprazole depot injection; or
- All of the following:
 - The patient has schizophrenia or other psychotic disorder; and
 - Has been unable to adhere to treatment using oral atypical antipsychotic agents; and
 - Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PALIPERIDONE PALMITATE – Special Authority see SA2167 below – Retail pharmacy				
Inj 175 mg syringe	815.85	1	✓	Invega Trinza
Inj 263 mg syringe	1,072.26	1	✓	Invega Trinza
Inj 350 mg syringe	1,305.36	1	✓	Invega Trinza
Inj 525 mg syringe	1,305.36	1	✓	Invega Trinza

► [SA2167](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Both:

- 1 The patient has schizophrenia; and
- 2 The patient has had an initial Special Authority approval for paliperidone once-monthly depot injection.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

RISPERIDONE – Special Authority see [SA2397 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg vial	135.98	1	✓	Risperdal Consta
Inj 37.5 mg vial	178.71	1	✓	Risperdal Consta
Inj 50 mg vial	217.56	1	✓	Risperdal Consta

► [SA2397](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection or aripiprazole depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has not been able to adhere with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO	19.80	5	✓	Clopixol
--	-------	---	---	-----------------

Anxiolytics

BUSPIRONE HYDROCHLORIDE

* Tab 5 mg	13.95	100	✓	Buspirone Viatrix
* Tab 10 mg	12.50	100	✓	Buspirone Viatrix

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 500 mcg	5.64	100	✓	Paxam
Tab 2 mg	10.78	100	✓	Paxam

DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 2 mg	95.00	500	✓	Arrow-Diazepam
Tab 5 mg	115.00	500	✓	Arrow-Diazepam

LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 1 mg	10.20	250	✓	Ativan
Tab 2.5 mg	13.13	100	✓	Ativan

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Multiple Sclerosis Treatments

►SA2274 Special Authority for Subsidy

Initial application — (Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
 - 1.2 Patient has an EDSS score between 0 – 6.0; and
 - 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
 - 1.4 All of the following:
 - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
 - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever ($T > 37.5^{\circ}\text{C}$); and
 - 1.4.5 Either:
 - 1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or
 - 1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
 - 1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and
 - 1.6 Any of the following:
 - 1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or
 - 1.6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
 - 1.6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
 - 1.6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or
 - 1.6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan; or
- 2 Patient has an active approval for ocrelizumab and does not have primary progressive MS.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Renewal — (Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use of unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months).

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

DIMETHYL FUMARATE – Special Authority see [SA2274 above](#) – Retail pharmacy

a) Wastage claimable

b) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Cap 120 mg	520.00	14	✓ Tecfidera
Cap 240 mg	2,000.00	56	✓ Tecfidera

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FINGOLIMOD – Special Authority see SA2274 on the previous page – Retail pharmacy				
a) Wastage claimable				
b) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Cap 0.5 mg	2,200.00	28	✓	Gilenya
GLATIRAMER ACETATE – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 40 mg prefilled syringe	1,137.48	12	✓	Copaxone
INTERFERON BETA-1-ALPHA – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 6 million iu prefilled syringe	1,170.00	4	✓	Avonex
INTERFERON BETA-1-BETA – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 8 million iu per 1 ml	1,322.89	15	✓	Betaferon
NATALIZUMAB – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 20 mg per ml, 15 ml vial	1,750.00	1	✓	Tysabri
TERIFLUNOMIDE – Special Authority see SA2274 on the previous page – Retail pharmacy				
a) Wastage claimable				
b) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Tab 14 mg	263.96	28	✓	Teriflunomide Sandoz

Multiple Sclerosis Treatments - Other

OCRELIZUMAB – Special Authority see SA2273 below – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 30 mg per ml, 10 ml vial	9,346.00	1	✓	Ocrevus

►SA2273 Special Authority for Subsidy

Initial application — (Multiple Sclerosis - ocrelizumab) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Either:

- 1 All of the following:
 - 1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
 - 1.2 Patient has an EDSS score between 0 – 6.0; and
 - 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
 - 1.4 All of the following:
 - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
 - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C); and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

1.4.5 Either:

1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or

1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and

1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and

1.6 Any of the following:

1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or

1.6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or

1.6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or

1.6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or

1.6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan; or

2 Patient has an active Special Authority approval for either dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab or teriflunomide.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Renewal — (Multiple Sclerosis - ocrelizumab) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use of unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months).

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Initial application — (Primary Progressive Multiple Sclerosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Diagnosis of primary progressive multiple sclerosis (PPMS) meets the 2017 McDonald criteria and has been confirmed by a neurologist; and
- 2 Patient has an EDSS 2.0 (score equal to or greater than 2 on pyramidal functions) to EDSS 6.5; and
- 3 Patient has no history of relapsing remitting multiple sclerosis.

Renewal — (Primary Progressive Multiple Sclerosis) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of less than or equal to 6.5 at any time in the last six months (ie patient has walked 20 metres with bilateral assistance/aids, without rest in the last six months).

Sedatives and Hypnotics

MELATONIN – Special Authority see [SA2523 below](#) – Retail pharmacy

Tab modified-release 2 mg – No more than 5 tab per day 5.80

30

✓ **Vigisom**

Restricted to patients aged 18 years or under.

► **SA2523** Special Authority for Subsidy

Initial application only from a psychiatrist, paediatrician, neurologist, respiratory specialist or any relevant practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder)*; and
- 2 Behavioural and environmental approaches have been tried and were unsuccessful, or are inappropriate; and
- 3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
- 4 Patient is aged 18 years or under*.

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Renewal only from a psychiatrist, paediatrician, neurologist, respiratory specialist or any relevant practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is aged 18 years or under*; and
- 2 Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
- 3 Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
- 4 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Note: Indications marked with * are unapproved indications.

MIDAZOLAM – Safety medicine; prescriber may determine dispensing frequency

Inj 1 mg per ml, 5 ml ampoule7.80 10 ✓ **Midazolam-Baxter**

Inj 1 mg per ml, 5 ml plastic ampoule – Up to 10 inj available

on a PSO29.90 10 ✓ **Midazolam-Pfizer**

On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.

Inj 5 mg per ml, 1 ml plastic ampoule – Up to 10 inj available

on a PSO22.50 10 ✓ **Midazolam-Pfizer**

On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.

Inj 5 mg per ml, 3 ml ampoule4.75 5 ✓ **Midazolam-Baxter**

Inj 5 mg per ml, 3 ml plastic ampoule – Up to 5 inj available on

a PSO22.50 5 ✓ **Midazolam-Pfizer**

On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.

PHENOBARBITONE SODIUM – Special Authority see [SA1386 below](#) – Retail pharmacy

Inj 200 mg per ml, 1 ml ampoule113.37 10 ✓ **Max Health** ^{S29}

➔**SA1386** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 For the treatment of terminal agitation that is unresponsive to other agents; and
- 2 The applicant is part of a multidisciplinary team working in palliative care.

TEMAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg1.40 25 ✓ **Normison**

ZOPICLONE – Safety medicine; prescriber may determine dispensing frequency

Tab 7.5 mg21.85 500 ✓ **Zopiclone Actavis**

Spinal Muscular Atrophy

NUSINERSEN – PCT only – Special Authority see [SA2174 below](#)

Inj 12 mg per 5 ml vial120,000.00 1 ✓ **Spinraza**

➔**SA2174** **Special Authority for Subsidy**

Initial application — (**spinal muscular atrophy (SMA)**) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2 Patient is 18 years of age or under; and
- 3 Either:
 - 3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or
 - 3.2 Both:
 - 3.2.1 Patient is pre-symptomatic; and
 - 3.2.2 Patient has three or less copies of SMN2.

Renewal — (spinal muscular atrophy (SMA)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with nusinersen; and
- 3 Nusinersen not to be administered in combination other SMA disease modifying treatments or gene therapy.

RISDIPLAM – [Xpharm] – Special Authority see [SA2203 below](#)

Note: the supply of risdiplam is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website <https://pharmac.govt.nz/risdiplam>

Powder for oral soln 750 mcg per ml, 60 mg per bottle..... 14,100.00 80 ml OP ✓ Evrysdi

►SA2203 Special Authority for Subsidy

Initial application — (spinal muscular atrophy (SMA)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and
- 2 Patient is 18 years of age or under; and
- 3 Either:
 - 3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or
 - 3.2 Both:
 - 3.2.1 Patient is pre-symptomatic; and
 - 3.2.2 Patient has three or less copies of SMN2.

Renewal — (spinal muscular atrophy (SMA)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam; and
- 3 Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy.

Stimulants/ADHD Treatments

ATOMOXETINE

Cap 10 mg.....	43.02	28	✓ <u>APO-Atomoxetine</u>
Cap 18 mg.....	45.57	28	✓ <u>APO-Atomoxetine</u>
Cap 25 mg.....	44.30	28	✓ <u>APO-Atomoxetine</u>
Cap 40 mg.....	46.21	28	✓ <u>APO-Atomoxetine</u>
Cap 60 mg.....	51.31	28	✓ <u>APO-Atomoxetine</u>
Cap 80 mg.....	65.20	28	✓ <u>APO-Atomoxetine</u>
Cap 100 mg.....	65.71	28	✓ <u>APO-Atomoxetine</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DEXAMFETAMINE SULFATE – Special Authority see SA2410 below – Retail pharmacy				
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensing frequency				
Tab 5 mg	29.80	100	✓	Noumed Dexamfetamine

➔SA2410 Special Authority for Subsidy

Initial application — (ADHD in patients aged 5 years or over) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients aged under 5 years) only from a paediatrician or psychiatrist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified where the patient suffers from narcolepsy.

LISDEXAMFETAMINE DIMESILATE – Special Authority see [SA2415 below](#) – Retail pharmacy

- | | | | |
|---|-------|----|-----------|
| a) Only on a controlled drug form | | | |
| b) Safety medicine; prescriber may determine dispensing frequency | | | |
| Cap 30 mg – No more than 1 cap per day | 60.00 | 30 | ✓ Vyvanse |
| Cap 50 mg | 60.00 | 30 | ✓ Vyvanse |
| Cap 70 mg | 60.00 | 30 | ✓ Vyvanse |

➔SA2415 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with lisdexamfetamine dimesilate and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 ADHD (Attention Deficit and Hyperactivity Disorder); and
 - 2.2 Diagnosed according to DSM-V or ICD 11 criteria; and
 - 2.3 Either:
 - 2.3.1 Applicant is a paediatrician or psychiatrist; or
 - 2.3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
 - 2.4 Any of the following:
 - 2.4.1 Patient is taking a currently subsidised formulation of atomoxetine or methylphenidate hydrochloride (extended-release) and has not received sufficient benefit or has experienced intolerable side effects; or
 - 2.4.2 Patient is taking a currently subsidised formulation of dexamfetamine sulfate (immediate-release) which has

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- not been effective due to significant administration and/or treatment adherence difficulties; or
- 2.4.3 There is significant concern regarding the risk of diversion or abuse of immediate release dexamfetamine sulfate; or
- 2.4.4 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained release) which has not been effective due to significant administration and/or treatment adherence difficulties; or
- 2.4.5 There is significant concern regarding the risk of diversion or abuse of immediate release methylphenidate hydrochloride; or
- 2.4.6 Both:
 - 2.4.6.1 Patient would have been prescribed a subsidised formulation of methylphenidate hydrochloride (extended-release) but has been unable to access due to supply issues with methylphenidate hydrochloride (extended-release); and
 - 2.4.6.2 Other alternative stimulant presentations (methylphenidate or dexamfetamine) are not appropriate; and
- 2.5 Lisdexamfetamine dimesilate is not to be used in combination with another funded methylphenidate presentation.

METHYLPHENIDATE HYDROCHLORIDE – Special Authority see [SA2411 below](#) – Retail pharmacy

a) Only on a controlled drug form		
b) Safety medicine; prescriber may determine dispensing frequency		
Tab immediate-release 5 mg.....	3.20	30
Tab immediate-release 10 mg.....	3.00	30
	4.00	
Tab extended-release 18 mg.....	7.75	30
		✓ Rubifen
		✓ Rubifen
		✓ Ritalin
		✓ Methylphenidate ER
		- Teva
Tab immediate-release 20 mg.....	7.85	30
Tab sustained-release 20 mg.....	10.95	30
Tab extended-release 27 mg.....	11.45	30
		✓ Methylphenidate ER
		- Teva
Tab extended-release 36 mg.....	15.50	30
		✓ Methylphenidate ER
		- Teva
Tab extended-release 54 mg.....	22.25	30
		✓ Methylphenidate ER
		- Teva

► **SA2411** Special Authority for Subsidy

Initial application — (ADHD in patients aged 5 years or over) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid without further renewal unless notified for applications meeting the following criteria:
All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients aged under 5 years) only from a paediatrician or psychiatrist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients under 5 years of age; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified where the patient suffers from narcolepsy.

Note: *narcolepsy is not a registered indication for Methylphenidate ER – Teva.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see [SA2450 below](#) – Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab extended-release 18 mg.....	58.96	30	✓	Concerta
Tab extended-release 27 mg.....	65.44	30	✓	Concerta
Tab extended-release 36 mg.....	71.93	30	✓	Concerta
Tab extended-release 54 mg.....	86.24	30	✓	Concerta
Cap modified-release 10 mg.....	19.41	30	✓	Ritalin LA
Cap modified-release 20 mg.....	27.72	30	✓	Ritalin LA
Cap modified-release 30 mg.....	34.39	30	✓	Ritalin LA
Cap modified-release 40 mg.....	38.67	30	✓	Ritalin LA

►SA2450 Special Authority for Subsidy

Initial application — (ADHD) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 All of the following:

1.1 ADHD (Attention Deficit and Hyperactivity Disorder); and

1.2 Diagnosed according to DSM-IV or ICD 10 criteria; and

1.3 Either:

1.3.1 Applicant is a paediatrician or psychiatrist; or

1.3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and

1.4 Either:

1.4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or difficulties with adherence; or

1.4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride; or

2 Both:

2.1 Patient meets the Special Authority criteria for SA2411 methylphenidate hydrochloride; and

2.2 Patient is unable to access other methylphenidate hydrochloride presentations under Special Authority criteria SA2411 due to an out of stock (see note).

Note: Criterion 2 is to permit short-term funding to cover an out-of-stock on tab extended-release Methylphenidate ER – Teva and tab sustained-release 20 mg Rubifen SR subsidised under SA2411 (<https://schedule.pharmac.govt.nz/2025/02/01/SA2411.pdf>).

Initial application — (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified where the patient suffers from narcolepsy.

Note: *narcolepsy is not a registered indication for Concerta or Ritalin LA.

MODAFINIL – Special Authority see [SA2451 on the next page](#) – Retail pharmacy

Tab 100 mg.....	14.27	30	✓	Modafinil Max Health
-----------------	-------	----	---	-------------------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2451 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 All of the following:

- 1.1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 1.2 Either:
 - 1.2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 1.2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 1.3 Either:
 - 1.3.1 An effective dose of a subsidised formulation of methylphenidate or dexamfetamine has been trialled and discontinued because of intolerable side effects; or
 - 1.3.2 Methylphenidate and dexamfetamine are contraindicated; or

2 Both:

- 2.1 Patient meets the Special Authority criteria for methylphenidate hydrochloride or methylphenidate hydrochloride extended-release for narcolepsy; and
- 2.2 Patient is unable to access methylphenidate hydrochloride presentations due to an out of stock (see note).

Note: Criterion 2 is to permit short-term funding to cover an out-of-stock of methylphenidate hydrochloride or methylphenidate hydrochloride extended release.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

* Tab 5 mg	3.70	84	✓ <u>Ipca-Donepezil</u>
* Tab 10 mg	5.50	84	✓ <u>Ipca-Donepezil</u>

RIVASTIGMINE – Special Authority see SA2524 below – Retail pharmacy

Patch 4.6 mg per 24 hour	49.40	30	✓ <u>Rivastigmine Patch</u> <u>BNM 5</u>
Patch 9.5 mg per 24 hour	49.40	30	✓ <u>Rivastigmine Patch</u> <u>BNM 10</u>

►SA2524 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient is contraindicated to or has experienced intolerable side effects from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Special Authority see [SA1203 below](#) – Retail pharmacy

a) No patient co-payment payable		
b) Safety medicine; prescriber may determine dispensing frequency		
Tab sublingual 2 mg with naloxone 0.5 mg	11.76	28
		✓ Buprenorphine Naloxone BNM
Tab sublingual 8 mg with naloxone 2 mg	34.00	28
		✓ Buprenorphine Naloxone BNM

►SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health..

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg.....	15.00	30	✓ <u>Zyban</u>
----------------------------------	-------	----	----------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DISULFIRAM				
Tab 200 mg	236.40	100	✓	Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA1408 below – Retail pharmacy				
Tab 50 mg	83.33	30	✓	Nalttraccord

► **SA1408** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to Health NZ or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

- a) Nicotine will not be funded in amounts less than 4 weeks of treatment.
- b) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.

Patch 7 mg – Up to 28 patch available on a PSO	19.62	28	✓	Habitrol
Patch 14 mg – Up to 28 patch available on a PSO	21.57	28	✓	Habitrol
Patch 14 mg for direct distribution only – [Xpharm]	12.49	7	✓	Habitrol
Patch 21 mg – Up to 28 patch available on a PSO	24.72	28	✓	Habitrol
Patch 21 mg for direct distribution only – [Xpharm]	13.19	7	✓	Habitrol
Lozenge 1 mg – Up to 216 loz available on a PSO	22.53	216	✓	Habitrol
Lozenge 1 mg for direct distribution only – [Xpharm]	12.89	36	✓	Habitrol
Lozenge 2 mg – Up to 216 loz available on a PSO	24.68	216	✓	Habitrol
Lozenge 2 mg for direct distribution only – [Xpharm]	13.25	36	✓	Habitrol
Gum 2 mg (Fruit) – Up to 204 piece available on a PSO	23.02	204	✓	Habitrol
Gum 2 mg (Fruit) for direct distribution only – [Xpharm]	17.57	96	✓	Habitrol
Gum 2 mg (Mint) – Up to 204 piece available on a PSO	23.02	204	✓	Habitrol
Gum 2 mg (Mint) for direct distribution only – [Xpharm]	17.57	96	✓	Habitrol
Gum 4 mg (Fruit) – Up to 204 piece available on a PSO	25.98	204	✓	Habitrol
Gum 4 mg (Fruit) for direct distribution only – [Xpharm]	23.87	96	✓	Habitrol
Gum 4 mg (Mint) – Up to 204 piece available on a PSO	25.98	204	✓	Habitrol
Gum 4 mg (Mint) for direct distribution only – [Xpharm]	23.87	96	✓	Habitrol

VARENICLINE TARTRATE – Special Authority see [SA1845 below](#) – Retail pharmacy

- a) A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack
- b) Varenicline will not be funded in amounts less than 4 weeks of treatment.
- c) The 6-month time period in which a patient can receive a funded 12-week course of varenicline tartrate starts from the date the Special Authority is approved.

Tab 0.5 mg x 11 and 1 mg x 42	16.67	53 OP	✓	Champix
Tab 1 mg	17.62	56	✓	Champix

► **SA1845** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:
All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 It has been 6 months since the patient's previous Special Authority was approved; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

The patient must not have had an approval in the past 6 months.

Notes: a maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval.
This includes the 4-week 'starter' pack.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see [SA2398 below](#)

Inj 25 mg vial	50.05	1	✓ Bendamustine Sandoz
	77.00		✓ Ribomustin
Inj 100 mg vial	200.20	1	✓ Bendamustine Sandoz
	308.00		✓ Ribomustin
Inj 1 mg for ECP	2.11	1 mg	✓ Baxter

►SA2398 Special Authority for Subsidy

Initial application — (CLL*) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has chronic lymphocytic leukaemia requiring treatment; and
- 2 Patient has ECOG performance status of 0-2; and
- 3 Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: Indication marked with a * includes indications that are unapproved. 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL).

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has indolent low grade NHL requiring treatment; and
- 2 The patient has ECOG performance status of 0-2; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient is treatment naive; and
 - 3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
 - 3.2 Both:
 - 3.2.1 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen; and
 - 3.2.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or
 - 3.3 All of the following:
 - 3.3.1 The patient has not received prior bendamustine therapy; and
 - 3.3.2 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
 - 3.3.3 Patient has had a rituximab treatment-free interval of 12 months or more; or
 - 3.4 Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
1.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or				
2 Both:				
2.1 Patients have not received a bendamustine regimen within the last 12 months; and				
2.2 Either:				
2.2.1 Both:				
2.2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and				
2.2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or				
2.2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.				
Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenstrom's macroglobulinaemia.				
Initial application — (Hodgkin's lymphoma*) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:				
All of the following:				
1 Patient has Hodgkin's lymphoma requiring treatment; and				
2 Patient has a ECOG performance status of 0-2; and				
3 Patient has received one prior line of chemotherapy; and				
4 Patient's disease relapsed or was refractory following prior chemotherapy; and				
5 Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m ² twice per cycle, for a maximum of four cycles.				
Note: Indications marked with * are unapproved indications.				
BUSULFAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg	89.25	100	✓	Myleran
CARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 45 ml vial.....	25.73	1	✓	Carboplatin Accord
			✓	DBL Carboplatin
	32.59			S29 S29
	48.50		✓	DBL Carboplatin
			✓	Carbaccord
Inj 1 mg for ECP	0.06	1 mg	✓	Baxter
CARMUSTINE – PCT only – Specialist				
Inj 100 mg vial	710.00	1	✓	BiCNU
Inj 100 mg for ECP	710.00	100 mg OP	✓	Baxter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg	29.06	25	✓	Leukeran FC
CISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml vial.....	9.45	1	✓	Cisplatin Accord
	15.00		✓	Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial.....	18.90	1	✓	Cisplatin Accord
	21.00		✓	Cisplatin Ebewe
	29.66		✓	DBL Cisplatin
Inj 1 mg for ECP	0.19	1 mg	✓	Baxter
CYCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist.....	145.00	50	✓	Cyclonex
Inj 1 g vial – PCT – Retail pharmacy-Specialist.....	47.46	1	✓	Endoxan
	127.80	6	✓	Cytoxan
Inj 2 g vial – PCT only – Specialist.....	95.06	1	✓	Endoxan
Inj 1 mg for ECP – PCT only – Specialist.....	0.05	1 mg	✓	Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
IFOSFAMIDE – PCT only – Specialist				
Inj 1 g.....	96.00	1	✓	Holoxan
Inj 2 g.....	180.00	1	✓	Holoxan
Inj 1 mg for ECP	0.10	1 mg	✓	Baxter
LOMUSTINE – PCT – Retail pharmacy-Specialist				
Cap 40 mg.....	880.00	20	✓	Medac ^{S29}
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist.....	40.70	25	✓	Alkeran
Inj 50 mg – PCT only – Specialist.....	48.25	1	✓	Melpha
	67.80		✓	Alkeran
OXALIPLATIN – PCT only – Specialist				
Inj 100 mg vial	25.01	1	✓	Oxaliplatin Actavis 100
	110.00		✓	Oxaliplatin Ebewe
Inj 5 mg per ml, 20 ml vial.....	33.35	1	✓	Alchemy Oxaliplatin
	46.32		✓	Oxaliplatin Accord
Inj 1 mg for ECP	0.35	1 mg	✓	Baxter
THIOTEPA – PCT only – Specialist				
Inj 15 mg vial	CBS	1	✓	Bedford ^{S29}
			✓	Max Health ^{S29}
			✓	THIO-TEPA ^{S29}
	398.00		✓	Tepadina
Inj 100 mg vial	CBS	1	✓	Max Health ^{S29}
	1,800.00		✓	Tepadina

Antimetabolites

AZACITIDINE – PCT only – Specialist – Special Authority see SA2479 below

Inj 100 mg vial	50.00	1	✓	Azacitidine Dr Reddy's
Inj 1 mg for ECP	0.54	1 mg	✓	Baxter

►SA2479 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Both:

- Any of the following:
 - The individual has intermediate or high risk MDS based on an internationally recognised scoring system; or
 - The individual has chronic myelomonocytic leukaemia (based on an intermediate or high risk score from an internationally recognised scoring system or 10%-29% marrow blasts without myeloproliferative disorder); or
 - The individual has acute myeloid leukaemia according to World Health Organisation Classification (WHO); and
- The individual has an estimated life expectancy of at least 3 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where there is no evidence of disease progression.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CALCIUM FOLINATE				
Tab 15 mg – PCT – Retail pharmacy-Specialist.....	135.33	10	✓	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	17.10	5	✓	Hospira
Inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	7.28	1	✓	Calcium Folate Sandoz
			✓	Calcium Folate Sandoz S29 S29
	112.20	5	✓	Eurofolic S29
Inj 50 mg – PCT – Retail pharmacy-Specialist.....	72.80	10	✓	Leucovorin Pharmacia S29
Inj 10 mg per ml, 10 ml vial – PCT only – Specialist	9.49	1	✓	Calcium Folate Sandoz
	163.35	5	✓	Eurofolic S29
Inj 100 mg – PCT only – Specialist.....	7.33	1	✓	Calcium Folate Ebewe
	94.90	10	✓	Leucovorin Pharmacia S29
Inj 300 mg – PCT only – Specialist.....	21.55	1	✓	Leucovorin DBL S29
	22.51		✓	Calcium Folate Ebewe
Inj 10 mg per ml, 35 ml vial – PCT only – Specialist	25.14	1	✓	Calcium Folate Sandoz
			✓	Calcium Folate Sandoz S29 S29
Inj 1 g – PCT only – Specialist.....	67.51	1	✓	Calcium Folate Ebewe
Inj 10 mg per ml, 100 ml vial – PCT only – Specialist	72.00	1	✓	Calcium Folate Sandoz
	139.48		✓	Eurofolic S29
Inj 1 mg for ECP – PCT only – Specialist.....	0.14	1 mg	✓	Baxter
<i>(Calcium Folate Sandoz Inj 10 mg per ml, 5 ml vial to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Sandoz S29 S29 Inj 10 mg per ml, 5 ml vial to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Sandoz Inj 10 mg per ml, 10 ml vial to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Ebewe Inj 100 mg to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Ebewe Inj 300 mg to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Sandoz Inj 10 mg per ml, 35 ml vial to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Sandoz S29 S29 Inj 10 mg per ml, 35 ml vial to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Ebewe Inj 1 g to be delisted 1 November 2025)</i>				
<i>(Calcium Folate Sandoz Inj 10 mg per ml, 100 ml vial to be delisted 1 November 2025)</i>				
CAPECITABINE – Retail pharmacy-Specialist				
Tab 150 mg	10.92	60	✓	Capecitabine Viatris
Tab 500 mg	50.96	120	✓	Capecitabine Viatris
CLADRIBINE – PCT only – Specialist				
Inj 1 mg per ml, 10 ml	749.96	1	✓	Leustatin
Inj 10 mg for ECP	749.96	10 mg OP	✓	Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CYTARABINE				
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	472.00	5	✓	Pfizer
Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist	48.80	1	✓	Cytarabine DBL
			✓	Pfizer
Inj 1 mg for ECP – PCT only – Specialist.....	0.29	10 mg	✓	Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist.....	94.40	100 mg OP	✓	Baxter
FLUDARABINE PHOSPHATE				
Tab 10 mg – PCT – Retail pharmacy-Specialist.....	412.00	20	✓	Fludara Oral
Inj 50 mg vial – PCT only – Specialist	126.80	1	✓	Fludarabine Sagent ^{S29}
	634.00	5	✓	Fludarabine Ebewe
Inj 50 mg for ECP – PCT only – Specialist.....	126.80	50 mg OP	✓	Baxter
<i>(Fludarabine Sagent ^{S29} Inj 50 mg vial to be delisted 1 November 2025)</i>				
FLUOROURACIL				
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist	10.51	1	✓	Fluorouracil Accord
Inj 50 mg per ml, 50 ml vial – PCT only – Specialist	14.72	1	✓	Fluorouracil Accord
Inj 50 mg per ml, 100 ml vial – PCT only – Specialist	19.36	1	✓	Fluorouracil Accord
Inj 1 mg for ECP – PCT only – Specialist.....	0.41	100 mg	✓	Baxter
GEMCITABINE HYDROCHLORIDE – PCT only – Specialist				
Inj 43.3 mg per ml (equivalent to 38 mg per ml gemcitabine), 26.3 ml vial	18.94	1	✓	DBL Gemcitabine
Inj 1 g.....	15.89	1	✓	Gemcitabine Ebewe
Inj 1 mg for ECP	0.02	1 mg	✓	Baxter
IRINOTECAN HYDROCHLORIDE – PCT only – Specialist				
Inj 20 mg per ml, 5 ml vial.....	52.57	1	✓	Accord
	71.44		✓	Irinotecan Actavis 100
	100.00		✓	Irinotecan-Rex
Inj 20 mg per ml, 25 ml vial.....	262.85	1	✓	Accord ^{S29}
Inj 1 mg for ECP	0.54	1 mg	✓	Baxter
MERCAPTOPURINE				
Tab 50 mg – PCT – Retail pharmacy-Specialist.....	19.50	25	✓	Puri-nethol
Puri-nethol to be Principal Supply on 1 December 2025				
Oral suspension 20 mg per ml – Retail pharmacy-Specialist – Special Authority see SA1725 below.....	428.00	100 ml OP	✓	Allmercap
			✓	Xaluprine ^{S29}

»SA1725 Special Authority for Subsidy

Initial application only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where the patient requires a total dose of less than one full 50 mg tablet per day.

Renewal only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where patient still requires a total dose of less than one full 50 mg tablet per day.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHOTREXATE				
* Tab 2.5 mg – PCT – Retail pharmacy-Specialist.....	7.80	90	✓	Trexate
* Tab 10 mg – PCT – Retail pharmacy-Specialist.....	26.40	90	✓	Trexate
* Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	95.29	5	✓	Methotrexate DBL
* Inj 7.5 mg prefilled syringe.....	29.17	1	✓	Methotrexate Sandoz
* Inj 10 mg prefilled syringe.....	19.09	1	✓	Methotrexate Sandoz
* Inj 15 mg prefilled syringe.....	24.53	1	✓	Methotrexate Sandoz
* Inj 20 mg prefilled syringe.....	16.64	1	✓	Methotrexate Sandoz
* Inj 25 mg prefilled syringe.....	20.72	1	✓	Methotrexate Sandoz
* Inj 30 mg prefilled syringe.....	55.00	1	✓	Methotrexate Sandoz
* Inj 25 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist.....	30.00	5	✓	Methotrexate DBL Onco-Vial
* Inj 25 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist.....	45.00	1	✓	DBL Methotrexate Onco-Vial
* Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist	25.00	1	✓	Methotrexate Ebewe
* Inj 100 mg per ml, 50 ml vial – PCT – Retail pharmacy-Specialist	67.99	1	✓	Methotrexate Ebewe
* Inj 1 mg for ECP – PCT only – Specialist.....	0.06	1 mg	✓	Baxter
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist.....	19.06	5 mg OP	✓	Baxter
PEMETREXED – PCT only – Specialist				
Inj 100 mg vial	8.99	1	✓	Pemetrexed-AFT
	60.89		✓	Juno Pemetrexed
Inj 500 mg vial	29.99	1	✓	Pemetrexed-AFT
	217.77		✓	Juno Pemetrexed
Inj 1 mg for ECP	0.11	1 mg	✓	Baxter
THIOGUANINE – PCT – Retail pharmacy-Specialist				
Tab 40 mg	126.31	25	✓	Lanvis

Other Cytotoxic Agents

AMSACRINE – PCT only – Specialist				
Inj 50 mg per ml, 1.5 ml ampoule	4,736.00	6	✓	Amsidine ^{S29}
Inj 75 mg.....	6,218.00	5	✓	AmsaLyo ^{S29}
ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist				
Cap 0.5 mg.....	1,175.87	100	✓	Agrylin
ARSENIC TRIOXIDE – PCT only – Specialist				
Inj 1 mg per ml, 10 ml vial.....	4,817.00	10	✓	Phenasen
Inj 10 mg for ECP	481.70	10 mg OP	✓	Baxter
BLEOMYCIN SULPHATE – PCT only – Specialist				
Inj 15,000 iu, vial.....	185.16	1	✓	DBL Bleomycin Sulfate
Inj 1,000 iu for ECP	14.32	1,000 iu	✓	Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BORTEZOMIB – PCT only – Specialist – Special Authority see SA2355 below				
Inj 3.5 mg vial	74.93	1	✓	DBL Bortezomib
Inj 1 mg for ECP	22.26	1 mg	✓	Baxter
►SA2355 Special Authority for Subsidy				
Initial application — (plasma cell dyscrasia) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment.				
DACARBAZINE – PCT only – Specialist				
Inj 200 mg vial	72.11	1	✓	DBLDACarbazine
Inj 200 mg for ECP	72.11	200 mg OP	✓	Baxter
DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist				
Inj 0.5 mg vial	255.00	1	✓	Cosmegen
Inj 0.5 mg for ECP	255.00	0.5 mg OP	✓	Baxter
DAUNORUBICIN – PCT only – Specialist				
Inj 2 mg per ml, 10 ml	171.93	1	✓	Pfizer
Inj 18.7 mg for ECP	171.93	18.7 mg OP	✓	Baxter
Inj 20 mg for ECP	171.93	20 mg OP	✓	Baxter
Inj 18.7 mg vial	171.93	1	✓	Pfizer
<i>(Pfizer Inj 2 mg per ml, 10 ml to be delisted 1 January 2026)</i>				
<i>(Baxter Inj 20 mg for ECP to be delisted 1 January 2026)</i>				
DOCETAXEL – PCT only – Specialist				
Inj 20 mg	48.75	1	✓	Docetaxel Sandoz
Inj 10 mg per ml, 8 ml vial	24.91	1	✓	DBL Docetaxel
Inj 20 mg per ml, 4 ml vial	26.95	1	✓	Docetaxel
				Accord S29
Inj 80 mg	195.00	1	✓	Docetaxel Sandoz
Inj 1 mg for ECP	0.35	1 mg	✓	Baxter
DOXORUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml vial	10.00	1	✓	Doxorubicin Ebewe
Inj 2 mg per ml, 25 ml vial	11.50	1	✓	Doxorubicin Ebewe
	17.00		✓	Arrow-Doxorubicin
Inj 2 mg per ml, 50 ml vial	23.00	1	✓	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial	65.00	1	✓	Arrow-Doxorubicin
	69.99		✓	Doxorubicin Ebewe
Inj 1 mg for ECP	0.35	1 mg	✓	Baxter
EPIRUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml vial	25.00	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial	30.00	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial	99.99	1	✓	Epirubicin Ebewe
Inj 1 mg for ECP	0.50	1 mg	✓	Baxter
ETOPOSIDE				
Cap 50 mg – PCT – Retail pharmacy-Specialist	340.73	20	✓	Vepesid
Wastage claimable				
Cap 100 mg – PCT – Retail pharmacy-Specialist	340.73	10	✓	Vepesid
Wastage claimable				
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist	7.90	1	✓	Rex Medical
Inj 1 mg for ECP – PCT only – Specialist	0.09	1 mg	✓	Baxter
ETOPOSIDE PHOSPHATE – PCT only – Specialist				
Inj 100 mg (of etoposide base)	40.00	1	✓	Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	✓	Baxter

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HYDROXYUREA [HYDROXYCARBAMIDE] – PCT – Retail pharmacy-Specialist				
Cap 500 mg.....	20.72	100	✓	Devatis
IBRUTINIB – Special Authority see SA2480 below – Retail pharmacy				
Tab 140 mg	3,217.00	30	✓	Imbruvica
Tab 420 mg	9,652.00	30	✓	Imbruvica
►SA2480 Special Authority for Subsidy				
Initial application — (chronic lymphocytic leukaemia (CLL)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:				
All of the following:				
1 Individual has chronic lymphocytic leukaemia (CLL) requiring therapy; and				
2 Individual has not previously received funded ibrutinib; and				
3 Ibrutinib is to be used as monotherapy; and				
4 Any of the following:				
4.1 Both:				
4.1.1 There is documentation confirming that the individual has 17p deletion or TP53 mutation; and				
4.1.2 Individual has experienced intolerable side effects with venetoclax monotherapy; or				
4.2 All of the following:				
4.2.1 Individual has received at least one prior immunochemotherapy for CLL; and				
4.2.2 Individual's CLL has relapsed; and				
4.2.3 Individual has experienced intolerable side effects with venetoclax in combination with rituximab regimen; or				
4.3 Individual's CLL is refractory to or has relapsed following a venetoclax regimen.				
Renewal — (chronic lymphocytic leukaemia (CLL)) from any relevant practitioner. Approvals valid for 12 months where there is no evidence of disease progression.				
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.				
IDARUBICIN HYDROCHLORIDE				
Inj 5 mg vial – PCT only – Specialist	109.74	1	✓	Zavedos
Inj 10 mg vial – PCT only – Specialist	233.64	1	✓	Zavedos
Inj 1 mg for ECP – PCT only – Specialist	25.77	1 mg	✓	Baxter
LENALIDOMIDE (VIATRIS) – Special Authority see SA2353 below – Retail pharmacy				
Cap 5 mg	76.92	21	✓	Lenalidomide Viatris
Cap 10 mg	50.30	21	✓	Lenalidomide Viatris
Cap 15 mg	62.13	21	✓	Lenalidomide Viatris
Cap 25 mg	65.09	21	✓	Lenalidomide Viatris

►SA2353 Special Authority for Subsidy

Initial application — (Plasma cell dyscrasia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment; and
- 2 Patient is not refractory to prior lenalidomide use.

Initial application — (Myelodysplastic syndrome) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

- 1 Patient has low or intermediate-1 risk myelodysplastic syndrome (based on IPSS or an IPSS-R score of less than 3.5) associated with a deletion 5q cytogenetic abnormality; and
- 2 Patient has transfusion-dependent anaemia.

Renewal — (Myelodysplastic syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has not needed a transfusion in the last 4 months; and
- 2 No evidence of disease progression.

MESNA

Tab 400 mg – PCT – Retail pharmacy-Specialist.....	314.00	50	✓ Uromitexan
Tab 600 mg – PCT – Retail pharmacy-Specialist.....	448.50	50	✓ Uromitexan
Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist.....	177.45	15	✓ Uromitexan
Inj 100 mg per ml, 10 ml ampoule – PCT only – Specialist.....	407.40	15	✓ Uromitexan
Inj 1 mg for ECP – PCT only – Specialist.....	2.96	100 mg	✓ Baxter

MITOMYCIN C – PCT only – Specialist

Inj 5 mg vial	517.65	1	✓ Accord ^{§29}
			✓ Mitomycin (Fresenius Kabi) ^{§29}
	526.00		✓ Mitomycin (Sagent) ^{§29}
Inj 20 mg vial	1,250.00	1	✓ Teva
Inj 1 mg for ECP	269.85	1 mg	✓ Baxter

MITOZANTRONE – PCT only – Specialist

Inj 2 mg per ml, 10 ml vial.....	97.50	1	✓ Mitozantrone Ebewe
Inj 1 mg for ECP	5.51	1 mg	✓ Baxter

NIRAPARIB – Special Authority see SA2325 below – Retail pharmacy

Wastage claimable			
Tab 100 mg	13,393.50	84	✓ Zejula
Cap 100 mg	8,929.84	56	✓ Zejula

➔SA2325 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:

- 1 Patient has advanced high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 Patient has received at least one line** of treatment with platinum-based chemotherapy; and
- 3 Patient has experienced a partial or complete response to the preceding treatment with platinum-based chemotherapy; and
- 4 Patient has not previously received funded treatment with a PARP inhibitor; and
- 5 Either:
 - 5.1 Treatment will be commenced within 12 weeks of the patient's last dose of the preceding platinum-based regimen; or
 - 5.2 Patient commenced treatment with niraparib prior to 1 May 2024; and
- 6 Treatment to be administered as maintenance treatment; and
- 7 Treatment not to be administered in combination with other chemotherapy.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 No evidence of progressive disease; and
- 2 Treatment to be administered as maintenance treatment; and
- 3 Treatment not to be administered in combination with other chemotherapy; and
- 4 Either:
 - 4.1 Treatment with niraparib to cease after a total duration of 36 months from commencement; or
 - 4.2 Treatment with niraparib is being used in the second-line or later maintenance setting.

Notes: * "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments

OLAPARIB – Retail pharmacy-Specialist – Special Authority see [SA2163 below](#)

Tab 100 mg	3,701.00	56	✓ Lynparza
Tab 150 mg	3,701.00	56	✓ Lynparza

►SA2163 Special Authority for Subsidy

Initial application — (Ovarian cancer) only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
- 3 Either:
 - 3.1 All of the following:
 - 3.1.1 Patient has newly diagnosed, advanced disease; and
 - 3.1.2 Patient has received one line** of previous treatment with platinum-based chemotherapy; and
 - 3.1.3 Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen; or
 - 3.2 All of the following:
 - 3.2.1 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy; and
 - 3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy; and
 - 3.2.3 Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and
 - 3.2.4 Patient has not previously received funded olaparib treatment; and
- 4 Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 5 Treatment to be administered as maintenance treatment; and
- 6 Treatment not to be administered in combination with other chemotherapy.

Renewal — (Ovarian cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- 2 Either:
 - 2.1 No evidence of progressive disease; or
 - 2.2 Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion; and
- 3 Treatment to be administered as maintenance treatment; and
- 4 Treatment not to be administered in combination with other chemotherapy; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
5 Either:				
5.1 Both:				
5.1.1 Patient has received one line** of previous treatment with platinum-based chemotherapy; and				
5.1.2 Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years; or				
5.2 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy.				
Notes: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.				
**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.				
PACLITAXEL – PCT only – Specialist				
Inj 30 mg.....	47.30	5	✓	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial.....	19.59	1	✓	Anzatax
	24.00		✓	Paclitaxel Ebewe
	91.67		✓	Paclitaxel Actavis
Inj 150 mg.....	26.69	1	✓	Paclitaxel Ebewe
	137.50		✓	Anzatax
			✓	Paclitaxel Actavis
Inj 6 mg per ml, 50 ml vial.....	37.89	1	✓	Anzatax
	44.00		✓	Paclitaxel Ebewe
	275.00		✓	Paclitaxel Actavis
Inj 1 mg for ECP	0.17	1 mg	✓	Baxter
PEGASPARGASE – PCT only – Special Authority see SA1979 below				
Inj 750 iu per ml, 5 ml vial.....	3,973.25	1	✓	Oncaspar LYO
►SA1979 Special Authority for Subsidy				
Initial application — (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 The patient has newly diagnosed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.				
Initial application — (Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has lymphoma requiring L-asparaginase containing protocols (e.g. SMILE).				
Renewal — (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 The patient has relapsed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.				
PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specialist				
Inj 10 mg.....	CBS	1	✓	Nipent §29
POMALIDOMIDE – Special Authority see SA2354 on the next page – Retail pharmacy				
Cap 1 mg.....	47.45	14	✓	Pomolide
	71.18	21	✓	Pomolide
Cap 2 mg.....	94.90	14	✓	Pomolide
	142.35	21	✓	Pomolide
Cap 3 mg.....	142.35	14	✓	Pomolide
	213.53	21	✓	Pomolide
Cap 4 mg.....	189.81	14	✓	Pomolide
	284.71	21	✓	Pomolide

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA2354 Special Authority for Subsidy

Initial application — (Relapsed/refractory plasma cell dyscrasia) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
- 1 Patient has relapsed or refractory plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment; and
 - 2 Patient has not received prior funded pomalidomide.

Renewal — (Relapsed/refractory plasma cell dyscrasia) from any relevant practitioner. Approvals valid for 12 months where there is no evidence of disease progression.

PROCARBAZINE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist

Cap 50 mg	980.00	50	✓ Natulan ^{\$29}
-----------------	--------	----	---------------------------

TEMOZOLOMIDE – Special Authority see SA2275 below – Retail pharmacy

Cap 5 mg	9.13	5	✓ Temaccord ✓ Temozolomide- Taro ^{\$29}
----------------	------	---	--

Cap 20 mg	16.38	5	✓ Temaccord
	18.30		✓ Apo-Temozolomide
Cap 100 mg	35.98	5	✓ Temaccord
	40.20		✓ Apo-Temozolomide
Cap 140 mg	50.12	5	✓ Temaccord
Cap 250 mg	86.34	5	✓ Temaccord

►SA2275 Special Authority for Subsidy

Initial application — (gliomas) only from a relevant specialist. Approvals valid for 12 months where the patient has a glioma.

Renewal — (gliomas) only from a relevant specialist. Approvals valid for 12 months where treatment remains appropriate and patient is benefitting from treatment.

Initial application — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

Renewal — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Initial application — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 9 months where the patient has relapsed/refractory Ewing's sarcoma.

Renewal — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
THALIDOMIDE – Retail pharmacy-Specialist – Special Authority see SA2356 below				
Cap 50 mg.....	378.00	28	✓	Thalomid
Cap 100 mg.....	756.00	28	✓	Thalomid

► **SA2356** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist	479.50	100	✓	Vesanoid
Wastage claimable				

VENETOCLAX – Retail pharmacy-Specialist – Special Authority see [SA2481](#) below

Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg	1,771.86	42 OP	✓	Venclexta
Tab 10 mg	13.68	2 OP	✓	Venclexta
Tab 50 mg	239.44	7 OP	✓	Venclexta
Tab 100 mg – Wastage claimable.....	8,209.41	120	✓	Venclexta

► **SA2481** **Special Authority for Subsidy**

Initial application — (relapsed/refractory chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 Individual has chronic lymphocytic leukaemia requiring treatment; and
- 2 Individual has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Individual has not previously received funded venetoclax; and
- 4 The individual's disease has relapsed; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Individual has an ECOG performance status of 0-2.

Renewal — (relapsed/refractory chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment remains clinically appropriate and the individual is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initial application — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Individual has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that individual has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Individual has an ECOG performance status of 0-2.

Renewal — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) from any relevant practitioner. Approvals valid for 6 months where the treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell polymorphous leukaemia (B-PLL)*. Indications marked with * are Unapproved indications

Initial application — (previously untreated acute myeloid leukaemia) from any relevant practitioner. Approvals valid for 6

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

months for applications meeting the following criteria:

Either:

- 1 The individual is currently on treatment with venetoclax and met all remaining special authority criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Individual has previously untreated acute myeloid leukaemia (see note a), according to World Health Organization (WHO) Classification; and
 - 2.2 Venetoclax not to be used in combination with standard intensive remission induction chemotherapy; and
 - 2.3 Venetoclax to be used in combination with azacitidine or low dose cytarabine.

Renewal — (previously untreated acute myeloid leukaemia) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Notes:

- a) 'Acute myeloid leukaemia' includes myeloid sarcoma*
- b) Indications marked with * are Unapproved indications

VINBLASTINE SULPHATE

Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist.....	270.37	5	✓ Hospira
Inj 1 mg for ECP – PCT only – Specialist.....	6.00	1 mg	✓ Baxter

VINCISTINE SULPHATE

Inj 1 mg per ml, 1 ml vial – PCT – Retail pharmacy-Specialist.....	74.52	5	✓ DBL Vincristine Sulfate
Inj 1 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist.....	102.73	5	✓ DBL Vincristine Sulfate
Inj 1 mg for ECP – PCT only – Specialist.....	12.60	1 mg	✓ Baxter

VINORELBINE

Cap 20 mg	32.10	1	✓ Vinorelbine Te Arai
Cap 30 mg	42.80	1	✓ Vinorelbine Te Arai
Cap 80 mg	80.00	1	✓ Vinorelbine Te Arai
Inj 10 mg per ml, 1 ml vial – PCT only – Specialist	42.00	1	✓ Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml vial – PCT only – Specialist	168.00	1	✓ Navelbine S29 ^{S29}
	210.00		✓ Vinorelbine Ebewe
Inj 1 mg for ECP – PCT only – Specialist.....	3.80	1 mg	✓ Baxter

Protein-tyrosine Kinase Inhibitors

ALECTINIB – Retail pharmacy-Specialist – Special Authority see [SA1870 below](#)

Wastage claimable

Cap 150 mg.....	7,935.00	224	✓ Alecensa
-----------------	----------	-----	------------

► [SA1870](#) Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
- 3 Patient has an ECOG performance score of 0-2.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of progressive disease according to RECIST criteria; and
- 2 The patient is benefitting from and tolerating treatment.

AXITINIB – Special Authority see [SA2458 below](#) – Retail pharmacy

Wastage claimable

Tab 1 mg	536.40	28	✓ Inlyta
Tab 5 mg	2,682.00	28	✓ Inlyta

► **SA2458 Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 The disease is of predominant clear cell histology; and
- 3 The patient has documented disease progression following one previous line of treatment; and
- 4 The patient has ECOG performance status of 0-2.

Renewal from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression..

CRIZOTINIB – Special Authority see [SA2459 below](#) – Retail pharmacy

Cap 200 mg	7,250.00	60	✓ Xalkori
Cap 250 mg	7,250.00	60	✓ Xalkori

► **SA2459 Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-squamous non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has a ROS1 rearrangement using an appropriate ROS1 test; and
- 3 Patient has ECOG performance score of 0-3; and
- 4 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Response to treatment has been determined by comparable radiological assessment following the most recent treatment period; and
- 2 No evidence of disease progression..

DABRAFENIB – Special Authority see [SA2494 below](#) – Retail pharmacy

Cap 50 mg	6,320.86	120	✓ Tafinlar
Cap 75 mg	9,481.29	120	✓ Tafinlar

► **SA2494 Special Authority for Subsidy**

Initial application — (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The individual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a); or
 - 2.1.2 Both:
 - 2.1.2.1 The individual has received neoadjuvant treatment with a PD-1/PD-L1 inhibitor; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.1.2.2 Adjuvant treatment with dabrafenib is required; and
- 2.2 The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma; and
- 2.3 Treatment must be adjuvant to complete surgical resection; and
- 2.4 Treatment must be initiated within 13 weeks of surgical resection, unless delay is necessary due to post-surgery recovery (see note b); and
- 2.5 The individual has a confirmed BRAF mutation; and
- 2.6 Dabrafenib must be administered in combination with trametinib; and
- 2.7 The individual has ECOG performance score 0-2.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

Renewal — (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 No evidence of disease recurrence; and
 - 1.2 Dabrafenib must be administered in combination with trametinib; and
 - 1.3 Treatment to be discontinued at signs of disease recurrence or at completion of 12 months' total treatment course, including any systemic neoadjuvant treatment; or
- 2 All of the following:
 - 2.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 2.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.3 The individual meets initial application criteria for dabrafenib for unresectable or metastatic melanoma; or
- 3 All of the following:
 - 3.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 3.2 The individual has received a BRAF/MEK inhibitor for unresectable or metastatic melanoma; and
 - 3.3 The individual meets renewal criteria for dabrafenib for unresectable or metastatic melanoma.

Initial application — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The individual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
 - 2.3 The individual has ECOG performance score 0-2; and
 - 2.4 The individual has confirmed BRAF mutation; and
 - 2.5 Dabrafenib must be administered in combination with trametinib; and
 - 2.6 Any of the following:
 - 2.6.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
 - 2.6.2 The individual did not receive treatment in the adjuvant setting with a BRAF/MEK inhibitor; or
 - 2.6.3 All of the following:
 - 2.6.3.1 The individual received treatment in the adjuvant setting with a BRAF/MEK inhibitor; and
 - 2.6.3.2 The individual did not experience disease recurrence while on treatment with that BRAF/MEK inhibitor; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

2.6.3.3 The individual did not experience disease recurrence within six months of completing adjuvant treatment with a BRAF/MEK inhibitor.

Renewal — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

- Both:
- Any of the following:
 - The individual's disease has had a complete response to treatment; or
 - The individual's disease has had a partial response to treatment; or
 - The individual has stable disease with treatment; and
 - Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

DASATINIB – Special Authority see [SA2385 below](#) – Retail pharmacy

Wastage claimable

Tab 20 mg	132.88	60	✓ Dasatinib-Teva
Tab 50 mg	304.13	60	✓ Dasatinib-Teva
Tab 70 mg	415.75	60	✓ Dasatinib-Teva

➔SA2385 Special Authority for Subsidy

Initial application only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; or
- The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); or
- Both:
 - The patient has a diagnosis of CML in chronic phase; and
 - Any of the following:
 - Patient has documented treatment failure* with imatinib; or
 - Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
 - Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system.

Renewal only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- Lack of treatment failure while on dasatinib*; and
- Dasatinib treatment remains appropriate and the patient is benefiting from treatment.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines.

ERLOTINIB – Retail pharmacy-Specialist – Special Authority see [SA2422 below](#)

Tab 100 mg	280.84	30	✓ Alchemy
Tab 150 mg	484.24	30	✓ Alchemy

➔SA2422 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- There is documentation confirming that the disease expresses activating mutations of EGFR; and
- Any of the following:
 - Patient is treatment naive; or
 - Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

3.3 Both:

- 3.3.1 The patient has discontinued osimertinib or gefitinib due to intolerance; and
- 3.3.2 The cancer did not progress while on osimertinib or gefitinib.

Renewal from any relevant practitioner. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – Retail pharmacy-Specialist – Special Authority see [SA2423 below](#)

Tab 250 mg	918.00	30	✓	Iressa
------------------	--------	----	---	--------

► [SA2423](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:
All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Any of the following:
 - 2.1 Patient is treatment naive; or
 - 2.2 Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued osimertinib or erlotinib due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on osimertinib or erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR.

Renewal from any relevant practitioner. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

* Cap 100 mg	44.93	60	✓	<u>Imatinib-Rex</u>
* Cap 400 mg	69.76	30	✓	<u>Imatinib-Rex</u>

LENVATINIB – Special Authority see [SA2442 below](#) – Retail pharmacy

Wastage claimable

Cap 4 mg	3,407.40	30	✓	Lenvima
Cap 10 mg	3,407.40	30	✓	Lenvima

► [SA2442](#) Special Authority for Subsidy

Initial application — (thyroid cancer) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with lenvatinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The patient has locally advanced or metastatic differentiated thyroid cancer; and
 - 2.2 Either:
 - 2.2.1 Patient must have symptomatic progressive disease prior to treatment; or
 - 2.2.2 Patient must progressive disease at critical anatomical sites with a high risk of morbidity or mortality where local control cannot be achieved by other measures; and
 - 2.3 Any of the following:
 - 2.3.1 A lesion without iodine uptake in a RAI scan; or
 - 2.3.2 Receiving cumulative RAI greater than or equal to 600 mCi; or
 - 2.3.3 Experiencing disease progression after a RAI treatment within 12 months; or
 - 2.3.4 Experiencing disease progression after two RAI treatments administered within 12 months of each other; and
 - 2.4 Patient has thyroid stimulating hormone (TSH) adequately suppressed; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 2.5 Patient is not a candidate for radiotherapy with curative intent; and
- 2.6 Surgery is clinically inappropriate; and
- 2.7 Patient has an ECOG performance status of 0-2.

Renewal — (thyroid cancer) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Initial application — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has unresectable hepatocellular carcinoma; and
- 2 Patient has preserved liver function (Childs-Pugh A); and
- 3 Transarterial chemoembolisation (TACE) is unsuitable; and
- 4 Patient has an ECOG performance status of 0-2; and
- 5 Either:

- 5.1 Patient has not received prior systemic therapy for their disease in the palliative setting; or
- 5.2 Both:

- 5.2.1 Patient has experienced treatment-limiting toxicity from treatment with atezolizumab with bevacizumab; and
- 5.2.2 No disease progression since initiation of atezolizumab with bevacizumab.

Renewal — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Initial application — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic renal cell carcinoma; and
 - 1.2 The disease is of predominant clear-cell histology; and
 - 1.3 The patient has documented disease progression following one previous line of treatment; and
 - 1.4 The patient has an ECOG performance status of 0-2; and
 - 1.5 Lenvatinib is to be used in combination with everolimus; or
- 2 All of the following:
 - 2.1 Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma; and
 - 2.2 Patient has experienced treatment limiting toxicity from treatment with nivolumab; and
 - 2.3 Lenvatinib is to be used in combination with everolimus; and
 - 2.4 There is no evidence of disease progression.

Renewal — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

MIDOSTAURIN – PCT only – Special Authority see [SA2342 below](#)

Cap 25 mg	10,981.00	56	✓ Rydapt
-----------------	-----------	----	----------

➔ **SA2342** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of acute myeloid leukaemia; and
- 2 Condition must be FMS tyrosine kinase 3 (FLT3) mutation positive; and
- 3 Patient must not have received a prior line of intensive chemotherapy for acute myeloid leukaemia; and
- 4 Patient is to receive standard intensive chemotherapy in combination with midostaurin only; and
- 5 Midostaurin to be funded for a maximum of 4 cycles.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
NILOTINIB – Special Authority see SA2301 below – Retail pharmacy				
Wastage claimable				
Cap 150 mg.....	4,680.00	120	✓	Tasigna
Cap 200 mg.....	6,532.00	120	✓	Tasigna

► **SA2301** Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic phase, or in chronic phase; and
- 2 Either:
 - 2.1 Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI); or
 - 2.2 Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) precluding further treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

OSIMERTINIB – Special Authority see [SA2418 below](#) – Retail pharmacy

Tab 40 mg	9,310.00	30	✓	Tagrisso
Tab 80 mg	9,310.00	30	✓	Tagrisso

► **SA2418** Special Authority for Subsidy

Initial application — (NSCLC – first line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with osimertinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC); and
 - 2.2 Any of the following:
 - 2.2.1 Patient is treatment naïve; or
 - 2.2.2 Patient has received prior chemotherapy in the adjuvant setting and/or while awaiting EGFR results; or
 - 2.2.3 Both:
 - 2.2.3.1 The patient has discontinued gefitinib or erlotinib due to intolerance; and
 - 2.2.3.2 The cancer did not progress while on gefitinib or erlotinib; and
 - 2.3 There is documentation confirming that the cancer expresses activating mutations of EGFR; and
 - 2.4 Patient has an ECOG performance status 0-3; and
 - 2.5 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (NSCLC – first line) from any relevant practitioner. Approvals valid for 6 months where response to or stable disease with treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

Initial application — (NSCLC – second line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Patient is currently on treatment with osimertinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC); and
 - 2.2 Patient has an ECOG performance status 0-3; and
 - 2.3 The patient must have received previous treatment with erlotinib or gefitinib; and
 - 2.4 There is documentation confirming that the cancer expresses T790M mutation of EGFR following progression on or after erlotinib or gefitinib; and
 - 2.5 The treatment must be given as monotherapy; and
 - 2.6 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (NSCLC – second line) from any relevant practitioner. Approvals valid for 6 months where response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

PALBOCICLIB – Special Authority see [SA2345 below](#) – Retail pharmacy

Wastage claimable

Tab 75 mg	1,200.00	21	✓ Palbociclib Pfizer
	4,000.00		✓ Ibrance
Tab 100 mg	1,200.00	21	✓ Palbociclib Pfizer
	4,000.00		✓ Ibrance
Tab 125 mg	1,200.00	21	✓ Palbociclib Pfizer
	4,000.00		✓ Ibrance

(Ibrance Tab 75 mg to be delisted 1 December 2025)

(Ibrance Tab 100 mg to be delisted 1 December 2025)

(Ibrance Tab 125 mg to be delisted 1 December 2025)

➡SA2345 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has unresectable locally advanced or metastatic breast cancer; and
 - 1.2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
 - 1.3 Patient has an ECOG performance score of 0-2; and
 - 1.4 Either:
 - 1.4.1 Disease has relapsed or progressed during prior endocrine therapy; or
 - 1.4.2 Both:
 - 1.4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state; and
 - 1.4.2.2 Patient has not received prior systemic treatment for metastatic disease; and
 - 1.5 Treatment must be used in combination with an endocrine partner; and
 - 1.6 Patient has not received prior funded treatment with a CDK4/6 inhibitor; or
- 2 All of the following:
 - 2.1 Patient has an active Special Authority approval for ribociclib; and
 - 2.2 Patient has experienced a grade 3 or 4 adverse reaction to ribociclib that cannot be managed by dose reductions and requires treatment discontinuation; and
 - 2.3 Treatment must be used in combination with an endocrine partner; and
 - 2.4 There is no evidence of progressive disease since initiation of ribociclib.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 There is no evidence of progressive disease since initiation of palbociclib.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PAZOPANIB – Special Authority see SA2429 below – Retail pharmacy				
Tab 200 mg	172.88	30	✓	Pazopanib Teva
Tab 400 mg	464.00	30	✓	Pazopanib Teva

►SA2429 Special Authority for Subsidy

Initial application only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist.

Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic renal cell carcinoma of predominantly clear cell histology; and
 - 1.2 Either:
 - 1.2.1 The patient is treatment naive; or
 - 1.2.2 The patient has only received prior cytokine treatment; and
 - 1.3 The patient has an ECOG performance score of 0-2; and
The patient has intermediate or poor prognosis defined as:
 - 1.4 Any of the following:
 - 1.4.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 1.4.2 Haemoglobin level < lower limit of normal; or
 - 1.4.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 1.4.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 1.4.5 Karnofsky performance score of less than or equal to 70; or
 - 1.4.6 2 or more sites of organ metastasis; and
 - 1.5 Pazopanib to be used for a maximum of 3 months; or
- 2 All of the following:
 - 2.1 The patient has metastatic renal cell carcinoma; and
 - 2.2 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on sunitinib; and
 - 2.4 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months where there is no evidence of disease progression.

RIBOCICLIB – Special Authority see [SA2495 below](#) – Retail pharmacy

Wastage claimable

Tab 200 mg	1,883.00	21	✓	Kisqali
	3,767.00	42	✓	Kisqali
	5,650.00	63	✓	Kisqali

►SA2495 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has unresectable locally advanced or metastatic breast cancer; and
 - 1.2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
 - 1.3 Patient has an ECOG performance score of 0-2; and
 - 1.4 Either:
 - 1.4.1 Disease has relapsed or progressed during prior endocrine therapy; or
 - 1.4.2 Both:
 - 1.4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state; and
 - 1.4.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1.5 Treatment to be used in combination with an endocrine partner; and
- 1.6 Patient has not received prior funded treatment with a CDK4/6 inhibitor; or
- 2 All of the following:
 - 2.1 Patient has an active Special Authority approval for palbociclib; and
 - 2.2 Patient has experienced a grade 3 or 4 adverse reaction to palbociclib that cannot be managed by dose reductions and requires treatment discontinuation; and
 - 2.3 Treatment must be used in combination with an endocrine partner; and
 - 2.4 There is no evidence of progressive disease since initiation of palbociclib.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 There is no evidence of progressive disease since initiation of ribociclib.

RUXOLITINIB – Special Authority see [SA1890 below](#) – Retail pharmacy

Wastage claimable

Tab 5 mg	2,500.00	56	✓ Jakavi
Tab 10mg	5,000.00	56	✓ Jakavi
Tab 15 mg	5,000.00	56	✓ Jakavi
Tab 20 mg	5,000.00	56	✓ Jakavi

►SA1890 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
- 3 A maximum dose of 20 mg twice daily is to be given.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 A maximum dose of 20 mg twice daily is to be given.

SUNITINIB – Special Authority see [SA2452 on the next page](#) – Retail pharmacy

Cap 12.5 mg	103.11	28	✓ Sunitinib Rex
	208.38		✓ Sunitinib Pfizer
Cap 25 mg	203.15	28	✓ Sunitinib Rex
	416.77		✓ Sunitinib Pfizer
Cap 50 mg	694.62	28	✓ Sunitinib Pfizer

(Sunitinib Pfizer Cap 12.5 mg to be delisted 1 March 2026)

(Sunitinib Pfizer Cap 25 mg to be delisted 1 March 2026)

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA2452 Special Authority for Subsidy

Initial application — (RCC) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 The patient has not previously received funded sunitinib.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Renewal — (GIST pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal (GIST); and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

TRAMETINIB – Special Authority see [SA2496 below](#) – Retail pharmacy

Tab 0.5 mg	2,370.32	30	✓ Mekinist
Tab 2 mg	9,481.29	30	✓ Mekinist

►SA2496 Special Authority for Subsidy

Initial application — (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 The individual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a); or
 - 2.1.2 Both:
 - 2.1.2.1 The individual has received neoadjuvant treatment with a PD-1/PD-L1 inhibitor; and
 - 2.1.2.2 Adjuvant treatment with trametinib is required; and
 - 2.2 The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma; and
 - 2.3 Treatment must be adjuvant to complete surgical resection; and
 - 2.4 Treatment must be initiated within 13 weeks of surgical resection, unless delay is necessary due to post-surgery recovery (see note b); and
 - 2.5 The individual has a confirmed BRAF mutation; and
 - 2.6 Trametinib must be administered in combination with dabrafenib; and
 - 2.7 The individual has ECOG performance score 0-2.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

Renewal — (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 No evidence of disease recurrence; and
 - 1.2 Trametinib must be administered in combination with dabrafenib; and
 - 1.3 Treatment to be discontinued at signs of disease recurrence or at completion of 12 months' total treatment course, including any systemic neoadjuvant treatment; or
- 2 All of the following:
 - 2.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 2.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.3 The individual meets initial application criteria for trametinib for unresectable or metastatic melanoma; or
- 3 All of the following:
 - 3.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 3.2 The individual has received a BRAF/MEK inhibitor for unresectable or metastatic melanoma; and
 - 3.3 The individual meets renewal criteria for trametinib for unresectable or metastatic melanoma.

Initial application — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The individual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
 - 2.3 The individual has ECOG performance score 0-2; and
 - 2.4 The individual has confirmed BRAF mutation; and
 - 2.5 Trametinib must be administered in combination with dabrafenib; and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

2.6 Any of the following:

- 2.6.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
- 2.6.2 The individual did not receive treatment in the adjuvant setting with a BRAF/MEK inhibitor; or
- 2.6.3 All of the following:
 - 2.6.3.1 The individual received treatment in the adjuvant setting with a BRAF/MEK inhibitor; and
 - 2.6.3.2 The individual did not experience disease recurrence while on treatment with that BRAF/MEK inhibitor; and
 - 2.6.3.3 The individual did not experience disease recurrence within six months of completing adjuvant treatment with a BRAF/MEK inhibitor.

Renewal — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The individual's disease has had a complete response to treatment; or
 - 1.2 The individual's disease has had a partial response to treatment; or
 - 1.3 The individual has stable disease with treatment; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Tropic Hormones, [page 89](#)

ABIRATERONE ACETATE – Retail pharmacy-Specialist – Special Authority see [SA2118 below](#)

Wastage claimable

Tab 250 mg4,276.19 120 ✓ Zytiga

➔SA2118 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
 - 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Abiraterone acetate to be discontinued at progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

BICALUTAMIDE

Tab 50 mg	4.18	28	✓ Binarex
-----------------	------	----	------------------

FLUTAMIDE

Tab 250 mg	107.55	90	✓ Prostacur ^{\$29}
	119.50	100	✓ Flutamin

FULVESTRANT – Retail pharmacy-Specialist – Special Authority see [SA1895 below](#)

Inj 50 mg per ml, 5 ml prefilled syringe.....	1,068.00	2	✓ Faslodex
---	----------	---	-------------------

➔SA1895 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and
- 2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease; and
- 3 Treatment to be given at a dose of 500 mg monthly following loading doses; and
- 4 Treatment to be discontinued at disease progression.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains appropriate and patient is benefitting from treatment; and
- 2 Treatment to be given at a dose of 500 mg monthly; and
- 3 There is no evidence of disease progression.

OCTREOTIDE

Inj 100 mcg per ml, 1 ml ampoule	32.71	5	✓ Max Health
			✓ Octreotide GH ^{\$29}
			✓ Sun Pharma ^{\$29}
Inj 100 mcg per ml, 1 ml vial.....	48.50	5	✓ Omega ^{\$29}
Inj 50 mcg per ml, 1 ml vial.....	27.58	5	✓ Omega ^{\$29}
Inj 500 mcg per ml, 1 ml vial.....	113.10	5	✓ Omega ^{\$29}
Inj 50 mcg per ml, 1 ml ampoule	27.58	5	✓ Max Health
			✓ Octreotide GH ^{\$29}
Inj 500 mcg per ml, 1 ml ampoule	113.10	5	✓ Max Health
			✓ Octreotide GH ^{\$29}
			✓ Sun Pharma ^{\$29}

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TAMOXIFEN CITRATE				
* Tab 10 mg	15.00	60	✓	Tamoxifen Sandoz
* Tab 20 mg	5.32	60	✓	Tamoxifen Sandoz

Long-acting Somatostatin Analogues

►SA2445 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has not been successful; and
- 3 Treatment to be given for up to 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has acromegaly; and
- 2 Either:
 - 2.1 Treatment with surgery and radiotherapy is not suitable or was unsuccessful; or
 - 2.2 Treatment is for an interim period while awaiting the beneficial effects of radiotherapy; and
- 3 Treatment with a dopamine agonist has been unsuccessful.

Renewal — (Acromegaly) from any relevant practitioner. Approvals valid for 2 years where iGF1 levels have decreased since starting treatment.

Note: In patients with acromegaly, treatment should be discontinued if IGF1 levels have not decreased 3 months after treatment. In patients treated with radiotherapy treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following treatment withdrawal for at least 4 weeks

Initial application — (pre-operative acromegaly) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has acromegaly; and
- 2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and
- 3 Patient is scheduled to undergo pituitary surgery in the next six months.

Initial application — (Other Indications) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Surgery has been unsuccessful; or
 - 2.2.2 Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

3 Both:

3.1 Insulinomas; and

3.2 Surgery is contraindicated or has not been successful; or

4 For pre-operative control of hypoglycaemia and for maintenance therapy; or

5 Both:

5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and

5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded under Special Authority

Renewal — (Other Indications) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

LANREOTIDE – Special Authority see [SA2445 on the previous page](#) – Retail pharmacy

Inj 60 mg per 0.5 ml, 0.5 ml syringe	382.77	1	✓ Mytolac
			✓ Mytolac S29 S29
Inj 90 mg per 0.5 ml, 0.5 ml syringe	562.92	1	✓ Mytolac
Inj 120 mg per 0.5 ml, 0.5 ml syringe	646.70	1	✓ Mytolac

OCTREOTIDE LONG-ACTING – Special Authority see [SA2445 on the previous page](#) – Retail pharmacy

Inj depot 10 mg prefilled syringe.....	438.40	1	✓ Sandostatin LAR
Inj depot 20 mg prefilled syringe.....	583.70	1	✓ Sandostatin LAR
Inj depot 30 mg prefilled syringe.....	670.80	1	✓ Sandostatin LAR

Aromatase Inhibitors

ANASTROZOLE

* Tab 1 mg	4.39	30	✓ Anatrole
------------------	------	----	-------------------

EXEMESTANE

* Tab 25 mg	9.86	30	✓ Pfizer Exemestane
-------------------	------	----	----------------------------

LETROZOLE

* Tab 2.5 mg	4.36	28	✓ Accord S29
	4.67	30	✓ Letrole

Immunosuppressants

Cytotoxic Immunosuppressants

AZATHIOPRINE

* Tab 25 mg	10.15	60	✓ Azamun
* Tab 50 mg	10.34	100	✓ Azamun

MYCOPHENOLATE MOFETIL

Tab 500 mg	35.90	50	✓ Cellcept
Cap 250 mg	35.90	100	✓ Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement	187.25	165 ml OP	✓ Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Fusion Proteins				
ETANERCEPT – Special Authority see SA2399 below – Retail pharmacy				
Inj 25 mg.....	690.00	4	✓	Enbrel
Inj 25 mg autoinjector	690.00	4	✓	Enbrel
Inj 50 mg autoinjector	1,050.00	4	✓	Enbrel
Inj 50 mg prefilled syringe.....	1,050.00	4	✓	Enbrel

►SA2399 Special Authority for Subsidy

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a Health NZ Hospital; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

2.5 Either:

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (polyarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and

2.3 Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
- 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
- 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (polyarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (oligoarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate.

Renewal — (oligoarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab or secukinumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or secukinumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or secukinumab to meet the renewal criteria for adalimumab or secukinumab for psoriatic arthritis; or

2 All of the following:

- 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
- 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
- 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with * are unapproved indications.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (Arthritis - rheumatoid) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Renewal — (Arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist or any relevant practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or

2 All of the following:

- 2.1 Any of the following:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.3 Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; or

1.3 Both:

1.3.1 Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment; and

1.3.2 Either:

1.3.2.1 The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; or

1.3.2.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing etanercept; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Initial application — (undifferentiated spondyloarthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
- 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
- 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Renewal — (undifferentiated spondyloarthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist

Inj 50 mg per ml, 5 ml	4,439.17	5	✓ ATGAM
------------------------------	----------	---	---------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist				
Subsidised only for bladder cancer.				
Inj 2-8 × 100 million CFU	149.37	1	✓	OncoTICE
Inj 40 mg per ml, vial	182.45	3	✓	SII-Onco-BCG \$29

Monoclonal Antibodies

ADALIMUMAB (AMGEVITA) – Special Authority see [SA2525 below](#) – Retail pharmacy

Inj 20 mg per 0.4 ml prefilled syringe.....	190.00	1	✓	Amgevita
Inj 40 mg per 0.8 ml prefilled pen	375.00	2	✓	Amgevita
Inj 40 mg per 0.8 ml prefilled syringe.....	375.00	2	✓	Amgevita

► [SA2525](#) Special Authority for Subsidy

Initial application — (Behcet's disease - severe) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has severe Behcet's disease* that is significantly impacting the patient's quality of life; and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s); or
 - 2.2 The patient has severe gastrointestinal, rheumatological, and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s).

Note: Indications marked with * are unapproved indications.

Initial application — (Hidradenitis suppurativa) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 Patient has 3 or more active lesions; and
- 4 The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application.

Renewal — (Hidradenitis suppurativa) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a DLQI improvement of 4 or more from baseline.

Initial application — (Plaque psoriasis - severe chronic) only from a dermatologist or any relevant practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Any of the following:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a PASI score of greater than 10, where

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.3 Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10; and
- 2.2 Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.

Renewal — (Plaque psoriasis - severe chronic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced a 75% or more reduction in PASI score, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 1.2.2 The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 2 Both:
 - 2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2 Either:
 - 2.2.1 The patient has experienced reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2 The patient has experienced reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre treatment baseline value; or
- 3 Both:
 - 3.1 Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment; and
 - 3.2 Either:
 - 3.2.1 The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; or
 - 3.2.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing adalimumab.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and has not received an adequate response.

Note: Indications marked with * are unapproved indications.

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on adalimumab; or
- 2 CDAI score is 150 or less, or HBI is 4 or less; or
- 3 The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed.

Initial application — (Crohn's disease - children) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease - children) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
- 2 PCDAI score is 15 or less; or
- 3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed.

Initial application — (Crohn's disease - fistulising) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patient has complex peri-anal fistula; and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application.

Renewal — (Crohn's disease - fistulising) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Initial application — (Ocular inflammation - chronic) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (Ocular inflammation - chronic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 12 weeks' initial treatment; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initial application — (Ocular inflammation - severe) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (Ocular inflammation - severe) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

1 Both:

1.1 Patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects; or

1.2.2 The patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; or

2 All of the following:

2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and

2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and

2.3 Patient has bilateral sacroiliitis demonstrated by radiology imaging; and

2.4 Patient has not responded adequately to treatment with two or more NSAIDs, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

2.5 Either:

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender; and

2.6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment and is no more than 1 month old at the time of application.

Renewal — (ankylosing spondylitis) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (Arthritis - oligoarticular course juvenile idiopathic) only from a named specialist or rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 Patient has experienced intolerable side effects; or

1.2.2 Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and

2.3 Either:

2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or

2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose).

Renewal — (Arthritis - oligoarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist or rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 Patient has experienced intolerable side effects; or

1.2.2 Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and

2.3 Any of the following:

2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or

2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or

2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (Arthritis - polyarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - psoriatic) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects; or

1.2.2 The patient has received insufficient benefit from to meet the renewal criteria for psoriatic arthritis; or

2 All of the following:

2.1 Patient has had active psoriatic arthritis for six months duration or longer; and

2.2 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and

2.3 Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated); and

2.4 Either:

2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or

2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:

2.5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

2.5.2 Patient has an ESR greater than 25 mm per hour; or

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (Arthritis - psoriatic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant response in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initial application — (Arthritis - rheumatoid) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is CCP antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin (unless contraindicated); or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide (unless contraindicated) alone or in combination with methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Renewal — (Arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Initial application — (Still's disease - adult-onset (AOSD)) only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for AOSD; and

1.2 Either:

1.2.1 Patient has experienced intolerable side effects from etanercept and/or tocilizumab; or

1.2.2 Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria; and

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Patient has active ulcerative colitis; and

2 Either:

2.1 Patient's SCCAI score is greater than or equal to 4; or

2.2 Patient's PUCAI score is greater than or equal to 20; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from prior therapy with immunomodulators and systemic corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biologic therapy; or

2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiation on biologic therapy.

Initial application — (undifferentiated spondyloarthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2 Patient has tried and not responded to at least three months of each of methotrexate, sulfasalazine and leflunomide, at maximum tolerated doses (unless contraindicated); and

3 Any of the following:

3.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or

3.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or

3.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications

Renewal — (undifferentiated spondyloarthritis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initial application — (inflammatory bowel arthritis – axial) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- Patient has axial inflammatory pain for six months or more; and
- Patient is unable to take NSAIDs; and
- Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- Patient has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

Renewal — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (inflammatory bowel arthritis – peripheral) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- Patient has tried and not experienced a response to at least three months of methotrexate, or azathioprine at a maximum tolerated dose (unless contraindicated); and
- Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- Any of the following:
 - Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- Following initial treatment, patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) – Special Authority see [SA2157 below](#) – Retail pharmacy

Inj 20 mg per 0.2 ml prefilled syringe.....	595.50	2	✓ Humira
Inj 40 mg per 0.4 ml prefilled pen	595.50	2	✓ HumiraPen
Inj 40 mg per 0.4 ml prefilled syringe.....	595.50	2	✓ Humira

► **SA2157** Special Authority for Subsidy

Initial application — (Behcet's disease – severe) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Behcet's disease – severe) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has had a good clinical response to treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 7 days. Fortnightly dosing has been considered.

Renewal — (Hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

Initial application — (Psoriasis - severe chronic plaque) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Psoriasis - severe chronic plaque) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Pyoderma gangrenosum) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 A maximum of 8 doses.

Renewal — (Pyoderma gangrenosum) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated clinical improvement and continues to require treatment; and
- 2 A maximum of 8 doses.

Initial application — (Crohn's disease - adult) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - adult) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment, but PCDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - fistulising) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - fistulising) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Ocular inflammation – chronic) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Ocular inflammation – chronic) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Ocular inflammation – severe) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Ocular inflammation – severe) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and

- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita); and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Arthritis – oligoarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Renewal — (Arthritis – oligoarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months where the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months where the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - psoriatic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Arthritis - psoriatic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Arthritis - rheumatoid) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Arthritis - rheumatoid) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Either:
 - 2.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 2.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initial application — (Still's disease - adult-onset (AOSD)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

1 Either:

- 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
- 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and

2 Patient has received a maximum of 6 months treatment with Amgevita; and

3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Renewal — (Still's disease – adult-onset (AOSD)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has demonstrated a sustained improvement in inflammatory markers and functional status.

AFLIBERCEPT – Special Authority see [SA1772 below](#) – Retail pharmacy

Inj 40 mg per ml, 0.1 ml vial..... 1,250.00 1 ✓ Eylea

► **SA1772 Special Authority for Subsidy**

Initial application — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

1 All of the following:

1.1 Any of the following:

- 1.1.1 Wet age-related macular degeneration (wet AMD); or
- 1.1.2 Polypoidal choroidal vasculopathy; or
- 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and

1.2 Either:

- 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
- 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

1.3 There is no structural damage to the central fovea of the treated eye; and

1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or

2 Either:

2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or

2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Initial application — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Renewal — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 3 There is no structural damage to the central fovea of the treated eye.
- Renewal — (diabetic macular oedema)** only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:
- All of the following:
- 1 There is stability or two lines of Snellen visual acuity gain; and
 - 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
 - 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
 - 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
 - 5 After each consecutive 12 months treatment with (2nd line anti-VEGF agent), patient has retrialled with at least one injection of bevacizumab and had no response.

BENRALIZUMAB – Special Authority see SA2151 on the next page – Retail pharmacy			
Inj 30 mg per ml, 1 ml prefilled pen	3,539.00	1	✓ Fasenra

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

►SA2151 Special Authority for Subsidy

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5×10^9 cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long-acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever therapy plus maintenance regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised mepolizumab; and
- 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or
 - 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

BEVACIZUMAB – PCT only – Special Authority see [SA2453 below](#)

Inj 25 mg per ml, 4 ml vial.....	69.00	1	✓ Vegzelma
Inj 25 mg per ml, 16 ml vial.....	276.00	1	✓ Vegzelma
Inj 1 mg for ECP.....	0.71	1 mg	✓ Baxter

►SA2453 Special Authority for Subsidy

Initial application — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with bevacizumab, and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.2 Patient has preserved liver function (Child-Pugh A); and
- 2.3 Transarterial chemoembolisation (TACE) is unsuitable; and
- 2.4 Any of the following:
 - 2.4.1 Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma; or
 - 2.4.2 Patient received funded lenvatinib before 1 March 2025; or
 - 2.4.3 Both:
 - 2.4.3.1 Patient has experienced treatment-limiting toxicity from treatment with lenvatinib; and
 - 2.4.3.2 No disease progression since initiation of lenvatinib; and
- 2.5 Patient has an ECOG performance status of 0-2; and
- 2.6 To be given in combination with atezolizumab.

Renewal — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Initial application — (advanced or metastatic ovarian cancer) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has FIGO Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; or
 - 1.2 Both:
 - 1.2.1 The patient has previously untreated advanced (FIGO Stage IIIB or IIIC) epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
 - 1.2.2 Either:
 - 1.2.2.1 Debulking surgery is inappropriate; or
 - 1.2.2.2 The cancer is sub-optimally debulked (maximum diameter of any gross residual disease greater than 1cm); and
- 2 Bevacizumab to be administered at a maximum dose of 15 mg/kg every three weeks; and
- 3 18 weeks concurrent treatment with chemotherapy is planned.

Renewal — (advanced or metastatic ovarian cancer) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

Initial application — (Recurrent Respiratory Papillomatosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Maximum of 6 doses; and
- 2 The patient has recurrent respiratory papillomatosis; and
- 3 The treatment is for intra-lesional administration.

Renewal — (Recurrent Respiratory Papillomatosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Maximum of 6 doses; and
- 2 The treatment is for intra-lesional administration; and
- 3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

Initial application — (Ocular Conditions) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Ocular neovascularisation; or
- 2 Exudative ocular angiopathy.

BRENTUXIMAB VEDOTIN – PCT only – Special Authority see [SA2289 on the next page](#)

Inj 50 mg vial	5,275.18	1	✓ Adcetris
----------------------	----------	---	------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

►SA2289 Special Authority for Subsidy

Initial application — (relapsed/refractory Hodgkin lymphoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma after two or more lines of chemotherapy; and
 - 1.1.2 Patient is ineligible for autologous stem cell transplant; or
 - 1.2 Both:
 - 1.2.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma; and
 - 1.2.2 Patient has previously undergone autologous stem cell transplant; and
- 2 Patient has not previously received funded brentuximab vedotin; and
- 3 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
- 4 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Renewal — (relapsed/refractory Hodgkin lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles; and
- 2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and
- 3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment.

Initial application — (anaplastic large cell lymphoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has relapsed/refractory CD30-positive systemic anaplastic large cell lymphoma; and
- 2 Patient has an ECOG performance status of 0-1; and
- 3 Patient has not previously received brentuximab vedotin; and
- 4 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
- 5 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Renewal — (anaplastic large cell lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles; and
- 2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and
- 3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment.

CETUXIMAB – PCT only – Specialist – Special Authority see [SA2401 below](#)

Inj 5 mg per ml, 20 ml vial.....	364.00	1	✓ Erbitux
Inj 5 mg per ml, 100 ml vial.....	1,820.00	1	✓ Erbitux
Inj 1 mg for ECP.....	3.82	1 mg	✓ Baxter

►SA2401 Special Authority for Subsidy

Initial application — (head and neck cancer, locally advanced) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
- 2 Cisplatin is contraindicated or has resulted in intolerable side effects; and
- 3 Patient has an ECOG performance score of 0-2; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 4 To be administered in combination with radiation therapy.

Initial application — (colorectal cancer, metastatic) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic colorectal cancer located on the left side of the colon (see Note); and
- 2 There is documentation confirming disease is RAS and BRAF wild-type; and
- 3 Patient has an ECOG performance score of 0-2; and
- 4 Patient has not received prior funded treatment with cetuximab; and
- 5 Either:
 - 5.1 Cetuximab is to be used in combination with chemotherapy; or
 - 5.2 Chemotherapy is determined to not be in the best interest of the patient based on clinician assessment.

Renewal — (colorectal cancer, metastatic) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where there is no evidence of disease progression.

Note: Left-sided colorectal cancer comprises of the distal one-third of the transverse colon, the splenic flexure, the descending colon, the sigmoid colon, or the rectum.

GEMTUZUMAB OZOGAMICIN – PCT only – Specialist – Special Authority see [SA2269 below](#)

Inj 5 mg vial	12,973.00	1	✓ Mylotarg
---------------------	-----------	---	------------

► **SA2269 Special Authority for Subsidy**

Initial application only from a haematologist, paediatric haematologist or paediatric oncologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has not received prior chemotherapy for this condition; and
- 2 Patient has de novo CD33-positive acute myeloid leukaemia; and
- 3 Patient does not have acute promyelocytic leukaemia; and
- 4 Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC); and
- 5 Patient is being treated with curative intent; and
- 6 Patient's disease risk has been assessed by cytogenetic testing to be good or intermediate; and
- 7 Patient must be considered eligible for standard intensive remission induction chemotherapy with standard anthracycline and cytarabine (AraC); and
- 8 Gemtuzumab ozogamicin to be funded for one course only (one dose at 3 mg per m² body surface area or up to 2 vials of 5 mg as separate doses).

Note: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (eg myelodysplasia or myeloproliferative disorder).

INFLIXIMAB – PCT only – Special Authority see [SA2487 below](#)

Inj 100 mg	428.00	1	✓ Remicade
Inj 1 mg for ECP	4.40	1 mg	✓ Baxter

► **SA2487 Special Authority for Subsidy**

Initial application — (Crohn's disease (adults)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a CDAI score of greater than or equal to 300 or HBI score of greater than or equal to 10; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease (adults)) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Crohn's disease (children)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease (children)) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Graft vs host disease) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has steroid-refractory acute graft vs. host disease of the gut.

Initial application — (Pulmonary sarcoidosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has life-threatening pulmonary sarcoidosis diagnosed by a multidisciplinary team that is refractory to other treatments.

Initial application — (acute fulminant ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient has acute, fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initial application — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Initial application — (fistulising Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patient has complex peri-anal fistula.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist.

Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with neurosarcoidosis by a multidisciplinary team; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Renewal — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months for applications meeting the following criteria:

Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and
 - 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initial application — (plaque psoriasis) only from a dermatologist or any relevant practitioner on the recommendation of a dermatologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; or

2 All of the following:

2.1 Any of the following:

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.3 Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10; and

- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

- 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (plaque psoriasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Any of the following:

1.1 Both:

- 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or

1.2 Both:

- 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

- 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
- 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; or

1.3 Both:

- 1.3.1 Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment; and
- 1.3.2 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

1.3.2.1 The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; or

1.3.2.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing infliximab; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Patient was being treated with infliximab prior to 1 February 2019; and

2 Any of the following:

- 2.1 Rheumatoid arthritis; or
- 2.2 Ankylosing spondylitis; or
- 2.3 Psoriatic arthritis; or
- 2.4 Severe ocular inflammation; or
- 2.5 Chronic ocular inflammation; or
- 2.6 Crohn's disease (adults); or
- 2.7 Crohn's disease (children); or
- 2.8 Fistulising Crohn's disease; or
- 2.9 Severe fulminant ulcerative colitis; or
- 2.10 Severe ulcerative colitis; or
- 2.11 Plaque psoriasis; or
- 2.12 Neurosarcoidosis; or
- 2.13 Severe Behcet's disease.

Initial application — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 4 months for applications meeting the following criteria:

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis; and

2 Either:

- 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept and/or secukinumab; or
- 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:

- 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and

3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initial application — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and

2 Either:

2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or

2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and

3 The patient is experiencing significant loss of quality of life.

Notes: Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.

Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Renewal — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Renewal — (fulminant ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
 - 2.1 Patients SCCAI is greater than or equal to 4; or
 - 2.2 Patients PUCAI score is greater than or equal to 20; and
- 3 Patient has tried but has experienced an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
 - 1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has had axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient's disease has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 Patient has a BASDAI of at least 6 on a 0 - 10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

Renewal — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:
 - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Renewal — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

Initial application — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual requires treatment for moderate to severe autoimmune toxicity following immune checkpoint inhibitor treatment for malignancy; and
- 2 The individual has received insufficient benefit from use of corticosteroids; and
- 3 Infliximab is to be administered at up to 5mg/kg for up to four doses.

Renewal — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The individual has shown clinical improvement and ongoing treatment is required; and
- 2 Infliximab is to be administered at up to 5mg/kg for up to a total of 8 doses.

Note: Indications marked with * are unapproved indications.

INOTUZUMAB OZOGAMICIN – PCT only – Specialist – Special Authority see [SA2460 below](#)

Inj 1 mg vial	14,457.00	1	✓ Besponsa
Inj 1 mg for ECP	14,457.00	1 mg	✓ Baxter

➔ **SA2460** **Special Authority for Subsidy**

Initial application only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia/lymphoma, including minimal residual disease; and
- 2 Patient has ECOG performance status of 0-2; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient has Philadelphia chromosome positive B-Cell ALL; and
 - 3.1.2 Patient has previously received a tyrosine kinase inhibitor; or
 - 3.2 Patient has received one prior line of treatment involving intensive chemotherapy; and
- 4 Treatment is to be administered for a maximum of 3 cycles.

Renewal only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient is not proceeding to a stem cell transplant; and
- 2 Either:
 - 2.1 Patient has experienced complete disease response; or
 - 2.2 Patient has experienced complete remission with incomplete haematological recovery; and
- 3 Treatment with inotuzumab ozogamicin is to cease after a total duration of 6 cycles.

MEPOLIZUMAB – Special Authority see [SA2331 on the next page](#) – Retail pharmacy

Inj 100 mg pre-filled pen	1,638.00	1	✓ Nucala
---------------------------------	----------	---	-----------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2331 Special Authority for Subsidy

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5×10^9 cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised benralizumab; and
- 8 When an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or
 - 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

Initial application — (eosinophilic granulomatosis with polyangiitis) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has eosinophilic granulomatosis with polyangiitis; and
- 2 The patient has trialled and not received adequate benefit from at least one of the following for at least three months (unless contraindicated to all): azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate, or rituximab; and
- 3 Either:
 - 3.1 The patient has trialled prednisone for a minimum of three months and is unable to maintain disease control at

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

doses below 7.5 mg per day; or

3.2 Corticosteroids are contraindicated.

Renewal — (eosinophilic granulomatosis with polyangiitis) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where patient has no evidence of clinical disease progression.

OBINUTUZUMAB – PCT only – Specialist – Special Authority see [SA2155 below](#)

Inj 25 mg per ml, 40 ml vial.....	5,910.00	1	✓ Gazyva
Inj 1 mg for ECP.....	6.21	1 mg	✓ Baxter

➔ **SA2155 Special Authority for Subsidy**

Initial application — (chronic lymphocytic leukaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* Neutrophil greater than or equal to $1.5 \times 10^9/L$ and platelets greater than or equal to $75 \times 10^9/L$.

Initial application — (follicular / marginal zone lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has follicular lymphoma; or
 - 1.2 Patient has marginal zone lymphoma; and
- 2 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen*; and
- 3 Patient has an ECOG performance status of 0-2; and
- 4 Patient has been previously treated with no more than four chemotherapy regimens; and
- 5 Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy*.

Note: * includes unapproved indications

Renewal — (follicular / marginal zone lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 Patient has no evidence of disease progression following obinutuzumab induction therapy; and
- 2 Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and
- 3 Obinutuzumab to be discontinued at disease progression.

OMALIZUMAB – Special Authority see [SA1744 on the next page](#) – Retail pharmacy

Inj 150 mg prefilled syringe.....	450.00	1	✓ Xolair
Inj 150 mg vial	450.00	1	✓ Xolair AU
			✓ Xolair

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1744 Special Authority for Subsidy

Initial application — (severe asthma) only from a respiratory specialist or clinical immunologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 6 years or older; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or formoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
 - 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Initial application — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; or
 - 2.2 Patient has a Urticaria Control Test (UCT) of 8 or less; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
 - 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
 - 4.2 Complete response* to 6 doses of omalizumab.

Renewal — (severe asthma) only from a clinical immunologist or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Renewal — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient has previously adequately responded* to 6 doses of omalizumab; or
- 2 Both:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PALIVIZUMAB – PCT only – Special Authority see [SA2419 below](#)

Inj 100 mg per ml, 1 ml vial..... 1,700.00 1 ✓ Synagis

➔SA2419 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Palivizumab to be administered during the annual RSV season; and
- 2 Either:

2.1 Both:

- 2.1.1 Infant was born in the last 12 months; and
- 2.1.2 Infant was born at less than 32 weeks zero days' gestation; or

2.2 Both:

2.2.1 Child was born in the last 24 months; and

2.2.2 Any of the following:

2.2.2.1 Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community; or

2.2.2.2 Both:

2.2.2.2.1 Child has haemodynamically significant heart disease; and

2.2.2.2.2 Any of the following:

2.2.2.2.2.1 Child has unoperated simple congenital heart disease with significant left to right shunt (see Note B); or

2.2.2.2.2.2 Child has unoperated or surgically palliated complex congenital heart disease; or

2.2.2.2.2.3 Child has severe pulmonary hypertension (see Note C); or

2.2.2.2.2.4 Child has moderate or severe left ventricular (LV) failure (see Note D); or

2.2.2.3 Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell transplant; or

2.2.2.4 Child has inborn errors of immunity (see Note E) that increase susceptibility to life-threatening viral respiratory infections, confirmed by an immunologist.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Palivizumab to be administered during the annual RSV season; and
- 2 Child was born in the last 24 months; and
- 3 Any of the following:

3.1 Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community; or

3.2 Both:

3.2.1 Child has haemodynamically significant heart disease; and

3.2.2 Any of the following:

3.2.2.1 Child has unoperated simple congenital heart disease with significant left to right shunt (see Note B); or

3.2.2.2 Child has unoperated or surgically palliated complex congenital heart disease; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 3.2.2.3 Child has severe pulmonary hypertension (see Note C); or
- 3.2.2.4 Child has moderate or severe left ventricular (LV) failure (see Note D); or
- 3.3 Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell transplant; or
- 3.4 Child has inborn errors of immunity (see Note E) that increase susceptibility to life-threatening viral respiratory infections, confirmed by an immunologist.

Notes:

- a) Ventilatory/respiratory support includes those on home oxygen, CPAP/VPAP and those with tracheostomies in situ managed at home
- b) Child requires/will require heart failure medication, and/or child has significant pulmonary hypertension, and/or infant will require surgical palliation/definitive repair within the next 3 months
- c) Mean pulmonary artery pressure more than 25 mmHg
- d) LV Ejection Fraction less than 40%
- e) Inborn errors of immunity include, but are not limited to, IFNAR deficiencies

PERTUZUMAB – PCT only – Specialist – Special Authority see [SA2276 below](#)

Inj 30 mg per ml, 14 ml vial.....	3,927.00	1	✓ Perjeta
Inj 420 mg for ECP	3,927.00	420 mg OP	✓ Baxter

► **SA2276** **Special Authority for Subsidy**

Initial application — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 Patient is chemotherapy treatment naïve; or
 - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pertuzumab and trastuzumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pertuzumab and trastuzumab.

RITUXIMAB (MABTHERA) – PCT only – Specialist – Special Authority see [SA1976 on the next page](#)

Inj 100 mg per 10 ml vial	1,075.50	2	✓ Mabthera
Inj 500 mg per 50 ml vial	2,688.30	1	✓ Mabthera
Inj 1 mg for ECP	5.64	1 mg	✓ Baxter (Mabthera)

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1976 Special Authority for Subsidy

Initial application — (rheumatoid arthritis - TNF inhibitors contraindicated) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initial application — (rheumatoid arthritis - prior TNF inhibitor use) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'partial responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

1 Any of the following:

- 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

- 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

- 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

RITUXIMAB (RIXIMYO) – PCT only – Specialist – Special Authority see SA2497 below

Inj 100 mg per 10 ml vial	275.33	2	✓ Riximyo
Inj 500 mg per 50 ml vial	688.20	1	✓ Riximyo
Inj 1 mg for ECP	1.38	1 mg	✓ Baxter (Riximyo)

►SA2497 Special Authority for Subsidy

Initial application — (ABO-incompatible organ transplant) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

Initial application — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- course of cyclophosphamide would result in a cumulative dose > 15 g; or
- 3.3 Cyclophosphamide and methotrexate are contraindicated; or
- 3.4 Patient is a female of child-bearing potential; or
- 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Renewal — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Antibody-mediated organ transplant rejection) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has been diagnosed with antibody-mediated organ transplant rejection*.

Note: Indications marked with * are unapproved indications.

Initial application — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
 - 2.1 The patient is rituximab treatment naive; or
 - 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or
 - 2.2.2 Both:
 - 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
 - 2.3 The patient's disease has relapsed and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and
- 4 Either:
 - 4.1 The patient does not have chromosome 17p deletion CLL; or
 - 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Renewal — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

1 Either:

- 1.1 The patient's disease has relapsed and rituximab treatment is to be used in combination with funded venetoclax; or
- 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and

- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initial application — (Neuromyelitis Optica Spectrum Disorder(NMOSD)) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Renewal — (Neuromyelitis Optica Spectrum Disorder) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initial application — (Post-transplant) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Post-transplant) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Renewal — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
 - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initial application — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SDNS* or FRNS*; and
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Note: Indications marked with * are unapproved indications.

Initial application — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naïve aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Renewal — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initial application — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Renewal — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Initial application — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Renewal — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initial application — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has cold haemagglutinin disease*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks; and
- 2 Either:
 - 2.1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Renewal — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Renewal — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initial application — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

3 Either:

- 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not been effective at controlling active disease; or
- 3.2 Rapid treatment is required due to life threatening complications; and

4 Maximum of four 1,000mg infusions of rituximab.

Renewal — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 Maximum of two cycles of 2 × 1,000mg infusions of rituximab given two weeks apart.

Initial application — (graft versus host disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not been effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initial application — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
 - 2.1 Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
- 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
- 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 The patient has experienced a relapse and now requires further treatment; and
- 4 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Renewal — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- 2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m² every 8 weeks (maximum of 12 cycles).

Initial application — (Membranous nephropathy) only from a nephrologist or any relevant practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has biopsy-proven primary/idiopathic membranous nephropathy*; or
 - 1.2 Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m²; and
- 2 Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note); and
- 3 The total rituximab dose would not exceed the equivalent of 375mg/m² of body surface area per week for a total of 4 weeks.

Renewal — (Membranous nephropathy) only from a nephrologist or any relevant practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for membranous nephropathy*; and
- 2 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.1 Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; or
- 2.2 Patient achieved partial response to treatment and requires repeat treatment (see Note); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Notes:

- a) Indications marked with * are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.
- d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

Initial application — (B-cell acute lymphoblastic leukaemia/lymphoma*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*; and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² per dose for a maximum of 18 doses.

Note: Indications marked with * are unapproved indications.

Initial application — (desensitisation prior to transplant) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires desensitisation prior to mismatched allogeneic stem cell transplant*; and
- 2 Patient would receive no more than two doses at 375 mg/m² of body-surface area.

Note: Indications marked with * are unapproved indications.

Initial application — (pemphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has severe rapidly progressive pemphigus; and
 - 1.2 Is used in combination with systemic corticosteroids (20 mg/day); and
 - 1.3 Any of the following:
 - 1.3.1 Skin involvement is at least 5% body surface area; or
 - 1.3.2 Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions; or
 - 1.3.3 Involvement of two or more mucosal sites; or
- 2 Both:
 - 2.1 Patient has pemphigus; and
 - 2.2 Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated.

Note: Indications marked with * are unapproved indications.

Renewal — (pemphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

skin ulceration and reduction in corticosteroid requirement; and

2 Patient has not received rituximab in the previous 6 months.

Note: Indications marked with * are unapproved indications.

Initial application — (immunoglobulin G4-related disease (IgG4-RD*)) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

1 Patient has confirmed diagnosis of IgG4-RD*; and

2 Either:

2.1 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse; or

2.2 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance; and

3 Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with * are unapproved indications.

Renewal — (immunoglobulin G4-related disease (IgG4-RD*)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Treatment with rituximab for IgG4-RD* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed; or

1.2 Patient is receiving maintenance treatment for IgG4-RD*; and

2 Rituximab re-treatment not to be given within 6 months of previous course of treatment; and

3 Maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with * are unapproved indications.

SECUKINUMAB – Special Authority see [SA2488 below](#) – Retail pharmacy

Inj 150 mg per ml, 1 ml prefilled syringe.....	799.50	1	✓ Cosentyx
	1,599.00	2	✓ Cosentyx

►SA2488 Special Authority for Subsidy

Initial application — (severe chronic plaque psoriasis – second-line biologic) only from a dermatologist or any relevant practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a Health NZ Hospital, for severe chronic plaque psoriasis; and

2 Either:

2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or

2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and

3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Initial application — (severe chronic plaque psoriasis – first-line biologic) only from a dermatologist or any relevant practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or
- 1.3 Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand, foot, genital or flexural areas, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis – first and second-line biologic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Either:
 - 1.1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
 - 1.1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; or
 - 1.2.2.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initial application — (ankylosing spondylitis – second-line biologic) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Renewal — (ankylosing spondylitis – second-line biologic) only from a rheumatologist or medical practitioner on the

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate; and
- 3 Secukinumab to be administered at doses no greater than 300 mg monthly.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or infliximab to meet the renewal criteria for adalimumab, etanercept or infliximab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician; and
- 2 Secukinumab to be administered at doses no greater than 300 mg monthly.

SILTUXIMAB – Special Authority see [SA1596 on the next page](#) – Retail pharmacy

Note: Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Inj 100 mg vial	770.57	1	✓ Sylvant
Inj 400 mg vial	3,082.33	1	✓ Sylvant

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

➤SA1596 Special Authority for Subsidy

Initial application only from a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Renewal only from a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TOCILIZUMAB – PCT only – Special Authority see [SA2489 below](#)

Inj 20 mg per ml, 4 ml vial.....	220.00	1	✓ Actemra
Inj 20 mg per ml, 10 ml vial.....	550.00	1	✓ Actemra
Inj 20 mg per ml, 20 ml vial.....	1,100.00	1	✓ Actemra
Inj 1 mg for ECP	2.85	1 mg	✓ Baxter

➤SA2489 Special Authority for Subsidy

Initial application — (cytokine release syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - 1.2 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or
- 2 All of the following:
 - 2.1 The patient is enrolled in the Malaghan Institute of Medical Research ENABLE trial programme; and
 - 2.2 The patient has developed CRS or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) following CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
 - 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS or ICANS for CAR T-cell therapy at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initial application — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:
 - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
 - 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 5 Either:
 - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initial application — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1.2 The patient has been started on tocilizumab for AOSD in a Health NZ Hospital; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:
Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:
 - 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.4 Any of the following:
 - 2.4.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Initial application — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Initial application — (moderate to severe COVID-19) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose; and
- 5 Tocilizumab is not to be administered in combination with baricitinib.

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Renewal — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has a sustained improvement in inflammatory markers and functional status.

Renewal — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual requires treatment for moderate to severe autoimmune toxicity following immune checkpoint inhibitor treatment for malignancy; and
- 2 The individual has received insufficient benefit from use of corticosteroids; and
- 3 Tocilizumab is to be administered at a maximum dose of 8 mg/kg fortnightly.

Renewal — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The individual has shown clinical improvement and ongoing treatment is required; and
- 2 Tocilizumab is to be administered at a maximum dose of 8 mg/kg fortnightly.

Note: Indications marked with * are unapproved indications.

TRASTUZUMAB (HERZUMA) – PCT only – Special Authority see [SA2293](#) below

Inj 150 mg vial	100.00	1	✓ Herzuma
Inj 440 mg vial	293.35	1	✓ Herzuma
Inj 1 mg for ECP	0.70	1 mg	✓ Baxter

► [SA2293](#) Special Authority for Subsidy

Initial application — (early breast cancer) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 The patient has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment).

Renewal — (early breast cancer*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
 - 1.3 Any of the following:
 - 1.3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 1.3.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; or
 - 1.3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 1.4 Either:
 - 1.4.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 1.4.2 All of the following:
 - 1.4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 1.4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 1.4.2.3 The patient has good performance status (ECOG grade 0-1); and
 - 1.5 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with trastuzumab.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer

Initial application — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 4 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 1.3 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with trastuzumab.

Initial application — (gastric, gastro-oesophageal junction and oesophageal cancer) from any relevant practitioner.

Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other current technology); and
- 2 Patient has an ECOG score of 0-2.

Renewal — (gastric, gastro-oesophageal junction and oesophageal cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 2 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB DERUXTECAN – PCT only – Special Authority see [SA2420 below](#)

Inj 100 mg per ml, 1 ml vial.....	2,550.00	1	✓ Enhertu
Inj 1 mg for ECP	27.05	1 mg	✓ Baxter

►SA2420 Special Authority for Subsidy

Initial application only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with trastuzumab deruxtecan and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has metastatic breast cancer expressing HER-2 IHC3+ or ISH+ (including FISH or other current technology); and
 - 2.2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
 - 2.3 Either:
 - 2.3.1 The patient has received prior therapy for metastatic disease; or
 - 2.3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy; and
 - 2.4 Patient has a good performance status (ECOG 0-1); and
 - 2.5 Patient has not received prior funded trastuzumab deruxtecan treatment; and
 - 2.6 Treatment to be discontinued at disease progression.

Renewal only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab deruxtecan; and
- 2 Treatment to be discontinued at disease progression.

Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

TRASTUZUMAB EMTANSINE – PCT only – Specialist – Special Authority see [SA2424 below](#)

Inj 100 mg vial	2,320.00	1	✓ Kadcyla
Inj 160 mg vial	3,712.00	1	✓ Kadcyla
Inj 1 mg for ECP	24.52	1 mg	✓ Baxter

►SA2424 Special Authority for Subsidy

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has early breast cancer expressing HER2 IHC3+ or ISH+; and
- 2 Documentation of pathological invasive residual disease in the breast and/or axillary lymph nodes following completion of surgery; and
- 3 Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery; and
- 4 Disease has not progressed during neoadjuvant therapy; and
- 5 Patient has left ventricular ejection fraction of 45% or greater; and
- 6 Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery; and
- 7 Trastuzumab emtansine to be discontinued at disease progression; and
- 8 Total adjuvant treatment duration must not exceed 42 weeks (14 cycles).

Initial application — (metastatic breast cancer) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
- 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
- 4 Patient has a good performance status (ECOG 0-1); and
- 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
- 6 Either:
 - 6.1 Patient has not received prior funded trastuzumab emtansine or trastuzumab deruxtecan treatment; or
 - 6.2 Both:
 - 6.2.1 Patient has discontinued trastuzumab deruxtecan due to intolerance; and
 - 6.2.2 The cancer did not progress while on trastuzumab deruxtecan; and
- 7 Treatment to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
- 2 Treatment to be discontinued at disease progression.

Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

USTEKINUMAB – Special Authority see [SA2182 on the next page](#) – Retail pharmacy

Inj 90 mg per ml, 1 ml pre-filled syringe.....	4,162.00	1	✓ Stelara
--	----------	---	-----------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

➔SA2182 Special Authority for Subsidy

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
 - 2.1 Patient has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy for Crohn's disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Ustekinumab to be administered at a dose no greater than 90 mg every 8 weeks.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
 - 2.1 Patient has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Ustekinumab to administered at a dose no greater than 90 mg every 8 weeks.

Note: Indication marked with * is an unapproved indication.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or

2 Both:

- 2.1 Patient has active ulcerative colitis; and

2.2 Either:

- 2.2.1 Patient has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or

2.2.2 Both:

- 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for ulcerative colitis; and

- 2.2.2.2 Other biologics for ulcerative colitis are contraindicated.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or
- 1.2 PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy*; and

2 Ustekinumab will be used at a dose no greater than 90 mg intravenously every 8 weeks.

Note: Criterion marked with * is for an unapproved indication.

VEDOLIZUMAB – PCT only – Special Authority see [SA2183 below](#)

Inj 300 mg vial	3,313.00	1	✓ Entyvio
-----------------------	----------	---	-----------

➔**SA2183** Special Authority for Subsidy

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Patient has active Crohn's disease; and

2 Any of the following:

- 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or

- 2.2 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or

- 2.3 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or

- 2.4 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or

- 2.5 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Any of the following:

- 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or

- 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or

- 3.3 Immunomodulators and corticosteroids are contraindicated.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Any of the following:

- 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- on biologic therapy; or
- 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
- 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.3 Patient has extensive small intestine disease; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300mg every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a SCCAI score is greater than or equal to 4; or
 - 2.3 Patient's PUCAI score is greater than or equal to 20*; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

1 Either:

- 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or
- 1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy *; and

2 Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Programmed Cell Death-1 (PD-1) Inhibitors

ATEZOLIZUMAB – PCT only – Specialist – Special Authority see [SA2443](#) below

Inj 60 mg per ml, 20 ml vial.....	9,503.00	1	✓ Tecentriq
Inj 1 mg for ECP	8.08	1 mg	✓ Baxter

►SA2443 Special Authority for Subsidy

Initial application — (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic non-small cell lung cancer; and
- 2 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 3 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 4 Patient has an ECOG 0-2; and
- 5 Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and
- 6 Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 7 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent); and
- 6 Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with atezolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma; and
 - 2.2 Patient has preserved liver function (Child-Pugh A); and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2.3 Transarterial chemoembolisation (TACE) is unsuitable; and
- 2.4 Any of the following:
 - 2.4.1 Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma; or
 - 2.4.2 Patient received funded lenvatinib before 1 March 2025; or
 - 2.4.3 Both:
 - 2.4.3.1 Patient has experienced treatment-limiting toxicity from treatment with lenvatinib; and
 - 2.4.3.2 No disease progression since initiation of lenvatinib; and
- 2.5 Patient has an ECOG performance status of 0-2; and
- 2.6 To be given in combination with bevacizumab.

Renewal — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

DURVALUMAB – PCT only – Specialist – Special Authority see [SA2425 below](#)

Inj 50 mg per ml, 10 ml vial.....	4,700.00	1	✓ Imfinzi
Inj 50 mg per ml, 2.4 ml vial.....	1,128.00	1	✓ Imfinzi
Inj 1 mg for ECP	9.59	1 mg	✓ Baxter

►SA2425 Special Authority for Subsidy

Initial application — (Non-small cell lung cancer) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); or
 - 1.2 Patient has histologically or cytologically documented stage IIb (T1N2a only), locally advanced, unresectable non-small cell lung cancer (NSCLC); and
- 2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and
- 3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and
- 4 Patient has a ECOG performance status of 0 or 1; and
- 5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and
- 6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and
- 7 Either:
 - 7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
 - 7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 8 Treatment with durvalumab to cease upon signs of disease progression.

Renewal — (Non-small cell lung cancer) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and
- 2 Either:
 - 2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
 - 2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 3 Treatment with durvalumab to cease upon signs of disease progression; and
- 4 Total continuous treatment duration must not exceed 12 months.

IPILIMUMAB – PCT only – Specialist – Special Authority see [SA2461 on the next page](#)

Inj 5 mg per ml, 10 ml vial.....	5,000.00	1	✓ Yervoy
Inj 5 mg per ml, 40 ml vial.....	20,000.00	1	✓ Yervoy
Inj 1 mg for ECP	106.00	1 mg	✓ Baxter

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2461 Special Authority for Subsidy

Initial application — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The patient is currently on treatment with ipilimumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The patient has metastatic renal cell carcinoma; and
 - 2.2 The patient is treatment naive; and
 - 2.3 The patient has ECOG performance status 0-2; and
 - 2.4 The disease is predominantly of clear cell histology; and
 - 2.5 Any of the following:
 - 2.5.1 The patient has sarcomatoid histology; or
 - 2.5.2 Haemoglobin levels less than the lower limit of normal; or
 - 2.5.3 Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L); or
 - 2.5.4 Neutrophils greater than the upper limit of normal; or
 - 2.5.5 Platelets greater than the upper limit of normal; or
 - 2.5.6 Interval of less than 1 year from original diagnosis to the start of systemic therapy; or
 - 2.5.7 Karnofsky performance score of less than or equal to 70; and
 - 2.6 Ipilimumab is to be used at a maximum dose of 1 mg/kg for up to four cycles in combination with nivolumab..

NIVOLUMAB – PCT only – Specialist – Special Authority see [SA2490 below](#)

Inj 10 mg per ml, 4 ml vial.....	1,051.98	1	✓ Opdivo
Inj 10 mg per ml, 10 ml vial.....	2,629.96	1	✓ Opdivo
Inj 1 mg for ECP	27.22	1 mg	✓ Baxter

►SA2490 Special Authority for Subsidy

Initial application — (unresectable or metastatic melanoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The individual has ECOG performance 0-2; and
- 4 Either:
 - 4.1 The individual has not received funded pembrolizumab; or
 - 4.2 Both:
 - 4.2.1 The individual has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the individual was on pembrolizumab; and
- 5 Any of the following:
 - 5.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
 - 5.2 The individual did not receive treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; or
 - 5.3 All of the following:
 - 5.3.1 The individual received treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; and
 - 5.3.2 The individual did not experience disease recurrence while on treatment with that PD-1/PD-L1 inhibitor; and
 - 5.3.3 The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor.

Renewal — (unresectable or metastatic melanoma, less than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

1 Both:

1.1 Any of the following:

- 1.1.1 The individual's disease has had a complete response to treatment; or
- 1.1.2 The individual's disease has had a partial response to treatment; or
- 1.1.3 The individual has stable disease; and

1.2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; or

2 All of the following:

- 2.1 The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
- 2.2 The individual has signs of disease progression; and
- 2.3 Disease has not progressed during previous treatment with nivolumab.

Renewal — (unresectable or metastatic melanoma, more than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

1 The individual has been on treatment for more than 24 months; and

2 Either:

2.1 Both:

2.1.1 Any of the following:

- 2.1.1.1 The individual's disease has had a complete response to treatment; or
- 2.1.1.2 The individual's disease has had a partial response to treatment; or
- 2.1.1.3 The individual has stable disease; and

2.1.2 Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period; or

2.2 All of the following:

- 2.2.1 The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
- 2.2.2 The individual has signs of disease progression; and
- 2.2.3 Disease has not progressed during previous treatment with nivolumab.

Initial application — (renal cell carcinoma, first line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Patient is currently on treatment with nivolumab and met all remaining criteria prior to commencing treatment; or

2 All of the following:

- 2.1 The patient has metastatic renal cell carcinoma; and
- 2.2 The patient is treatment naive; and
- 2.3 The patient has ECOG performance status 0-2; and
- 2.4 The disease is predominantly of clear cell histology; and
- 2.5 Any of the following:
 - 2.5.1 The patient has sarcomatoid histology; or
 - 2.5.2 Haemoglobin levels less than the lower limit of normal; or
 - 2.5.3 Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L); or
 - 2.5.4 Neutrophils greater than the upper limit of normal; or
 - 2.5.5 Platelets greater than the upper limit of normal; or
 - 2.5.6 Interval of less than 1 year from original diagnosis to the start of systemic therapy; or
 - 2.5.7 Karnofsky performance score of less than or equal to 70; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.6 Nivolumab is to be used in combination with ipilimumab for the first four treatment cycles at a maximum dose of 3 mg/kg; and
- 2.7 Nivolumab is to be used as monotherapy at a maximum maintenance dose of 240 mg every 2 weeks (or equivalent).

Initial application — (Renal cell carcinoma, second line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic renal-cell carcinoma; and
- 2 The disease is of predominant clear-cell histology; and
- 3 Patient has ECOG performance status 0-2; and
- 4 Patient has documented disease progression following one or two previous regimens of antiangiogenic therapy; and
- 5 Patient has not previously received a funded immune checkpoint inhibitor; and
- 6 Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression.

Renewal — (Renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 No evidence of disease progression; and
- 3 Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression.

PEMBROLIZUMAB – PCT only – Specialist – Special Authority see [SA2498 below](#)

Inj 25 mg per ml, 4 ml vial.....	4,680.00	1	✓ Keytruda
Inj 1 mg for ECP	47.74	1 mg	✓ Baxter

► **SA2498 Special Authority for Subsidy**

Initial application — (stage III or IV resectable melanoma - neoadjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note); and
 - 2.2 The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma; and
 - 2.3 Treatment must be prior to complete surgical resection; and
 - 2.4 Pembrolizumab must be administered as monotherapy; and
 - 2.5 The individual has ECOG performance score 0-2; and
 - 2.6 Pembrolizumab to be administered at a fixed dose of 200 mg every 3 weeks (or equivalent).

Renewal — (stage III or IV resectable melanoma - neoadjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.1 The individual has received neoadjuvant treatment with an immune checkpoint inhibitor; and
- 1.2 The individual meets initial application criteria for pembrolizumab for stage III or IV resected melanoma – adjuvant; or
- 2 Both:
 - 2.1 The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor; and
 - 2.2 The individual meets renewal criteria for pembrolizumab for stage III or IV resected melanoma – adjuvant; or
- 3 All of the following:
 - 3.1 The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor; and
 - 3.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 3.3 The individual meets initial application criteria for pembrolizumab for unresectable or metastatic melanoma; or
- 4 All of the following:
 - 4.1 The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor; and
 - 4.2 The individual has received treatment with an immune checkpoint inhibitor for unresectable or metastatic melanoma; and
 - 4.3 The individual meets renewal criteria for pembrolizumab for unresectable or metastatic melanoma.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means either 13 weeks after resection (primary or lymphadenectomy) or 13 weeks prior to the scheduled date of the resection (primary or lymphadenectomy)

Initial application — (stage III or IV resected melanoma - adjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a); and
 - 2.2 Adjuvant treatment with pembrolizumab is required; and
 - 2.3 The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma; and
 - 2.4 Treatment must be in addition to complete surgical resection; and
 - 2.5 Treatment must be initiated within 13 weeks of complete surgical resection, unless delay is necessary due to post-surgery recovery (see note b); and
 - 2.6 Pembrolizumab must be administered as monotherapy; and
 - 2.7 The individual has ECOG performance score 0-2; and
 - 2.8 Pembrolizumab to be administered at a fixed dose of 200 mg every 3 weeks (or equivalent).

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

Renewal — (stage III or IV resected melanoma - adjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 No evidence of disease recurrence; and
 - 1.2 Pembrolizumab must be administered as monotherapy; and
 - 1.3 Pembrolizumab to be administered at a fixed dose of 200 mg every three weeks (or equivalent) for a maximum of 12 months total treatment course, including any systemic neoadjuvant treatment; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.4 Treatment to be discontinued at signs of disease recurrence or at completion of 12 months total treatment course (equivalent to 18 cycles at a dose of 200 mg every 3 weeks), including any systemic neoadjuvant treatment; or
- 2 All of the following:
 - 2.1 The individual has received adjuvant treatment with an immune checkpoint inhibitor; and
 - 2.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.3 The individual meets initial application criteria for pembrolizumab for unresectable or metastatic melanoma; or
- 3 All of the following:
 - 3.1 The individual has received adjuvant treatment with an immune checkpoint inhibitor; and
 - 3.2 The individual has received treatment with an immune checkpoint inhibitor for unresectable or metastatic melanoma; and
 - 3.3 The individual meets renewal criteria for pembrolizumab for unresectable or metastatic melanoma.

Initial application — (unresectable or metastatic melanoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The individual has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 The individual has not received funded nivolumab; or
 - 4.2 Both:
 - 4.2.1 The individual has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the individual was on nivolumab; and
- 5 Any of the following:
 - 5.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
 - 5.2 The individual did not receive treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; or
 - 5.3 All of the following:
 - 5.3.1 The individual received treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; and
 - 5.3.2 The individual did not experience disease recurrence while on treatment with that PD-1/PD-L1 inhibitor; and
 - 5.3.3 The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor.

Renewal — (unresectable or metastatic melanoma, less than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Any of the following:
 - 1.1.1 The individual's disease has had a complete response to treatment; or
 - 1.1.2 The individual's disease has had a partial response to treatment; or
 - 1.1.3 The individual has stable disease; and
 - 1.2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; or
- 2 All of the following:
 - 2.1 The individual has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 The individual has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Renewal — (unresectable or metastatic melanoma, more than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

1 The individual has been on treatment for more than 24 months; and

2 Either:

2.1 Both:

2.1.1 Any of the following:

2.1.1.1 The individual's disease has had a complete response to treatment; or

2.1.1.2 The individual's disease has had a partial response to treatment; or

2.1.1.3 The individual has stable disease; and

2.1.2 Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period; or

2.2 All of the following:

2.2.1 The individual has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and

2.2.2 The individual has signs of disease progression; and

2.2.3 Disease has not progressed during previous treatment with pembrolizumab.

Initial application — (non-small cell lung cancer first-line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and

2 Patient has not had chemotherapy for their disease in the palliative setting; and

3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and

4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and

5 Pembrolizumab to be used as monotherapy; and

6 Either:

6.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain; or

6.2 Both:

6.2.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain; and

6.2.2 Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment; and

7 Patient has an ECOG 0-2; and

8 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and

9 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (non-small cell lung cancer first line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

1.1 Patient's disease has had a complete response to treatment; or

1.2 Patient's disease has had a partial response to treatment; or

1.3 Patient has stable disease; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (non-small cell lung cancer first-line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 The patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used in combination with platinum-based chemotherapy; and
- 6 Patient has an ECOG 0-2; and
- 7 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 8 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (non-small cell lung cancer first line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (breast cancer, advanced) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has recurrent or de novo unresectable, inoperable locally advanced triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology]); or
 - 2.1.2 Patient has recurrent or de novo metastatic triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology]); and
 - 2.2 Patient is treated with palliative intent; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.3 Patient's cancer has confirmed PD-L1 Combined Positive Score (CPS) is greater than or equal to 10; and
- 2.4 Patient has received no prior systemic therapy in the palliative setting; and
- 2.5 Patient has an ECOG score of 0–2; and
- 2.6 Pembrolizumab is to be used in combination with chemotherapy; and
- 2.7 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 2.8 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (breast cancer, advanced) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 No evidence of disease progression; and
- 3 Response to treatment in target lesions has been determined by a comparable radiologic assessment following the most recent treatment period; and
- 4 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 5 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (head and neck squamous cell carcinoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has recurrent or metastatic head and neck squamous cell carcinoma of mucosal origin (excluding nasopharyngeal carcinoma) that is incurable by local therapies; and
 - 2.2 Patient has not received prior systemic therapy in the recurrent or metastatic setting; and
 - 2.3 Patient has a positive PD-L1 combined positive score (CPS) of greater than or equal to 1; and
 - 2.4 Patient has an ECOG performance score of 0-2; and
 - 2.5 Either:
 - 2.5.1 Pembrolizumab to be used in combination with platinum-based chemotherapy; or
 - 2.5.2 Pembrolizumab to be used as monotherapy; and
 - 2.6 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (head and neck squamous cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 No evidence of disease progression; and
- 3 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 4 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (MSI-H/dMMR advanced colorectal cancer) only from a relevant specialist or any relevant practitioner on

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:
Either:

- 1 Individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer; or
 - 2.1.2 Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) unresectable colorectal cancer; and
 - 2.2 Individual is treated with palliative intent; and
 - 2.3 Individual has not previously received funded treatment with pembrolizumab for MSI-H/dMMR advanced colorectal cancer; and
 - 2.4 Individual has an ECOG performance score of 0-2; and
 - 2.5 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
 - 2.6 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (MSI-H/dMMR advanced colorectal cancer) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 3 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (Urothelial carcinoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has inoperable locally advanced (T4) or metastatic urothelial carcinoma; and
 - 2.2 Patient has an ECOG performance score of 0-2; and
 - 2.3 Patient has documented disease progression following treatment with chemotherapy; and
 - 2.4 Pembrolizumab to be used as monotherapy at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (Urothelial carcinoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 No evidence of disease progression; and
- 3 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 4 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (relapsed/refractory Hodgkin lymphoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

- 1 Individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Both:
 - 2.1.1.1 Individual has relapsed/refractory Hodgkin lymphoma after two or more lines of chemotherapy; and
 - 2.1.1.2 Individual is ineligible for autologous stem cell transplant; or
 - 2.1.2 Individual has relapsed/refractory Hodgkin lymphoma and has previously undergone an autologous stem cell transplant; and
 - 2.2 Individual has not previously received funded pembrolizumab for relapsed/refractory Hodgkin lymphoma; and
 - 2.3 Pembrolizumab to be administered at doses no greater than 200 mg once every 3 weeks.

Renewal — (relapsed/refractory Hodgkin lymphoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has received a partial or complete response to pembrolizumab; and
- 2 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Other Immunosuppressants

CICLOSPORIN

Cap 25 mg	44.63	50	✓ Neoral
Cap 50 mg	88.91	50	✓ Neoral
Cap 100 mg	177.81	50	✓ Neoral
Oral liq 100 mg per ml	198.13	50 ml OP	✓ Neoral

EVEROLIMUS – Special Authority see [SA2414 below](#) – Retail pharmacy

Wastage claimable

Tab 10 mg	6,512.29	30	✓ Afinitor
Tab 5 mg	4,555.76	30	✓ Afinitor

►SA2414 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Initial application — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic renal cell carcinoma; and
 - 1.2 The disease is of predominant clear-cell histology; and
 - 1.3 The patient has documented disease progression following one previous line of treatment; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 1.4 The patient has an ECOG performance status of 0-2; and
- 1.5 Everolimus is to be used in combination with lenvatinib; or
- 2 All of the following:
 - 2.1 Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma; and
 - 2.2 Patient has experienced treatment limiting toxicity from treatment with nivolumab; and
 - 2.3 Everolimus is to be used in combination with lenvatinib; and
 - 2.4 There is no evidence of disease progression.

Renewal — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

SIRIOLIMUS – Special Authority see [SA2270 below](#) – Retail pharmacy

Tab 1 mg	749.99	100	✓ Rapamune
Tab 2 mg	1,499.99	100	✓ Rapamune
Oral liq 1 mg per ml	449.99	60 ml OP	✓ Rapamune

► [SA2270](#) Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

Initial application — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe non-malignant lymphovascular malformation*; and
- 2 Any of the following:
 - 2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or
 - 2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or
 - 2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and
- 3 Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and
- 4 Patient has measurable disease as defined by RECIST version 1.1 (see Note).

Renewal — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); or
 - 1.2 Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly documents in patient notes; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains clinically appropriate and the patient is benefitting from the treatment.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Tumours (RECISt) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with * are unapproved indications

Initial application — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) only from a nephrologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis complex*; and
- 2 Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth.

Renewal — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) from any relevant practitioner.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound; and
- 2 Demonstrated stabilisation or improvement in renal function; and
- 3 The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment; and
- 4 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indications marked with * are unapproved indications

Initial application — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has epilepsy with a background of documented tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Vigabatrin has been trialled and has not adequately controlled seizures; and
 - 2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or
 - 2.2 Both:
 - 2.2.1 Vigabatrin is contraindicated; and
 - 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and
- 3 Seizures have a significant impact on quality of life; and
- 4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: Those of childbearing age potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.

Renewal — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 12 months where demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment.

Note: Indications marked with * are unapproved indications

TACROLIMUS – Special Authority see [SA2455 on the next page](#) – Retail pharmacy

Cap 0.5 mg	49.60	100	✓ Tacrolimus Sandoz
Cap 0.75 mg	99.30	100	✓ Tacrolimus Sandoz
Cap 1 mg	84.30	100	✓ Tacrolimus Sandoz
Cap 5 mg	248.20	50	✓ Tacrolimus Sandoz

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2455 Special Authority for Subsidy

Initial application — (organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The individual is an organ transplant recipient; or
- 2 The individual is receiving induction therapy for an organ transplant.

Note: Subsidy applies for either primary or rescue therapy.

Initial application — (non-transplant indications*) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient requires long-term systemic immunosuppression; and
- 2 Either:
 - 2.1 Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response; or
 - 2.2 Patient is a child with nephrotic syndrome*.

Note: Indications marked with * are unapproved indications

JAK inhibitors

UPADACITINIB – Special Authority see [SA2483 below](#) – Retail pharmacy

Tab modified-release 15 mg.....	1,271.00	28	✓ Rinvoq
Tab modified-release 30 mg.....	2,033.00	28	✓ Rinvoq
Tab modified-release 45 mg.....	3,049.00	28	✓ Rinvoq

►SA2483 Special Authority for Subsidy

Initial application — (Rheumatoid Arthritis (previously treated with adalimumab or etanercept)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The individual has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The individual has experienced intolerable side effects with adalimumab and/or etanercept; or
 - 2.2 The individual has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Any of the following:
 - 3.1 Rituximab is not clinically appropriate; or
 - 3.2 The individual is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.3 Both:
 - 3.3.1 The individual has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and
 - 3.3.2 Either:
 - 3.3.2.1 The individual has experienced intolerable side effects with rituximab; or
 - 3.3.2.2 At four months following the initial course of rituximab the individual has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Renewal — (Rheumatoid Arthritis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline; or
- 2 On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

from baseline.

Initial application — (atopic dermatitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for atopic dermatitis and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10; and
 - 2.2 Individual has received insufficient benefit from topical therapy (including topical corticosteroids or topical calcineurin inhibitors) for a 28-day trial within the last 6 months, unless contraindicated to all; and
 - 2.3 Individual has trialled and received insufficient benefit from at least one systemic therapy for a minimum of three months (eg ciclosporin, azathioprine, methotrexate or mycophenolate mofetil), unless contraindicated to all; and
 - 2.4 An EASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.5 The most recent EASI or DLQI assessment is no more than 1 month old at the time of application.

Renewal — (atopic dermatitis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Individual has received a 75% or greater reduction in EASI score (EASI 75) as compared to baseline EASI prior to commencing upadacitinib; or
- 2 Individual has received a DLQI improvement of 4 or more as compared to baseline DLQI prior to commencing upadacitinib.

Initial application — (Crohn's disease - adult) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for Crohn's disease and met all remaining criteria prior to commencing treatment; or
- 2 Both:
 - 2.1 Individual has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Individual has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Individual meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologic therapies for Crohn's disease are contraindicated.

Renewal — (Crohn's disease - adult) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 CDAI score has reduced by 100 points from the CDAI score when the individual was initiated on biologic therapy; or
- 2 HBI score has reduced by 3 points from when individual was initiated on biologic therapy; or
- 3 CDAI score is 150 or less; or
- 4 HBI score is 4 or less; or
- 5 The individual has experienced an adequate response to treatment, but CDAI score cannot be assessed.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for Crohn's disease and met all remaining criteria prior to commencing treatment; or
- 2 Both:
 - 2.1 Child has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Child has had an initial approval for prior biologic therapy for Crohn's disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Child meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologic therapies for Crohn's disease are contraindicated.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 PCDAI score has reduced by 10 points from the child was initiated on treatment; or
- 2 PCDAI score is 15 or less; or
- 3 The child has experienced an adequate response to treatment, but PCDAI score cannot be assessed.

Note: Indications marked with * are unapproved indications.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for ulcerative colitis and met all remaining criteria prior to commencing treatment; or
- 2 Both:
 - 2.1 Individual has active ulcerative colitis; and
 - 2.2 Either:
 - 2.2.1 Individual has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Individual meets the initiation criteria for prior biologic therapies for ulcerative colitis; and
 - 2.2.2.2 Other biologic therapies for ulcerative colitis are contraindicated.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the individual was initiated on treatment; or
- 2 PUCAI score has reduced by 10 points or more from the PUCAI score when the individual was initiated on treatment.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Antiallergy Preparations

Allergic Emergencies

ADRENALINE – Special Authority see [SA2185 below](#) – Retail pharmacy

- Maximum of 2 inj per prescription
- Additional prescriptions limited to replacement of up to two devices prior to expiry, or replacement of used device for treatment of anaphylaxis.

Inj 0.15 mg per 0.3 ml auto-injector.....	85.50	1 OP	✓ Epipen Jr
Epipen Jr to be Principal Supply on 1 December 2025			

Inj 0.3 mg per 0.3 ml auto-injector.....	85.50	1 OP	✓ Epipen
Epipen to be Principal Supply on 1 December 2025			

►SA2185 Special Authority for Subsidy

Initial application — (anaphylaxis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- Either:
 - Patient has experienced an anaphylactic reaction which has resulted in presentation to a hospital or emergency department; or
 - Patient has been assessed to be at significant risk of anaphylaxis by a relevant practitioner; and
- Patient is not to be prescribed more than two devices in initial prescription.

ICATIBANT – Special Authority see [SA1558 below](#) – Retail pharmacy

Inj 10 mg per ml, 3 ml prefilled syringe.....	2,668.00	1	✓ Firazyr
---	----------	---	-----------

►SA1558 Special Authority for Subsidy

Initial application only from a clinical immunologist or relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
- The patient has undergone product training and has agreed upon an action plan for self-administration.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Allergy Desensitisation

►SA1367 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- RAST or skin test positive; and
- Patient has had severe generalised reaction to the sensitising agent.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BEE VENOM ALLERGY TREATMENT – Special Authority see SA1367 on the previous page – Retail pharmacy				
Initiation kit - 1 vial freeze dried venom with diluent	305.00	1 OP	✓	VENOX ^{\$29}
Maintenance kit - 1 vial freeze dried venom with diluent	305.00	1 OP	✓	VENOX ^{\$29}
Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent	285.00	1 OP	✓	Venomil ^{\$29}
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml	334.39	1 OP	✓	Albey
Treatment kit - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Hymenoptera ^{\$29}
WASP VENOM ALLERGY TREATMENT – Special Authority see SA1367 on the previous page – Retail pharmacy				
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polistes venom, 1 diluent 9 ml, 3 diluent 1.8 ml	382.23	1 OP	✓	Albey
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Hymenoptera ^{\$29}
Treatment kit (Paper wasp venom) - 6 vials 120 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Venomil ^{\$29}
Treatment kit (Yellow Jacket venom) - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Hymenoptera ^{\$29}
Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 3 diluent 1.8 ml	431.24	1 OP	✓	Albey
Treatment kit (Yellow jacket venom) - 6 vials 120 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Venomil ^{\$29}

Antihistamines

CETIRIZINE HYDROCHLORIDE				
* Tab 10 mg	1.71	100	✓	Zista
* Oral liq 1 mg per ml	3.99	200 ml	✓	Histaclear
DEXTROCHLORPHENIRAMINE MALEATE				
* Tab 2 mg	2.02 (8.40)	40		Polaramine
	1.01 (5.99)	20		Polaramine
* Oral liq 2 mg per 5 ml	1.77 (10.29)	100 ml		Polaramine
FEXOFENADINE HYDROCHLORIDE				
* Tab 60 mg	4.34 (8.23)	20		Telfast
* Tab 120 mg	3.49	30	✓	Fexaclear
* Tab 180 mg	4.10	30	✓	Fexaclear
LORATADINE				
* Tab 10 mg	1.78	100	✓	Lorafix
* Oral liq 1 mg per ml	1.43	100 ml	✓	Haylor syrup
PROMETHAZINE HYDROCHLORIDE				
* Tab 10 mg	2.19	100	✓	Allersoothe
Allersoothe to be Principal Supply on 1 December 2025				
* Tab 25 mg	2.69	100	✓	Allersoothe
Allersoothe to be Principal Supply on 1 December 2025				
* Oral liq 1 mg per 1 ml	3.39	100 ml	✓	Allersoothe
* Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	21.09	5	✓	Hospira

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Inhaled Corticosteroids				
BECLOMETHASONE DIPROPIONATE				
Aerosol inhaler, 50 mcg per dose.....	14.01	200 dose OP	✓	Qvar
Aerosol inhaler, 50 mcg per dose CFC-free.....	8.54	200 dose OP	✓	Beclazone 50
Aerosol inhaler, 100 mcg per dose.....	17.52	200 dose OP	✓	Qvar
Aerosol inhaler, 100 mcg per dose CFC-free.....	12.50	200 dose OP	✓	Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free.....	22.67	200 dose OP	✓	Beclazone 250
BUDESONIDE				
Powder for inhalation, 100 mcg per dose.....	17.00	200 dose OP	✓	Pulmicort Turbuhaler
Powder for inhalation, 200 mcg per dose.....	19.00	200 dose OP	✓	Pulmicort Turbuhaler
Powder for inhalation, 400 mcg per dose.....	32.00	200 dose OP	✓	Pulmicort Turbuhaler
FLUTICASONE				
Aerosol inhaler, 50 mcg per dose.....	7.19	120 dose OP	✓	Flixotide
Powder for inhalation, 50 mcg per dose.....	8.61	60 dose OP	✓	Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose.....	7.81	60 dose OP	✓	Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose.....	13.60	120 dose OP	✓	Flixotide
Aerosol inhaler, 250 mcg per dose.....	24.62	120 dose OP	✓	Flixotide
Powder for inhalation, 250 mcg per dose.....	11.93	60 dose OP	✓	Flixotide Accuhaler
Inhaled Long-acting Beta-adrenoceptor Agonists				
EFORMOTEROL FUMARATE DIHYDRATE				
Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose).....	10.32 (16.90)	60 dose OP		Oxis Turbuhaler
INDACATEROL				
Powder for inhalation 150 mcg.....	61.00	30 dose OP	✓	Onbrez Breezhaler
Powder for inhalation 300 mcg.....	61.00	30 dose OP	✓	Onbrez Breezhaler
SALMETEROL				
Aerosol inhaler CFC-free, 25 mcg per dose.....	26.25	120 dose OP	✓	Serevent
Powder for inhalation, 50 mcg per dose, breath activated.....	26.25	60 dose OP	✓	Serevent Accuhaler

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL

* Powder for inhalation 160 mcg with 4.5 mcg eformoterol fumarate per dose (equivalent to 200 mcg budesonide with 6 mcg eformoterol fumarate metered dose) – Up to 120 dose available on a PSO	41.50	120 dose OP	✓ DuoResp Spiromax
Powder for inhalation 320 mcg with 9 mcg eformoterol fumarate per dose (equivalent to 400 mcg budesonide with 12 mcg eformoterol fumarate metered dose) – No more than 2 dose per day	82.50	120 dose OP	✓ DuoResp Spiromax
* Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	18.23	120 dose OP	✓ Vannair
* Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	33.74	120 dose OP	✓ Symbicort Turbuhaler 100/6
* Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	21.40	120 dose OP	✓ Vannair
* Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	33.74	120 dose OP	✓ Symbicort Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day	33.74	60 dose OP	✓ Symbicort Turbuhaler 400/12

FLUTICASONE FUROATE WITH VILANTEROL

Powder for inhalation 100 mcg with vilanterol 25 mcg	44.08	30 dose OP	✓ Breo Ellipta
--	-------	------------	----------------

FLUTICASONE WITH SALMETEROL

Aerosol inhaler 50 mcg with salmeterol 25 mcg	25.79	120 dose OP	✓ Seretide
Aerosol inhaler 125 mcg with salmeterol 25 mcg	32.60	120 dose OP	✓ Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg – No more than 2 dose per day	33.74	60 dose OP	✓ Seretide Accuhaler
Powder for inhalation 250 mcg with salmeterol 50 mcg – No more than 2 dose per day	44.08	60 dose OP	✓ Seretide Accuhaler

Beta-Adrenoceptor Agonists

SALBUTAMOL

Oral liq 400 mcg per ml	50.00	150 ml	✓ Ventolin
Infusion 1 mg per ml, 5 ml	130.00	10	✓ Ventolin
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	130.00	5	✓ Ventolin

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Inhaled Beta-Adrenoceptor Agonists

SALBUTAMOL

Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO	4.18 (6.80)	200 dose OP	✓	SalAir Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	8.96	20	✓	Asthalin
			✓	UK Cipla ^{\$29}
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	9.43	20	✓	Asthalin
			✓	UK Cipla ^{\$29}

TERBUTALINE SULPHATE

Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated	22.20	120 dose OP	✓	Bricanyl Turbuhaler
--	-------	-------------	---	---------------------

Anticholinergic Agents

IPRATROPIUM BROMIDE

Aerosol inhaler, 20 mcg per dose CFC-free – Up to 400 dose available on a PSO	16.20	200 dose OP	✓	Atrovent
Nebuliser soln, 250 mcg per ml, 2 ml ampoule – Up to 40 neb available on a PSO	11.73	20	✓	Accord ^{\$29}
			✓	Univent

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE

Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free	12.19	200 dose OP	✓	Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule – Up to 20 neb available on a PSO	11.04	20	✓	Duolin

Long-Acting Muscarinic Antagonists

GLYCOPYRRONIUM – Subsidy by endorsement

- Inhaled glycopyrronium treatment will not be subsidised if patient is also receiving treatment with subsidised tiotropium or umecclidinium.
- Glycopyrronium powder for inhalation 50 mcg per dose is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly.

Powder for inhalation 50 mcg per dose	61.00	30 dose OP	✓	Seebri Breezhaler
---	-------	------------	---	-------------------

TIOTROPIUM BROMIDE – Subsidy by endorsement

- Tiotropium treatment will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or umecclidinium.
- Tiotropium bromide is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly. Patients who had tiotropium dispensed before 1 October 2018 with a valid Special Authority are deemed endorsed.

Powder for inhalation, 18 mcg per dose	50.37	30 dose	✓	Spiriva
Soln for inhalation 2.5 mcg per dose	50.37	60 dose OP	✓	Spiriva Respimat

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
UMECLIDINIUM – Subsidy by endorsement			
a) Umeclidinium will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.			
b) Umeclidinium powder for inhalation 62.5 mcg per dose is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly.			
Powder for inhalation 62.5 mcg per dose	61.50	30 dose OP	✓ Incruse Ellipta

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

►SA1584 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

GLYCOPYRRONIUM WITH INDACATEROL – Special Authority see SA1584 above – Retail pharmacy

Powder for Inhalation 50 mcg with indacaterol 110 mcg 81.00 30 dose OP ✓ Ultibro Breezhaler

TIOTROPIUM BROMIDE WITH OLODATEROL – Special Authority see SA1584 above – Retail pharmacy

Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg 81.00 60 dose OP ✓ Spiolto Respimat

UMECLIDINIUM WITH VILANTEROL – Special Authority see SA1584 above – Retail pharmacy

Powder for inhalation 62.5 mcg with vilanterol 25 mcg 77.00 30 dose OP ✓ Anoro Ellipta

Inhaled Corticosteroid with Long-Acting Muscarinic Antagonist and Beta Agonist

BUDESONIDE WITH GLYCOPYRRONIUM AND EFORMOTEROL – Special Authority see SA2421 below – Retail pharmacy

Aerosol inhaler budesonide 160 mcg with glycopyrronium

7.2 mcg and formoterol 5 mcg per dose 79.15 120 dose OP ✓ Breztri Aerosphere

►SA2421 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible; and
- 2 Either:

2.1 Both:

- 2.1.1 Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA); and
- 2.1.2 Any of the following:

Clinical criteria:

- 2.1.2.1 Patient has a COPD Assessment Test (CAT) score greater than 10; or
- 2.1.2.2 Patient has had 2 or more exacerbations in the previous 12 months; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.1.2.3 Patient has had one exacerbation requiring hospitalisation in the previous 12 months; or
- 2.1.2.4 Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months; or

- 2.2 Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long-acting muscarinic antagonist and long-acting beta-2 agonist – ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler therapy.

FLUTICASONE FUROATE WITH UMECLIDINIUM AND VILANTEROL – Special Authority see [SA2326 below](#) – Retail pharmacy
Powder for inhalation fluticasone furoate 100 mcg with
umeclidinium 62.5 mcg and vilanterol 25 mcg..... 104.24 30 dose OP ✓ **Trelegy Ellipta**

► [SA2326](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible; and

- 2 Either:

- 2.1 Both:

- 2.1.1 Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA); and

- 2.1.2 Any of the following:

Clinical criteria:

- 2.1.2.1 Patient has a COPD Assessment Test (CAT) score greater than 10; or
- 2.1.2.2 Patient has had 2 or more exacerbations in the previous 12 months; or
- 2.1.2.3 Patient has had one exacerbation requiring hospitalisation in the previous 12 months; or
- 2.1.2.4 Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months; or

- 2.2 Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long acting muscarinic antagonist and long acting beta-2 agonist – ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler triple therapy.

Antifibrotics

NINTEDANIB – Special Authority see [SA2012 below](#) – Retail pharmacy

Note: Nintedanib not subsidised in combination with subsidised pirfenidone.

Cap 100 mg.....	2,554.00	60 OP	✓ Ofev
Cap 150 mg.....	3,870.00	60 OP	✓ Ofev

► [SA2012](#) Special Authority for Subsidy

Initial application — (**idiopathic pulmonary fibrosis**) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:

- 5.1 The patient has not previously received treatment with pirfenidone; or

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
- 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – Retail pharmacy-Specialist – Special Authority see [SA2013 below](#)

Note: Pirfenidone is not subsidised in combination with subsidised nintedanib.

Tab 801 mg	3,645.00	90 OP	✓ Esbriet
Tab 267 mg	1,215.00	90	✓ Esbriet

►SA2013 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and

5 Any of the following:

- 5.1 The patient has not previously received treatment with nintedanib; or
- 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
- 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

Leukotriene Receptor Antagonists

MONTELUKAST

* Tab 4 mg	3.10	28	✓ Montelukast Viatris
Montelukast Viatris to be Principal Supply on 1 December 2025			
* Tab 5 mg	3.10	28	✓ Montelukast Viatris
Montelukast Viatris to be Principal Supply on 1 December 2025			
* Tab 10 mg	2.45	28	✓ Montelukast Viatris
Montelukast Viatris to be Principal Supply on 1 December 2025			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Methylxanthines

AMINOPHYLLINE

* Inj 25 mg per ml, 10 ml ampoule – Up to 5 inj available on a PSO	180.00	5	✓	DBL Aminophylline
--	--------	---	---	-------------------

THEOPHYLLINE

* Tab long-acting 250 mg	25.65	100	✓	Nuelin-SR
* Oral liq 80 mg per 15 ml	18.49	500 ml	✓	Nuelin

Mucolytics

DORNASE ALFA – Special Authority see SA1978 below – Retail pharmacy Nebuliser soln, 2.5 mg per 2.5 ml ampoule	250.00	6	✓	Pulmozyme
--	--------	---	---	-----------

►SA1978 Special Authority for Subsidy

Initial application — (cystic fibrosis) only from a respiratory physician or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of cystic fibrosis; and
- 2 Patient has previously undergone a trial with, or is currently being treated with, hypertonic saline; and
- 3 Any of the following:
 - 3.1 Patient has required one or more hospital inpatient respiratory admissions in the previous 12 month period; or
 - 3.2 Patient has had 3 exacerbations due to CF, requiring oral or intravenous (IV) antibiotics in the previous 12 month period; or
 - 3.3 Patient has had 1 exacerbation due to CF, requiring oral or IV antibiotics in the previous 12 month period and a Brasfield score of < 22/25; or
 - 3.4 Patient has a diagnosis of allergic bronchopulmonary aspergillosis (ABPA).

Renewal — (cystic fibrosis) only from a respiratory physician or paediatrician. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient continues to benefit from treatment.

ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR – PCT only – Special Authority see [SA2456 below](#)

Tab elexacافت 50 mg with tezacافت 25 mg, ivacافت 37.5 mg (56) and ivacافت 75 mg (28)	27,647.39	84 OP	✓	Trikafta
Tab elexacافت 100 mg with tezacافت 50 mg, ivacافت 75 mg (56) and ivacافت 150 mg (28)	27,647.39	84 OP	✓	Trikafta

►SA2456 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Patient is 6 years of age or older; and
- 3 Either:
 - 3.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
 - 3.2 Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and
- 4 Either:
 - 4.1 Patient has a heterozygous or homozygous F508del mutation; or
 - 4.2 Patient has a G551D mutation or other mutation responsive in vitro to elexacافت/tezacافت/ivacافت (see note a);

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

and

- 5 The treatment must be the sole funded CFTR modulator therapy for this condition; and
- 6 Treatment with elxacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition.

Notes:

- a) Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information
<https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/f354423a-85c2-41c3-a9db-0f3aee135d8d/spl-doc>

IVACAFTOR – PCT only – Specialist – Special Authority see [SA2017 below](#)

Tab 150 mg	29,386.00	56	✓ Kalydeco
Oral granules 50 mg, sachet	29,386.00	56	✓ Kalydeco
Oral granules 75 mg, sachet	29,386.00	56	✓ Kalydeco

►SA2017 Special Authority for Subsidy

Initial application only from a respiratory specialist or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Either:
 - 2.1 Patient must have G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on at least 1 allele; or
 - 2.2 Patient must have other gating (class III) mutation (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R) in the CFTR gene on at least 1 allele; and
- 3 Patients must have a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and
- 4 Treatment with ivacaftor must be given concomitantly with standard therapy for this condition; and
- 5 Patient must not have an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing treatment with ivacaftor; and
- 6 The dose of ivacaftor will not exceed one tablet or one sachet twice daily; and
- 7 Applicant has experience and expertise in the management of cystic fibrosis.

SODIUM CHLORIDE

Not funded for use as a nasal drop.

Soln 7%	25.73	90 ml OP	✓ Biomed
---------------	-------	----------	-----------------

Nasal Preparations

Allergy Prophylactics

BUDESONIDE

Metered aqueous nasal spray, 50 mcg per dose	2.59	200 dose OP	✓ SteroClear
Metered aqueous nasal spray, 100 mcg per dose	2.89	200 dose OP	✓ SteroClear

FLUTICASONE PROPIONATE

Metered aqueous nasal spray, 50 mcg per dose	2.57	120 dose OP	✓ Flixonase Hayfever & Allergy
--	------	-------------	---

IPRATROPIUM BROMIDE

Aqueous nasal spray, 0.03%	5.23	15 ml OP	✓ Univent
----------------------------------	------	----------	------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Respiratory Devices

MASK FOR SPACER DEVICE

a) Up to 50 dev available on a PSO				
b) Only on a PSO				
c) Only for children aged six years and under				
Small.....	2.70	1	✓	e-chamber Mask

PEAK FLOW METER

a) Up to 25 dev available on a PSO				
b) Only on a PSO				
Low range.....	9.54	1	✓	Mini-Wright AFS Low Range
Normal range.....	9.54	1	✓	Mini-Wright Standard

SPACER DEVICE

a) Up to 50 dev available on a PSO				
b) Only on a PSO				
220 ml (single patient)	3.65	1	✓	e-chamber Turbo
510 ml (single patient)	5.95	1	✓	e-chamber La Grande
800 ml.....	6.50	1	✓	Volumatic

Respiratory Stimulants

CAFFEINE CITRATE

Oral liq 20 mg per ml (10 mg base per ml)	16.91	25 ml OP	✓	Biomed
---	-------	----------	---	--------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Ear Preparations

FLUMETASONE PIVALATE

Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	✓ Locacorten-Viaform ED's
			✓ Locorten-Vioform

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN

Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml OP	✓ Kenacomb
--	------	-----------	-------------------

Ear/Eye Preparations

DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN

Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml	4.50 (9.27) (9.27)	8 ml OP	Otodex ^{§29} Sofradex
---	--------------------------	---------	-----------------------------------

(Otodex ^{§29} Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml to be delisted 1 November 2025)

FRAMYCETIN SULPHATE

Ear/Eye drops 0.5%.....	4.13 (8.65)	8 ml OP	Soframycin
-------------------------	----------------	---------	------------

Eye Preparations

Eye preparations are only funded for use in the eye, unless explicitly stated otherwise.

Anti-Infective Preparations

ACICLOVIR

* Eye oint 3%	15.89	4.5 g OP	✓ ViruPOS
---------------------	-------	----------	------------------

CHLORAMPHENICOL

Eye oint 1%	1.55	5 g OP	✓ Devatis
Eye drops 0.5%	1.45	10 ml OP	✓ Chlorsig
	1.84		✓ Chlorafast

Funded for use in the ear*. Indications marked with * are unapproved indications.

(Chlorsig Eye drops 0.5% to be delisted 1 March 2026)

CIPROFLOXACIN

Eye drops 0.3% – Subsidy by endorsement.....	10.85	5 ml OP	✓ Ciprofloxacin Teva
When prescribed for the treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol; or for the second line treatment of chronic suppurative otitis media (CSOM)*; and the prescription is endorsed accordingly.			
Note: Indication marked with a * is an unapproved indication.			

SODIUM FUSIDATE [FUSIDIC ACID]

Eye drops 1%	5.29	5 g OP	✓ Fucithalmic
			✓ Fucithalmic Canada (ON) ^{§29}
			✓ Fucithalmic Spain ^{§29}

TOBRAMYCIN

Eye oint 0.3%	10.45	3.5 g OP	✓ Tobrex
Eye drops 0.3%	11.48	5 ml OP	✓ Tobrex

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Corticosteroids and Other Anti-Inflammatory Preparations				
DEXAMETHASONE				
* Eye oint 0.1%	5.86	3.5 g OP	✓	Maxidex
* Eye drops 0.1%	4.50	5 ml OP	✓	Maxidex
Ocular implant 700 mcg – Special Authority see SA1680 below				
– Retail pharmacy.....	1,444.50	1	✓	Ozurdex
» SA1680 Special Authority for Subsidy				
Initial application — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 Patient has diabetic macular oedema with pseudophakic lens; and				
2 Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and				
3 Either:				
3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or				
3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and				
4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.				
Renewal — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 Patient's vision is stable or has improved (prescriber determined); and				
2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.				
Initial application — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 Patient has diabetic macular oedema; and				
2 Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and				
3 Patient is of child bearing potential and has not yet completed a family; and				
4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.				
Renewal — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 Patient's vision is stable or has improved (prescriber determined); and				
2 Patient is of child bearing potential and has not yet completed a family; and				
3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.				
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE				
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g.....	5.39	3.5 g OP	✓	Maxitrol
* Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml.....	4.50	5 ml OP	✓	Maxitrol
DICLOFENAC SODIUM				
Eye drops 0.1%, single dose.....	1.85	10 dose	✓	Diclofenac Devatis
	5.54	30 dose	✓	Diclofenac Devatis
FLUOROMETHOLONE				
* Eye drops 0.1%	3.09	5 ml OP	✓	FML
	5.20		✓	Flucon

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEVOCABASTINE				
Eye drops 0.5 mg per ml	8.71 (10.34)	4 ml OP		Livostin
LODOXAMIDE				
Eye drops 0.1%	8.71	10 ml OP	✓	Lomide
PREDNISOLONE ACETATE				
Eye drops 1%	6.92 7.00	10 ml OP 5 ml OP	✓	Prednisolone-AFT Pred Forte
PREDNISOLONE SODIUM PHOSPHATE – Special Authority see SA1715 below – Retail pharmacy				
Eye drops 0.5%, single dose (preservative free)	43.26	20 dose	✓	Minims Prednisolone

►**SA1715** Special Authority for Subsidy

Initial application only from an ophthalmologist or optometrist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has severe inflammation; and
- 2 Patient has a confirmed allergic reaction to preservative in eye drops.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

SODIUM CROMOGLICATE

Eye drops 2%	2.91	10 ml OP	✓	Allerfix
--------------------	------	----------	---	----------

Glaucoma Preparations - Beta Blockers

BETAXOLOL

* Eye drops 0.25%	11.80	5 ml OP	✓	Betoptic S
* Eye drops 0.5%	7.50	5 ml OP	✓	Betoptic

(Betoptic S Eye drops 0.25% to be delisted 1 December 2025)

(Betoptic Eye drops 0.5% to be delisted 1 December 2025)

TIMOLOL

* Eye drops 0.25%	2.42	5 ml OP	✓	Arrow-Timolol
* Eye drops 0.5%	2.50	5 ml OP	✓	Arrow-Timolol

Glaucoma Preparations - Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE

* Tab 250 mg	13.96	100	✓	Medsurge
--------------------	-------	-----	---	----------

BRINZOLAMIDE

* Eye drops 1%	5.11	5 ml OP	✓	Azopt
----------------------	------	---------	---	-------

DORZOLAMIDE WITH TIMOLOL

* Eye drops 2% with timolol 0.5%	3.58	5 ml OP	✓	Dortimopt
--	------	---------	---	-----------

Glaucoma Preparations - Prostaglandin Analogues

BIMATOPROST

* Eye drops 0.03%	5.15	3 ml OP	✓	Lumigan
-------------------------	------	---------	---	---------

LATANOPROST

* Eye drops 0.005%	2.08	2.5 ml OP	✓	Teva
--------------------------	------	-----------	---	------

TRAVOPROST

* Eye drops 0.004%	6.80	2.5 ml OP	✓	Travatan
--------------------------	------	-----------	---	----------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

Glaucoma Preparations - Other

BRIMONIDINE TARTRATE

* Eye drops 0.2%5.16 5 ml OP ✓ **Arrow-Brimonidine**

BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE

* Eye drops 0.2% with timolol maleate 0.5%7.13 5 ml OP ✓ **Combigan**

LATANOPROST WITH TIMOLOL

* Eye drops 0.005% with timolol 0.5%4.95 2.5 ml OP ✓ **Arrow - Lattim**

PILOCARPINE HYDROCHLORIDE

* Eye drops 1%4.26 15 ml OP ✓ **Isopto Carpine**

* Eye drops 2%5.35 15 ml OP ✓ **Isopto Carpine**

* Eye drops 4%7.99 15 ml OP ✓ **Isopto Carpine**

Subsidised for oral use pursuant to the Standard Formulae.

PILOCARPINE NITRATE

* Eye drops 2% single dose – Special Authority see [SA0895](#)
below – Retail pharmacy35.90 20 dose ✓ **Minims Pilocarpine**

► [SA0895](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE

* Eye drops 1%18.27 15 ml OP ✓ **Atropt**

CYCLOPENTOLATE HYDROCHLORIDE

* Eye drops 1%25.16 15 ml OP ✓ **Cyclogyl**

TROPICAMIDE

* Eye drops 0.5%20.52 15 ml OP ✓ **Mydriacyl**

* Eye drops 1%24.82 15 ml OP ✓ **Mydriacyl**

Preparations for Tear Deficiency

For acetylcysteine eye drops refer Standard Formulae, [page 284](#)

HYPROMELLOSE

* Eye drops 0.5%19.50 15 ml OP ✓ **Methopt**

HYPROMELLOSE WITH DEXTRAN

* Eye drops 0.3% with dextran 0.1%2.30 15 ml OP ✓ **Poly-Tears**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Preservative Free Ocular Lubricants

►SA2431 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed diagnosis by slit lamp or Schirmer test of severe secretory dry eye; and
- 2 Either:
 - 2.1 Patient is using eye drops more than four times daily on a regular basis; or
 - 2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL – Special Authority see [SA2431 above](#) – Retail pharmacy
 Eye drops 0.4% and propylene glycol 0.3%, 0.8 ml 10.78 30 ✓ **Systane Unit Dose**

SODIUM HYALURONATE [HYALURONIC ACID] – Special Authority see [SA2431 above](#) – Retail pharmacy
 Eye drops 1 mg per ml 13.58 10 ml OP ✓ **Hylo-Fresh**
 Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Procedures Manual restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed.

Other Eye Preparations

NAPHAZOLINE HYDROCHLORIDE		
* Eye drops 0.1%	5.65	15 ml OP ✓ Albalon
OLOPATADINE		
Eye drops 0.1%	3.39	5 ml OP ✓ Olopatadine Teva
PARAFFIN LIQUID WITH WOOL FAT		
* Eye oint 3% with wool fat 3%	3.63	3.5 g OP ✓ Poly-Visc
RETINOL PALMITATE		
Eye oint 138 mcg per g	3.80	5 g OP ✓ VitA-POS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Various

PHARMACY SERVICES

* Immunisation administration fee - flu.....	0.00	1 fee	✓	Immunisation - Flu
* Immunisation administration fee - other	0.00	1 fee	✓	Immunisation Other
* Immunisation co-administration fee - flu and shingles.....	0.00	1 fee	✓	Immunisation Flu and Shingles

Agents Used in the Treatment of Poisonings

Antidotes

ACETYL CYSTEINE

Inj 200 mg per ml, 10 ml ampoule	42.99	10	✓	DBL Acetylcysteine
	52.88		✓	Martindale Pharma
Inj 200 mg per ml, 10 ml vial.....	42.99	10	✓	Hikma
				Acetylcysteine ^{\$29}

(Martindale Pharma Inj 200 mg per ml, 10 ml ampoule to be delisted 1 November 2025)

NALOXONE HYDROCHLORIDE

a) Up to 10 inj available on a PSO				
b) Only on a PSO				
* Inj 400 mcg per ml, 1 ml ampoule	13.29	5	✓	DBL Naloxone Hydrochloride

Removal and Elimination

CHARCOAL

* Oral liq 50 g per 250 ml	59.85	250 ml OP	✓	Carbosorb-X
a) Up to 250 ml available on a PSO				
b) Only on a PSO				

DEFERASIROX – Special Authority see [SA1492 below](#) – Retail pharmacy

Wastage claimable

Tab 125 mg dispersible	276.00	28	✓	Exjade
Tab 250 mg dispersible	552.00	28	✓	Exjade
Tab 500 mg dispersible	1,105.00	28	✓	Exjade

➔ [SA1492](#) Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis; or
 - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

0.5 - 1.0 cells per µL).

Renewal only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:
Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Special Authority see [SA1480 below](#) – Retail pharmacy

Tab 500 mg	533.17	100	✓ Feriprox
Oral liq 100 mg per 1 ml	266.59	250 ml OP	✓ Feriprox

➔**SA1480** **Special Authority for Subsidy**

Initial application only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
- 2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DEFERIOXAMINE MESILATE

* Inj 500 mg vial	332.88	10	✓ DBL Desferrioxamine Mesylate for Inj BP
-------------------------	--------	----	--

SODIUM CALCIUM EDETATE

* Inj 200 mg per ml, 5 ml	53.31 (156.71)	6	Calcium Disodium Versenate
---------------------------------	-------------------	---	-------------------------------

Standard Formulae

ACETYL CYSTEINE EYE DROPS

Acetylcysteine inj 200 mg per ml, 10 ml qs
 Suitable eye drop base qs

CODEINE LINCTUS (3 mg per 5 ml)

Codeine phosphate 60 mg
 Glycerol 40 ml
 Preservative qs
 Water to 100 ml

CODEINE LINCTUS (15 mg per 5 ml)

Codeine phosphate 300 mg
 Glycerol 40 ml
 Preservative qs
 Water to 100 ml

FOLINIC MOUTHWASH

Calcium folinate 15 mg tab 1 tab
 Preservative qs
 Water to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

METHYL HYDROXYBENZOATE 10% SOLUTION

Methyl hydroxybenzoate 10 g
 Propylene glycol to 100 ml
 (Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

OMEPRAZOLE SUSPENSION

Omeprazole capsules or powder qs
 Sodium bicarbonate powder BP 8.4 g
 Water to 100 ml

PHENOBARBITONE ORAL LIQUID

Phenobarbitone Sodium 1 g
 Glycerol BP 70 ml
 Water to 100 ml

PHENOBARBITONE SODIUM PAEDIATRIC ORAL LIQUID (10 mg per ml)

Phenobarbitone Sodium 400 mg
 Glycerol BP 4 ml
 Water to 40 ml

PILOCARPINE ORAL LIQUID

Pilocarpine 4% eye drops qs
 Preservative qs
 Water to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days.)

SALIVA SUBSTITUTE FORMULA

Methylcellulose 5 g
 Preservative qs
 Water to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

SODIUM CHLORIDE ORAL LIQUID

Sodium chloride inj 23.4%, 20 ml qs
 Water qs

(Only funded if prescribed for treatment of hyponatraemia)

VANCOMYCIN ORAL SOLUTION (25 mg per ml)

Vancomycin 500 mg injection 5 vials
 Glycerin with sucrose suspension 37.5 ml
 Water to 100 ml

(Only funded if prescribed for treatment of Clostridium difficile following metronidazole failure)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Extemporaneously Compounded Preparations and Galenicals				
COLLODION FLEXIBLE				
Note: This product is no longer being manufactured by the supplier and will be delisted from the Schedule at a date to be determined.				
Collodion flexible	19.30	100 ml	✓	PSM
COMPOUND HYDROXYBENZOATE – Only in combination				
Only in extemporaneously compounded oral mixtures.				
Soln	30.00	100 ml	✓	Midwest
GLYCERIN WITH SODIUM SACCHARIN – Only in combination				
Suspension.....	30.95	473 ml	✓	Ora-Sweet SF
GLYCERIN WITH SUCROSE – Only in combination				
Suspension.....	30.95	473 ml	✓	Ora-Sweet
GLYCEROL				
* Liquid – Only in combination	3.23	500 ml	✓	healthE Glycerol BP
Only in extemporaneously compounded oral liquid preparations.				
METHYL HYDROXYBENZOATE				
Powder	8.98	25 g	✓	Midwest
METHYLCELLULOSE				
Powder	36.95	100 g	✓	MidWest
Suspension – Only in combination	30.95	473 ml	✓	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN – Only in combination				
Suspension.....	30.95	473 ml	✓	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE – Only in combination				
Suspension.....	30.95	473 ml	✓	Ora-Blend
PHENOBARBITONE SODIUM				
Powder – Only in combination.....	52.50	10 g	✓	MidWest
Only in children up to 12 years				
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.				
Liq.....	11.25	500 ml	✓	Midwest
SODIUM BICARBONATE				
Powder BP – Only in combination.....	10.05	500 g	✓	Midwest
Only in extemporaneously compounded omeprazole and lansoprazole suspension.				
SYRUP (PHARMACEUTICAL GRADE) – Only in combination				
Only in extemporaneously compounded oral liquid preparations.				
Liq.....	14.95	500 ml	✓	Midwest
WATER				
Tap – Only in combination.....	0.00	1 ml	✓	Tap water

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Nutrient Modules

Carbohydrate

»SA1930 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Either:
- 1 cystic fibrosis; or
 - 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Any of the following:
- 1 cancer in children; or
 - 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
 - 3 faltering growth in an infant/child; or
 - 4 bronchopulmonary dysplasia; or
 - 5 premature and post premature infant; or
 - 6 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1930 above – Hospital pharmacy [HP3]
Powder6.72 400 g OP ✓ Polycal

Carbohydrate And Fat

»SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see [SA1376 on the previous page](#) – Hospital pharmacy [HP3]
Powder (neutral)71.77 400 g OP ✓ **Duocal Super Soluble Powder**

Fat

»SA2204 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has an inborn error of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

10 ascites; or

11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT – Special Authority see [SA2204 on the previous page](#) – Hospital pharmacy [HP3]

Emulsion (neutral)	15.38	200 ml OP	✓ Calogen
Emulsion (strawberry).....	15.38	200 ml OP	✓ Calogen
Oil	37.50	500 ml OP	✓ MCT oil (Nutricia)
MCT Emulsion, 250 ml	143.65	4 OP	✓ Liquigen

Protein

►SA1524 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see [SA1524 above](#) – Hospital pharmacy [HP3]

Powder	8.95	227 g OP	✓ Resource Beneprotein
	13.82	225 g OP	✓ Protifar

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Oral and Enteral Feeds

Diabetic Products

►SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]

Liquid, 500 ml bottle	4.65	1 OP	✓ Glucerna Select
-----------------------------	------	------	-------------------

DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]

Liquid (strawberry), 200 ml bottle	2.25	1 OP	✓ Diasip
Liquid (vanilla), 200 ml bottle.....	2.10	1 OP	✓ Nutren Diabetes
	2.25		✓ Diasip

Fat Modified Products

►SA2205 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has an inborn error of metabolism.

Initial application — (Indications other than errors of inborn metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient has a chyle leak; or
- 2 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA2205 above – Hospital pharmacy [HP3]

Powder	62.90	400 g OP	✓ Monogen
--------------	-------	----------	-----------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Paediatric Products For Children Awaiting Liver Transplant

►SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see [SA1098 above](#) – Hospital pharmacy [HP3]

Powder (unflavoured) 93.97 400 g OP ✓ **Heparon Junior**

Paediatric Products For Children With Chronic Renal Failure

►SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see [SA1099 above](#) – Hospital pharmacy [HP3]

Powder 64.26 400 g OP ✓ **Kindergen**

Paediatric Products

►SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 Child is aged one to ten years; and
 - 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
applications meeting the following criteria:				
Both:				
1 The treatment remains appropriate and the patient is benefiting from treatment; and				
2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.				
PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid, 500 ml bottle	7.46	1 OP	✓	Nutrini Energy RTH
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid, 500 ml bottle	3.32	1 OP	✓	Pediasure RTH
	4.69		✓	Nutrini RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid, 500 ml bottle	7.14	1 OP	✓	Nutrini Energy Multi Fibre
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (strawberry), 200 ml bottle	1.90	1 OP	✓	Fortini
Liquid (vanilla), 200 ml bottle	1.90	1 OP	✓	Fortini
Liquid (vanilla), 500 ml bottle	8.67	1 OP	✓	Pediasure Plus
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (chocolate), 200 ml bottle	1.33	1 OP	✓	Pediasure
Liquid (strawberry), 200 ml bottle	1.33	1 OP	✓	Pediasure
Liquid (vanilla), 200 ml bottle	1.33	1 OP	✓	Pediasure
Liquid (vanilla), 250 ml can	1.66	1 OP	✓	Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (chocolate), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
Liquid (strawberry), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
Liquid (unflavoured), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
Liquid (vanilla), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
PEPTIDE-BASED ORAL FEED – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Powder	43.60	400 g OP	✓	Peptamen Junior

Renal Products

►SA1101 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see [SA1101 above](#) – Hospital pharmacy [HP3]

Liquid, 220 ml bottle	3.31	1 OP	✓	Nepro HP (strawberry)
			✓	Nepro HP (vanilla)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA1101 on the previous page – Hospital pharmacy [HP3]				
Liquid, 200 ml bottle	13.24	4 OP	✓	NovaSource Renal
Liquid (apricot) 125 ml	13.72	4 OP	✓	Renilon 7.5
Liquid (caramel) 125 ml	13.72	4 OP	✓	Renilon 7.5

Specialised And Elemental Products

►SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Liquid, 1,000 ml bottle	22.39	1 OP	✓	Vital
-------------------------------	-------	------	---	--------------

ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Liquid (grapefruit), 250 ml carton	179.46	18 OP	✓	Elemental 028 Extra
Liquid (pineapple & orange), 250 ml carton	179.46	18 OP	✓	Elemental 028 Extra
Liquid (summer fruits), 250 ml carton	179.46	18 OP	✓	Elemental 028 Extra

ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Powder (unflavoured), 80 g sachet	4.50	1 OP	✓	Vivonex TEN
---	------	------	---	--------------------

SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Liquid, 500 ml bottle	7.47	1 OP	✓	Nutrison Advanced Peptisorb
-----------------------------	------	------	---	------------------------------------

Paediatric Products For Children With Low Energy Requirements

►SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML – Special Authority see [SA1196 on the previous page](#) – Hospital pharmacy [HP3]

Liquid, 500 ml bottle	6.27	1 OP	✓ Nutrini Low Energy Multi Fibre
-----------------------------	------	------	---

Standard Supplements

►SA1859 Special Authority for Subsidy

Initial application — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist or dietitian on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Renewal — (Children - exclusive enteral nutrition for Crohn's disease) from any relevant practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Initial application — (Adults) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

Patient is Malnourished

- 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
- 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 1.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months; and

2 Any of the following:

Patient has not responded to first-line dietary measures over a 4 week period by:

- 2.1 Increasing their food intake frequency (eg snacks between meals); or
- 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
- 2.3 Using over the counter supplements (e.g. Complan); and

3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 A nutrition goal has been set (eg reach a specific weight or BMI); and

2 Any of the following:

Patient is Malnourished

- 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
- 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 2.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or

2 Malignancy and is considered likely to develop malnutrition as a result; or

3 Is undergoing a bone marrow transplant; or

4 Tempomandibular surgery or glossectomy; or

5 Both:

5.1 Pregnant; and

5.2 Any of the following:

5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or

5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or

5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 Is being fed via a nasogastric tube; or

2 Malignancy and is considered likely to develop malnutrition as a result; or

3 Has undergone a bone marrow transplant; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

4 Tempomandibular surgery or glossectomy; or

5 Both:

5.1 Pregnant; and

5.2 Any of the following:

5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or

5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or

5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see [SA1859 on page 293](#) – Hospital pharmacy [HP3]

Liquid, 1,000 ml bottle	8.68	1 OP	✓ Ensure Plus HN RTH
	9.00		✓ Nutrison Energy
Liquid, 250 ml can	2.17	1 OP	✓ Ensure Plus HN

ENTERAL FEED 1KCAL/ML – Special Authority see [SA1859 on page 293](#) – Hospital pharmacy [HP3]

Liquid, 1,000 ml bottle	6.56	1 OP	✓ Osmolite RTH
	6.90		✓ Nutrison RTH

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Special Authority see SA1859 on page 293 – Hospital pharmacy [HP3]				
Liquid, 1,000 ml bottle	9.05	1 OP	✓	Nutrison 800 Complete Multi Fibre
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1859 on page 293 – Hospital pharmacy [HP3]				
Liquid, 1,000 ml bottle	6.56	1 OP	✓	Jevity RTH
	7.21		✓	Nutrison Multi Fibre
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1859 on page 293 – Hospital pharmacy [HP3]				
Liquid, 1,000 ml bottle	8.68	1 OP	✓	Jevity HiCal RTH
			✓	Nutrison Energy Multi Fibre
ORAL FEED (POWDER) – Special Authority see SA1859 on page 293 – Hospital pharmacy [HP3]				
Powder (chocolate).....	15.90	840 g OP	✓	Sustagen Hospital Formula
	40.00	850 g OP	✓	Ensure
Powder (vanilla).....	15.90	840 g OP	✓	Sustagen Hospital Formula
	40.00	850 g OP	✓	Ensure
ORAL FEED 1.5KCAL/ML – Special Authority see SA1859 on page 293 – Hospital pharmacy [HP3]				
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, who have severe epidermolysis bullosa, or as exclusive enteral nutrition for the treatment of Crohn's disease, or for patients with COPD and hypercapnia, defined as CO2 value exceeding 55mmHg. The prescription must be endorsed accordingly.				
Liquid (banana), 200 ml bottle – Higher subsidy of up to \$1.76				
per 1 btl with Endorsement.....	0.72	1 OP		
	(1.56)			Ensure Plus
	(1.76)			Fortisip
Liquid (chocolate), 200 ml bottle – Higher subsidy of up to \$1.76 per 1 btl with Endorsement.....				
	0.72	1 OP		
	(1.56)			Ensure Plus
	(1.76)			Fortisip
Liquid (fruit of the forest), 200 ml bottle – Higher subsidy of \$1.56 per 1 btl with Endorsement.....				
	0.72	1 OP		
	(1.56)			Ensure Plus
Liquid (strawberry), 200 ml bottle – Higher subsidy of \$1.76 per 1 btl with Endorsement.....				
	0.72	1 OP		
	(1.76)			Fortisip
Liquid (vanilla), 200 ml bottle – Higher subsidy of up to \$1.76 per 1 btl with Endorsement.....				
	0.72	1 OP		
	(1.56)			Ensure Plus
	(1.76)			Fortisip
Liquid (vanilla), 237 ml can – Higher subsidy of \$1.65 per 1 can with Endorsement.....				
	0.85	1 OP		
	(1.65)			Ensure Plus

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1859 on page 293 – Hospital pharmacy [HP3]			
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.			
Liquid (chocolate), 200 ml bottle – Higher subsidy of \$1.76 per			
1 btl with Endorsement.....	0.72 (1.76)	1 OP	Fortisip Multi Fibre
Liquid (strawberry), 200 ml bottle – Higher subsidy of \$1.76 per			
1 btl with Endorsement.....	0.72 (1.76)	1 OP	Fortisip Multi Fibre
Liquid (vanilla), 200 ml bottle – Higher subsidy of \$1.76 per			
1 btl with Endorsement.....	0.72 (1.76)	1 OP	Fortisip Multi Fibre

High Calorie Products

►SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner.

Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ENTERAL FEED 2 KCAL/ML – Special Authority see SA1195 on the previous page – Hospital pharmacy [HP3]				
Liquid, 1,000 ml bottle	13.64	1 OP	✓	Ensure Two Cal HN RTH
Liquid, 500 ml bottle	6.82	1 OP	✓	Nutrison Concentrated
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 on the previous page – Hospital pharmacy [HP3]				
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.				
Liquid (vanilla), 200 ml bottle – Higher subsidy of \$2.34 per				
1 btl with Endorsement.....	0.96 (2.34)	1 OP		Two Cal HN

Food Thickeners

►SA1106 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FOOD THICKENER – Special Authority see [SA1106 above](#) – Hospital pharmacy [HP3]

Powder	8.29	300 g OP	✓	Nutrilis
	24.00	380 g OP	✓	Aptamil Feed Thickener

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by Pharmac from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

►SA1729 Special Authority for Subsidy

Initial application — (all patients) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Either:
- 1 Gluten enteropathy has been diagnosed by biopsy; or
 - 2 Patient suffers from dermatitis herpetiformis.

Initial application — (paediatric patients diagnosed by ESPGHAN criteria) only from a paediatric gastroenterologist. Approvals valid without further renewal unless notified where the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease.

GLUTEN FREE BAKING MIX – Special Authority see [SA1729 above](#) – Hospital pharmacy [HP3]

Powder	2.81 (5.15)	1,000 g OP		Healthies Simple Baking Mix
--------------	----------------	------------	--	--------------------------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
GLUTEN FREE BREAD MIX – Special Authority see SA1729 on the previous page – Hospital pharmacy [HP3]			
Powder	3.93 (7.32)	1,000 g OP	NZB Low Gluten Bread Mix
	3.51 (10.87)		Horleys Bread Mix
GLUTEN FREE FLOUR – Special Authority see SA1729 on the previous page – Hospital pharmacy [HP3]			
Powder	5.62 (18.10)	2,000 g OP	Horleys Flour

Foods And Supplements For Inherited Metabolic Disease

► [SA2357](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where patient requires dietary management of inherited metabolic disorders.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA2357 above – Hospital pharmacy [HP3]			
Powder (neutral), 36 g sachets.....	750.30	30	✓ HCU Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓ HCU Explore 5
Powder, 25 g sachets	1,048.95	30	✓ HCU Express 15
Powder (neutral), can	480.42	500 g OP	✓ XMET Maxamum
Powder (unflavoured), can	260.00	400 g OP	✓ HCU Anamix Infant
Liquid (juicy berries), 125 ml bottle.....	1,684.80	30	✓ HCU Lophlex LQ
Liquid (orange), 125 ml bottle.....	941.40	36	✓ HCU Anamix Junior LQ

Supplements For MSUD and short chain enoyl coA hydratase deficiency

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA2357 above – Hospital pharmacy [HP3]			
Powder (neutral) 36 g sachets.....	750.00	30	✓ MSUD Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓ MSUD Explore 5
Powder, 25 g sachets	1,048.95	30	✓ MSUD Express 15
Powder (neutral), can	454.71	500 g OP	✓ MSUD Maxamum
Powder (orange), can	454.71	500 g OP	✓ MSUD Maxamum
Powder (unflavoured), can	260.00	400 g OP	✓ MSUD Anamix Infant
Liquid (orange) 125 ml bottles.....	941.40	36	✓ MSUD Anamix Junior LQ
Liquid (juicy berries) 125 ml pouches.....	1,684.80	30	✓ MSUD Lophlex LQ 20

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Supplements For PKU				
AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA2357 on the previous page – Hospital pharmacy [HP3]				
Tabs.....	99.00	75 OP	✓	Phlexy 10
Powder (Lemon), 34 g sachets.....	883.50	30	✓	PKU Express 20
Powder (Neutral), 12.5 g sachets.....	220.88	30	✓	PKU Explore 5
Powder (Neutral), 34 g sachets.....	883.50	30	✓	PKU Express 20
Powder (Orange), 25 g sachets.....	441.75	30	✓	PKU Explore 10
Powder (Orange), 34 g sachets.....	883.50	30	✓	PKU Express 20
Powder (Raspberry), 25 g sachets.....	441.75	30	✓	PKU Explore 10
Powder (Tropical), 34 g sachets.....	883.50	30	✓	PKU Express 20
Powder (berry) 28 g sachets	936.00	30	✓	PKU Lophlex Powder
Powder (chocolate) 36 g sachet.....	393.00	30	✓	PKU Anamix Junior Chocolate
Powder (neutral) 28 g sachets.....	936.00	30	✓	PKU Lophlex Powder
Powder (neutral) 36 g sachets.....	393.00	30	✓	PKU Anamix Junior
Powder (orange) 28 g sachets	936.00	30	✓	PKU Lophlex Powder
Powder (orange) 36 g sachet.....	393.00	30	✓	PKU Anamix Junior Orange
Powder (unflavoured) 12.5 g sachets.....	234.00	30	✓	PKU First Spoon
Powder (vanilla) 36 g sachet	393.00	30	✓	PKU Anamix Junior Vanilla
Infant formula.....	174.72	400 g OP	✓	PKU Anamix Infant
Powder (neutral), 4 x 400 g can	715.16	1,600 g OP	✓	Pku Start
Powder (orange).....	320.00	500 g OP	✓	XP Maxamum
Powder (unflavoured)	320.00	500 g OP	✓	XP Maxamum
Liquid (berry), 125 ml bottle.....	13.10	1 OP	✓	PKU Anamix Junior LQ
Liquid (orange), 125 ml bottle.....	13.10	1 OP	✓	PKU Anamix Junior LQ
Liquid (forest berries), 250 ml carton.....	540.00	18 OP	✓	Easiphen Liquid
Liquid (juicy tropical) 125 ml.....	936.00	30 OP	✓	PKU Lophlex LQ 20
Oral semi-solid (berries) 109 g.....	1,123.20	36 OP	✓	PKU Lophlex Sensation 20
Liquid (juicy berries) 62.5 ml.....	939.00	60 OP	✓	PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml.....	936.00	30 OP	✓	PKU Lophlex LQ 20
Liquid (juicy orange) 125 ml	936.00	30 OP	✓	PKU Lophlex LQ 20

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder (Banana) 35 g sachets	930.00	30	✓	PKU sphere20 Banana
Powder (Berry), 20 g sachets	449.28	60	✓	PKU Restore Powder
Powder (Chocolate) 32 g sachets	898.56	30	✓	PKU Build 20 Chocolate
Powder (Chocolate) 35 g sachets	930.00	30	✓	PKU sphere20 Chocolate
Powder (Lemon) 35 g sachets.....	930.00	30	✓	PKU sphere20 Lemon
Powder (Lemonade) 33.4 g sachets.....	936.00	30	✓	PKU GMPPro Ultra Lemonade
Powder (Neutral), 15 g sachets	449.28	30	✓	PKU Build 10
Powder (Orange), 20 g sachets.....	449.28	60	✓	PKU Restore Powder
Powder (Raspberry Lemonade) 31 g sachets.....	898.56	30	✓	PKU Build 20 Raspberry Lemonade
Powder (Smooth) 31 g sachets	898.56	30	✓	PKU Build 20 Smooth
Powder (Vanilla) 33 g sachets.....	898.56	30	✓	PKU Build 20 Vanilla
Powder (neutral), 40 g sachets.....	673.92	30	✓	Glytactin Bettermilk
Powder (unflavoured) 12.5 g sachets.....	468.00	30	✓	PKU GMPPro Mix-In
Powder (vanilla) 33.4 g sachets	936.00	30	✓	PKU GMPPro Ultra Vanilla
Powder (Red Berry) 35 g sachets	930.00	30	✓	PKU sphere20 Red Berry
Powder (Vanilla) 35 g sachets.....	930.00	30	✓	PKU sphere20 Vanilla
Liquid (neutral), 250 ml carton.....	280.80	18	✓	PKU GMPPro LQ
Liquid (original), 250 ml carton	684.45	30 OP	✓	PKU Glytactin RTD 15
Liquid (Coffee Mocha), 250 ml carton	684.45	30 OP	✓	PKU Glytactin RTD 15 Lite
Liquid (chocolate), 250 ml carton	684.45	30 OP	✓	PKU Glytactin RTD 15
Liquid (vanilla), 250 ml carton.....	684.45	30 OP	✓	PKU Glytactin RTD 15 Lite

Foods

LOW PROTEIN BAKING MIX – Special Authority see [SA2357](#) on [page 299](#) – Hospital pharmacy [HP3]

Powder	8.55	500 g OP	✓	Loprofin Mix
--------------	------	----------	---	--------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LOW PROTEIN PASTA – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Animal shapes.....	12.39	500 g OP	✓	Loprofin
Lasagne.....	6.19	250 g OP	✓	Loprofin
Low protein rice pasta	12.39	500 g OP	✓	Loprofin
Macaroni.....	6.19	250 g OP	✓	Loprofin
Penne	12.39	500 g OP	✓	Loprofin
Spaghetti	12.39	500 g OP	✓	Loprofin
Spirals.....	12.39	500 g OP	✓	Loprofin

Supplements for Tyrosinaemia

AMINOACID FORMULA WITHOUT PHENYLALANINE AND TYROSINE – Special Authority see [SA2357 on page 299](#) – Hospital pharmacy [HP3]

Powder (Neutral), 12.5 g sachets.....	349.65	30	✓	TYR Explore 5
Powder (neutral) 36 g sachets.....	471.00	30	✓	TYR Anamix Junior
Powder, can.....	260.00	400 g OP	✓	TYR Anamix Infant
Liquid (juicy berries) 125 ml pouches	1,684.80	30	✓	TYR Lophlex LQ 20
Liquid (orange) 125 ml bottle.....	941.40	36	✓	TYR Anamix Junior LQ

GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME TYROSINE AND PHENYLALANINE – Special Authority see [SA2357 on page 299](#) – Hospital pharmacy [HP3]

Powder (Red Berry), 35 g sachets	1,398.60	30	✓	TYR Sphere 20
Powder (Vanilla), 35 g sachets.....	1,398.60	30	✓	TYR Sphere 20

Supplements for Organic Acidaemias

AMINOACID FORMULA WITHOUT Isoleucine, Methionine, Threonine and Valine – Special Authority see [SA2357 on page 299](#) – Hospital pharmacy [HP3]

Powder, can.....	260.00	400 g OP	✓	MMA/PA Anamix Infant
------------------	--------	----------	---	-----------------------------

AMINOACID FORMULA WITHOUT Methionine, Threonine and Valine – Special Authority see [SA2357 on page 299](#) – Hospital pharmacy [HP3]

Powder (neutral), 18 g sachets.....	750.30	30	✓	MMA/PA Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓	MMA/PA Explore 5
Powder, 25 g sachets.....	1,048.95	30	✓	MMA/PA Express 15

Supplements for Glutaric Aciduria type 1

AMINOACID FORMULA WITHOUT LYSINE – Special Authority see [SA2357 on page 299](#) – Hospital pharmacy [HP3]

Powder (neutral), 18 g sachets.....	750.30	30	✓	GA1 Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓	GA Explore 5
Powder, can.....	260.00	400 g OP	✓	GA1 Anamix Infant

Supplements for Glycogen Storage Disease

HIGH AMYLOPECTIN CORN-STARCH – Special Authority see [SA2357 on page 299](#) – Hospital pharmacy [HP3]

Powder, 60 g sachets.....	241.62	30	✓	Glycosade
---------------------------	--------	----	---	------------------

Single dose amino acids

ARGININE – Special Authority see [SA2357 on page 299](#) – Hospital pharmacy [HP3]

Powder, 4 g sachets.....	211.45	30	✓	Arginine2000
--------------------------	--------	----	---	---------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CITRULLINE – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder, 4 g sachets	211.45	30	✓	Citrulline1000
ISOLEUCINE – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder, 4 g sachets	141.05	30	✓	Isoleucine50
LEUCINE – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder, 4 g sachets	141.05	30	✓	Leucine100
PHENYLALANINE – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder, 4 g sachets	141.05	30	✓	Phenylalanine50
TYROSINE – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder, 4 g sachets	211.45	30	✓	Tyrosine1000
VALINE – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder, 4 g sachets	141.05	30	✓	Valine50

Other Fat Modified Products

ELEMENTAL FEED WITH HIGH MEDIUM CHAIN TRIGLYCERIDES – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder (neutral), 100 g sachets.....	47.01	10	✓	Emsogen

Carbohydrate and Fat with added vitamins and minerals

PROTEIN FREE SUPPLEMENT CONTAINING CARBOHYDRATE, FAT WITH ADDED VITAMINS AND MINERALS – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder (neutral), can	49.29	400 g OP	✓	Energivit

Essential Amino Acids

ESSENTIAL AMINOACID FORMULA – Special Authority see SA2357 on page 299 – Hospital pharmacy [HP3]				
Powder (neutral), can	313.73	200 g OP	✓	Essential Amino Acid Mix

Infant Formulae

For Williams Syndrome

➤ [SA1110](#) Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3]				
Powder	46.18	400 g OP	✓	Locasol

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Gastrointestinal and Other Malabsorptive Problems				
AMINO ACID FORMULA – Special Authority see SA2092 below – Hospital pharmacy [HP3]				
Powder	43.60	400 g OP	✓	Alfamino
			✓	Alfamino Junior
Powder (unflavoured)	55.61	400 g OP	✓	Neocate Gold
			✓	Neocate Junior Unflavoured
	65.72		✓	Neocate SYNEO
			✓	Elecare
Powder (vanilla).....	55.61	400 g OP	✓	Elecare LCP
			✓	Neocate Junior Vanilla
	65.72		✓	Elecare

➤ **SA2092** Special Authority for Subsidy

Initial application — (Infants under 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 History of anaphylaxis to cow's milk protein formula or dairy products; or
- 2 Eosinophilic oesophagitis; or
- 3 Ultra-short gut; or
- 4 Severe Immune deficiency; or
- 5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
- 6 Both:
 - 6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 6.2 Either:
 - 6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 6.2.2 Patient has IgE mediated allergy.

Initial application — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or
 - 1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and
- 2 Any of the following:
 - 2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or
 - 2.2 Eosinophilic oesophagitis; or
 - 2.3 Ultra-short gut; or
 - 2.4 Severe Immune deficiency; or
 - 2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
 - 2.6 Both:
 - 2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 2.6.2 Either:
 - 2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

number; or

2.6.2.2 Patient has IgE mediated allergy.

Renewal — (Infants up to 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has IgE mediated allergy; and

1.2 All of the following:

1.2.1 Patient remains allergic to cow's milk; and

1.2.2 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy or extensively hydrolysed infant formula has been undertaken; and

1.2.3 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and

1.2.4 Amino acid formula is required for a nutritional deficit; and

1.2.5 It has been more than three months from the previous approval; or

2 Both:

2.1 Patient has non IgE mediated severe gastrointestinal intolerance (including eosinophilic oesophagitis, ultra-short gut and severe immune deficiency); and

2.2 All of the following:

2.2.1 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and

2.2.2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and

2.2.3 Amino acid formula is required for a nutritional deficit; and

2.2.4 It has been more than three months from the previous approval.

Renewal — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or

1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and

2 Any of the following:

2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or

2.2 Eosinophilic oesophagitis; or

2.3 Ultra-short gut; or

2.4 Severe Immune deficiency; or

2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or

2.6 Both:

2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and

2.6.2 Either:

2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or

2.6.2.2 Patient has IgE mediated allergy.

Initial application — (for patients who have a current funding under Special Authority form SA1557) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 Patient has a valid Special Authority approval for extensively hydrolysed formula (SA1557); and
- 2 Extensively hydrolysed formula (Aptamil Gold+ Pepti Junior, AllerPro SYNEO 1 and 2) is unable to be supplied at this time; and
- 3 The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Special Authority form SA1557. There is no renewal criteria under this restriction.

ENTERAL LIQUID PEPTIDE FORMULA – Special Authority see [SA1953 below](#) – Hospital pharmacy [HP3]

Liquid 1 kcal/ml, 500 ml bottle	12.44	1 OP	✓ Nutrini Peptisorb
Liquid 1.5 kcal/ml, 500 ml bottle	18.66	1 OP	✓ Nutrini Peptisorb Energy

►SA1953 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and
- 2 Any of the following:
 - 2.1 Severe malabsorption; or
 - 2.2 Short bowel syndrome; or
 - 2.3 Intractable diarrhoea; or
 - 2.4 Biliary atresia; or
 - 2.5 Cholestatic liver diseases causing malabsorption; or
 - 2.6 Cystic fibrosis; or
 - 2.7 Proven fat malabsorption; or
 - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
 - 2.9 Intestinal failure; or
 - 2.10 Both:
 - 2.10.1 The patient is currently receiving funded amino acid formula; and
 - 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
- 3 Either:
 - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
 - 3.2 For step down from intravenous nutrition.

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula; and
- 3 General practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

EXTENSIVELY HYDROLYSED FORMULA – Special Authority see [SA1557 on the next page](#) – Hospital pharmacy [HP3]

Powder	18.10	450 g OP	✓ Pepti-Junior
	36.20	900 g OP	✓ Allerpro Syneo 1
			✓ Allerpro Syneo 2

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1557 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 All of the following:
 - 11.1 For step down from Amino Acid Formula; and
 - 11.2 The infant is currently receiving funded amino acid formula; and
 - 11.3 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
 - 11.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Fluid Restricted

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Special Authority see [SA1698 below](#) – Hospital pharmacy [HP3]

Liquid, 125 ml bottle2.80 1 OP ✓ **Infatrini**

►SA1698 Special Authority for Subsidy

Initial application only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth; and
- 2 Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Renewal only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient continues to be fluid restricted or volume intolerant and has faltering growth; and
- 2 Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Ketogenic Diet

►SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see [SA1197 above](#) – Hospital pharmacy [HP3]

Powder (unflavoured)	36.92	300 g OP	✓ KetoCal 4:1
			✓ Ketocal 3:1
Powder (vanilla)	36.92	300 g OP	✓ KetoCal 4:1

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Vaccinations

BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm]

For infants at increased risk of tuberculosis. Increased risk is defined as:

- 1) living in a house or family with a person with current or past history of TB; or
- 2) having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or
- 3) during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000

Note a list of countries with high rates of TB are available at www.health.govt.nz/tuberculosis (search for downloads) or www.bcgatlas.org/index.php.

Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin),

Danish strain 1331, live attenuated, vial with diluent.....	0.00	10	✓ BCG Vaccine AJV
---	------	----	--------------------------

COVID-19 VACCINE – [Xpharm]

Inj 3 mcg bretovameran per 0.3 ml, 0.48 ml vial; infant vaccine, yellow cap.....	0.00	10	✓ Comirnaty Omicron (JN.1)
---	------	----	---------------------------------------

Up to three doses for previously unvaccinated children aged 6 months - 4 years at high risk of severe illness.

Inj 10 mcg bretovameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap	0.00	10	✓ Comirnaty Omicron (JN.1)
---	------	----	---------------------------------------

Either:

- 1) One dose for previously unvaccinated children aged 5–11 years old; or
- 2) Up to three doses for immunocompromised children aged 5–11 years old.

Inj 30 mcg bretovameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap	0.00	10	✓ Comirnaty Omicron (JN.1)
--	------	----	---------------------------------------

Any of the following:

- 1) One dose for previously unvaccinated people aged 12–15 years old; or
- 2) Up to three doses for immunocompromised people aged 12–15 years old; or
- 3) Up to two doses for previously unvaccinated people 16–29 years old; or
- 4) Up to four doses for people aged 16–29 at high risk of severe illness; or
- 5) One dose for previously unvaccinated people aged 30 and older; or
- 6) One additional dose every 6 months for previously vaccinated people aged 30 years and over – additional dose is given at least 6 months after last dose.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Funded for any of the following criteria:				
1) A single dose for pregnant women in the second or third trimester of each pregnancy; or				
2) A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or				
3) A course of up to four doses is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or				
4) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or				
5) A single dose for vaccination of patients aged from 65 years old; or				
6) A single dose for vaccination of patients aged from 45 years old who have not had 4 previous tetanus doses; or				
7) For vaccination of previously unimmunised or partially immunised patients; or				
8) For revaccination following immunosuppression; or				
9) For boosting of patients with tetanus-prone wounds.				
Notes: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.				
B) Contractors will be entitled to claim payment from the Funder for the supply of diphtheria, tetanus and pertussis vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the diphtheria, tetanus and pertussis vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs 1 – 9 above.				
Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml prefilled syringe	0.00	10	✓	<u>Boostrix</u>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c)
 - A) Funded for any of the following:
 - 1) A single dose for children up to the age of 7 who have completed primary immunisation; or
 - 2) A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
 - 3) An additional four doses (as appropriate) are funded for (re-)immunisation for people post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
 - 4) Five doses will be funded for children requiring solid organ transplantation.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis and polio vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis and polio vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe 0.00 10 ✓ **Infanrix IPV**

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c)
 - A) Funded for children meeting any of the following criteria
 - 1) Up to four doses for children under the age of 10 years for primary immunisation; or
 - 2) An additional four doses (as appropriate) for (re-)immunisation of children under the age of 18 years post haematopoietic stem cell transplantation; or
 - 3) An additional four doses (as appropriate) for (re-)immunisation of children under the age of 10 years who are post chemotherapy; pre or post splenectomy; undergoing renal dialysis and other severely immunosuppressive regimens; or
 - 4) Up to five doses for children under the age of 10 years receiving solid organ transplantation.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Inj 30IU diphtheria with 40IU tetanus and 25mcg pertussis toxoids, 25mcg pertussis filamentous haemagglutinin, 8mcg pertactin, 80D-AgU polio virus, 10mcg hepatitis B antigen, 10mcg H. influenzae type b with tetanus toxoid 20-40mcg in 0.5ml syringe 0.00 10 ✓ **Infanrix-hexa**

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

HAEMOPHILUS INFLUENZAE TYPE B VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c)
 - A) One dose for people meeting any of the following:
 - 1) For primary vaccination in children; or
 - 2) An additional dose (as appropriate) is funded for (re-)immunisation for people post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
 - 3) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Inj 10 mcg vial with diluent syringe 0.00 1 ✓ **Act-HIB**

HEPATITIS A VACCINE – [Xpharm]

Funded for patients meeting any of the following criteria:

- 1) Two vaccinations for use in transplant patients; or
- 2) Two vaccinations for use in children with chronic liver disease; or
- 3) One dose of vaccine for close contacts of known hepatitis A cases.

Inj 1440 ELISA units in 1 ml syringe 0.00 1 ✓ **Havrix 1440**
 Inj 720 ELISA units in 0.5 ml syringe 0.00 1 ✓ **Havrix Junior**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HEPATITIS B RECOMBINANT VACCINE – [Xpharm]				
Inj 10 mcg per 0.5 ml prefilled syringe.....	0.00	1	✓	<u>Engerix-B</u>
Funded for patients meeting any of the following criteria:				
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or 2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or 3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or 4) for HIV positive patients; or 5) for hepatitis C positive patients; or 6) for patients following non-consensual sexual intercourse; or 7) for patients prior to planned immunosuppression for greater than 28 days; or 8) for patients following immunosuppression; or 9) for solid organ transplant patients; or 10) for post-haematopoietic stem cell transplant (HSCT) patients; or 11) following needle stick injury.				
Inj 20 mcg per 1 ml prefilled syringe.....	0.00	1	✓	<u>Engerix-B</u>
Funded for patients meeting any of the following criteria:				
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or 2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or 3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or 4) for HIV positive patients; or 5) for hepatitis C positive patients; or 6) for patients following non-consensual sexual intercourse; or 7) for patients prior to planned immunosuppression for greater than 28 days; or 8) for patients following immunosuppression; or 9) for solid organ transplant patients; or 10) for post-haematopoietic stem cell transplant (HSCT) patients; or 11) following needle stick injury; or 12) for dialysis patients; or 13) for liver or kidney transplant patients.				

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV]				
a) Maximum of 1 inj per prescription b) Only on a prescription c) No patient co-payment payable d)				
a) A) Any of the following: 1) Maximum of two doses for children aged 14 years and under; or 2) Maximum of three doses for people meeting any of the following criteria: 1) People aged 15 to 26 years inclusive; or 2) Either: - People aged 9 to 26 years inclusive who have 1) Confirmed HIV infection; or 2) Received a transplant (including stem cell): or 3) Maximum of four doses for people aged 9 to 26 years inclusive post chemotherapy				
B) Contractors will be entitled to claim payment from the Funder for the supply of Human papillomavirus vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Human papillomavirus vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A above.				
Inj 270 mcg in 0.5 ml syringe.....	0.00	10	✓	<u>Gardasil 9</u>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised ✓	Brand or Generic Manufacturer
INFLUENZA VACCINE			
Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).....	120.00	10	✓ Influvac Tetra (2025 formulation)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
a) Maximum of 1 inj per prescription				
b) Only on a prescription				
c) No patient co-payment payable				
d)				
A) INFLUENZA VACCINE				
is available each year for patients who meet the following criteria, as set by Pharmac:				
a) all people 65 years of age and over; or				
b) people under 65 years of age who:				
i) have any of the following cardiovascular diseases:				
a) ischaemic heart disease, or				
b) congestive heart failure, or				
c) rheumatic heart disease, or				
d) congenital heart disease, or				
e) cerebo-vascular disease; or				
ii) have either of the following chronic respiratory diseases:				
a) asthma, if on a regular preventative therapy, or				
b) other chronic respiratory disease with impaired lung function; or				
iii) have diabetes; or				
iv) have chronic renal disease; or				
v) have any cancer, excluding basal and squamous skin cancers if not invasive; or				
vi) have any of the following other conditions:				
a) autoimmune disease, or				
b) immune suppression or immune deficiency, or				
c) HIV, or				
d) transplant recipients, or				
e) neuromuscular and CNS diseases/disorders, or				
f) haemoglobinopathies, or				
g) are children on long term aspirin, or				
h) have a cochlear implant, or				
i) errors of metabolism at risk of major metabolic decompensation, or				
j) pre and post splenectomy, or				
k) Down syndrome, or				
vii) are pregnant; or				
c) children 4 years of age and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or				
d) people under 65 years of age who:				
i) have any of the following serious mental health conditions:				
a) schizophrenia, or				
b) major depressive disorder, or				
c) bipolar disorder, or				
d) schizoaffective disorder, or				
ii) are currently accessing secondary or tertiary mental health and addiction services; or				
Unless meeting the criteria set out above, the following conditions are excluded from funding:				
a) asthma not requiring regular preventative therapy,				
b) hypertension and/or dyslipidaemia without evidence of end-organ disease.				
B) Contractors will be entitled to claim payment for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
MEASLES, MUMPS AND RUBELLA VACCINE			
a) Only on a prescription			
b) No patient co-payment payable			
c)			
A) Measles, mumps and rubella vaccine			
A maximum of two doses for any patient meeting the following criteria:			
1) For primary vaccination in children; or			
2) For revaccination following immunosuppression; or			
3) For any individual susceptible to measles, mumps or rubella; or			
4) A maximum of three doses for children who have had their first dose prior to 12 months.			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes. Although a price is listed for the vaccine, doctors can still order measles mumps and rubella vaccine free of charge, as with other Schedule vaccines.			
B) Contractors will be entitled to claim payment for the supply of measles, mumps and rubella vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the measles, mumps and rubella vaccine listed in the Pharmaceutical Schedule.			
C) Contractors can only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.			
Inj, measles virus 1,000 CCID ₅₀ , mumps virus 5,012 CCID ₅₀ , Rubella virus 1,000 CCID ₅₀ ; prefilled syringe/ampoule of diluent 0.5 ml	0.00	10	✓ Priorix

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE VACCINE				
Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial	0.00	1	✓	MenQuadfi
a) Only on a prescription b) No patient co-payment payable c)				
A) Any of the following: - Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or - One dose for close contacts of meningococcal cases of any group; or - One dose for person who has previously had meningococcal disease of any group; or - A maximum of two doses for bone marrow transplant patients; or - A maximum of two doses for person pre- and post-immunosuppression*; or				
B) Both: - Person is aged between 13 and 25 years, inclusive; and - Either: - One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences, or prisons; or - One dose for individuals who turn 13 years of age while living in boarding school hostels.				
C) Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal A, C, Y and W-135 vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Meningococcal A, C, Y and W-135 vaccine listed in the Pharmaceutical Schedule.				
D) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-B above.				
Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.				
Inj 5 mcg of each meningococcal polysaccharide conjugated to a total of approximately 44 mcg of tetanus toxoid carrier per 0.5 ml vial – [Xpharm].....	0.00	1	✓	Nimenrix
A) Both: - The child is under 12 months of age; and - Any of the following: - A maximum of three doses (dependant on age at first dose) for patients pre- and post- splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post- solid organ transplant; or - A maximum of three doses (dependant on age at first dose) for close contacts of meningococcal cases of any group; or - A maximum of three doses (dependant on age at first dose) for child who has previously had meningococcal disease of any group; or - A maximum of three doses (dependant on age at first dose) for bone marrow transplant patients; or - A maximum of three doses (dependant on age at first dose) for child pre- and post-immunosuppression*.				
Note: infants from 6 weeks to less than 6 months of age require a 2+1 schedule, infants from 6 months to less than 12 months of age require a 1+1 schedule. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
MENINGOCOCCAL B MULTICOMPONENT VACCINE			
a) Only on a prescription b) No patient co-payment payable c) Any of the following: A) A primary course of up to three doses for children up to the age of 59 months inclusive; or B) Both: 1) Person is 5 years of age or over; and 2) Any of the following: i) up to two doses and a booster every five years for patients pre- and post-splenectomy; or ii) up to two doses and a booster every five years for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited); or iii) up to two doses and a booster every five years pre- or post-solid organ transplant; or iv) up to two doses for close contacts of meningococcal cases of any group; or v) up to two doses for person who has previously had meningococcal disease of any group; or vi) up to two doses for bone marrow transplant patients; or vii) up to two doses for person pre- and post-immunosuppression*; or C) Both: 1) Person is aged between 13 and 25 years (inclusive); and 2) Either: i) Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences or prison; or ii) Two doses for individuals who turn 13 years of age while living in boarding school hostels. D) Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal B multicomponent vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Meningococcal B multicomponent vaccine listed in the Pharmaceutical Schedule. E) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-C above. *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.			
Inj 175 mcg per 0.5 ml prefilled syringe.....	0.00	1 10	✓ Bexsero ✓ Bexsero

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Any of the following:				
1) A course of three doses for previously unvaccinated children up to the age of 59 months inclusive; or				
2) Two doses are funded for high risk individuals (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10; or				
3) Up to an additional four doses (as appropriate) are funded for the (re)immunisation of high risk children aged under 5 years with any of the following:				
a) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or				
b) primary immune deficiencies; or				
c) HIV infection; or				
d) renal failure, or nephrotic syndrome; or				
e) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or				
f) cochlear implants or intracranial shunts; or				
g) cerebrospinal fluid leaks; or				
h) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or				
i) chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or				
j) pre term infants, born before 28 weeks gestation; or				
k) cardiac disease, with cyanosis or failure; or				
l) diabetes; or				
m) Down syndrome; or				
n) who are pre-or post-splenectomy, or with functional asplenia; or				
4) Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency; or				
5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.				
B) Contractors will be entitled to claim payment from the Funder for the supply of Pneumococcal (PCV13) conjugate vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Pneumococcal (PCV13) conjugate vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				
Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes				
Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml				
syringe	0.00	10	✓	Prevenar 13
		1	✓	Prevenar 13

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – [Xpharm]

Any of the following:

- 1) Up to three doses (as appropriate) for patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
- 2) All of the following:
 - a) Patient is a child under 18 years for (re-)immunisation; and
 - b) Treatment is for a maximum of two doses; and
 - c) Any of the following:
 - i) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - ii) with primary immune deficiencies; or
 - iii) with HIV infection; or
 - iv) with renal failure, or nephrotic syndrome; or
 - v) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - vi) with cochlear implants or intracranial shunts; or
 - vii) with cerebrospinal fluid leaks; or
 - viii) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - ix) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - x) pre term infants, born before 28 weeks gestation; or
 - xi) with cardiac disease, with cyanosis or failure; or
 - xii) with diabetes; or
 - xiii) with Down syndrome; or
 - xiv) who are pre-or post-splenectomy, or with functional asplenia; or
- 3) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each

23 pneumococcal serotype) 0.00

1

✓ **Pneumovax 23**

POLIOMYELITIS VACCINE – [Xpharm]

Up to three doses for patients meeting either of the following:

- 1) For partially vaccinated or previously unvaccinated individuals; or
- 2) For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.

Inj 80D antigen units in 0.5 ml syringe..... 0.00

1

✓ **IPOL**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ROTAVIRUS ORAL VACCINE				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Maximum of two doses for people meeting the following:				
1) first dose to be administered in infants aged under 14 weeks of age; and				
2) no vaccination being administered to children aged 24 weeks or over.				
B) Contractors will be entitled to claim payment from the Funder for the supply of Rotavirus oral vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Rotavirus oral vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				
Oral susp live attenuated human rotavirus				
1,000,000 CCID50 per dose, squeezable tube0.00		10	✓	Rotarix
Oral susp live attenuated human rotavirus				
1,000,000 CCID50 per dose, squeezable tube (PVC free)0.00		10	✓	Rotarix
Oral susp live attenuated human rotavirus				
1,000,000 CCID50 per dose, prefilled oral applicator.....0.00		10	✓	<u>Rotarix</u>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
VARICELLA VACCINE [CHICKENPOX VACCINE]			
a) Only on a prescription b) No patient co-payment payable c)			
A) Either: 1) Maximum of one dose for primary vaccination for either: a) Any infant born on or after 1 April 2016; or b) For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox), or 2) Maximum of two doses for any of the following: a) Any of the following for non-immune individuals: i) with chronic liver disease who may in future be candidates for transplantation; or ii) with deteriorating renal function before transplantation; or iii) prior to solid organ transplant; or iv) prior to any elective immunosuppression*; or v) for post exposure prophylaxis who are immune competent inpatients; or b) For individuals at least 2 years after bone marrow transplantation, on advice of their specialist; or c) For individuals at least 6 months after completion of chemotherapy, on advice of their specialist; or d) For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or e) For individuals with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or f) For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or g) For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.			
B) Contractors will be entitled to claim payment from the Funder for the supply of Varicella vaccine [Chickenpox vaccine] vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Varicella vaccine [Chickenpox vaccine] listed in the Pharmaceutical Schedule.			
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A above.			
* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days			
Inj 2000 PFU prefilled syringe plus vial	0.00	10	✓ Varilrix

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
VARICELLA ZOSTER VACCINE [SHINGLES VACCINE]				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Funded for patients meeting the following criteria:				
1) Either:				
1) Two doses for all people aged 65 years, or				
2) Two doses for people 18 years of age or older with any of the following:				
a) pre- and post-haematopoietic stem cell transplant or cellular therapy; or				
b) pre- or post-solid organ transplant; or				
c) haematological malignancies; or				
d) people living with poorly controlled HIV infection; or				
e) planned or receiving disease modifying anti-rheumatic drugs (DMARDs – targeted synthetic, biologic, or conventional synthetic) for polymyalgia rheumatica, systemic lupus erythematosus or rheumatoid arthritis; or				
f) end stage kidney disease (CKD 4 or 5); or				
g) primary immunodeficiency				
B) Contractors will be entitled to claim payment from the Funder for the supply of Varicella zoster vaccine (Shingles vaccine) to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Varicella zoster vaccine [Shingles vaccine] listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				
Inj 50 mcg per 0.5 ml vial plus vial.....	0.00	1 10	✓ ✓	Shingrix Shingrix

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST – [Xpharm]				
Inj 5 TU per 0.1 ml, 1 ml vial.....	0.00	1	✓	<u>Tubersol</u>

- Symbols -		
3TC.....	114	
- A -		
A-Scabies.....	72	
Abacavir sulphate.....	114	
Abacavir sulphate with lamivudine.....	114	
Abacavir/Lamivudine Viatris.....	114	
Abilify Maintena.....	138	
Abiraterone acetate.....	178	
Acarbose.....	11	
Accarb.....	11	
Acetazolamide.....	279	
Acetec.....	46	
Acetic acid with hydroxyquinoline and ricinoleic acid.....	80	
Acetylcysteine.....	282	
Aci-Jel.....	80	
Aciclovir Infection.....	108	
Sensory.....	277	
Acidex.....	6	
Acipimox.....	53	
Acitretin.....	73	
Act-HIB.....	312	
Actemra.....	239	
Actinomycin D.....	159	
Actrapid.....	10	
Actrapid Penfill.....	10	
Acupan.....	126	
Adalimumab (Amgevita).....	189	
Adalimumab (Humira - Alternative brand).....	197	
Adapalene.....	67	
Adcetris.....	207	
ADR Cartridge 1.8.....	22	
Adrenaline Cardiovascular.....	55	
Respiratory.....	266	
Advantan.....	70	
Advate.....	39	
Adynovate.....	39	
Afinitor.....	260	
Aflibercept.....	204	
AFT-Pyrazinamide.....	108	
Agents Affecting the Renin-Angiotensin System.....	46	
Agents for Parkinsonism and Related Disorders.....	124	
Agents Used in the Treatment of Poisonings.....	282	
Agrylin.....	158	
Albalon.....	281	
Albendazole.....	95	
Albey.....	267	
Albustix.....	82	
Alchemy Oxaliplatin.....	155	
Alchemy Oxybutynin.....	82	
Aldurazyme.....	28	
Alecensa.....	166	
Alectinib.....	166	
Alendronate sodium.....	120	
Alendronate sodium with colecalciferol.....	120	
Alfacalcidol.....	32	
Alfamino.....	304	
Alfamino Junior.....	304	
Alginic acid.....	6	
Alglucosidase alfa.....	26	
Alkeran.....	155	
Allegron.....	130	
Allerfix.....	279	
Allerpro Syneo 1.....	306	
Allerpro Syneo 2.....	306	
Allersoothe.....	267	
Allmercap.....	157	
Allopurinol.....	122	
Almarytm.....	48	
Alpha-Adrenoceptor Blockers.....	46	
Alpha-Keri Lotion.....	71	
Alphamox 125.....	98	
Alphamox 250.....	98	
Alprolix.....	37	
Alu-Tab.....	6	
Aluminium hydroxide.....	6	
Alyacen.....	79	
Amantadine hydrochloride.....	124	
Ambrisentan.....	56	
Ambrisentan Viatris.....	56	
Amgevita.....	189	
Amiloride hydrochloride.....	52	
Amiloride hydrochloride with furosemide.....	52	
Amiloride hydrochloride with hydrochlorothiazide.....	52	
Aminophylline.....	274	
Amiodarone hydrochloride.....	48	
Amisulpride.....	136	
Amitriptyline.....	130	
Amlodipine.....	50	
Amorolfine.....	68	
Amoxicillin.....	98	
Amoxicillin with clavulanic acid.....	98	
Amoxiclav Devatis Forte.....	98	
Amphotericin B.....	32	
Amsacrine.....	158	
AmsaLyo.....	158	
Amsidine.....	158	
Amzoate.....	30	
Anaesthetics.....	125	
Anagrelide hydrochloride.....	158	
Analgesics.....	126	
Anastrozole.....	181	
Anatrole.....	181	
Anoro Ellipta.....	271	
Antabuse.....	151	
Antacids and Antiflatulents.....	6	
Anthelmintics.....	95	
Antiacne Preparations.....	67	
Antiallergy Preparations.....	266	
Antianaemics.....	36	
Antiandrogen Oral Contraceptives.....	80	
Antiarrhythmics.....	48	
Antibacterials.....	95	
Antibacterials Topical.....	67	
Anticholinergic Agents.....	270	
Anticholinesterases.....	119	
Antidepressants.....	130	
Antidiarrhoeals.....	6	
Antiepilepsy Drugs.....	131	
Antifibrinolytics, Haemostatics and Local Sclerosants.....	37	
Antifibrotics.....	272	
Antifungals.....	102	
Antifungals Topical.....	68	
Antihistamines.....	267	
Antihypotensives.....	48	
Antimalarials.....	105	
Antimigraine Preparations.....	135	
Antinausea and Vertigo Agents.....	135	
Antipruritic Preparations.....	69	
Antipsychotics.....	136	
Antiretrovirals.....	112	
Antirheumatoid Agents.....	120	
Antispasmodics and Other Agents Altering Gut Motility.....	8	
Antithrombotic Agents.....	40	
Antithymocyte globulin (equine).....	188	
Antitrichomonal Agents.....	106	
Antituberculositics and Antileprotics.....	106	
Antulcerants.....	8	
Antivirals.....	108	
Anxiolytics.....	140	
Anzatax.....	163	
Apidra.....	11	
Apidra SoloStar.....	11	
APO Clomipramine.....	130	
APO Health Macrogol.....	25	
APO-Atomoxetine.....	145	

Apo-Azithromycin	96	Ativan.....	140	Benzylpenicillin sodium [Penicillin G].....	98
APO-Candesartan HCTZ 16/12.5.....	47	Atnabs Olsalazine.....	8	Besponsa.....	218
APO-Candesartan HCTZ 32/12.5.....	47	Atomoxetine.....	145	Beta Cream	69
Apo-Temozolomide	164	Atorvastatin.....	54	Beta Ointment.....	69
Apomorphine hydrochloride.....	124	Atropine sulphate Cardiovascular	48	Beta Scalp	74
Aprepitant	135	Sensory	280	Beta-Adrenoceptor Agonists.....	269
Apresoline.....	55	Atropt	280	Beta-Adrenoceptor Blockers.....	49
Aptamil Feed Thickener.....	298	Atrovent	270	Beta-hCG low sensitivity urine test kit.....	81
Aqueous cream	70	Augmentin	98	Betadine	71
Aratac	48	Aurorix	130	Betadine Skin Prep	71
Arava	120	AutoSoft 30.....	21	Betaferon	142
Arginine	26	AutoSoft 90.....	21	Betahistine dihydrochloride	135
Arginine2000	302	Avelox	100	Betaine	27
Aripiprazole.....	136, 138	Avonex.....	142	Betamethasone dipropionate.....	69
Aripiprazole Sandoz	136	Axitinib	167	Betamethasone dipropionate with calcipotriol.....	73
Aristocort	70	Azacididine	155	Betamethasone sodium phosphate with betamethasone acetate.....	84
Arrotex-Prazosin S29	46	Azacididine Dr Reddy's	155	Betamethasone valerate.....	69, 74
Arrow - Clopid	40	Azamun	181	Betamethasone valerate with sodium fusidate [fusidic acid]	70
Arrow - Lattin	280	Azathioprine	181	Betaxolol	279
Arrow-Amitriptyline	130	Azilect	124	Betnovate	69
Arrow-Bendrofluzide	52	Azithromycin	96	Betoptic	279
Arrow-Brimonidine	280	Azopt	279	Betoptic S	279
Arrow-Diazepam.....	140	AZT	114	Bevacizumab	206
Arrow-Doxorubicin	159	- B -		Bexsero	319
Arrow-Fluoxetine	131	B-D Micro-Fine	16	Bezafibrate	53
Arrow-Losartan & Hydrochlorothiazide	47	B-D Ultra Fine	17	Bezalip	53
Arrow-Norfloxacin	118	B-D Ultra Fine II.....	17	Bezalip Retard.....	53
Arrow-Ornidazole	106	Bacillus Calmette-Guerin (BCG) vaccine	189	Bicalutamide	179
Arrow-Quinapril 10.....	46	Bacillus Calmette-Guerin vaccine	309	Bicillin LA	98
Arrow-Quinapril 20.....	46	Baclofen.....	123	BiCNU.....	154
Arrow-Quinapril 5.....	46	Bactroban	67	Bile and Liver Therapy.....	10
Arrow-Roxithromycin	97	Balance.....	28	Biltricide	95
Arrow-Timolol	279	Barrier Creams and Emollients.....	70	Bimatoprost	279
Arrow-Tramadol	129	Bayshore	105	Binarex	179
Arsenic trioxide	158	BCG Vaccine AJV	309	Binocrit.....	36
Asacol	7	Beclazone 100.....	268	Biocon	49
Asacol S29	7	Beclazone 250.....	268	Biodone	128
Ascend-Cefuroxime	96	Beclazone 50.....	268	Biodone Extra Forte.....	128
Ascorbic acid	32	Beclomethasone dipropionate.....	268	Biodone Forte.....	128
Aspen Adrenaline	55	Bedaquiline	106	Bisacodyl	25
Aspirin		Bee venom allergy treatment.....	267	Bisacodyl Viatris	25
Blood.....	40	Bendamustine hydrochloride	153	Bisoprolol fumarate.....	49
Nervous.....	126	Bendamustine Sandoz	153	BK Lotion	71
Asthalin	270	Bendrofluzide.....	52	Bleomycin sulphate	158
Atazanavir Mylan	115	Bendroflumethiazide [Bendrofluzide].....	52	Blood Colony-stimulating Factors.....	43
Atazanavir sulphate	115	Benralizumab	205	Blood glucose diagnostic test meter	15
Atazanavir Viatris.....	115	Benzathine benzylpenicillin	98	Blood glucose diagnostic test strip.....	16
Atenolol.....	49	Benzatropine mesylate	124	Blood glucose test strips (visually	
Atenolol AFT	49	Benzbromarone	122		
Atenolol Viatris.....	49	Benzetacil	98		
Atezolizumab	249	Benztrop	124		
ATGAM.....	188	Benzylamine hydrochloride	31		

impaired).....	16	Calogen.....	288	Charcoal.....	282
Blood Ketone Diagnostic Test Strip.....	14	Camber.....	55	CheckTop.....	81
Boostrix.....	310	Candesartan cilexetil.....	47	Chemotherapeutic Agents.....	153
Bortezomib.....	159	Candesartan cilexetil with hydrochlorothiazide.....	47	Chickenpox vaccine.....	323
Bosentan.....	59	Candestar.....	47	Chlorafast.....	277
Bosentan Dr Reddy's.....	59	Canesten.....	68	Chlorambucil.....	154
Bplex.....	32	Capecitabine.....	156	Chloramphenicol.....	277
Brentuximab Vedotin.....	207	Capecitabine Viatris.....	156	Chlorothiazide.....	52
Breo Ellipta.....	269	Capsaicin.....		Chlorpromazine hydrochloride.....	136
Brevinor 1/28.....	79	Musculoskeletal.....	120	Chlorsig.....	277
Breztri Aerosphere.....	271	Nervous.....	126	Chlortalidone [Chlorthalidone].....	52
Bricanyl Turbuhaler.....	270	Captopril.....	46	Chlorthalidone.....	52
Brimonidine tartrate.....	280	Carafate.....	9	Chlorvescent.....	44
Brimonidine tartrate with timolol maleate.....	280	Carbaccord.....	154	Choice 380 7med Nsha Silver/copper Short.....	78
Brinzolamide.....	279	Carbamazepine.....	132	Ciclosporin.....	260
Budesonide.....		Carbimazole.....	89	Cidomycin P/Free.....	100
Alimentary.....	6	Carboplatin.....	154	Cilicaine VK.....	99
Respiratory.....	268, 275	Carboplatin Accord.....	154	Cinacalcet.....	83
Budesonide Te Arai.....	6	Carbosorb-X.....	282	Cinacalcet Devatis.....	83
Budesonide with eformoterol.....	269	Cardinol LA.....	50	Ciprofloxacin Infection.....	100
Budesonide with glycopyrronium and eformoterol.....	271	Cardizem CD.....	51	Sensory.....	277
Bumetanide.....	51	CareSens Dual.....	15	Ciprofloxacin Teva.....	277
Buprenorphine Naloxone BNM.....	150	CareSens N.....	15-16	Cisplatin.....	154
Buprenorphine with naloxone.....	150	CareSens N POP.....	15	Cisplatin Accord.....	154
Bupropion hydrochloride.....	150	CareSens N Premier.....	15	Cisplatin Ebewe.....	154
Burel.....	103	CareSens PRO.....	16	Citalopram hydrobromide.....	130
Burinex.....	51	Carmellose sodium with gelatin and pectin.....	31	Citrulline1000.....	303
Buspirone hydrochloride.....	140	Carmustine.....	154	Cladribine.....	156
Buspirone Viatris.....	140	Carvedilol.....	49	Clarithromycin Alimentary.....	9
Busulfan.....	154	Carvedilol Sandoz.....	49	Infection.....	96
- C -		Catapres.....	51	Clexane.....	41
Cabergoline.....	94	Cefaclor monohydrate.....	95	Clexane Forte.....	41
Caffeine citrate.....	276	Cefalexin.....	95	Clexane Forte.....	41
Calamine.....	69	Cefalexin Sandoz.....	95	Clindamycin.....	100
Calci-Tab 500.....	33	Cefazolin.....	95	Clinicians.....	26, 32
Calcipotriol.....	73	Cefazolin-AFT.....	95	Clinicians Renal Vit.....	33
Calcitonin.....	83	Ceftriaxone.....	95	Clobazam.....	132
Calcitriol.....	32	Ceftriaxone-AFT.....	95	Clobetasol propionate.....	69, 74
Calcitriol XL.....	32	Cefuroxime axetil.....	96	Clobetasone butyrate.....	69
Calcitriol-AFT.....	32	Celapram.....	130	Clofazimine.....	106
Calcium 500 mg Hexal.....	33	Celebrex.....	119	Clomazol Dermatological.....	68
Calcium carbonate.....	6, 33	Celecoxib.....	119	Genito-Urinary.....	80
Calcium carbonate PAI.....	6	Celecoxib Pfizer.....	119	Clomifene citrate.....	94
Calcium Channel Blockers.....	50	Celestone Chronodose.....	84	Clomipramine hydrochloride.....	130
Calcium Disodium Versenate.....	283	Cellcept.....	181	Clomipramine Teva.....	130
Calcium folinate.....	156	Centrally-Acting Agents.....	51	Clonazepam.....	132, 140
Calcium Folate Ebewe.....	156	Cephalexin ABM.....	95	Clonidine.....	51
Calcium Folate Sandoz.....	156	Cerazette.....	79	Clonidine hydrochloride.....	51
Calcium Folate Sandoz S29.....	156	Cetirizine hydrochloride.....	267	Clonidine Teva.....	51
Calcium gluconate.....	33	Cetomacrogol.....	70	Clopidogrel.....	40
Calcium Homeostasis.....	83	Cetomacrogol with glycerol.....	71	Clopine.....	137
Calcium polystyrene sulphonate.....	44	Cetomacrogol-AFT.....	70	Clopixol.....	138, 140
Calcium Resonium.....	44	Cetuximab.....	208		
		Champix.....	151		

Clotrimazole		Crizotinib	167	DBL Docetaxel	159
Dermatological	68	Crotamiton	69	DBL Ergometrine	80
Genito-Urinary	80	Crystaderm	67	DBL Gemcitabine	157
Clozapine	137	Cu 375 Standard	78	DBL Gentamicin	100
Clozaril	137	Curam Duo 500/125	98	DBL Leucovorin Calcium	156
Clustran	135	Cvite	32	DBL Methotrexate Onco-Vial	158
Co-trimoxazole	102	Cyclizine hydrochloride	135	DBL Naloxone Hydrochloride	282
Coal tar	73	Cyclizine lactate	135	DBL Pethidine Hydrochloride	129
Coal tar with allantoin, menthol, phenol and sulphur	73	Cyclogyl	280	DBL Vincristine Sulfate	166
Coal tar with salicylic acid and sulphur	73	Cyclonex	154	Decozol	32
Coco-Scalp	73	Cyclopentolate hydrochloride	280	Deferasirox	282
Codeine phosphate	128	Cyclophosphamide	154	Deferiprone	283
Coenzyme Q10	27	Cyclorin	106	Denosumab	120
Colchicine	123	Cycloserine	106	Deolate	104
Colecalciferol	32	Cyklokapron	39	Deoxycoformycin	163
Colestyramine	53	Cyproterone acetate	85	Depo-Medrol	85
Colestyramine - Mylan	53	Cyproterone acetate with ethinyloestradiol	80	Depo-Provera	80
Colgout	123	Cystadane	27	Depo-Testosterone	85
Colifoam	7	Cytarabine	157	Deprim	102
Colistin sulphomethate	100	Cytotec	8	Dermol	69, 74
Collodion flexible	285	Cytoxan	154	Desferrioxamine mesilate	283
Colloidal bismuth subcitrate	9	- D -		Desmopressin	94
Colofac	8	D-Penamine	120	Desmopressin acetate	94
Colomycin	100	Dabigatran	42	Desmopressin-PH&T	94
Coloxyl	24	Dabrafenib	167	Desogestrel	79
Combigan	280	Dacarbazine	159	Detection of Substances in Urine	82
Comirnaty Omicron (JN.1)	309	Dactinomycin [Actinomycin D]	159	Dexamethasone	
Compound electrolytes	44	Daivobet	73	Hormone	84
Compound electrolytes with glucose [Dextrose]	44	Daivonex	73	Sensory	278
Compound hydroxybenzoate	285	Daktarin	68	Dexamethasone phosphate	84
Concerta	148	Dalacin C	100	Dexamethasone with framycetin and gramicidin	277
Condoms	77	Dantrium	123	Dexamethasone with neomycin sulphate and polymyxin B sulphate	278
Condyline	75	Dantrium S29	123	Dexamfetamine sulfate	146
Condyline S29	75	Dantrolene	123	Dexcom G6	22
Continuous glucose monitor (interoperable)	22	Daonil	11	Dexcom G7	22
Continuous glucose monitor (standalone)	23	Dapa-Tabs	53	Dexcom ONE+	23
Contraceptives - Hormonal	78	Dapsone	107	Dexmethsone	84
Contraceptives - Non-hormonal	76	Darunavir	115	Dextrochlorpheniramine maleate	267
Copaxone	142	Darunavir Viatrix	115	Dextrose	43-44
Corticosteroids and Related Agents for Systemic Use	84	Dasatinib	169	DHC Continus	128
Corticosteroids Topical	69	Dasatinib-Teva	169	Diabetes	10
Cosentyx	236	Daunorubicin	159	Diabetes Management	14
Cosmegen	159	David One Step Cassette Pregnancy Test	81	Diacomit	133
Coumadin	43	DBL Acetylcysteine	282	Diagnostic Agents	324
Country Life	29	DBL Adrenaline	55	Diamide Relief	6
Coversyl	46	DBL Aminophylline	274	Diasip	289
COVID-19 vaccine	309	DBL Bleomycin Sulfate	158	Diazepam	131, 140
Creon 10000	23	DBL Bortezomib	159	Diazoxide	10
Creon 25000	23	DBL Carboplatin	154	Diclofenac Devatis	278
Creon Micro	23	DBL Carboplatin S29	154	Diclofenac Sandoz	119
		DBL Cisplatin	154		
		DBL Dacarbazine	159		
		DBL Desferrioxamine Mesylate for Inj BP	283		

Diclofenac sodium		Doxorubicin hydrochloride	159	Empagliflozin with metformin	
Musculoskeletal	119	Doxycycline	99	hydrochloride	14
Sensory	278	DP Lotion	71	Emsogen	303
Differin	67	DP Lotn HC	69	Emtricitabine	114
Diffiam	31	DP-Captopril	46	Emtricitabine with tenofovir	
Diffucan	102	Dr Reddy's Omeprazole	9	disoproxil	111
Digestives Including Enzymes	23	Drofate	50	Emtriva	114
Digoxin	48	Drugs Affecting Bone		Emulsifying ointment	71
Dihydrocodeine tartrate	128	Metabolism	120	Enalapril maleate	46
Dilantin	133	Dual blood glucose and blood ketone		Enbrel	182
Dilantin Infatab	133	diagnostic test meter	15	Endocrine Therapy	178
Dilantin Paediatric	133	Dulaglutide	12	Endoxan	154
Diltiazem CD Clinect	51	Dulcolax SP Drop	25	Energivit	303
Diltiazem hydrochloride	51	Duocal Super Soluble Powder	287	Engerix-B	313
Dimethicone	70, 72	Duolin	270	Enhertu	244
Dimethyl fumarate	141	Duolin HFA	270	Enlax XR	131
Dipentum	8	DuoResp Spiromax	269	Enoxaparin sodium	41
Diphtheria, tetanus and pertussis		Duride	55	Enstilar	73
vaccine	310	Durvalumab	250	Ensure	296
Diphtheria, tetanus, pertussis and		- E -		Ensure Plus	296
polio vaccine	311	e-chamber La Grande	276	Ensure Plus HN	295
Diphtheria, tetanus, pertussis, polio,		e-chamber Mask	276	Ensure Plus HN RTH	295
hepatitis B and haemophilus		e-chamber Turbo	276	Ensure Two Cal HN RTH	298
influenzae type B vaccine	311	E-Mycin	97	Entacapone	124
Diprosone	69	e5 Pharma	10	Entacapone Viatrix	124
Diprosone OV	69	Ear Preparations	277	Entecavir	108
Dipyridamole	40	Ear/Eye Preparations	277	Entecavir (Rex)	108
Dipyridamole - Strides	40	Easiphen Liquid	300	Entresto 24/26	47
Disopyramide phosphate	48	Econazole nitrate	68	Entresto 49/51	47
Distoside	95	Efavirenz	114	Entresto 97/103	47
Disulfiram	151	Efavirenz Milpharm	114	Entyvio	247
Diuretics	51	Efavirenz with emtricitabine and		Epilim	133
Docetaxel	159	tenofovir disoproxil	114	Epilim Crushable	133
Docetaxel Accord	159	Eformoterol fumarate dihydrate	268	Epilim IV	133
Docetaxel Sandoz	159	Eltrenonacog alfa [Recombinant		Epilim S/F Liquid	133
Docusate sodium	24	factor IX]	37	Epilim Syrup	133
Docusate sodium with		Efudix	75	Epipen	266
sennosides	24	Egopsoryl TA	73	Epipen Jr	266
Dolutegravir	115	Elaprase	28	Epirubicin Ebewe	159
Dolutegravir with lamivudine	115	Elecare	304	Epirubicin hydrochloride	159
Domperidone	135	Elecare LCP	304	Eplerenone	52
Domperidone Viatrix	135	Electral	44	Epoetin alfa	36
Donepezil hydrochloride	149	Elelyso	30	Epoprostenol	62
Dornase alfa	274	Elemental 028 Extra	292	Eptacog alfa [Recombinant factor	
Dortimopt	279	Elhexacafter with tezacafter, ivacafter		VIIa]	38
Dorzolamide with timolol	279	and ivacafter	274	Erbix	208
Dostinex	94	Elidel	73	Ergometrine maleate	80
Dosulepin [Dothiepin]		Elocon	70	Erlotinib	169
hydrochloride	130	Elocon Alcohol Free	70	Erythrocin IV	97
Dosulepin Viatrix	130	Eltrombopag	37	Erythromycin (as lactobionate)	97
Dothiepin	130	Eltroxin	89	Erythromycin ethyl succinate	97
Dovato	115	EMB Fatol	107	Esbriet	273
Doxazosin	46	Emend Tri-Pack	135	Escitalopram	131
Doxazosin Clinect	46	Emicizumab	38	Escitalopram (Ethics)	131
Doxine	99	EMLA	126	Eskazole	95
Doxorubicin Ebewe	159	Empagliflozin	14	Essential Amino Acid Mix	303

Essential Ethosuximide	132	Felodipine	50	Flutamide	179
Estraderm MX	87	Fentanyl	128	Flutamin	179
Estradiol Sandoz	87	Fentanyl Sandoz	128	Fluticasone	268
Estradiol TDP Mylan	87	Ferinject	34	Fluticasone furoate with umeclidinium and vilanterol	272
Estradiol Viatrix	87	Ferodan	34	Fluticasone furoate with vilanterol	269
Estradot	87	Ferriprox	283	Fluticasone propionate	275
Estrofem	87	Ferro-F-Tabs	34	Fluticasone with salmeterol	269
Estrogel	87	Ferro-Liquid	34	Flynn	95
Etanercept	182	Ferro-tab	34	FML	278
Ethambutol hydrochloride	107	Ferrograd	34	Foban	68
Ethics Aspirin	126	Ferrosig	35	Folic acid	37
Ethics Aspirin EC	40	Ferrous fumarate	34	Folic Acid multichem	37
Ethinylloestradiol with desogestrel	78	Ferrous fumarate with folic acid	34	Folic Acid Viatrix	37
Ethinylloestradiol with levonorgestrel	79	Ferrous sulfate	34	Food Thickeners	298
Ethinylloestradiol with norethisterone	79	Fexaclear	267	Foods And Supplements For Inherited Metabolic Disease	299
Ethosuximide	132	Fexofenadine hydrochloride	267	Fortini	291
Etopophos	159	Fibro-vein	39	Fortini Multi Fibre	291
Etoposide	159	Filgrastim	43	Fortisip	296
Etoposide phosphate	159	Finasteride	81	Fortisip Multi Fibre	297
Etavirine	114	Fingolimod	142	Fosamax	120
Eumovate	69	Firazyr	266	Fosamax Plus	120
Eurofolic	156	Flagyl	106	Fosfomycin	117
Evara	70-71	Flagyl-S	106	Framycetin sulphate	277
Evara Emulsifying Ointment	71	Flamazine	68	Freestyle Libre 2	23
EVARA White Soft Paraffin	71	Flecainide acetate	48	Freestyle Libre 2 Plus	23
Everet	133	Flecainide BNM	48	Freestyle Libre 3 Plus	22
Everolimus	260	Flecainide Controlled Release Teva	48	Frisium	132
Evista	121	Fleet Phosphate Enema	25	Frumil	52
Evrysdi	145	Flixonase Hayfever & Allergy	275	Fruclose	52
Exemestane	181	Flixotide	268	Fucicort	70
Exjade	282	Flixotide Accuhaler	268	Fucidin	101
Extemporaneously Compounded Preparations and Galenicals	285	Florinef	84	Fucithalmic	277
Eye Preparations	277	Fluanxol	139	Fucithalmic Canada (ON)	277
Eylea	204	Flucil	98	Fucithalmic Spain	277
Ezetimibe	55	Flucon	98	Fulvestrant	179
Ezetimibe Sandoz	55	Fluconazole	102	Fungilin	32
Ezetimibe with simvastatin	55	Fludara Oral	157	Furosemide [Frusemide]	52
- F -		Fludarabine Ebewe	157	Furosemide-Baxter	52
Factor eight inhibitor bypassing fraction	39	Fludarabine phosphate	157	fusidic acid Dermatological	68, 70
Famotidine	9	Fludarabine Sagent	157	Infection	101
Famotidine Hovid	9	Fludrocortisone acetate	84	Sensory	277
Famotidine Hovid MY	9	Fluids and Electrolytes	43	- G -	
Fasenra	205	Flumetasone pivalate	277	GA Explore 5	302
Faslodex	179	Fluocortolone caproate with fluocortolone pivalate and cinchocaine	8	GA1 Anamix Infant	302
Fatty Emulsion Cream (Evara)	71	Fluorometholone	278	GA1 Anamix Junior	302
Febuxostat	123	Fluorouracil	157	Gabapentin	132
Febuxostat (Teva)	123	Fluorouracil Accord	157	Gacet	127-128
FEIBA NF	39	Fluorouracil sodium	75	Galsulfase	27
Felo 10 ER	50	Fluox	131	Galvumet	12
Felo 5 ER	50	Fluoxetine hydrochloride	131	Galvus	12
		Flupenthixol decanoate	139	Gardasil 9	314
				Gastrodenol	9

Gaviscon Extra Strength.....	6	HCU Anamix Junior LQ.....	299	Hydrocortisone butyrate.....	70, 74
Gaviscon Infant.....	6	HCU Explore 5.....	299	Hydrocortisone with cinchocaine.....	8
Gazyva.....	220	HCU Express 15.....	299	Hydrocortisone with miconazole.....	70
Gefitinib.....	170	HCU Lophlex LQ.....	299	Hydrocortisone with natamycin and neomycin.....	70
Gemcitabine Ebewe.....	157	healthE Calamine Aqueous.....	69	Hydrogen peroxide.....	67
Gemcitabine hydrochloride.....	157	healthE Dimethicone 10%.....	70	Hydroxocobalamin.....	32
Gemtuzumab ozogamicin.....	209	healthE Dimethicone 4% Lotion.....	72	Hydroxocobalamin Panpharma.....	32
Gentamicin Amdipharm.....	100	healthE Dimethicone 5%.....	70	hydroxycarbamide.....	160
Gentamicin Noridem.....	100	healthE Glycerol BP.....	285	Hydroxychloroquine sulphate.....	120
Gentamicin sulphate.....	100	healthE Urea Cream.....	71	Hydroxyurea	
Gilenya.....	142	Healtheries Simple Baking Mix.....	298	[hydroxycarbamide].....	160
Ginet.....	80	Hemastix.....	82	Hygroton.....	52
Glatiramer acetate.....	142	Hemibra.....	38	Hylo-Fresh.....	281
Glecaprevir with pibrentasvir.....	110	Heparin sodium.....	42	Hymenoptera.....	267
Glibenclamide.....	11	Heparin Sodium Panpharma.....	42	Hyoscine butylbromide.....	8
Gliclazide.....	11	Heparinised saline.....	42	Hyoscine Butylbromide	
Glipizide.....	11	Heparon Junior.....	290	(Adiramedica).....	8
Glizide.....	11	Hepatitis A vaccine.....	312	Hyoscine hydrobromide.....	135
Glucagen Hypokit.....	10	Hepatitis B recombinant vaccine.....	313	Hyperuricaemia and Antigout.....	122
Glucagon hydrochloride.....	10	Herzuma.....	242	Hypromellose.....	280
Glucerna Select.....	289	Hikma.....	48	Hypromellose with dextran.....	280
Glucose [Dextrose].....	43	Hikma Acetylcysteine.....	282	- I -	
Gluten Free Foods.....	298	Hikma-Propranolol.....	50	Ibiamox.....	98
Glycerin with sodium saccharin.....	285	Hiprex.....	118	Ibrance.....	173
Glycerin with sucrose.....	285	Histaclear.....	267	Ibrutinib.....	160
Glycerol		Holoxan.....	155	Ibuprofen.....	119
Alimentary.....	25	Horleys Bread Mix.....	299	Ibuprofen SR BNM.....	119
Extemporaneous.....	285	Horleys Flour.....	299	Icatibant.....	266
Glyceryl trinitrate		Hormone Replacement Therapy - Systemic.....	86	Idarubicin hydrochloride.....	160
Alimentary.....	8	HPV.....	314	Idursulfase.....	28
Cardiovascular.....	55	Humalog.....	11	Ifosfamide.....	155
Glycopyrronium.....	270	Humalog Mix 25.....	11	Iloprost.....	64
Glycopyrronium bromide.....	8	Humalog Mix 50.....	11	Imatinib mesilate.....	170
Glycopyrronium with indacaterol.....	271	Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV].....	314	Imatinib-Rex.....	170
Glycosade.....	302	Humatin.....	101	Imbruvica.....	160
Glytactin Bettermilk.....	301	Humira.....	197	Imfinzi.....	250
Gold Knight.....	77	HumiraPen.....	197	Imipramine Crescent.....	130
Gold Knight XL.....	77	Humulin 30/70.....	11	Imipramine hydrochloride.....	130
Goserelin.....	93	Humulin NPH.....	10	Imiquimod.....	75
Gynaecological Anti-infectives.....	80	Humulin R.....	10	Immune Modulators.....	115
- H -		Hyaluronic acid.....	281	Immunisation - Flu.....	282
Habitrol.....	151	Hydralazine.....	55	Immunisation Flu and Shingles.....	282
Haemophilus influenzae type B vaccine.....	312	Hydralazine hydrochloride.....	55	Immunisation Other.....	282
Haldol.....	139	Hydralyte - Lemonade.....	44	Immunosuppressants.....	181
Haldol Concentrate.....	139	Hydrocortisone		Incruse Ellipta.....	271
Haldol Decanoas.....	139	Dermatological.....	69	Indacaterol.....	268
Haloperidol.....	137	Hormone.....	84	Indapamide.....	53
Haloperidol decanoate.....	139	Hydrocortisone acetate.....	7	Infanrix IPV.....	311
Harvoni.....	110	Hydrocortisone acetate with pramoxine hydrochloride.....	7	Infanrix-hexa.....	311
Havrix 1440.....	312	Hydrocortisone and paraffin liquid and lanolin.....	69	Infant Formulae.....	303
Havrix Junior.....	312			Infatrin.....	307
Haylor syrup.....	267			Infliximab.....	209
HCU Anamix Infant.....	299			Influenza vaccine.....	315
HCU Anamix Junior.....	299			Influvac Tetra	
				(2025 formulation).....	315

Inhaled Corticosteroids.....	268	IPCA-Frusemide.....	52	Ketoconazole	
Inhaled Long-acting		Ipca-Hydroxychloroquine.....	120	Dermatological.....	74
Beta-adrenoceptor Agonists.....	268	IPCA-Metoprolol.....	49	Infection.....	103
Inlyta.....	167	IPCA-Propranolol.....	50	Ketogenic Diet.....	308
Inotuzumab ozogamicin.....	218	Ipilimumab.....	250	Ketoprofen.....	119
Inresa.....	35	IPOS.....	321	KetoSens.....	14
Inspra.....	52	Ipratropium bromide.....	270, 275	Keytruda.....	253
Instillagel Lido.....	125	Iressa.....	170	Kindergen.....	290
Insulin aspart.....	11	Irinotecan Actavis 100.....	157	Kisqali.....	174
Insulin aspart with insulin aspart		Irinotecan hydrochloride.....	157	Klacid	
protamine.....	10	Irinotecan-Rex.....	157	Alimentary.....	9
Insulin degludec with insulin		Iron (as ferric carboxymaltose).....	34	Infection.....	96
aspart.....	10	Iron polymaltose.....	35	Klaricid.....	96
Insulin glargine.....	11	Isentress.....	115	Kliogest.....	88
Insulin glulisine.....	11	Isentress HD.....	115	Kliovance.....	88
Insulin isophane.....	10	Ismo 20.....	55	Kogenate FS.....	39
Insulin isophane with insulin		Ismo 40 Retard.....	55	Konakion MM.....	40
neutral.....	11	Isoleucine50.....	303	Konakion MM Paediatric.....	40
Insulin lispro.....	11	Isoniazid.....	107	Konsyl-D.....	24
Insulin lispro with insulin lispro		Isoniazid Teva.....	107	Kuvan.....	29
protamine.....	11	Isoniazid with rifampicin.....	107		
Insulin neutral.....	10	Isoptin.....	51	- L -	
Insulin pen needles.....	16	Isoptin Retard.....	51	Labetalol.....	49
Insulin pump cartridge.....	18	Isoptin SR.....	51	Lacosamide.....	132
Insulin pump infusion set (steel		Isopto Carpine.....	280	Lactulose.....	25
cannula).....	18	Isosorbide mononitrate.....	55	Lacuna.....	28
Insulin pump infusion set (steel		Isotretinoin.....	67	Laevolac.....	25
cannula, straight insertion).....	19	Ispaghula (psyllium) husk.....	24	Lamictal.....	132
Insulin pump infusion set (teflon		Itch-Soothe.....	69	Lamivudine.....	108, 114
cannula).....	20	Itracap.....	103	Lamivudine Viatrix.....	114
Insulin pump infusion set (teflon		Itraconazole.....	103	Lamivudine/Zidovudine Viatrix.....	114
cannula, angle insertion with		Itraconazole Crescent.....	103	Lamotrigine.....	132
insertion device).....	21	Itraconazole Kent.....	103	Lamprene.....	106
Insulin pump infusion set (teflon		Itrazole.....	103	Lanoxin.....	48
cannula, flexible insertion with		Ivacaftor.....	275	Lanoxin PG.....	48
insertion device).....	21	Ivermectin.....	72	Lanoxin S29.....	48
Insulin pump infusion set (teflon				Lanreotide.....	181
cannula, straight insertion with		- J -		Lansoprazole.....	9
insertion device).....	21	Jadelle.....	79	Lantus.....	11
Insulin pump infusion set (teflon		Jakavi.....	175	Lantus SoloStar.....	11
cannula, variable insertion).....	21	Jardiamet.....	14	Lanvis.....	158
Insulin pump reservoir.....	22	Jardiance.....	14	Lanzol Relief.....	9
Insulin pump with algorithm.....	17	Jaydess.....	79	Largactil.....	136
Insulin syringes, disposable with		Jevity HiCal RTH.....	296	Laronidase.....	28
attached needle.....	17	Jevity RTH.....	296	Lasix.....	52
Intelence.....	114	Jinarc.....	53	Latanoprost.....	279
Interferon beta-1-alpha.....	142	Juno Pemetrexed.....	158	Latanoprost with timolol.....	280
Interferon beta-1-beta.....	142			Lax-Suppositories.....	25
Intra-uterine device.....	78	- K -		Lax-suppositories Glycerol.....	25
Invega Sustenna.....	139	Kadcyla.....	245	Laxatives.....	24
Invega Trinza.....	140	Kalydeco.....	275	Laxsol.....	24
Ipca-Allopurinol.....	122	Kemadrin.....	125	Ledipasvir with sofosbuvir.....	110
Ipca-Bisoprolol.....	49	Kenacomb.....	277	Leflunomide.....	120
Ipca-Ciprofloxacin.....	100	Kenacort-A 10.....	85	Lenalidomide (Viatrix).....	160
Ipca-Donepezil.....	149	Kenacort-A 40.....	85	Lenalidomide Viatrix.....	160
Ipca-Escitalopram.....	131	Kenalog in Orabase.....	32	Lenvatinib.....	170
		Ketocal 3:1.....	308	Lenvima.....	170
		KetoCal 4:1.....	308		

Letrole.....	181	Lopinavir/Ritonavir Mylan.....	115	Melphalan.....	155
Letrozole.....	181	Loprofin.....	302	Meningococcal (groups A, C, Y and W-135) conjugate vaccine.....	318
Leucine100.....	303	Loprofin Mix.....	301	Meningococcal B multicomponent vaccine.....	319
Leukeran FC.....	154	Lorafix.....	267	MenQuadfi.....	318
Leukotriene Receptor Antagonists.....	273	Loratadine.....	267	Menthol.....	69
Leuprorelin.....	93	Lorazepam.....	140	Mepolizumab.....	218
Leustatin.....	156	Lorstat.....	54	Mercaptopurine.....	157
Levetiracetam.....	133	Losartan Actavis.....	47	Mercilon 28.....	78
Levetiracetam-AFT.....	133	Losartan potassium.....	47	Mesalazine.....	7
Levocabastine.....	279	Losartan potassium with hydrochlorothiazide.....	47	Mesna.....	161
Levocarnitine.....	28	Lovir.....	108	Mestinon.....	119
Levodopa with benserazide.....	124	Loxamine.....	131	Metabolic Disorder Agents.....	26
Levodopa with carbidopa.....	124	Lucrin Depot 1-month.....	93	Metabolics.....	28
Levodopa with carbidopa and entacapone.....	124	Lucrin Depot 3-month.....	93	Metformin hydrochloride.....	11
Levomepromazine.....	137	LumaCina.....	43	Metformin Viatrix.....	11
Levomepromazine hydrochloride.....	137	Lumigan.....	279	Methadone BNM.....	128
Levonorgestrel.....	79-80	Lyllana.....	87	Methadone hydrochloride.....	128
Levonorgestrel BNM.....	80	Lynparza.....	162	Methenamine (hexamine) hippurate.....	118
Levothyroxine.....	89	Lyrica.....	133	Methopt.....	280
Lidocaine [Lignocaine].....	125-126	- M -			
Lidocaine [Lignocaine] hydrochloride.....	126	m-Eslon.....	129	Methotrexate.....	158
Lidocaine [Lignocaine] with prilocaine.....	126	Mabthera.....	223	Methotrexate DBL Onco-Vial.....	158
Lidocaine-Baxter.....	126	Macrobid.....	118	Methotrexate Ebewe.....	158
Life Extension.....	30	Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride.....	25	Methotrexate Sandoz.....	158
Lignocaine.....	125-126	Madopar 125.....	124	Methyl hydroxybenzoate.....	285
Linezolid.....	107	Madopar 250.....	124	Methylcellulose.....	285
Lioresal Intrathecal.....	123	Madopar 62.5.....	124	Methylcellulose with glycerin and sodium saccharin.....	285
Lipid-Modifying Agents.....	53	Madopar HBS.....	124	Methylcellulose with glycerin and sucrose.....	285
Liquigen.....	288	Madopar Rapid.....	124	Methyldopa.....	51
Liraglutide.....	12	Magnesium hydroxide.....	35	Methyldopa Viatrix.....	51
Lisdexamfetamine dimesilate.....	146	Magnesium sulphate.....	35	Methylnaltrexone bromide.....	25
Lisinopril.....	46	Mantoux.....	324	Methylphenidate ER - Teva.....	147
Lithium carbonate.....	137	Marevan.....	43	Methylphenidate hydrochloride.....	147
Livostin.....	279	Marine Blue Lotion SPF 50+.....	75	Methylphenidate hydrochloride extended-release.....	148
LMX4.....	126	Martindale Pharma.....	282	Methylprednisolone.....	84
Lo-Oralcon 20 ED.....	79	Mask for spacer device.....	276	Methylprednisolone (as sodium succinate).....	85
Locacorten-Viaform ED's.....	277	Maviret.....	110	Methylprednisolone aceponate.....	70
Local preparations for Anal and Rectal Disorders.....	8	Maxidex.....	278	Methylprednisolone acetate.....	85
Locasol.....	303	Maxitrol.....	278	Methylxanthines.....	274
Locoid.....	70, 74	MCT oil (Nutricia).....	288	Metoclopramide Actavis 10.....	136
Locoid Crelo.....	70	Measles, mumps and rubella vaccine.....	317	Metoclopramide hydrochloride.....	136
Locoid Lipocream.....	70	Mebendazole.....	95	Metolazone.....	53
Locorten-Vioform.....	277	Mebeverine hydrochloride.....	8	Metopirone.....	94
Lodoxamide.....	279	Medac.....	155	Metoprolol IV Mylan.....	49
Logem.....	132	Medrol.....	84	Metoprolol IV Viatrix.....	49
Lomide.....	279	Medroxyprogesterone acetate Genito-Urinary.....	80	Metoprolol succinate.....	49
Lomustine.....	155	Hormone.....	88-89	Metoprolol tartrate.....	49
Loniten.....	56	Mefenamic acid.....	119	Metronidamed.....	106
Loperamide hydrochloride.....	6	Mekinist.....	176	Metronidazole.....	106
Lopinavir with ritonavir.....	115	Melatonin.....	143	Metyrapone.....	94
		Melpha.....	155		

1

1009

Nirmatrelvir with ritonavir	112	Nutrison 800 Complete Multi Fibre	296	Ora-Blend	285
Nitrates	55	Nutrison Advanced Peptisorb	292	Ora-Blend SF	285
Nitroderm TTS	55	Nutrison Concentrated	298	Ora-Plus	285
Nitrofurantoin	118	Nutrison Energy	295	Ora-Sweet	285
Nitrolingual Pump Spray	55	Nutrison Energy Multi Fibre	296	Ora-Sweet SF	285
Nivestim	43	Nutrison Multi Fibre	296	Orabase	31
Nivolumab	251	Nutrison RTH	295	Oral and Enteral Feeds	289
Nodia	6	Nyefax Retard	51	Oralcon 30 ED	79
Noflam 250	119	Nystatin		Oramorph	129
Noflam 500	119	Alimentary	32	Oramorph CDC S29	129
Non-Steroidal Anti-Inflammatory Drugs	119	Genito-Urinary	80	Oratane	67
Nonacog gamma, [Recombinant Factor IX]	39	Infection	103	Omidazole	106
Norethindrone - CDC	80	NZB Low Gluten Bread Mix	299	Orphenadrine citrate	123
Norethisterone		- O -		Ortho-tolidine	82
Genito-Urinary	80	Obinutuzumab	220	Oruvail SR	119
Hormone	89	Obstetric Preparations	82	Osimertinib	172
Norflex	123	Ocicure	9	Osmolite RTH	295
Norfloxacin	118	Ocrelizumab	142	Other Endocrine Agents	94
Noriday	80	Ocrevus	142	Other Oestrogen Preparations	88
Noriday 28	80	Octasa	7	Other Progestogen Preparations	89
Norimin	79	Octocog alfa [Recombinant factor VIII] (Advate)	39	Other Skin Preparations	75
Normison	144	Octocog alfa [Recombinant factor VIII] (Kogenate FS)	39	Otodex	277
Norpress	130	Octreotide	179	Ovestin	
Nortriptyline hydrochloride	130	Octreotide GH	179	Genito-Urinary	81
Norvir	115	Octreotide long-acting	181	Hormone	88
Noumed Dexamfetamine	146	Oestradiol	87	Oxaliplatin	155
Noumed Isoniazid	107	Oestradiol valerate	88	Oxaliplatin Accord	155
Noumed Paracetamol	127	Oestradiol with norethisterone	88	Oxaliplatin Actavis 100	155
Noumed Pethidine	129	Oestriol		Oxaliplatin Ebewe	155
Noumed Phenobarbitone	133	Genito-Urinary	81	Oxis Turbuhaler	268
NovaSource Renal	292	Hormone	88	Oxpentifylline	56
Novatrein	73	Oestrogens	88	Oxybutynin	82
Novitium Sugar Free	28	Ofev	272	Oxycodone Amneal	129
NovoMix 30 FlexPen	10	Oil in water emulsion	71	Oxycodone hydrochloride	129
NovoRapid	11	Olanzapine	137, 139	Oxycodone Lucis	129
NovoRapid FlexPen	11	Olaparib	162	Oxycodone Sandoz	129
NovoRapid Penfill	11	Olbetam	53	Oxytocin	81
NovoSeven RT	38	Olopatadine	281	Oxytocin BNM	81
Nozinan	137	Olopatadine Teva	281	Oxytocin with ergometrine maleate	81
Nozinan (Swiss)	137	Olsalazine	8	Ozurdex	278
Nucala	218	Omalizumab	220	- P -	
Nuelin	274	Omeprazole	9	Pacifen	123
Nuelin-SR	274	Omeprazole actavis 10	9	Pacimol	127
Nupentin	132	Omeprazole actavis 20	9	Paclitaxel	163
Nusinersen	144	Omeprazole actavis 40	9	Paclitaxel Actavis	163
Nutilis	298	Omeprazole Teva	9	Paclitaxel Ebewe	163
Nutren Diabetes	289	Omnirope	89	Padagis	52
Nutrient Modules	286	Onbrez Breezhaler	268	Paediatric Seravit	33
Nutrini Energy Multi Fibre	291	Oncaspar LYO	163	Palbociclib	173
Nutrini Energy RTH	291	OncotICE	189	Palbociclib Pfizer	173
Nutrini Low Energy Multi Fibre	293	Ondansetron	136	Paliperidone	139
Nutrini Peptisorb	306	One-Alpha	32	Paliperidone palmitate	140
Nutrini Peptisorb Energy	306	Opdivo	251	Palivizumab	222
Nutrini RTH	291			Pamidronate disodium	121

Pamisol.....	121	Pethidine hydrochloride.....	129	PKU Lophlex Powder.....	300
Pamol.....	127	Pevaryl.....	68	PKU Lophlex Sensation 20.....	300
Pancreatic enzyme.....	23	Pexsig.....	51	PKU Restore Powder.....	301
Pantoprazole.....	9	Pfizer Exemestane.....	181	PKU sphere20 Banana.....	301
Panzop Relief.....	9	Pharmacy Services.....	282	PKU sphere20 Chocolate.....	301
Papaverine hydrochloride.....	56	Pheburane.....	30	PKU sphere20 Lemon.....	301
Para-amino salicylic acid.....	107	Phenasen.....	158	PKU sphere20 Red Berry.....	301
Paracetamol.....	127	Phenobarbitone.....	133	PKU sphere20 Vanilla.....	301
Paracetamol (Ethics).....	127	Phenobarbitone sodium		Pku Start.....	300
Paracetamol + Codeine		Extemporaneous.....	285	Plendil ER.....	50
(Relieve).....	129	Nervous.....	144	Pneumococcal (PCV13) conjugate	
Paracetamol with codeine.....	129	Phenoxybenzamine		vaccine.....	320
Paraffin.....	71	hydrochloride.....	46	Pneumococcal (PPV23)	
Paraffin liquid with wool fat.....	281	Phenoxyethylpenicillin (Penicillin		polysaccharide vaccine.....	321
Parasiticial Preparations.....	72	V).....	99	Pneumovax 23.....	321
Parnate.....	130	Phenylalanine50.....	303	Podophyllotoxin.....	75
Paromomycin.....	101	Phenytoin sodium.....	131, 133	Polaramine.....	267
Paroxetine.....	131	Phillips Milk of Magnesia.....	35	Poliomyelitis vaccine.....	321
Paser.....	107	Phlexy 10.....	300	Poloxamer.....	24
Paxam.....	140	Phosphate Phebra.....	44	Poly-Tears.....	280
Paxlovid.....	112	Phosphorus.....	44	Poly-Visc.....	281
Paxlovid (Pharmac).....	112	Phytomenadione.....	40	Polycal.....	286
Paxtine.....	131	Pilocarpine hydrochloride.....	280	Polyethylene glycol 400 and	
Pazopanib.....	174	Pilocarpine nitrate.....	280	propylene glycol.....	281
Pazopanib Teva.....	174	Pimafucort.....	70	Pomalidomide.....	163
Peak flow meter.....	276	Pimecrolimus.....	73	Pomolide.....	163
Pediasure.....	291	Pine tar with trolamine laurilsulfate		Ponstan.....	119
Pediasure Plus.....	291	and fluorescein.....	74	Posaconazole.....	103
Pediasure RTH.....	291	Pinetarsol.....	74	Posaconazole Juno.....	103
Pegaspargase.....	163	Pioglitazone.....	11	Potassium chloride.....	43-44
Pegasys.....	115	Pirfenidone.....	273	Potassium citrate.....	82
Pegasys (S29).....	115	Pizotifen.....	135	Potassium iodate.....	33
Pegasys S29.....	115	PKU Anamix Infant.....	300	Povidone iodine.....	71
Pegfilgrastim.....	43	PKU Anamix Junior.....	300	Pradaxa.....	42
Pegylated interferon alfa-2a.....	115	PKU Anamix Junior Chocolate.....	300	Pramipexole hydrochloride.....	124
Pembrolizumab.....	253	PKU Anamix Junior LQ.....	300	Pravastatin.....	54
Pemetrexed.....	158	PKU Anamix Junior Orange.....	300	Praziquantel.....	95
Pemetrexed-AFT.....	158	PKU Anamix Junior Vanilla.....	300	Prazosin.....	46
Penicillamine.....	120	PKU Build 10.....	301	Prazosin Mylan.....	46
Penicillin G.....	98	PKU Build 20 Chocolate.....	301	Pred Forte.....	279
PenMix 30.....	11	PKU Build 20 Raspberry		Prednisolone.....	85
Pentasa.....	7	Lemonade.....	301	Prednisolone acetate.....	279
Pentostatin [Deoxycyformycin].....	163	PKU Build 20 Smooth.....	301	Prednisolone sodium	
Pentoxifylline [Oxpentifylline].....	56	PKU Build 20 Vanilla.....	301	phosphate.....	279
Peptamen Junior.....	291	PKU Explore 10.....	300	Prednisolone-AFT.....	279
Pepti-Junior.....	306	PKU Explore 5.....	300	Prednisone.....	85
Perhexiline maleate.....	51	PKU Express 20.....	300	Prednisone Clinect.....	85
Pericyazine.....	137	PKU First Spoon.....	300	Pregabalin.....	133
Perindopril.....	46	PKU Glytactin RTD 15.....	301	Pregabalin Pfizer.....	133
Periset.....	136	PKU Glytactin RTD 15 Lite.....	301	Pregnancy Tests - hCG Urine.....	81
Periset ODT.....	136	PKU GMPPro LQ.....	301	Premarin.....	88
Perjeta.....	223	PKU GMPPro Mix-In.....	301	Presolol.....	49
Permethrin.....	72	PKU GMPPro Ultra Lemonade.....	301	Prevenar 13.....	320
Perrigo.....	75	PKU GMPPro Ultra Vanilla.....	301	Priadel.....	137
Pertuzumab.....	223	PKU Lophlex LQ 10.....	300	Primaquine.....	105
Peteha.....	107	PKU Lophlex LQ 20.....	300	Primidone.....	133

Primidone Clinect	133	Rapamune	261	Rizamelt	135
Primolut N	89	Rasagiline	124	Rizatriptan	135
Priorix	317	Reandron 1000	85	Robinul	8
Probenecid	123	Recombinant factor IX	37, 39	Ropin	124
Probenecid-AFT	123	Recombinant factor VIIa	38	Ropinirole hydrochloride	124
Procarbazine hydrochloride	164	Recombinant factor VIII	39	Rosuvastatin	54
Prochlorperazine	136	Rectogesic	8	Rosuvastatin Viatris	54
Prochlorperazine maleate (Brown & Burk)	136	Redipred	85	Rotarix	322
Proctofoam	7	Relieve	119	Rotavirus oral vaccine	322
Proctosedyl	8	Relistor	25	Roxane-Propranolol	50
Procyclidine hydrochloride	125	Remdesivir	112	Roxithromycin	97
Progesterone	89	Remicade	209	Rubifen	147
Proglcem	10	Renilon 7.5	292	Rubifen SR	147
Progynova	88	Resonium-A	45	Rurioctocog alfa pegol [Recombinant factor VIII]	39
Prolia	120	Resource Beneprotein	288	Ruxolitinib	175
Promethazine hydrochloride	267	Respiratory Devices	276	Rydapt	171
Propafenone hydrochloride	48	Respiratory Stimulants	276	Rythmodan	48
Propranolol	50	Retinol palmitate	281	Rythmodan - Cheplafarm	48
Propylene glycol	285	ReTrieve	67	Rythmodan Neon	48
Propylthiouracil	89	Retrovir	114	Rythmonorm	48
Prostacur	179	Revolade	37	Ryzodeg 70/30 Penfill	10
Protaphane	10	Ribociclib	174	- S -	
Protaphane Penfill	10	Riboflavin	29	Sabril	134
Protifar	288	Ribomustin	153	Sacubitril with valsartan	47
Protionamide	107	Ricit	81	SalAir	270
Provera	88	Ricovir	108	Salazopyrin	8
Provera HD	89	Rifabutin	108	Salazopyrin EN	8
Psoriasis and Eczema Preparations	73	Rifadin	108	Salbutamol	269-270
PTU	89	Rifadin Sanofi	108	Salbutamol with ipratropium bromide	270
Pulmicort Turbuhaler	268	Rifampicin	108	Salicylic acid	74
Pulmozyme	274	Rifaximin	10	Salmeterol	268
Puri-nethol	157	Rifinah	107	Sandomigran	135
Puritan's Pride Vitamin B-2 100 mg	29	Rilutek	125	Sandostatin LAR	181
Pyrazinamide	108	Riluzole	125	Sanofi Primaquine	105
Pyridostigmine bromide	119	Rinvog	263	Saproterin dihydrochloride	29
Pyridoxine hydrochloride	32	Riodine	71	Scalp Preparations	74
Pyridoxine multichem	32	Risdiplam	145	Scopolamine Transdermal System Viatris	135
Pytazen SR	40	Risedronate Sandoz	122	Sebizole	74
- Q -		Risedronate sodium	122	Secukinumab	236
Quantalan sugar free	53	Risperdal	138	Sedatives and Hypnotics	143
Quetapel	138	Risperdal Consta	140	Seebri Breezhaler	270
Quetiapine	138	Risperidone	138, 140	Senna	25
Quetiapine Viatris	138	Risperidone (Teva)	138	Senokot	25
Quinapril	46	Risperon	138	SensoCard	16
Qvar	268	Ritalin	147	Serc	135
- R -		Ritalin LA	148	Serenace	137
RA-Morph	128	Ritonavir	115	Seretide	269
Rallicrom	8	Rituximab (Mabthera)	223	Seretide Accuhaler	269
Raloxifene hydrochloride	121	Rituximab (Riximyo)	225	Serevent	268
Raltegravir potassium	115	Rivaroxaban	42	Serevent Accuhaler	268
Ramipex	124	Rivastigmine	149	Sertraline	131
Ramipril	47	Rivastigmine Patch BNM 10	149	Setrona	131
Ranbaxy-Cefaclor	95	Rivastigmine Patch BNM 5	149	Sevredol	129
		Rivotril	132		
		Riximyo	225		
		RIXUBIS	39		

Sex Hormones Non		Sotalol.....	50	Tacrolimus	
Contraceptive.....	85	Sotalol Viatris.....	50	Dermatological.....	74
Shingles vaccine.....	324	Spacer device.....	276	Oncology.....	262
Shingrix.....	324	Span-K.....	44	Tacrolimus Sandoz.....	262
SII-Onco-BCG.....	189	Spazmol.....	8	Tafinlar.....	167
Sildenafil.....	61	Spinal Muscular Atrophy.....	144	Tagrisso.....	172
Siltuximab.....	238	Spinraza.....	144	Taliglucerase alfa.....	30
Simvastatin.....	55	Spiocto Respimat.....	271	Tambocor.....	48
Simvastatin Mylan.....	55	Spiractin.....	52	Tambocor German.....	48
Simvastatin Viatris.....	55	Spiriva.....	270	Tamoxifen citrate.....	180
Sinemet.....	124	Spiriva Respimat.....	270	Tamoxifen Sandoz.....	180
Sinemet CR.....	124	Spiroolactone.....	52	Tamsulosin hydrochloride.....	81
Sintetica Baclofen Intrathecal.....	123	Stalevo.....	124	Tamsulosin-Rex.....	81
Sirolimus.....	261	Staphlex.....	98	Tandem Cartridge.....	18
Sirturo.....	106	Stelara.....	245	Tandem t:slim X2 with Basal-IQ.....	17
Siterone.....	85	Stemetil.....	136	Tandem t:slim X2 with	
Slow-Lopresor.....	49	Steril-Gene.....	85	Control-IQ.....	17
Sodibic.....	45	SteroClear.....	275	Tap water.....	285
Sodium acid phosphate.....	25	Stesolid.....	131	Taro.....	103
Sodium alginate.....	6	Stimulants/ADHD Treatments.....	145	Tasigna.....	172
Sodium benzoate.....	30	Stiripentol.....	133	Tasmar.....	124
Sodium bicarbonate		Stomahesive.....	31	Taurine.....	30
Blood.....	44–45	Strides Shasun.....	103	TCu 380 Plus Normal.....	78
Extemporaneous.....	285	Stromectol.....	72	Tecentriq.....	249
Sodium calcium edetate.....	283	Sucrafate.....	9	Tecfidera.....	141
Sodium chloride		Sulfadiazin-Heyl.....	101	TEEVIR.....	114
Blood.....	44	Sulfadiazine Silver.....	68	Tegretol.....	132
Respiratory.....	275	Sulfadiazine sodium.....	101	Tegretol CR.....	132
Sodium citrate with sodium lauryl		Sulfasalazine.....	8	Telfast.....	267
sulphoacetate.....	25	Sulphur.....	74	Temaccord.....	164
Sodium citro-tartrate.....	82	Sulprix.....	136	Temazepam.....	144
Sodium cromoglicate		Sumagran.....	135	Temozolomide.....	164
Alimentary.....	8	Sumatriptan.....	135	Temozolomide-Taro.....	164
Sensory.....	279	Sunitinib.....	175	Tenofovir disoproxil.....	108
Sodium Fusidate [fusidic acid]		Sunitinib Pfizer.....	175	Tenofovir Disoproxil Emtricitabine	
Dermatological.....	68	Sunitinib Rex.....	175	Viatr.....	111
Infection.....	101	Sunscreens.....	75	Tenofovir Disoproxil Viatris.....	108
Sensory.....	277	Sunscreens, proprietary.....	75	Tenoxicam.....	119
Sodium hyaluronate [Hyaluronic		Sustagen Hospital Formula.....	296	Tensipine MR10.....	51
acid].....	281	Sustanon Ampoules.....	85	Tepadina.....	155
Sodium phenylbutyrate.....	30	Sylvant.....	238	Terbinafine.....	104
Sodium picosulfate.....	25	Symbicort Turbuhaler 100/6.....	269	Terbutaline sulphate.....	270
Sodium polystyrene sulphonate.....	45	Symbicort Turbuhaler 200/6.....	269	Teriflunomide.....	142
Sodium tetradecyl sulphate.....	39	Symbicort Turbuhaler 400/12.....	269	Teriflunomide Sandoz.....	142
Sodium valproate.....	133	Symmetrel.....	124	Teriparatide.....	122
Sofradex.....	277	Sympathomimetics.....	55	Teriparatide - Teva.....	122
Soframycin.....	277	Synacthen.....	85	Testogel.....	85
Solgar.....	26–30	Synacthen Depot.....	85	Testosterone.....	85
Solifenacin succinate.....	82	Synacthene Retard.....	85	Testosterone cipionate.....	85
Solifenacin succinate Max		Synagis.....	222	Testosterone esters.....	85
Health.....	82	Synthroid.....	89	Testosterone undecanoate.....	85
Solifenacin Viatris.....	82	Syntometrine.....	81	Tetrabenazine.....	125
Solu-Cortef.....	84	Syrup (pharmaceutical grade).....	285	Tetrabromophenol.....	82
Solu-Medrol.....	85	Systane Unit Dose.....	281	Tetracosactrin.....	85
Solu-Medrol-Act-O-Vial.....	85			Tetracycline.....	99
Somatropin (Omnitrope).....	89				

Teva Lisinopril	46	Tretinoin	23
Teva-Ketoconazole.....	103	Dermatological.....	67
Thalidomide.....	165	Oncology.....	165
Thalomid.....	165	Trexate	158
Theophylline	274	Triamcinolone acetoneide	
Thiamine hydrochloride	32	Alimentary	32
Thiamine multichem	32	Dermatological.....	70
THIO-TEPA	155	Hormone	85
Thioguanine.....	158	Triamcinolone acetoneide with	
Thiotepa.....	155	gramicidin, neomycin and nystatin	
Thyroid and Antithyroid Agents	89	Dermatological.....	70
Ticagrelor.....	40	Sensory.....	277
Ticagrelor Sandoz	40	Trientine.....	30
Tilcotil	119	Trientine Waymade	30
Timolol.....	279	Trikafta.....	274
Tiotropium bromide.....	270	Trimethoprim	102
Tiotropium bromide with		Trimethoprim with	
olodaterol.....	271	sulphamethoxazole	
Tivicay	115	[Co-trimoxazole]	102
TMP	102	Triovir.....	114
Tobramycin		Trisequens.....	88
Infection	102	Trisul	102
Sensory.....	277	Trophic Hormones.....	89
Tobramycin (Viatris).....	102	Tropicamide.....	280
Tobramycin BNM.....	102	Trulicity	12
Tobrex	277	TruSteel.....	19
Tocilizumab	239	Tryzan.....	47
Tofranil.....	130	Tuberculin PPD [Mantoux] test.....	324
Tolcapone	124	Tubersol.....	324
Tolvaptan.....	53	Two Cal HN	298
Topamax.....	134	TYR Anamix Infant	302
Topical Products for Joint and		TYR Anamix Junior.....	302
Muscular Pain.....	120	TYR Anamix Junior LQ.....	302
Topiramate	134	TYR Explore 5	302
Topiramate Actavis.....	134	TYR Lophlex LQ 20	302
Total parenteral nutrition (TPN).....	44	TYR Sphere 20	302
TPN	44	Tyrosine1000.....	303
Tramadol hydrochloride.....	129	Tysabri	142
Tramal SR 100	129		
Tramal SR 150	129	- U -	
Tramal SR 200	129	UK Cipla	270
Trametinib.....	176	UK Synacthen.....	85
Trandate	49	Ultibro Breezhaler.....	271
Tranexamic acid	39	Ultraproct	8
Tranylcypromine sulphate	130	Umeclidinium	271
Trastuzumab (Herzuma).....	242	Umeclidinium with vilanterol	271
Trastuzumab deruxtecan.....	244	Univent	270, 275
Trastuzumab emtansine.....	245	Upadacitinib.....	263
Travatan	279	Ural	82
Travoprost	279	Urea.....	71
Treatments for Dementia.....	149	Urex Forte.....	52
Treatments for Substance		Urinary Agents.....	81
Dependence	150	Urinary Tract Infections	117
Trelegy Ellipta.....	272	UroFos.....	117
Trental 400	56	Uromitexan	161
		Ursodeoxycholic acid.....	23
		Ursosan	23
		Ustekinumab.....	245
		Utrogestan	89
		- V -	
		Vaccinations	309
		Vaclovir.....	109
		Valaciclovir	109
		Valganciclovir	109
		Valganciclovir Viatris	109
		Valine50.....	303
		Vancomycin.....	102
		Vannair	269
		Varenicline tartrate	151
		Varicella vaccine [Chickenpox	
		vaccine]	323
		Varicella zoster vaccine [Shingles	
		vaccine]	324
		Varilrix.....	323
		Various	282
		VariSoft.....	21
		Vasodilators.....	55
		Vasopressin Agonists.....	94
		Vasorex	50
		Vebulis.....	64
		Vedafil.....	61
		Vedolizumab.....	247
		Vegzelma.....	206
		Veklury.....	112
		Veletri	62
		Venclexta.....	165
		Venetoclax.....	165
		Venlafaxine.....	131
		Venomil.....	267
		VENOX.....	267
		Ventolin.....	269-270
		Vepesid.....	159
		Verapamil hydrochloride.....	51
		Vermox	95
		Versacloz.....	137
		Vesanoid.....	165
		Vexazone.....	11
		Vfend	104
		Viaderm KC	70
		Victoza	12
		Vigabatrin	134
		Vigisom	143
		Vildagliptin	12
		Vildagliptin with metformin	
		hydrochloride.....	12
		Vimpat	132
		Vinblastine sulphate	166
		Vincristine sulphate	166
		Vinorelbine.....	166
		Vinorelbine Ebewe.....	166
		Vinorelbine Te Arai.....	166
		Viramune Suspension	114

VirusPOS.....	277	Zinc sulphate.....	35
Vit.D3.....	32	Zincaps.....	35
VitA-POS.....	281	Zincaps S29.....	35
Vitabdeck.....	33	Ziprasidone.....	138
Vital.....	292	Zista.....	267
Vitamin B complex.....	32	Zithromax.....	96
Vitamin B6 25.....	32	Zo-Rub HP.....	126
Vitamins.....	32–33	Zo-Rub Osteo.....	120
Vivonex TEN.....	292	Zoladex.....	93
Voltaren.....	119	Zoledronic acid	
Voltaren D.....	119	Hormone.....	84
Voltaren SR.....	119	Musculoskeletal.....	122
Volumatic.....	276	Zoledronic acid Injection Mylan.....	84
Voriconazole.....	104	Zoledronic acid Viatrix	
Vttack.....	104	Hormone.....	84
Vyvanse.....	146	Musculoskeletal.....	122
- W -			
Warfarin sodium.....	43	Zopiclone.....	144
Wart Preparations.....	75	Zopiclone Actavis.....	144
Wasp venom allergy treatment.....	267	Zostrix.....	120
Water		Zostrix HP.....	126
Blood.....	44	Zuclopenthixol decanoate.....	140
Extemporaneous.....	285	Zuclopenthixol hydrochloride.....	138
White Soft Liquid Paraffin AFT.....	71	Zusdone.....	138
Wool fat with mineral oil.....	71	Zyban.....	150
- X -			
Xalkori.....	167	Zypine.....	137
Xaluprine.....	157	Zypine ODT.....	137
Xarelto.....	42	Zyprexa Relprevv.....	139
Xgeva.....	120	Zytiga.....	178
Xifaxan.....	10	Zyvox.....	107
XMET Maxamum.....	299		
Xolair.....	220		
Xolair AU.....	220		
XP Maxamum.....	300		
Xylocaine.....	126		
Xylocaine 2% Jelly.....	125		
Xylocard 500.....	126		
Xyntha.....	39		
- Y -			
Yervoy.....	250		
- Z -			
Zarontin.....	132		
Zaroxolyn.....	53		
Zavedos.....	160		
Zeffix.....	108		
Zejula.....	161		
Zematop.....	74		
Zetlam.....	108		
Ziagen.....	114		
Zidovudine [AZT].....	114		
Zidovudine [AZT] with			
lamivudine.....	114		
Ziextenzo.....	43		
Zimybe.....	55		
Zinc and castor oil.....	70		















